,datetime,title,source,link,sentiment_class,sentiment_score
0,9/26/2016 1:20:23 PM,"BRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA (REGN, SAN)",Reuters,/news/stocks/brief-sanofi-and-regeneron-accepted-for-priority-review-by-u-s-fda-regn-san-1001417230,positive,0.7814623713493347
1,9/26/2016 1:40:20 PM,"Sanofi may win U.S. approval of $3 bln eczema drug by March (SAN, REGN, AZN)",Reuters,/news/stocks/sanofi-may-win-u-s-approval-of-$3-bln-eczema-drug-by-march-san-regn-azn-1001417519,negative,0.8872337341308594
2,9/30/2016 4:00:25 PM,BRIEF-Regeneron announces phase 2 study of aflibercept (REGN),Reuters,/news/stocks/brief-regeneron-announces-phase-2-study-of-aflibercept-regn-1001429758,positive,0.8262313008308411
3,9/30/2016 4:30:22 PM,Regeneron's Eylea combination therapy fails mid-stage study (REGN),Reuters,/news/stocks/regenerons-eylea-combination-therapy-fails-mid-stage-study-regn-1001429867,positive,0.8337081670761108
4,9/30/2016 5:20:23 PM,UPDATE 1-Regeneron's Eylea combination therapy fails mid-stage study (REGN),Reuters,/news/stocks/update-1-regenerons-eylea-combination-therapy-fails-mid-stage-study-regn-1001430010,positive,0.7335696816444397
5,10/3/2016 10:10:21 AM,"Regeneron eczema drug reduces itch and anxiety, two studies show (SAN, REGN)",Reuters,/news/stocks/regeneron-eczema-drug-reduces-itch-and-anxiety-two-studies-show-san-regn-1001431491,negative,0.49152112007141113
6,10/13/2016 3:10:22 PM,BRIEF-Ocular and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept (REGN),Reuters,/news/stocks/brief-ocular-and-regeneron-enter-into-strategic-collaboration-to-develop-sustained-release-formulation-of-aflibercept-regn-1001454399,negative,0.8990793228149414
7,10/17/2016 3:10:25 PM,"BRIEF-Regeneron, Teva provide update on fasinumab clinical development programs (REGN, TEVA)",Reuters,/news/stocks/brief-regeneron-teva-provide-update-on-fasinumab-clinical-development-programs-regn-teva-1001459690,positive,0.9374034404754639
8,10/17/2016 3:20:20 PM,"FDA places Regeneron and Teva's pain-drug study on hold (REGN, TEVA)",Reuters,/news/stocks/fda-places-regeneron-and-tevas-pain-drug-study-on-hold-regn-teva-1001459741,positive,0.5616438984870911
9,10/17/2016 4:20:24 PM,"UPDATE 1-FDA places Regeneron and Teva's pain-drug study on hold (REGN, TEVA)",Reuters,/news/stocks/update-1-fda-places-regeneron-and-tevas-pain-drug-study-on-hold-regn-teva-1001459859,positive,0.611797034740448
10,11/4/2016 12:42:18 PM,"Eylea sales lift Regeneron revenue 7.3 percent (SAN, BAYN, REGN)",Reuters,http://www.businessinsider.com/r-eylea-sales-lift-regeneron-revenue-73-percent-2016-11,negative,0.9527384042739868
11,11/4/2016 1:06:22 PM,BRIEF-Regeneron Pharmaceuticals Q3 gaap EPS $2.27 (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-q3-gaap-eps-227-2016-11,positive,0.9100497961044312
12,11/4/2016 1:18:18 PM,"UPDATE 1-Regeneron profit beats Street, Eylea sales growth slows (SAN, BAYN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-profit-beats-street-eylea-sales-growth-slows-2016-11,neutral,0.9549915790557861
13,11/5/2016 6:34:20 PM,"US STOCKS-S&P 500 losing streak extends to 9th straight day (REGN, HUM)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-500-losing-streak-extends-to-9th-straight-day-2016-11,neutral,0.8726784586906433
14,11/11/2016 8:06:18 PM,BRIEF-Regeneron and sanofi to present data from clinical trials (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-to-present-data-from-clinical-trials-2016-11,positive,0.9097245931625366
15,11/15/2016 10:10:17 PM,"Amgen cholesterol drug reduces artery-clogging plaque in study (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-amgen-cholesterol-drug-reduces-artery-clogging-plaque-in-study-2016-11,positive,0.5241137146949768
16,11/16/2016 4:18:24 PM,"BRIEF-Sanofi says Sarilumab phase 3 study shows positive results (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-says-sarilumab-phase-3-study-shows-positive-results-2016-11,negative,0.931766927242279
17,11/16/2016 5:06:20 PM,"BRIEF-Regeneron and Sanofi Present Results from late-stage Monarch study at American College of Rheumatology Annual Meeting (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-present-results-from-late-stage-monarch-study-at-american-college-of-rheumatology-annual-meeting-2016-11,positive,0.9171870350837708
18,11/17/2016 1:16:18 PM,"No early win for Sanofi, Regeneron cholesterol drug in study",Reuters,http://www.businessinsider.com/r-no-early-win-for-sanofi-regeneron-cholesterol-drug-in-study-2016-11,negative,0.920124351978302
19,11/18/2016 2:06:17 PM,BRIEF-Regeneron entered into termination agreement relating to master terms and conditions for warrants (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-entered-into-termination-agreement-relating-to-master-terms-and-conditions-for-warrants-2016-11,negative,0.4803922772407532
20,12/8/2016 12:34:03 PM,"UPDATE 1-EU regulator accepts Sanofi/Regeneron's Dupixent product for review (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-eu-regulator-accepts-sanofi/regenerons-dupixent-product-for-review-2016-12,positive,0.8275799751281738
21,12/12/2016 1:20:05 PM,UPDATE 1-Novartis eye drug franchise hit by failed Fovista studies (REGN),Reuters,http://www.businessinsider.com/r-update-1-novartis-eye-drug-franchise-hit-by-failed-fovista-studies-2016-12,neutral,0.9719898700714111
22,12/13/2016 3:04:03 PM,"As drug approvals dive in 2016, returns on R&D deteriorate",Reuters,http://www.businessinsider.com/r-as-drug-approvals-dive-in-2016-returns-on-rd-deteriorate-2016-12,neutral,0.9679107069969177
23,12/30/2016 10:30:05 PM,"BRIEF-Regeneron Pharmaceuticals to purchase existing corporate headquarters from BMR-Landmark at Eastview LLC, BMR-Landmark at Eastview IV LLC (REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-to-purchase-existing-corporate-headquarters-from-bmr-landmark-at-eastview-llc-bmr-landmark-at-eastview-iv-llc-2016-12,positive,0.7338699102401733
24,1/2/2017 10:18:03 AM,"New drug approvals fall to six-year low in 2016 (SAN, REGN)",Reuters,http://www.businessinsider.com/r-new-drug-approvals-fall-to-six-year-low-in-2016-2017-1,neutral,0.9625184535980225
25,1/6/2017 7:00:04 AM,"PRESS DIGEST - Wall Street Journal - Jan 6 (7203, AAPL, SHLD, YHOO, VZ, WMT, 005930, SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---jan-6-2017-1,positive,0.942533016204834
26,1/6/2017 1:44:03 PM,"US STOCKS-Futures flat as investors await jobs data (SAN, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-flat-as-investors-await-jobs-data-2017-1,neutral,0.9470498561859131
27,1/6/2017 5:11:54 PM,"2 drugmakers just got banned from selling their cholesterol drug — and their rival's stock is jumping (AMGN, REGN, SNYNF)",Reuters,http://www.businessinsider.com/r-judge-blocks-sanofi-regeneron-from-selling-cholesterol-drug-2017-1,positive,0.6052228808403015
28,1/9/2017 11:52:03 PM,BRIEF-Regeneron Pharmaceuticals reports preliminary Q4 U.S. net sales of eylea injection of $858 mln (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-reports-preliminary-q4-us-net-sales-of-eylea-injection-of-858-mln-2017-1,negative,0.5845116376876831
29,1/10/2017 1:48:05 AM,"BRIEF-Regeneron says Sanofi plant used to fill drugs now deemed acceptable (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-sanofi-plant-used-to-fill-drugs-now-deemed-acceptable-2017-1,positive,0.7220893502235413
30,1/10/2017 2:16:08 AM,"Regeneron CEO says Amgen not putting patients first in patent dispute (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-regeneron-ceo-says-amgen-not-putting-patients-first-in-patent-dispute-2017-1,positive,0.8796365261077881
31,1/10/2017 3:14:03 AM,"BRIEF-Amgen comments on Delaware court's ruling on PCSK9 patent litigation (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-amgen-comments-on-delaware-courts-ruling-on-pcsk9-patent-litigation-2017-1,positive,0.9104564785957336
32,1/10/2017 5:38:05 AM,"UPDATE 1-Regeneron CEO says Amgen not putting patients first in patent dispute (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-ceo-says-amgen-not-putting-patients-first-in-patent-dispute-2017-1,positive,0.8062507510185242
33,1/31/2017 3:10:07 PM,BRIEF-Tony Coles elected to Regeneron board (REGN),Reuters,http://www.businessinsider.com/r-brief-tony-coles-elected-to-regeneron-board-2017-1,positive,0.931203305721283
34,2/1/2017 7:07:01 AM,Regeneron And Sanofi Say Canada Approves Kevzara ,RTTNews,/news/stocks/regeneron-and-sanofi-say-canada-approves-kevzara-1001711423,positive,0.745663583278656
35,2/8/2017 10:06:11 AM,"UPDATE 1-Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A (SAN, JNJ, REGN, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-sanofi-sees-weak-2017-earnings-not-in-hurry-for-ma-2017-2,neutral,0.9732018709182739
36,2/8/2017 11:10:09 AM,"BRIEF-Sanofi CEO: no ""Plan B"" regarding anti cholesterol drug Praluent (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-ceo-no-plan-b-regarding-anti-cholesterol-drug-praluent-2017-2,positive,0.9160144925117493
37,2/8/2017 11:50:11 PM,"BRIEF-Regeneron pharmaceuticals says appeals court grants stay of permanent injunction for praluent (REGN, SAN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-says-appeals-court-grants-stay-of-permanent-injunction-for-praluent-2017-2,negative,0.48044076561927795
38,2/9/2017 2:31:52 AM,Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent ,RTTNews,/news/stocks/sanofi-says-appeals-court-grants-stay-of-permanent-injunction-for-praluent-1001735367,neutral,0.5624993443489075
39,2/9/2017 10:20:27 AM,"AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban ",RTTNews,/news/stocks/agtc-on-watch-it-s-advantage-regn-no-need-for-fda-panel-review-for-betrixaban-1001736305,positive,0.8549907207489014
40,2/9/2017 12:35:18 PM,Regeneron Pharmaceuticals Reports 37% Rise In Q4 Profit,RTTNews,/news/stocks/regeneron-pharmaceuticals-reports-37-rise-in-q4-profit-1001736847,negative,0.9431812763214111
41,2/9/2017 12:42:09 PM,Regeneron revenue rises 11.7 pct on Eylea eye drug (REGN),Reuters,http://www.businessinsider.com/r-regeneron-revenue-rises-117-pct-on-eylea-eye-drug-2017-2,negative,0.9482712149620056
42,2/9/2017 12:56:09 PM,"BRIEF-Regeneron posts Q4 adj. profit $3.04/shr (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-posts-q4-adj-profit-304-shr-2017-2,positive,0.8740977048873901
43,2/9/2017 1:10:11 PM,"UPDATE 1-Regeneron profit edges past estimates (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-profit-edges-past-estimates-2017-2,negative,0.9426037669181824
44,2/9/2017 4:00:09 PM,"BRIEF-Regeneron says price increases unrelated from innovation will be pushed back on (AMGN, BAYN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-price-increases-unrelated-from-innovation-will-be-pushed-back-on-2017-2,positive,0.6810702085494995
45,2/10/2017 2:42:25 AM,Regeneron Gets Subpoena On Patient Assistance Non-profit ,RTTNews,/news/stocks/regeneron-gets-subpoena-on-patient-assistance-non-profit-1001739702,neutral,0.6850444078445435
46,2/25/2017 9:22:15 AM,"UPDATE 1-Pfizer subpoenaed in U.S. over patient assistance plans (PFE, VRX, REGN)",Reuters,http://www.businessinsider.com/r-update-1-pfizer-subpoenaed-in-us-over-patient-assistance-plans-2017-2,positive,0.5027251243591309
47,2/27/2017 11:43:16 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1001785169,positive,0.7348417639732361
48,2/27/2017 2:30:00 PM,Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-data-on-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-at-upcoming-medical-congresses-1001785946,positive,0.7887138724327087
49,2/27/2017 2:30:00 PM,Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses,PR Newswire,/news/stocks/sanofi-and-regeneron-to-present-new-data-on-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-at-upcoming-medical-congresses-1001785948,positive,0.7915524840354919
50,3/1/2017 11:14:20 PM,BRIEF-Adverum says Regeneron Pharma elects to extend research term of deal (REGN),Reuters,http://www.businessinsider.com/r-brief-adverum-says-regeneron-pharma-elects-to-extend-research-term-of-deal-2017-3,positive,0.8467934727668762
51,3/4/2017 7:50:20 PM,"Sanofi, Regeneron say latest Dupixent eczema drug tests positive",Reuters,http://www.businessinsider.com/r-sanofi-regeneron-say-latest-dupixent-eczema-drug-tests-positive-2017-3,positive,0.9202196002006531
52,3/5/2017 6:42:12 AM,"Regeneron, Sanofi: DUPIXENT Study In Atopic Dermatitis Shows Positive Data ",RTTNews,/news/stocks/regeneron-sanofi-dupixent-study-in-atopic-dermatitis-shows-positive-data-1001804735,negative,0.950369119644165
53,3/7/2017 2:00:00 PM,Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-phase-3-praluent-alirocumab-injection-clinical-trial-analyses-at-acc-17-scientific-sessions-1001810991,positive,0.8519306182861328
54,3/7/2017 3:50:22 PM,"BRIEF-Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-to-present-new-phase-3-praluent-alirocumab-injection-clinical-trial-analyses-at-acc17-scientific-sessions-2017-3,positive,0.8533616065979004
55,3/13/2017 6:48:23 AM,"Data on heart benefits of Amgen drug is key to unlocking sales (AMGN, REGN, SAN, ESRX)",Reuters,http://www.businessinsider.com/r-data-on-heart-benefits-of-amgen-drug-is-key-to-unlocking-sales-2017-3,negative,0.5304710865020752
56,3/13/2017 11:16:26 AM,"RPT-Data on heart benefits of Amgen drug is key to unlocking sales (AMGN, REGN, SAN, ESRX)",Reuters,http://www.businessinsider.com/r-rpt-data-on-heart-benefits-of-amgen-drug-is-key-to-unlocking-sales-2017-3,negative,0.6397761702537537
57,3/13/2017 2:28:23 PM,"Amgen's Repatha lowers need for cholesterol-lowering procedure (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-amgens-repatha-lowers-need-for-cholesterol-lowering-procedure-2017-3,positive,0.6664590835571289
58,3/14/2017 10:00:24 AM,"BRIEF-UK regulator gives positive opinion on Sanofi/Regeneron's dupilumab product (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-uk-regulator-gives-positive-opinion-on-sanofi-regenerons-dupilumab-product-2017-3,negative,0.8772442936897278
59,3/14/2017 10:24:24 AM,"UK gives early green light to Sanofi eczema drug (SAN, REGN)",Reuters,http://www.businessinsider.com/r-uk-gives-early-green-light-to-sanofi-eczema-drug-2017-3,negative,0.9248565435409546
60,3/15/2017 2:29:00 AM,Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017,PR Newswire,/news/stocks/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017-1001835605,negative,0.8310732245445251
61,3/15/2017 3:45:00 AM,Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017,PR Newswire,/news/stocks/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017-1001835653,negative,0.8310732245445251
62,3/17/2017 2:34:43 PM,"RPT-Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-rpt-amgen-cholesterol-drug-cuts-heart-attack-stroke-risk-more-than-20-pct-study-2017-3,negative,0.5584462881088257
63,3/17/2017 3:04:33 PM,"Amgen is getting whacked after disappointing study results for its $14,000 heart drug (AMGN)",Reuters,http://www.businessinsider.com/r-amgen-cholesterol-drug-cuts-heart-attack-stroke-risk-more-than-20-percent-study-2017-3,neutral,0.9715656042098999
64,3/17/2017 4:46:43 PM,"Express Scripts says Amgen data opens door to patients (ESRX, AMGN, SAN, REGN)",Reuters,http://www.businessinsider.com/r-express-scripts-says-amgen-data-opens-door-to-patients-2017-3,negative,0.7733339071273804
65,3/17/2017 6:28:43 PM,"CVS Health says Amgen data may increase eligible patients by millions (CVS, SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-cvs-health-says-amgen-data-may-increase-eligible-patients-by-millions-2017-3,negative,0.9413390159606934
66,3/17/2017 10:04:45 PM,"Amgen discounts cholesterol drug, but payers want more (AMGN, CVS, ESRX, REGN, SAN, PFE)",Reuters,http://www.businessinsider.com/r-amgen-discounts-cholesterol-drug-but-payers-want-more-2017-3,positive,0.734501838684082
67,3/18/2017 7:00:46 AM,"UPDATE 1-Amgen discounts cholesterol drug, but payers want more (AMGN, CVS, ESRX, REGN, SAN, PFE, MDCO)",Reuters,http://www.businessinsider.com/r-update-1-amgen-discounts-cholesterol-drug-but-payers-want-more-2017-3,negative,0.8283330202102661
68,3/21/2017 6:04:45 PM,"Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims",Reuters,http://www.businessinsider.com/r-sanofi-regeneron-sue-amgen-to-protect-eczema-drug-from-patent-claims-2017-3,positive,0.5710179209709167
69,3/21/2017 6:28:44 PM,"UPDATE 1-Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-regeneron-sue-amgen-to-protect-eczema-drug-from-patent-claims-2017-3,positive,0.7895969748497009
70,3/23/2017 1:00:00 AM,"U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis",PR Newswire,/news/stocks/u-k-biobank-regeneron-and-gsk-announce-largest-gene-sequencing-initiative-on-world-s-most-detailed-health-database-to-improve-drug-discovery-and-disease-diagnosis-1001860001,negative,0.6226078867912292
71,3/23/2017 1:42:50 AM,"GSK and Regeneron to mine gene data from 500,000 Britons",Reuters,http://www.businessinsider.com/r-gsk-and-regeneron-to-mine-gene-data-from-500000-britons-2017-3,positive,0.9264296889305115
72,3/23/2017 9:06:50 AM,"UPDATE 1-UK Stocks-Factors to watch on March 23 (NXT, IGG, KIE, GSK, REGN, RDSA, TSO, CVX, XOM, BARC, TSCO, HEIA, BLT, UKX, BVS, CBG, DNLM, FEV, GFRD, MGGT, RDW, SGRO, HSBA, BHP, SIA, FUM, PVCS, ARBB)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-march-23-2017-3,positive,0.9418438673019409
73,3/23/2017 12:46:45 PM,"Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency (SAN, GSK, REGN, AMGN, MYL, HIK, VEC)",Reuters,http://www.businessinsider.com/r-crunch-week-looms-for-sanofi-roche-and-gsk-at-us-drugs-agency-2017-3,neutral,0.6524233222007751
74,3/28/2017 5:40:00 PM,"Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis",PR Newswire,/news/stocks/regeneron-and-sanofi-announce-fda-approval-of-dupixent-dupilumab-the-first-targeted-biologic-therapy-for-adults-with-moderate-to-severe-atopic-dermatitis-1001874808,negative,0.8292615413665771
75,3/28/2017 5:40:00 PM,"Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis",PR Newswire,/news/stocks/sanofi-and-regeneron-announce-fda-approval-of-dupixent-dupilumab-the-first-targeted-biologic-therapy-for-adults-with-moderate-to-severe-atopic-dermatitis-1001874809,negative,0.8513553142547607
76,3/28/2017 5:48:49 PM,"FDA approves Regeneron, Sanofi eczema drug (REGN, SAN)",Reuters,http://www.businessinsider.com/r-fda-approves-regeneron-sanofi-eczema-drug-2017-3,positive,0.7195936441421509
77,3/28/2017 5:56:49 PM,"BRIEF-U.S. list price for Sanofi, Regeneron's Dupixent $37,000 (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-us-list-price-for-sanofi-regenerons-dupixent-37000-2017-3,positive,0.9352796077728271
78,3/28/2017 6:04:49 PM,"BRIEF-U.S. FDA says approves new eczema drug Dupixent (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-us-fda-says-approves-new-eczema-drug-dupixent-2017-3,positive,0.660082221031189
79,3/28/2017 6:42:36 PM,"The FDA just approved a new drug to treat eczema that costs $37,000 a year (REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-fda-approves-regeneron-sanofi-37000-per-year-eczema-drug-2017-3,positive,0.7650905847549438
80,3/28/2017 6:44:49 PM,"BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-announce-fda-approval-of-dupixent-2017-3,positive,0.5407224893569946
81,3/28/2017 7:50:00 PM,Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval,PR Newswire,/news/stocks/regeneron-and-sanofi-to-host-investor-conference-call-to-discuss-dupixent-dupilumab-approval-1001875193,positive,0.8567096590995789
82,3/29/2017 3:03:59 AM,Regeneron Says FDA Okays New Eczema Drug Dupixent ,RTTNews,/news/stocks/regeneron-says-fda-okays-new-eczema-drug-dupixent-1001875832,negative,0.8158360123634338
83,3/29/2017 8:47:42 AM,"First Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data ",RTTNews,/news/stocks/first-drug-for-2-forms-of-ms-gets-fda-nod-rttr-abuzz-vrtx-gains-on-trial-data-1001876362,negative,0.9143662452697754
84,4/5/2017 12:55:00 PM,"Biotech Stocks on Investors' Radar -- Puma Biotechnology, Regeneron Pharma, Calithera, and Lexicon Pharma",PR Newswire,/news/stocks/biotech-stocks-on-investors-radar-puma-biotechnology-regeneron-pharma-calithera-and-lexicon-pharma-1001898041,positive,0.9364338517189026
85,4/6/2017 1:30:50 PM,BRIEF-Regeneron announces Evinacumab has received FDA breakthrough therapy designation (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-announces-evinacumab-has-received-fda-breakthrough-therapy-designation-2017-4,negative,0.9312507510185242
86,4/14/2017 3:30:00 PM,"Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017",PR Newswire,/news/stocks/regeneron-to-report-first-quarter-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-4-2017-1001593672,positive,0.9470986127853394
87,4/21/2017 8:35:05 PM,"BRIEF-EU Medicines Agency recommendations for April 2017 (BIIB, BMRN, MYL, PFE, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-eu-medicines-agency-recommendations-for-april-2017-2017-4,positive,0.9410563111305237
88,4/21/2017 9:51:09 PM,"EMA panel recommends nod for Sanofi, Regeneron's arthritis drug (SAN, REGN, JNJ, LLY, INCY)",Reuters,http://www.businessinsider.com/r-ema-panel-recommends-nod-for-sanofi-regenerons-arthritis-drug-2017-4,positive,0.6911615133285522
89,4/24/2017 7:31:37 AM,"Sanofi, Regeneron Say Kevzara Gets CHMP Positive Opinion For RA In Adults ",RTTNews,/news/stocks/sanofi-regeneron-say-kevzara-gets-chmp-positive-opinion-for-ra-in-adults-1001940422,negative,0.8890774846076965
90,4/25/2017 1:47:06 PM,BRIEF-Regeneron Pharmaceuticals say CEO Leonard Schleifer's 2016 total compensation was $28.3 mln - SEC filing (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-say-ceo-leonard-schleifers-2016-total-compensation-was-283-mln---sec-filing-2017-4,positive,0.5560941696166992
91,4/25/2017 2:00:00 PM,Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-fda-approval-of-a-new-once-monthly-dosing-option-for-praluent-alirocumab-injection-1001946211,negative,0.9072315692901611
92,4/25/2017 2:15:08 PM,"BRIEF-Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-and-regeneron-announce-fda-approval-of-a-once-monthly-dosing-option-for-praluent-2017-4,negative,0.8479227423667908
93,4/25/2017 2:41:12 PM,"BRIEF-Regeneron says FDA approved for praluent injection (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-fda-approved-for-praluent-injection-2017-4,negative,0.6266305446624756
94,4/26/2017 8:13:29 AM,"AKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE... ",RTTNews,/news/stocks/akba-jumps-on-otsuka-deal-mnov-abuzz-capr-counting-on-hope-1001949569,negative,0.8117045760154724
95,4/28/2017 7:00:00 AM,Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-kevzara-sarilumab-biologics-license-application-resubmission-accepted-for-review-by-u-s-fda-1001959684,negative,0.6548473834991455
96,4/28/2017 7:19:37 AM,"Sanofi: FDA Sets New Action Date For Kevzara BLA As May 22, 2017 - Quick Facts ",RTTNews,/news/stocks/sanofi-fda-sets-new-action-date-for-kevzara-bla-as-may-22-2017-quick-facts-1001959752,positive,0.9399318695068359
97,4/28/2017 8:39:08 AM,"BRIEF-Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-announce-kevzara-license-application-resubmission-for-review-by-fda-2017-4,positive,0.8807328939437866
98,4/28/2017 10:45:07 AM,"UPDATE 1-Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent (REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-genzyme-chc-lift-sanofis-first-quarter-figures-upbeat-on-dupixent-2017-4,positive,0.6090301871299744
99,4/30/2017 8:16:25 AM,"Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda ",RTTNews,/news/stocks/monday-is-d-day-for-aezs-watch-out-for-mrus-fda-nod-for-rdus-takeda-1001964351,positive,0.9274955987930298
100,5/2/2017 2:30:00 PM,"Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment",PR Newswire,/news/stocks/survey-results-show-eighty-percent-of-rheumatoid-arthritis-patients-report-life-altering-pain-daily-or-multiple-times-a-week-despite-treatment-624100,neutral,0.772429347038269
101,5/2/2017 2:30:00 PM,"Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment",PR Newswire,/news/stocks/survey-results-show-eighty-percent-of-rheumatoid-arthritis-patients-report-life-altering-pain-daily-or-multiple-times-a-week-despite-treatment-1001969402,neutral,0.772429347038269
102,5/4/2017 12:30:00 PM,Regeneron Reports First Quarter 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-first-quarter-2017-financial-and-operating-results-637465,positive,0.55452561378479
103,5/4/2017 12:42:47 PM,Regeneron Pharmaceuticals Profit Rises 23% In Q1,RTTNews,/news/stocks/regeneron-pharmaceuticals-profit-rises-23-in-q1-1001978904,negative,0.9409195184707642
104,5/4/2017 12:46:03 PM,"Biotech Regeneron's profit jumps 37 pct on higher Eylea sales (REGN, SAN, BAYN)",Reuters,http://www.businessinsider.com/r-biotech-regenerons-profit-jumps-37-pct-on-higher-eylea-sales-2017-5,negative,0.9494783282279968
105,5/4/2017 2:32:03 PM,BRIEF-Regeneron Pharmaceuticals says it received subpoena (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-says-it-received-subpoena-2017-5,positive,0.8336629271507263
106,5/4/2017 4:06:02 PM,"BRIEF-Regeneron says over 3,500 new prescriptions been written for Dupixent (REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-over-3500-new-prescriptions-been-written-for-dupixent-2017-5,positive,0.7194151878356934
107,5/4/2017 5:56:04 PM,"US STOCKS-Tech, energy stocks weigh on Wall Street (XOM, CVX, OXY, CHK, AAPL, CAT, TSLA, CHTR, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-energy-stocks-weigh-on-wall-street-2017-5,neutral,0.553890585899353
108,5/4/2017 6:51:50 PM,Regeneron Extending Recent Strong Move To The Upside ,RTTNews,/news/stocks/regeneron-extending-recent-strong-move-to-the-upside-1001980936,negative,0.943294882774353
109,5/4/2017 9:12:03 PM,"US STOCKS-Wall Street drops with oil prices, health bill vote awaited (XOM, CVX, AAPL, TSLA, CHTR, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-drops-with-oil-prices-health-bill-vote-awaited-2017-5,neutral,0.9589381814002991
110,5/4/2017 9:30:05 PM,"US STOCKS-Wall Street stays flat after House clears health bill (XOM, CVX, TSLA, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-stays-flat-after-house-clears-health-bill-2017-5,neutral,0.8478612899780273
111,5/5/2017 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentations-1001984342,positive,0.9307904839515686
112,5/8/2017 12:48:05 AM,Regeneron shares poised for rebound - Barron's (REGN),Reuters,http://www.businessinsider.com/r-regeneron-shares-poised-for-rebound---barrons-2017-5,positive,0.4773818254470825
113,5/8/2017 1:30:00 PM,Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy,PR Newswire,/news/stocks/regeneron-and-inovio-enter-immuno-oncology-clinical-study-agreement-for-glioblastoma-combination-therapy-1001989016,negative,0.9047231078147888
114,5/8/2017 1:50:07 PM,"BRIEF-Regeneron and Inovio enter immuno-oncology clinical study agreement (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-inovio-enter-immuno-oncology-clinical-study-agreement-2017-5,positive,0.5016235709190369
115,5/8/2017 2:30:00 PM,Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer,PR Newswire,/news/stocks/regeneron-and-sillajen-announce-immuno-oncology-clinical-study-agreement-for-combination-treatment-in-kidney-cancer-1001651794,negative,0.8860310316085815
116,5/8/2017 3:10:07 PM,"BRIEF-Regeneron and Sillajen report immuno-oncology clinical study agreement (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sillajen-report-immuno-oncology-clinical-study-agreement-2017-5,positive,0.8967713117599487
117,5/22/2017 9:18:07 PM,"Severe asthma drug shows AstraZeneca promise beyond cancer (AZN, GSK, TEVA, PFE, SAN, REGN)",Reuters,http://www.businessinsider.com/r-severe-asthma-drug-shows-astrazeneca-promise-beyond-cancer-2017-5,negative,0.6530019044876099
118,5/23/2017 12:48:05 AM,"BRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-sanofi-ra-drug-wins-fda-nod-cos-price-it-at-39000-patient-yr-2017-5,negative,0.8022890090942383
119,5/23/2017 1:54:02 AM,"Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval (REGN, SAN)",Reuters,http://www.businessinsider.com/r-regeneron-sanofi-rheumatoid-arthritis-drug-wins-us-approval-2017-5,negative,0.8178998231887817
120,5/23/2017 1:54:02 AM,"UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval (REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-sanofi-rheumatoid-arthritis-drug-wins-us-approval-2017-5,negative,0.9207955002784729
121,5/25/2017 11:24:03 PM,"BRIEF-Diplomat Pharmacy begins dispensing prescriptions for RA drug Kevzara (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-diplomat-pharmacy-begins-dispensing-prescriptions-for-ra-drug-kevzara-2017-5,positive,0.8650370836257935
122,6/4/2017 4:00:00 PM,Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting,PR Newswire,/news/stocks/regeneron-and-sanofi-present-positive-study-results-for-investigational-pd-1-antibody-regn2810-at-american-society-of-clinical-oncology-asco-annual-meeting-1002065834,negative,0.9311185479164124
123,6/4/2017 6:07:55 PM,"Regeneron, Sanofi Present Positive Study Results For PD-1 Antibody REGN2810 ",RTTNews,/news/stocks/regeneron-sanofi-present-positive-study-results-for-pd-1-antibody-regn2810-1002065892,negative,0.9307306408882141
124,6/6/2017 11:48:05 PM,"Regeneron, Sanofi urge court to reverse ban on cholesterol drug (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-regeneron-sanofi-urge-court-to-reverse-ban-on-cholesterol-drug-2017-6,positive,0.6316444873809814
125,6/11/2017 5:00:00 PM,Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-results-from-first-dedicated-studies-evaluating-praluent-alirocumab-in-individuals-with-diabetes-and-hypercholesterolemia-1002083768,negative,0.9233170747756958
126,6/11/2017 5:01:00 PM,Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia,PR Newswire,/news/stocks/sanofi-and-regeneron-announce-positive-results-from-first-dedicated-studies-evaluating-praluent-alirocumab-in-individuals-with-diabetes-and-hypercholesterolemia-1002083769,negative,0.9186662435531616
127,6/11/2017 6:00:10 PM,"Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials (SAN, REGN)",Reuters,http://www.businessinsider.com/r-sanofi-regenerons-praluent-cuts-cholesterol-in-odyssey-trials-2017-6,negative,0.5851806402206421
128,6/12/2017 3:17:31 AM,Sanofi Announces Results From Two Phase 3b/4 ODYSSEY-DM Trials In Diabetes ,RTTNews,/news/stocks/sanofi-announces-results-from-two-phase-3b-4-odyssey-dm-trials-in-diabetes-1002083936,negative,0.5145549774169922
129,6/12/2017 3:22:27 AM,"LXRX Brings Sweet Tidings, PFE's PROSPER Ahead Of Schedule, XBIT Fails To Excite ",RTTNews,/news/stocks/lxrx-brings-sweet-tidings-pfe-s-prosper-ahead-of-schedule-xbit-fails-to-excite-1002083938,negative,0.9300626516342163
130,6/14/2017 1:38:05 PM,"UPDATE 1-Sanofi to invest further in biologics (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-to-invest-further-in-biologics-2017-6,negative,0.7952403426170349
131,6/20/2017 1:20:11 PM,"UPDATE 1-Novartis eye drug works with fewer injections than rivals (REGN, BAYN, AGN)",Reuters,http://www.businessinsider.com/r-update-1-novartis-eye-drug-works-with-fewer-injections-than-rivals-2017-6,positive,0.6269859075546265
132,6/20/2017 6:32:14 PM,"UPDATE 2-Novartis eye drug works with fewer injections than rival (REGN, BAYN, AGN)",Reuters,http://www.businessinsider.com/r-update-2-novartis-eye-drug-works-with-fewer-injections-than-rival-2017-6,positive,0.5646783709526062
133,6/21/2017 2:30:00 PM,"Regeneron Recognized on ""The Civic 50"" List of the Most Community-Minded Companies in the United States",PR Newswire,/news/stocks/regeneron-recognized-on-the-civic-50-list-of-the-most-community-minded-companies-in-the-united-states-1002111882,negative,0.7513356804847717
134,6/21/2017 5:42:03 PM,"US STOCKS-Nasdaq boosted by biotechs; banks weigh on Dow, S&P (CELG, REGN, AMGN, GS, BAC, CAT, GE, ADBE)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-boosted-by-biotechs-banks-weigh-on-dow-sp-2017-6,negative,0.7888187170028687
135,6/21/2017 7:26:05 PM,"US STOCKS-Nasdaq boosted by biotechs; energy, banks weigh on Dow, S&P (XOM, CVX, CELG, REGN, AMGN, GS, BAC, CAT, FDX)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-boosted-by-biotechs-energy-banks-weigh-on-dow-sp-2017-6,negative,0.8096580505371094
136,6/21/2017 9:32:03 PM,"US STOCKS-S&P, Dow hurt by Energy, banks; biotech boosts Nasdaq (CTL, T, CELG, REGN, CAT, FDX)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-hurt-by-energy-banks-biotech-boosts-nasdaq-2017-6,neutral,0.5353612303733826
137,6/21/2017 10:48:03 PM,"US STOCKS-S&P, Dow hurt by energy, banks; biotech boosts Nasdaq (CAT, FDX, T, CELG, REGN, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-hurt-by-energy-banks-biotech-boosts-nasdaq-2017-6,neutral,0.42568737268447876
138,6/22/2017 3:12:05 PM,BRIEF-Regeneron details royalty agreement with Novartis for canakinumab (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-details-royalty-agreement-with-novartis-for-canakinumab-2017-6,positive,0.6343843936920166
139,6/23/2017 4:08:05 PM,"US STOCKS-Wall St weighed down by health, consumer shares (UNH, REGN, AMGN, BAC, JPM, WFC, GS, CAT, BBBY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-weighed-down-by-health-consumer-shares-2017-6,neutral,0.9682051539421082
140,6/27/2017 7:00:00 AM,Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-approval-of-kevzara-sarilumab-to-treat-adult-patients-with-moderately-to-severely-active-rheumatoid-arthritis-in-the-european-union-1002125713,negative,0.8879557847976685
141,6/27/2017 7:15:09 AM,Regeneron: EC Okays Kevzara To Treat Moderately To Severely Active RA ,RTTNews,/news/stocks/regeneron-ec-okays-kevzara-to-treat-moderately-to-severely-active-ra-1002125750,negative,0.6734503507614136
142,6/27/2017 7:28:03 AM,"BRIEF-Sanofi and Regeneron announce EU approval for Kevzara (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-and-regeneron-announce-eu-approval-for-kevzara-2017-6,negative,0.7114591002464294
143,7/21/2017 1:32:03 PM,"EU follows U.S. in backing Sanofi, Regeneron eczema drug (REGN, SAN, GSK)",Reuters,http://www.businessinsider.com/r-eu-follows-us-in-backing-sanofi-regeneron-eczema-drug-2017-7,positive,0.5011987686157227
144,7/21/2017 1:41:15 PM,"Regeneron, Sanofi Get Positive CHMP Opinion For Dupixent - Quick Facts ",RTTNews,/news/stocks/regeneron-sanofi-get-positive-chmp-opinion-for-dupixent-quick-facts-1002194968,negative,0.7344720959663391
145,7/21/2017 1:42:05 PM,"BRIEF-EU Medicines Agency recommends approval of Novartis' leukaemia drug (REGN, SAN, 4568, NKTR)",Reuters,http://www.businessinsider.com/r-brief-eu-medicines-agency-recommends-approval-of-novartis-leukaemia-drug-2017-7,positive,0.7688753604888916
146,7/24/2017 5:21:39 AM,One Step Closer To EU Approval... ,RTTNews,/news/stocks/one-step-closer-to-eu-approval-1002197023,negative,0.5937835574150085
147,7/26/2017 2:00:00 PM,Generali Global Assistance Publishes White Paper On The Benefits Of Adding Identity Protection Services To Customer Loyalty Programs,PR Newswire,/news/stocks/generali-global-assistance-publishes-white-paper-on-the-benefits-of-adding-identity-protection-services-to-customer-loyalty-programs-1001549142,positive,0.6981792449951172
148,7/28/2017 12:24:03 AM,"Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label (AMGN, PFE, REGN, SAN)",Reuters,http://www.businessinsider.com/r-amgen-gets-fast-us-fda-review-for-adding-heart-benefits-to-cholesterol-drug-label-2017-7,negative,0.8885365724563599
149,7/28/2017 1:20:03 PM,BRIEF-U.S. Court of Appeals for Federal Circuit affirms Merus' inequitable conduct claim against Regeneron (REGN),Reuters,http://www.businessinsider.com/r-brief-us-court-of-appeals-for-federal-circuit-affirms-merus-inequitable-conduct-claim-against-regeneron-2017-7,neutral,0.8063504695892334
150,7/31/2017 10:20:05 AM,"UPDATE 1-Sanofi raises outlook after strong Q2 sales growth (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-raises-outlook-after-strong-q2-sales-growth-2017-7,negative,0.9468013644218445
151,8/1/2017 5:37:03 PM,"US STOCKS-Dow at record on strong earnings; Apple earnings awaited (AAPL, AMZN, PFE, REGN, S)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-at-record-on-strong-earnings-apple-earnings-awaited-2017-8,negative,0.898737370967865
152,8/1/2017 7:07:14 PM,"US STOCKS-Dow hits record on strong earnings; Apple results eyed (REGN, AAPL, VZ, JPM, F, GM, S, XRX)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-hits-record-on-strong-earnings-apple-results-eyed-2017-8,negative,0.8805534839630127
153,8/3/2017 12:30:00 PM,Regeneron Reports Second Quarter 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-second-quarter-2017-financial-and-operating-results-1002229803,positive,0.5138915181159973
154,8/3/2017 1:17:04 PM,"UPDATE 1-Regeneron profit blows past estimates (REGN, SAN, BAYN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-profit-blows-past-estimates-2017-8,negative,0.7330462336540222
155,8/3/2017 1:47:52 PM,Regeneron Q2 Results Top Estimates; Lifts FY View For EYLEA U.S. Sales Growth ,RTTNews,/news/stocks/regeneron-q2-results-top-estimates-lifts-fy-view-for-eylea-u-s-sales-growth-1002230200,negative,0.9530289769172668
156,8/3/2017 2:22:00 PM,Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast,PR Newswire,/news/stocks/accessing-the-regeneron-second-quarter-2017-financial-and-operating-results-webcast-1002230406,positive,0.9417550563812256
157,8/3/2017 2:52:03 PM,"US STOCKS-Wall St set to open flat after Dow breaches 22,000 (AAPL, TSLA, AET, REGN, YUM)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-flat-after-dow-breaches-22000-2017-8,neutral,0.884993314743042
158,8/3/2017 3:13:11 PM,Regeneron Pharmaceuticals Profit Rises 48% In Q2,RTTNews,/news/stocks/regeneron-pharmaceuticals-profit-rises-48-in-q2-1002230713,negative,0.9408525228500366
159,8/3/2017 3:31:00 PM,"Options Trades for Allergan, 3D Systems, Regeneron Pharmaceuticals, Tesla Motors and Yelp include trade ideas that offer returns of 26% or more!",PR Newswire,/news/stocks/options-trades-for-allergan-3d-systems-regeneron-pharmaceuticals-tesla-motors-and-yelp-include-trade-ideas-that-offer-returns-of-26-or-more-1002230795,positive,0.5720552802085876
160,8/3/2017 3:42:05 PM,BRIEF-Regeneron says expects that Dupixent will have broad market access in the United States by the end of the year (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-says-expects-that-dupixent-will-have-broad-market-access-in-the-united-states-by-the-end-of-the-year-2017-8,negative,0.858282208442688
161,8/3/2017 4:02:03 PM,"US STOCKS-Wall St opens flat as tech stocks slip (AAPL, AMZN, TSLA, AET, REGN, YUM)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-opens-flat-as-tech-stocks-slip-2017-8,neutral,0.9684869647026062
162,8/14/2017 3:06:00 PM,Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus,PR Newswire,/news/stocks/regeneron-to-discontinue-development-of-suptavumab-for-respiratory-syncytial-virus-1002255470,positive,0.8088937401771545
163,8/14/2017 3:07:03 PM,"BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene (JPM, BIIB, CELG, AMGN, RDSA, REGN)",Reuters,http://www.businessinsider.com/r-brief-temasek-holdings-takes-stake-in-jpmorgan-biogen-celgene-2017-8,positive,0.9486983418464661
164,8/14/2017 3:19:55 PM,Regeneron To Discontinue Development Of Suptavumab For RSV; Stock Down ,RTTNews,/news/stocks/regeneron-to-discontinue-development-of-suptavumab-for-rsv-stock-down-1002255505,neutral,0.8832162022590637
165,8/14/2017 3:27:07 PM,BRIEF-Regeneron's drug for respiratory virus fails late-stage study (REGN),Reuters,http://www.businessinsider.com/r-brief-regenerons-drug-for-respiratory-virus-fails-late-stage-study-2017-8,positive,0.7797275185585022
166,8/14/2017 3:42:08 PM,Regeneron to abandon drug for common respiratory virus (REGN),Reuters,http://www.businessinsider.com/r-regeneron-to-abandon-drug-for-common-respiratory-virus-2017-8,positive,0.810515820980072
167,8/15/2017 7:37:49 AM,"FDA Lifts Hold On CVM's Study, FATE On Track, REGN, OPHT, ZYNE All Flunk Trials ",RTTNews,/news/stocks/fda-lifts-hold-on-cvm-s-study-fate-on-track-regn-opht-zyne-all-flunk-trials-1002257293,neutral,0.7555862069129944
168,8/23/2017 3:30:00 PM,ALM Intelligence Names KPMG a Global 'Leader' in Employee Experience Consulting,PR Newswire,/news/stocks/alm-intelligence-names-kpmg-a-global-leader-in-employee-experience-consulting-1001946212,negative,0.878972053527832
169,8/23/2017 4:00:00 PM,Luxe Interiors + Design Names New Group Publisher And Chief Revenue Officer,PR Newswire,/news/stocks/luxe-interiors-+-design-names-new-group-publisher-and-chief-revenue-officer-597897,positive,0.9304283261299133
170,8/25/2017 2:00:00 PM,Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-analyses-from-praluent-alirocumab-injection-trials-at-the-esc-congress-2017-1002285257,positive,0.8214299082756042
171,8/27/2017 11:27:08 AM,"Novartis hopeful for novel heart drug, despite 'modest' benefit (SAN, REGN)",Reuters,http://www.businessinsider.com/r-novartis-hopeful-for-novel-heart-drug-despite-modest-benefit-2017-8,negative,0.8072130680084229
172,8/27/2017 7:22:03 PM,"UPDATE 1-Novartis hopeful for novel heart drug, despite 'modest' benefit (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-novartis-hopeful-for-novel-heart-drug-despite-modest-benefit-2017-8,negative,0.939052939414978
173,8/28/2017 11:25:00 PM,Ellen L. Behrens is recognized by Continental Who's Who,PR Newswire,/news/stocks/ellen-l-behrens-is-recognized-by-continental-who-s-who-1001625163,positive,0.8096394538879395
174,8/31/2017 10:01:00 PM,Regeneron Announces Upcoming Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentations-1002299970,positive,0.9307904839515686
175,9/7/2017 12:02:03 PM,"Quest to offer cholesterol testing without fasting requirement (DGX, AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-quest-to-offer-cholesterol-testing-without-fasting-requirement-2017-9,positive,0.8487964868545532
176,9/8/2017 7:27:06 AM,"BRIEF-Sanofi, Regeneron say Cemiplimab receives U.S. FDA breakthrough designation for advanced cutaneous squamous cell carcinoma (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-regeneron-say-cemiplimab-receives-us-fda-breakthrough-designation-for-advanced-cutaneous-squamous-cell-carcinoma-2017-9,negative,0.9405420422554016
177,9/8/2017 9:02:03 AM,"Sanofi says Cemiplimab skin cancer treatment gets FDA ""Breakthrough Designation"" (SAN, REGN)",Reuters,http://www.businessinsider.com/r-sanofi-says-cemiplimab-skin-cancer-treatment-gets-fda-breakthrough-designation-2017-9,negative,0.9208695888519287
178,9/11/2017 7:00:00 AM,Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-phase-3-trial-in-uncontrolled-persistent-asthma-1001658411,negative,0.9329751133918762
179,9/11/2017 7:02:03 AM,"Swiss stocks - Factors to watch on Sept. 11 (ESUN, REGN)",Reuters,http://www.businessinsider.com/r-swiss-stocks---factors-to-watch-on-sept-11-2017-9,positive,0.9293955564498901
180,9/11/2017 7:16:09 AM,"Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial ",RTTNews,/news/stocks/sanofi-regeneron-dupilumab-meets-main-objectives-in-late-stage-asthma-trial-1002356442,negative,0.6017125248908997
181,9/11/2017 8:02:03 AM,"Sanofi and Regeneron announce positive dupilumab topline results (SAN, REGN)",Reuters,http://www.businessinsider.com/r-sanofi-and-regeneron-announce-positive-dupilumab-topline-results-2017-9,negative,0.7019816637039185
182,9/11/2017 8:02:03 AM,"BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-sanofi-announce-positive-dupilumab-topline-results-from-phase-3-trial-in-uncontrolled-persistent-asthma-2017-9,negative,0.9266754388809204
183,9/11/2017 9:02:03 AM,"UPDATE 1-Sanofi and Regeneron score asthma hit with dupilumab (SAN, REGN, GSK, AZN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-and-regeneron-score-asthma-hit-with-dupilumab-2017-9,negative,0.894376277923584
184,9/12/2017 3:00:00 PM,Companies to Watch as Biotech Makes a Comeback in 2017,PR Newswire,/news/stocks/companies-to-watch-as-biotech-makes-a-comeback-in-2017-1002362146,positive,0.7505437135696411
185,9/13/2017 2:00:00 PM,Smart Medical Device Could Save Millions of Lives,PR Newswire,/news/stocks/smart-medical-device-could-save-millions-of-lives-1002365845,positive,0.7441995143890381
186,9/14/2017 12:50:00 PM,"Stocks Under Scanner in the Biotech Space -- Puma Biotech, Regeneron Pharma, Sarepta Therapeutics, and Seattle Genetics",PR Newswire,/news/stocks/stocks-under-scanner-in-the-biotech-space-puma-biotech-regeneron-pharma-sarepta-therapeutics-and-seattle-genetics-1002369693,positive,0.8206456899642944
187,9/14/2017 3:02:03 PM,"Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9,positive,0.5306563377380371
188,9/14/2017 8:52:15 PM,"UPDATE 1-Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9,negative,0.9154360294342041
189,9/16/2017 8:15:00 AM,Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-atopic-dermatitis-686238,negative,0.9439195990562439
190,9/21/2017 4:00:00 PM,"ELOQUII Debuts Exclusive Capsule Collection With Digital Influencer & Style Expert, Katie Sturino",PR Newswire,/news/stocks/eloquii-debuts-exclusive-capsule-collection-with-digital-influencer-&-style-expert-katie-sturino-699465,positive,0.7769724726676941
191,9/22/2017 11:02:07 PM,"UPDATE 1-U.S. FDA declines to approve J&J arthritis drug (JNJ, SAN, REGN, LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-declines-to-approve-jj-arthritis-drug-2017-9,neutral,0.8860206604003906
192,9/28/2017 7:00:00 AM,Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-approval-of-dupixent-dupilumab-to-treat-adult-patients-with-moderate-to-severe-atopic-dermatitis-in-the-european-union-1002703993,negative,0.870101809501648
193,9/28/2017 7:07:03 AM,"EU approves Sanofi and Regeneron's dupilumab in eczema (REGN, SAN)",Reuters,http://www.businessinsider.com/r-eu-approves-sanofi-and-regenerons-dupilumab-in-eczema-2017-9,negative,0.74455326795578
194,9/28/2017 7:24:13 AM,"Sanofi, Regeneron: Dupixent Gets EU Approval To Treat Atopic Dermatitis ",RTTNews,/news/stocks/sanofi-regeneron-dupixent-gets-eu-approval-to-treat-atopic-dermatitis-1002705292,negative,0.9353379011154175
195,9/29/2017 6:22:03 PM,"US invests $170 million in late-stage Ebola vaccines, drugs (MRK, JNJ, REGN)",Reuters,http://www.businessinsider.com/r-us-invests-170-million-in-late-stage-ebola-vaccines-drugs-2017-9,positive,0.8104274272918701
196,10/2/2017 1:00:00 PM,"Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens",PR Newswire,/news/stocks/regeneron-announces-new-collaborations-with-hhs-to-develop-antibodies-against-ebola-influenza-and-multiple-other-emerging-pathogens-1002913600,negative,0.8881763219833374
197,10/2/2017 1:37:03 PM,"BRIEF-Regeneron Pharmaceuticals ‍announces new collaborations with HHS to develop antibodies against ebola, influenza, multiple other emerging pathogens​ (REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-announces-new-collaborations-with-hhs-to-develop-antibodies-against-ebola-influenza-multiple-other-emerging-pathogens-2017-10,negative,0.8988714218139648
198,10/3/2017 3:00:00 PM,VOXX International Corporation Sets Date For Its Fiscal 2018 Second Quarter Results And Conference Call,PR Newswire,/news/stocks/voxx-international-corporation-sets-date-for-its-fiscal-2018-second-quarter-results-and-conference-call-1001728458,positive,0.9096522331237793
199,10/5/2017 4:17:03 PM,"U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-us-court-reverses-ban-on-sales-of-sanofi-regeneron-drug-praluent-2017-10,neutral,0.881125271320343
200,10/5/2017 4:32:03 PM,"UPDATE 1-U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-us-court-reverses-ban-on-sales-of-sanofi-regeneron-drug-praluent-2017-10,neutral,0.8312585353851318
201,10/5/2017 6:30:00 PM,Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab),PR Newswire,/news/stocks/appellate-court-orders-a-new-trial-and-vacates-permanent-injunction-in-ongoing-patent-case-regarding-praluent-alirocumab-1003090534,neutral,0.8396028280258179
202,10/5/2017 6:52:03 PM,"BRIEF-U.S. Appellate Court rules Sanofi, Regeneron can continue manufacturing PRALUENT in U.S. (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-us-appellate-court-rules-sanofi-regeneron-can-continue-manufacturing-praluent-in-us-2017-10,positive,0.893231987953186
203,10/11/2017 2:00:00 PM,Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis,PR Newswire,/news/stocks/internationally-acclaimed-writer-and-executive-producer-of-hbo-s-the-night-of-reveals-his-personal-story-detailing-the-harsh-realities-of-atopic-dermatitis-1003817426,positive,0.8227223753929138
204,10/11/2017 3:30:00 PM,"Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017",PR Newswire,/news/stocks/regeneron-to-report-third-quarter-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-8-2017-1002076275,positive,0.9459673762321472
205,10/16/2017 2:00:00 PM,Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-phase-2-study-results-for-dupilumab-in-patients-with-active-moderate-to-severe-eosinophilic-esophagitis-1001763336,negative,0.9431818127632141
206,10/16/2017 2:07:14 PM,"BRIEF-Regeneron and Sanofi announce positive phase 2 study results for dupilumab (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-announce-positive-phase-2-study-results-for-dupilumab-2017-10,negative,0.9408230781555176
207,10/16/2017 2:15:48 PM,"Regeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab ",RTTNews,/news/stocks/regeneron-pharma-sanofi-announce-positive-phase-2-study-results-for-dupilumab-1004483604,negative,0.9473573565483093
208,10/16/2017 2:22:16 PM,"BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-aimmune-therapeutics-collaborates-to-study-ar101-with-regeneron-and-sanofis-dupilumab-for-peanut-allergy-2017-10,negative,0.7825889587402344
209,10/16/2017 2:27:07 PM,"Regeneron-Sanofi throat infection drug succeeds key study (REGN, SAN)",Reuters,http://www.businessinsider.com/r-regeneron-sanofi-throat-infection-drug-succeeds-key-study-2017-10,positive,0.5737907886505127
210,10/16/2017 2:57:08 PM,"UPDATE 1-Regeneron-Sanofi food allergy drug succeeds mid-stage study (REGN, SAN, GSK)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-sanofi-food-allergy-drug-succeeds-mid-stage-study-2017-10,positive,0.8199241757392883
211,10/16/2017 3:22:03 PM,"Aimmune teams with Regeneron, Sanofi on peanut allergy drug (REGN, SAN)",Reuters,http://www.businessinsider.com/r-aimmune-teams-with-regeneron-sanofi-on-peanut-allergy-drug-2017-10,positive,0.7304412722587585
212,10/19/2017 8:30:00 PM,Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time,PR Newswire,/news/stocks/science-magazine-ranks-regeneron-1-biopharma-employer-for-fifth-time-1001781784,negative,0.6254843473434448
213,10/23/2017 7:49:33 AM,"DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS ",RTTNews,/news/stocks/dbvt-disappoints-gsk-gets-greenlight-aimt-catches-eyes-fda-snubs-atrs-1005302979,neutral,0.37625858187675476
214,10/24/2017 5:15:00 PM,IT and Management Consulting Firm Enlightened Selects 5WPR as AOR to Increase Brand Awareness as it Expands into Commercial,PR Newswire,/news/stocks/it-and-management-consulting-firm-enlightened-selects-5wpr-as-aor-to-increase-brand-awareness-as-it-expands-into-commercial-1002116216,negative,0.7689255475997925
215,10/27/2017 1:00:00 PM,Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations,PR Newswire,/news/stocks/regenerons-first-global-day-of-service-supports-over-100-non-profit-and-community-organizations-452309,negative,0.6558541655540466
216,10/27/2017 10:18:00 PM,"Philip Sweet, M.S.N., R.N., PMHCNS-BC, NP is recognized by Continental Who's Who",PR Newswire,/news/stocks/philip-sweet-m-s-n-r-n-pmhcns-bc-np-is-recognized-by-continental-who-s-who-1001804634,positive,0.7983230948448181
217,10/31/2017 12:00:00 PM,"Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma",PR Newswire,/news/stocks/dupilumab-significantly-reduced-steroid-use-asthma-attacks-and-improved-lung-function-in-phase-3-study-of-people-with-severe-steroid-dependent-asthma-1006292862,negative,0.9450389742851257
218,10/31/2017 12:28:13 PM,Regeneron And Sanofi Say Phase 3 Study On Dupilumab Meets Primary Endpoint ,RTTNews,/news/stocks/regeneron-and-sanofi-say-phase-3-study-on-dupilumab-meets-primary-endpoint-1006294902,negative,0.7025919556617737
219,11/1/2017 2:00:00 PM,Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting,PR Newswire,/news/stocks/regeneron-to-share-clinical-progress-of-regn1979-and-cemiplimab-regn2810-in-b-cell-lymphomas-at-the-2017-ash-annual-meeting-1006450496,negative,0.5107358694076538
220,11/7/2017 2:00:00 PM,Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-analyses-from-the-praluent-alirocumab-injection-odyssey-clinical-trial-program-at-the-aha-scientific-sessions-2017-1007155974,positive,0.8361570239067078
221,11/7/2017 2:27:03 PM,BRIEF-Regeneron and Sanofi to present new analyses from Praluent injection Odyssey clinical trial (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-to-present-new-analyses-from-praluent-injection-odyssey-clinical-trial-2017-11,positive,0.8320541977882385
222,11/8/2017 12:30:00 PM,Regeneron Reports Third Quarter 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-third-quarter-2017-financial-and-operating-results-1007280932,positive,0.5258209109306335
223,11/8/2017 12:33:54 PM,Regeneron Pharmaceuticals Earnings Rise 29% In Q3,RTTNews,/news/stocks/regeneron-pharmaceuticals-earnings-rise-29-in-q3-1007280959,negative,0.9462440013885498
224,11/8/2017 12:47:03 PM,Drugmaker Regeneron's quarterly profit surges 47 pct (REGN),Reuters,http://www.businessinsider.com/r-drugmaker-regenerons-quarterly-profit-surges-47-pct-2017-11,negative,0.9280514717102051
225,11/8/2017 1:37:03 PM,"US STOCKS-Futures slightly lower as investors track progress on tax bill (TTWO, REGN, HUM)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-slightly-lower-as-investors-track-progress-on-tax-bill-2017-11,neutral,0.9454058408737183
226,11/8/2017 2:47:03 PM,"US STOCKS-Wall St set to open flat with tax bill debate in focus (TTWO, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-flat-with-tax-bill-debate-in-focus-2017-11,positive,0.5726409554481506
227,11/8/2017 4:12:03 PM,"US STOCKS-Wall Street edges lower as bank stocks weigh (GS, BAC, TTWO, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-edges-lower-as-bank-stocks-weigh-2017-11,neutral,0.9635385274887085
228,11/8/2017 5:42:05 PM,"US STOCKS-Wall Street loses steam as banks, energy stocks weigh (CVX, BAC, TTWO, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-loses-steam-as-banks-energy-stocks-weigh-2017-11,neutral,0.9456902146339417
229,11/10/2017 11:32:03 PM,"Novartis posts eye drug data amid play for Eylea's turf (BAYN, REGN, AGN)",Reuters,http://www.businessinsider.com/r-novartis-posts-eye-drug-data-amid-play-for-eyleas-turf-2017-11,positive,0.7729215025901794
230,11/13/2017 5:07:03 PM,"Nanotech, gene editing used to edit cholesterol gene-US study (REGN, AMGN)",Reuters,http://www.businessinsider.com/r-nanotech-gene-editing-used-to-edit-cholesterol-gene-us-study-2017-11,positive,0.9087387919425964
231,11/15/2017 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentation,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentation-1008143081,positive,0.9278927445411682
232,11/24/2017 6:39:00 PM,"RD Training Systems Is Coming to Salt Lake City, Utah in December 2017",PR Newswire,/news/stocks/rd-training-systems-is-coming-to-salt-lake-city-utah-in-december-2017-532201,positive,0.9463624954223633
233,11/27/2017 8:00:00 AM,Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program,PR Newswire,/news/stocks/regeneron-provides-update-on-eylea-aflibercept-injection-and-nesvacumab-ang2-antibody-combination-program-1001895227,positive,0.9048569798469543
234,11/27/2017 8:13:13 AM,Regeneron Updates On EYLEA Injection And Nesvacumab Combination Program ,RTTNews,/news/stocks/regeneron-updates-on-eylea-injection-and-nesvacumab-combination-program-1009645601,positive,0.852635383605957
235,11/27/2017 9:02:04 AM,BRIEF-Regeneron Provides Update On Eylea (Aflibercept) Injection And Nesvacumab (Ang2 Antibody) Combination Program (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-provides-update-on-eylea-aflibercept-injection-and-nesvacumab-ang2-antibody-combination-program-2017-11,positive,0.9004461765289307
236,11/27/2017 1:22:04 PM,"Regeneron drops eye-drug combination as Novartis chases Eylea (REGN, BAYN)",Reuters,http://www.businessinsider.com/r-regeneron-drops-eye-drug-combination-as-novartis-chases-eylea-2017-11,positive,0.9242584705352783
237,11/28/2017 7:18:22 AM,"BIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises ",RTTNews,/news/stocks/biib-alks-team-up-for-ms-drug-regn-s-eylea-combo-fails-again-aezs-rises-1009751989,negative,0.4418783485889435
238,11/29/2017 1:00:00 PM,Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus,PR Newswire,/news/stocks/regeneron-and-decibel-therapeutics-announce-strategic-collaboration-to-discover-and-develop-therapeutics-for-hearing-loss-and-tinnitus-1009916181,negative,0.9037929177284241
239,11/29/2017 1:09:37 PM,"Regeneron Pharma, Decibel Announce Collaboration - Quick Facts ",RTTNews,/news/stocks/regeneron-pharma-decibel-announce-collaboration-quick-facts-1009916246,positive,0.7903158664703369
240,11/29/2017 1:12:06 PM,BRIEF-Regeneron And Decibel Therapeutics Announce Strategic Collaboration (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-decibel-therapeutics-announce-strategic-collaboration-2017-11,positive,0.6128681898117065
241,11/30/2017 7:33:21 AM,"TXMD Giving A 2nd Try, PLX On Watch, NAOV's Shield Against Suicide Disease ",RTTNews,/news/stocks/txmd-giving-a-2nd-try-plx-on-watch-naov-s-shield-against-suicide-disease-1010019422,positive,0.720712423324585
242,12/6/2017 9:52:03 PM,"FACBOX-Corporate alternative minimum tax threat hits pharma, tech (BA, VRTX, INCY, REGN, CDNS, CELG, ADSK)",Reuters,http://www.businessinsider.com/r-facbox-corporate-alternative-minimum-tax-threat-hits-pharma-tech-2017-12,neutral,0.796172022819519
243,12/10/2017 12:15:24 PM,Repatha & Praluent: A Tale Of Two Rivals... ,RTTNews,/news/stocks/repatha-praluent-a-tale-of-two-rivals-1010812436,positive,0.860059916973114
244,12/11/2017 1:00:00 PM,Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD,PR Newswire,/news/stocks/regeneron-announces-fda-acceptance-of-sbla-filing-for-12-week-dosing-of-eylea-aflibercept-injection-for-patients-with-wet-amd-580111,negative,0.8866823315620422
245,12/11/2017 1:20:21 PM,Regeneron Says FDA Accepts SBLA Filing For 12-week Dosing Of Eylea Injection ,RTTNews,/news/stocks/regeneron-says-fda-accepts-sbla-filing-for-12-week-dosing-of-eylea-injection-1010934782,positive,0.7732130885124207
246,12/11/2017 1:22:04 PM,BRIEF-Regeneron Announces FDA Acceptance Of SBLA Filing For 12-Week Dosing Of Eylea(Aflibercept) Injection For Patients With Wet AMD (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-announces-fda-acceptance-of-sbla-filing-for-12-week-dosing-of-eyleaaflibercept-injection-for-patients-with-wet-amd-2017-12,negative,0.8882895708084106
247,12/13/2017 7:01:00 AM,Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-topline-pivotal-results-for-pd-1-antibody-cemiplimab-in-advanced-cutaneous-squamous-cell-carcinoma-591108,negative,0.9468396306037903
248,12/13/2017 7:07:41 AM,"Regeneron, Sanofi Report Results For PD-1 Antibody Cemiplimab In Advanced CSCC ",RTTNews,/news/stocks/regeneron-sanofi-report-results-for-pd-1-antibody-cemiplimab-in-advanced-cscc-1011193237,positive,0.6889569759368896
249,12/13/2017 7:30:00 AM,Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day,PR Newswire,/news/stocks/regeneron-collaboration-programs-highlighted-during-sanofi-analyst-day-1002269745,positive,0.8380338549613953
250,12/18/2017 7:00:00 AM,Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration,PR Newswire,/news/stocks/regeneron-and-isa-pharmaceuticals-announce-strategic-immuno-oncology-collaboration-1011613434,positive,0.8622573614120483
251,12/18/2017 7:12:19 AM,"Regeneron, ISA Pharma Announce Strategic Immuno-Oncology Collaboration ",RTTNews,/news/stocks/regeneron-isa-pharma-announce-strategic-immuno-oncology-collaboration-1011613496,positive,0.752008318901062
252,12/18/2017 7:22:03 AM,BRIEF-Regeneron And Isa Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-isa-pharmaceuticals-announce-strategic-immuno-oncology-collaboration-2017-12,negative,0.7922095060348511
253,12/21/2017 1:00:00 PM,Vertek Corporation Partners With VeloCloud to Provide Remote Management & Monitoring (RMM) and Helpdesk Services,PR Newswire,/news/stocks/vertek-corporation-partners-with-velocloud-to-provide-remote-management-&-monitoring-rmm-and-helpdesk-services-622379,negative,0.5214983224868774
254,1/8/2018 1:00:00 PM,Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank,PR Newswire,/news/stocks/regeneron-forms-consortium-of-leading-life-sciences-companies-to-accelerate-largest-widely-available-big-data-human-sequencing-resource-with-uk-biobank-1012660493,negative,0.8622167110443115
255,1/8/2018 1:04:00 PM,Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs,PR Newswire,/news/stocks/regeneron-and-sanofi-to-accelerate-and-expand-investment-for-cemiplimab-and-dupilumab-development-programs-1001652118,negative,0.8926284313201904
256,1/8/2018 1:20:10 PM,"Sanofi, Regeneron To Expand Investment For Cemiplimab & Dupilumab Development ",RTTNews,/news/stocks/sanofi-regeneron-to-expand-investment-for-cemiplimab-dupilumab-development-1012660974,negative,0.8295914530754089
257,1/8/2018 3:00:00 PM,Infor Releases New Digital Innovation Enabler for Healthcare Industry,PR Newswire,/news/stocks/infor-releases-new-digital-innovation-enabler-for-healthcare-industry-1001647250,positive,0.6637569665908813
258,1/22/2018 1:00:00 PM,Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis,PR Newswire,/news/stocks/regeneron-announces-approval-of-dupixent-dupilumab-in-japan-for-the-treatment-of-atopic-dermatitis-685405,negative,0.8263186812400818
259,1/22/2018 1:12:14 PM,Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts ,RTTNews,/news/stocks/regeneron-announces-approval-of-dupixent-in-japan-quick-facts-1013586639,positive,0.7268608808517456
260,1/23/2018 6:01:00 PM,Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018,PR Newswire,/news/stocks/forty-of-the-nation-s-most-promising-young-scientists-named-finalists-in-regeneron-science-talent-search-2018-1001688777,negative,0.797315239906311
261,1/23/2018 6:01:00 PM,Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018,PR Newswire,/news/stocks/forty-of-the-nation-s-most-promising-young-scientists-named-finalists-in-regeneron-science-talent-search-2018-1001690637,negative,0.797315239906311
262,1/23/2018 10:05:00 PM,"Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018",PR Newswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-8-2018-1013759756,positive,0.9482064247131348
263,1/26/2018 3:00:00 PM,James Flicker Joins Sagent Advisors as a Managing Director and Head of Paper & Forest Products,PR Newswire,/news/stocks/james-flicker-joins-sagent-advisors-as-a-managing-director-and-head-of-paper-&-forest-products-708621,positive,0.9365196824073792
264,1/30/2018 4:07:00 PM,"Camp Bow Wow Showcases Impressive Start to 2018, Ranking #1 in Pet Care on Entrepreneur's Franchise 500 List and More",PR Newswire,/news/stocks/camp-bow-wow-showcases-impressive-start-to-2018-ranking-1-in-pet-care-on-entrepreneur-s-franchise-500-list-and-more-1001708290,negative,0.9369380474090576
265,2/6/2018 3:00:00 PM,New Molecular Test to Impact Influenza Pandemic Preparedness,PR Newswire,/news/stocks/new-molecular-test-to-impact-influenza-pandemic-preparedness-1002065833,positive,0.7669873237609863
266,2/8/2018 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2017-financial-and-operating-results-1015114058,positive,0.7374624013900757
267,2/8/2018 12:34:55 PM,Regeneron Pharmaceuticals Q4 Income Rises,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-income-rises-1015114084,negative,0.8306834697723389
268,2/12/2018 1:00:00 PM,Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial,PR Newswire,/news/stocks/regeneron-announces-appointment-of-marion-mccourt-as-senior-vice-president-and-head-of-commercial-1015506141,positive,0.933435320854187
269,3/2/2018 7:00:00 AM,FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma,PR Newswire,/news/stocks/fda-to-review-dupixent-dupilumab-as-potential-treatment-for-moderate-to-severe-asthma-456214,negative,0.8001933097839355
270,3/2/2018 7:11:18 AM,Sanofi:FDA Reviews DUPIXENT As Potential Treatment For Moderate-to-Severe Asthma ,RTTNews,/news/stocks/sanofi-fda-reviews-dupixent-as-potential-treatment-for-moderate-to-severe-asthma-1017661658,negative,0.680436909198761
271,3/4/2018 3:19:34 AM,An Ear To The Pharma: 7 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-7-stocks-to-watch-this-week-1017867022,positive,0.9022789001464844
272,3/10/2018 3:00:00 PM,"Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate",PR Newswire,/news/stocks/praluent-alirocumab-injection-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate-1018611949,negative,0.9353993535041809
273,3/10/2018 3:00:00 PM,"Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate",PR Newswire,/news/stocks/praluent-alirocumab-injection-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate-1018611950,negative,0.9353993535041809
274,3/10/2018 3:02:00 PM,Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-plans-to-make-praluent-alirocumab-more-accessible-and-affordable-for-patients-with-the-greatest-health-risk-and-unmet-need-1018611961,negative,0.8630335927009583
275,3/10/2018 3:02:00 PM,Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need,PR Newswire,/news/stocks/sanofi-and-regeneron-announce-plans-to-make-praluent-more-accessible-and-affordable-for-patients-with-the-greatest-health-risk-and-unmet-need-1018611960,negative,0.8361881971359253
276,3/10/2018 6:37:48 PM,"Regeneron, Sanofi To Cut Heart Drug's Price; Say Praluent Lowers Risk Of Death ",RTTNews,/news/stocks/regeneron-sanofi-to-cut-heart-drug-s-price-say-praluent-lowers-risk-of-death-1018612085,negative,0.7880964279174805
277,3/11/2018 6:22:03 AM,An Ear To The Pharma: 4 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-4-stocks-to-watch-this-week-1018612558,positive,0.8958630561828613
278,3/12/2018 5:30:17 AM,"SVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch ",RTTNews,/news/stocks/svra-disappoints-sny-regn-s-praluent-price-to-be-cut-obsv-on-watch-1018614563,neutral,0.9278159737586975
279,3/14/2018 2:29:00 AM,"Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease",PR Newswire,/news/stocks/teen-scientists-win-$1-8-million-at-regeneron-science-talent-search-2018-with-top-awards-for-novel-research-on-crop-blight-vaping-and-rare-disease-477879,negative,0.8759743571281433
280,3/19/2018 12:00:00 PM,EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial,PR Newswire,/news/stocks/eylea-aflibercept-injection-demonstrates-positive-topline-results-in-phase-3-non-proliferative-diabetic-retinopathy-trial-1018915518,negative,0.9522660970687866
281,3/19/2018 12:18:07 PM,Regeneron Reports Positive Results From Phase 3 PANORAMA Trial With EYLEA ,RTTNews,/news/stocks/regeneron-reports-positive-results-from-phase-3-panorama-trial-with-eylea-1018915715,negative,0.9512105584144592
282,3/21/2018 10:05:00 PM,Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease,PR Newswire,/news/stocks/regeneron-genetics-center-publication-in-new-england-journal-of-medicine-identifies-new-genetic-variant-providing-protection-from-chronic-liver-disease-1002184113,negative,0.5914717316627502
283,3/21/2018 10:06:00 PM,Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH),PR Newswire,/news/stocks/regeneron-and-alnylam-pharmaceuticals-announce-collaboration-to-discover-new-treatments-for-nonalcoholic-steatohepatitis-nash-503462,negative,0.8973228335380554
284,3/22/2018 7:35:17 AM,"FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY Team Up For NASH ",RTTNews,/news/stocks/fenc-on-fast-track-sphs-to-report-data-in-q2-regn-alny-team-up-for-nash-1019042163,positive,0.6094775795936584
285,4/3/2018 1:56:00 AM,Caroline S. Koblenzer is recognized by Continental Who's Who,PR Newswire,/news/stocks/caroline-s-koblenzer-is-recognized-by-continental-who-s-who-1001902146,positive,0.7406600713729858
286,4/3/2018 7:00:00 AM,EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/ema-to-review-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-1020310476,positive,0.6522125601768494
287,4/3/2018 7:01:00 AM,EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma,PR Newswire,/news/stocks/ema-to-review-dupixent-dupilumab-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma-1001896116,negative,0.6541644334793091
288,4/3/2018 7:12:54 AM,Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN ,RTTNews,/news/stocks/regeneron-and-sanofi-say-ema-accepts-for-review-application-for-dupixen-1020311193,positive,0.797309935092926
289,4/6/2018 9:00:00 PM,American Financial Benefits Center on Debt-Free College and Existing Repayment Options,PR Newswire,/news/stocks/american-financial-benefits-center-on-debt-free-college-and-existing-repayment-options-551705,positive,0.862444281578064
290,4/9/2018 3:30:00 PM,"Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018",PR Newswire,/news/stocks/regeneron-to-report-first-quarter-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-3-2018-1002237220,positive,0.9494761228561401
291,4/18/2018 2:30:00 PM,ARTiFACTS and Blockchain in Healthcare Today Partner to Expand Use of Blockchain in Scholarly Publishing,PR Newswire,/news/stocks/artifacts-and-blockchain-in-healthcare-today-partner-to-expand-use-of-blockchain-in-scholarly-publishing-1001940323,negative,0.7914244532585144
292,4/23/2018 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentations-1022000366,positive,0.9307904839515686
293,4/30/2018 7:00:00 AM,FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-1022853370,positive,0.6954172253608704
294,4/30/2018 7:00:00 AM,FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-1001643607,positive,0.6954172253608704
295,4/30/2018 7:11:20 AM,Regeneron And Sanofi Say FDA Accepts Priority Review BLA For Cemiplimab ,RTTNews,/news/stocks/regeneron-and-sanofi-say-fda-accepts-priority-review-bla-for-cemiplimab-1022854358,positive,0.5524543523788452
296,5/1/2018 7:42:04 AM,"INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM ",RTTNews,/news/stocks/ingn-soars-on-revised-outlook-mrk-faces-fda-in-sep-kpti-taken-by-storm-1022974414,neutral,0.7852576375007629
297,5/1/2018 12:59:00 PM,"Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients",PR Newswire,/news/stocks/regeneron-and-sanofi-to-lower-net-price-of-praluent-alirocumab-injection-in-exchange-for-straightforward-more-affordable-patient-access-for-express-scripts-patients-1001984218,negative,0.9117923378944397
298,5/1/2018 1:00:00 PM,"Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients",PR Newswire,/news/stocks/sanofi-and-regeneron-to-lower-net-price-of-praluent-alirocumab-injection-in-exchange-for-straightforward-more-affordable-patient-access-for-express-scripts-patients-1023001115,negative,0.9070112705230713
299,5/1/2018 1:58:11 PM,"Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts ",RTTNews,/news/stocks/sanofi-renegeron-to-lower-net-price-of-praluent-injection-quick-facts-1023005511,positive,0.5260782837867737
300,5/1/2018 2:00:00 PM,2018 Global Channel Report Reveals Clients Attacked Mostly Through Privileged Accounts,PR Newswire,/news/stocks/2018-global-channel-report-reveals-clients-attacked-mostly-through-privileged-accounts-1001625879,neutral,0.8342353105545044
301,5/2/2018 2:30:00 PM,DocPanel Announces Partnership with the University of Southern California Keck School of Medicine,PR Newswire,/news/stocks/docpanel-announces-partnership-with-the-university-of-southern-california-keck-school-of-medicine-646736,negative,0.7558634877204895
302,5/3/2018 12:30:00 PM,Regeneron Reports First Quarter 2018 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-first-quarter-2018-financial-and-operating-results-1023252250,positive,0.6613007187843323
303,5/3/2018 12:39:53 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-beat-estimates-1023252295,negative,0.9073371887207031
304,5/16/2018 7:01:00 AM,Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/positive-phase-3-trial-of-dupixent-dupilumab-in-adolescents-with-inadequately-controlled-moderate-to-severe-atopic-dermatitis-1024657017,negative,0.8290612101554871
305,5/16/2018 7:26:30 AM,"Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints ",RTTNews,/news/stocks/regeneron-sanofi-phase-3-dupixent-trial-meets-primary-key-secondary-endpoints-1024658863,negative,0.7818983197212219
306,5/16/2018 2:00:00 PM,Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis,PR Newswire,/news/stocks/dupixent-dupilumab-showed-positive-phase-3-results-in-adolescents-with-inadequately-controlled-moderate-to-severe-atopic-dermatitis-1024695853,negative,0.9401759505271912
307,5/16/2018 11:00:00 PM,Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO,PR Newswire,/news/stocks/regeneron-and-sanofi-share-first-positive-clinical-data-for-cemiplimab-in-advanced-non-small-cell-lung-cancer-at-asco-1024752454,negative,0.9028035998344421
308,5/18/2018 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentation,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentation-1024989217,positive,0.9278927445411682
309,5/21/2018 8:14:00 PM,New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-two-positive-phase-3-trials-showing-dupixent-dupilumab-improved-moderate-to-severe-asthma-1001713899,negative,0.9471136331558228
310,5/21/2018 8:15:00 PM,New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-two-positive-phase-3-trials-showing-dupixent-dupilumab-improved-moderate-to-severe-asthma-1025069745,negative,0.9471136331558228
311,5/31/2018 10:05:00 PM,Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak,PR Newswire,/news/stocks/regeneron-s-investigational-ebola-treatment-shipping-to-democratic-republic-of-the-congo-for-use-in-current-outbreak-1026022169,positive,0.6659008264541626
312,6/4/2018 8:15:00 PM,New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-pivotal-cemiplimab-trials-showing-positive-results-in-advanced-cutaneous-squamous-cell-carcinoma-1026470521,negative,0.8998870849609375
313,6/4/2018 8:15:00 PM,New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-pivotal-cemiplimab-trials-showing-positive-results-in-advanced-cutaneous-squamous-cell-carcinoma-1026470520,negative,0.8998870849609375
314,6/6/2018 1:00:00 PM,Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health,PR Newswire,/news/stocks/regeneron-and-zoetis-announce-collaboration-to-research-antibody-therapies-for-use-in-animal-health-1026693979,negative,0.77091383934021
315,6/6/2018 1:09:02 PM,"Regeneron, Zoetis Announce Research Collaboration - Quick Facts ",RTTNews,/news/stocks/regeneron-zoetis-announce-research-collaboration-quick-facts-1026694055,positive,0.8251034617424011
316,7/26/2018 9:39:05 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1027401882,positive,0.6419674754142761
317,7/31/2018 3:02:52 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-q2-earnings-preview-1027416458,positive,0.9262580871582031
318,8/2/2018 12:47:42 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1027425433,negative,0.89817875623703
319,8/2/2018 9:45:08 PM,Regeneron Showing Strong Move To The Upside ,RTTNews,/news/stocks/regeneron-showing-strong-move-to-the-upside-1027427549,negative,0.9432446956634521
320,8/4/2018 7:40:57 AM,"Week Ahead In Pharmaceuticals - 10 Stocks To Watch (ALNY, INSM, PRTK...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-10-stocks-to-watch-alny-insm-prtk-1027430855,positive,0.8669117093086243
321,8/6/2018 1:01:48 PM,"Regeneron, Bluebird Bio Announce Collaboration - Quick Facts ",RTTNews,/news/stocks/regeneron-bluebird-bio-announce-collaboration-quick-facts-1027433517,positive,0.894691526889801
322,8/11/2018 5:17:06 AM,"Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-5-stocks-to-watch-regn-pfe-alt-1027451315,positive,0.8848251700401306
323,8/13/2018 1:15:09 PM,Regeneron Pharma: FDA Issues Response Letter On SBLA For EYLEA - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-fda-issues-response-letter-on-sbla-for-eylea-quick-facts-1027453132,positive,0.5208801627159119
324,8/14/2018 9:44:04 AM,"MBIO & Bubble Boy Disease Gene Therapy, Busy Months Ahead For EIGR, UMRX ",RTTNews,/news/stocks/mbio-bubble-boy-disease-gene-therapy-busy-months-ahead-for-eigr-umrx-1027456018,positive,0.8245394825935364
325,8/16/2018 1:11:07 PM,Teva And Regeneron Announce Positive Phase 3 Fasinumab Results ,RTTNews,/news/stocks/teva-and-regeneron-announce-positive-phase-3-fasinumab-results-1027463949,negative,0.9084187746047974
326,8/17/2018 1:11:36 PM,Regeneron Pharma: FDA Okays EYLEA Injection SBLA In Wet AMD ,RTTNews,/news/stocks/regeneron-pharma-fda-okays-eylea-injection-sbla-in-wet-amd-1027467004,positive,0.834254801273346
327,8/19/2018 3:08:54 AM,"Week Ahead In Pharmaceuticals: 7 Stocks To Watch (TNXP, REGN, KALA...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-7-stocks-to-watch-tnxp-regn-kala-1027468476,positive,0.8715310096740723
328,9/12/2018 8:28:34 AM,"FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. ",RTTNews,/news/stocks/fomx-soars-on-acne-trial-data-glpg-abuzz-acrx-to-face-fda-panel-in-oct-1027526604,negative,0.711442232131958
329,9/12/2018 2:18:04 PM,Sanofi And Regeneron : FDA To Review SBLA For Praluent Injection ,RTTNews,/news/stocks/sanofi-and-regeneron-fda-to-review-sbla-for-praluent-injection-1027527994,positive,0.6969628930091858
330,9/13/2018 9:19:01 AM,"ADIL On Track, PGNX Slumps On Phase III Study Failure, VNDA On Watch ",RTTNews,/news/stocks/adil-on-track-pgnx-slumps-on-phase-iii-study-failure-vnda-on-watch-1027530783,neutral,0.913497269153595
331,9/28/2018 11:42:28 AM,Biotech Stocks Facing FDA Decision In October ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-1027574035,positive,0.635016918182373
332,9/28/2018 11:45:03 PM,"The FDA just approved a new treatment for a common form of skin cancer (REGN, SNY)",Business Insider,https://www.businessinsider.com/fda-approves-regeneron-and-sanofis-cancer-immunotherapy-libtayo-2018-9,negative,0.7839807271957397
333,10/16/2018 7:20:13 AM,Regeneron : Dupixent Shows Positive Results In Two Phase 3 Trials On CRSwNP ,RTTNews,/news/stocks/regeneron-dupixent-shows-positive-results-in-two-phase-3-trials-on-crswnp-1027619003,negative,0.9543068408966064
334,10/22/2018 5:43:33 AM,"FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch ",RTTNews,/news/stocks/fda-extends-date-on-bmy-s-sbla-genmab-meets-phase-3-goals-ncna-lptx-on-watch-1027636442,positive,0.8459467887878418
335,10/22/2018 1:21:44 PM,Regeneron Pharma: FDA Approves Asthma Indication For Dupixent - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-fda-approves-asthma-indication-for-dupixent-quick-facts-1027638313,negative,0.7889692187309265
336,10/25/2018 3:23:10 PM,"Regeneron: Eylea Phase 3 Panorama Trial Meets Primary, Secondary Endpoints ",RTTNews,/news/stocks/regeneron-eylea-phase-3-panorama-trial-meets-primary-secondary-endpoints-1027655401,positive,0.8720622062683105
337,11/4/2018 3:01:58 PM,Regeneron Pharmaceuticals is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-q3-earnings-preview-stock-1027687795,positive,0.9319632053375244
338,11/6/2018 7:12:17 AM,Regeneron : FDA Grants Priority Review For Dupixent ,RTTNews,/news/stocks/regeneron-fda-grants-priority-review-for-dupixent-1027694409,negative,0.5333462953567505
339,11/6/2018 12:47:37 PM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1027695820,negative,0.8955163359642029
340,1/4/2019 7:57:12 PM,Regeneron Posting Strong Gain On Upgrade By Guggenheim ,RTTNews,/news/stocks/regeneron-posting-strong-gain-on-upgrade-by-guggenheim-1027845090,negative,0.9473956823348999
341,1/7/2019 8:49:38 AM,"Regeneron, Sanofi Select Two Clinical-stage Antibodies For Ongoing Collaboration ",RTTNews,/news/stocks/regeneron-sanofi-select-two-clinical-stage-antibodies-for-ongoing-collaboration-1027846398,positive,0.5348237156867981
342,2/4/2019 3:02:00 PM,Here's what to expect from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-q4-earnings-preview-stock-1027920990,positive,0.9423273801803589
343,2/6/2019 12:36:34 PM,Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-1027929008,negative,0.9092124104499817
344,2/11/2019 1:37:06 PM,"Sanofi, Regeneron Offer Praluent At 60% Reduced U.S. List Price - Quick Facts ",RTTNews,/news/stocks/sanofi-regeneron-offer-praluent-at-60-reduced-u-s-list-price-quick-facts-1027940708,negative,0.5502196550369263
345,2/25/2019 11:13:40 PM,Amgen: Delaware Jury Upholds Validity Of Two Patents Related To PCSK9 Antibodies ,RTTNews,/news/stocks/amgen-delaware-jury-upholds-validity-of-two-patents-related-to-pcsk9-antibodies-1027981762,neutral,0.8669329285621643
346,2/27/2019 4:51:26 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1027987182,positive,0.7348417639732361
347,3/1/2019 2:43:22 PM,Regeneron Says CHMP Recommends Approval Of Dupixent For Asthma Indication ,RTTNews,/news/stocks/regeneron-says-chmp-recommends-approval-of-dupixent-for-asthma-indication-1027997025,positive,0.6333283185958862
348,3/8/2019 7:06:22 AM,Regeneron And Sanofi Say FDA Accept For Priority Review SBLA For Dupixent ,RTTNews,/news/stocks/regeneron-and-sanofi-say-fda-accept-for-priority-review-sbla-for-dupixent-1028014468,positive,0.6410016417503357
349,3/26/2019 12:16:18 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1028058579,positive,0.7716754078865051
350,4/8/2019 1:21:56 PM,Regeneron To Invest $800 Mln In Alnylam; To Jointly Develop RNAi Therapeutics ,RTTNews,/news/stocks/regeneron-to-invest-800-mln-in-alnylam-to-jointly-develop-rnai-therapeutics-1028092345,negative,0.6548765897750854
351,4/26/2019 9:15:22 AM,Biotech Stocks Facing FDA Decision In May 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2019-1028141774,positive,0.8594977855682373
352,4/29/2019 6:52:49 AM,"Sanofi: FDA Approves Praluent To Prevent Heart Attack, Stroke, Unstable Angina ",RTTNews,/news/stocks/sanofi-fda-approves-praluent-to-prevent-heart-attack-stroke-unstable-angina-1028146213,negative,0.938150942325592
353,5/5/2019 3:01:51 PM,Here's what Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q1-1028168249,positive,0.9321866631507874
354,5/7/2019 12:37:34 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Miss Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-miss-estimates-1028175571,neutral,0.9388075470924377
355,5/7/2019 3:21:59 PM,Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU ,RTTNews,/news/stocks/regeneron-sanofi-dupixent-approved-for-severe-asthma-indication-in-eu-1028177243,negative,0.690893828868866
356,5/25/2019 5:16:57 AM,Biotech Stocks Facing FDA Decision In June 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2019-1028230263,positive,0.8650785684585571
357,6/14/2019 1:35:09 PM,Regeneron Announces Positive Early-stage Data For REGN1979 - Quick Facts ,RTTNews,/news/stocks/regeneron-announces-positive-early-stage-data-for-regn1979-quick-facts-1028280099,negative,0.9158270955085754
358,6/21/2019 7:20:10 AM,Regeneron Pharma: REGN3500 Meets Primary Endpoint In Phase 2 Study ,RTTNews,/news/stocks/regeneron-pharma-regn3500-meets-primary-endpoint-in-phase-2-study-1028297034,positive,0.8245517611503601
359,6/26/2019 8:46:45 PM,"Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?",InvestorPlace,/news/stocks/nasdaq-today-semis-rally-micron-earnings-suing-fb-and-googl-1028311984,neutral,0.8470374941825867
360,6/28/2019 1:11:07 PM,Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-chmp-adopts-positive-opinion-for-dupixent-quick-facts-1028316892,negative,0.9386268854141235
361,7/1/2019 4:25:39 PM,Sanofi : EU Okays Libtayo For Advanced Cutaneous Squamous Cell Carcinoma ,RTTNews,/news/stocks/sanofi-eu-okays-libtayo-for-advanced-cutaneous-squamous-cell-carcinoma-1028321728,positive,0.8034136891365051
362,7/11/2019 8:54:32 PM,Nasdaq Today: Biotech Wrecked; Buy Microsoft? ,InvestorPlace,/news/stocks/nasdaq-today-biotech-wrecked-buy-microsoft-1028347970,positive,0.9275436997413635
363,7/26/2019 4:04:19 PM,4 Biotech Stocks Sliding Lower,InvestorPlace,/news/stocks/4-biotech-stocks-sliding-lower-1028389963,neutral,0.9591169953346252
364,8/4/2019 3:01:57 PM,Regeneron Pharmaceuticals earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-price-q2-earnings-preview-1028414530,positive,0.9300113916397095
365,8/6/2019 7:24:29 AM,Sanofi:EU Oks Dupixent For Adolescents With Moderate-to-Severe Atopic Dermatitis ,RTTNews,/news/stocks/sanofi-eu-oks-dupixent-for-adolescents-with-moderate-to-severe-atopic-dermatitis-1028420195,positive,0.8040934801101685
366,8/6/2019 8:36:23 AM,"ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN ",RTTNews,/news/stocks/alny-to-face-fda-in-feb-podd-ups-outlook-again-catalysts-galore-for-xlrn-1028420401,negative,0.8857188820838928
367,8/6/2019 12:33:34 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1028421037,negative,0.89817875623703
368,8/13/2019 1:14:43 PM,FDA Approves Regeneron's EYLEA Injection Prefilled Syringe - Quick Facts ,RTTNews,/news/stocks/fda-approves-regeneron-s-eylea-injection-prefilled-syringe-quick-facts-1028441359,negative,0.6785690188407898
369,8/14/2019 1:25:24 PM,Regeneron Pharma Reports Positive Phase 3 Results For Evinacumab - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-reports-positive-phase-3-results-for-evinacumab-quick-facts-1028445322,negative,0.9472984075546265
370,8/20/2019 5:06:30 PM,8 Biotech Stocks to Watch After the Q2 Earnings Season,InvestorPlace,/news/stocks/8-biotech-stocks-to-watch-after-the-q2-earnings-season-1028461460,positive,0.9249446392059326
371,9/14/2019 10:31:25 AM,"3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector",InvestorPlace,/news/stocks/3-biotech-stocks-that-show-the-good-the-bad-and-the-ugly-side-of-this-sector-1028524601,positive,0.9101839065551758
372,9/20/2019 1:17:57 PM,Regeneron And Sanofi Say CHMP Adopts Positive Opinion For Dupixent ,RTTNews,/news/stocks/regeneron-and-sanofi-say-chmp-adopts-positive-opinion-for-dupixent-1028540621,negative,0.8888790011405945
373,9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645,positive,0.9301358461380005
374,10/3/2019 7:02:17 PM,3 Cancer-Fighting Drug Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-cancer-fighting-drug-stocks-to-buy-right-now-1028575928,positive,0.9171133041381836
375,10/14/2019 3:46:28 PM,3 Undervalued Stocks to Buy According to Goldman Sachs,InvestorPlace,/news/stocks/undervalued-stocks-to-buy-goldman-sachs-1028597934,positive,0.531609833240509
376,10/29/2019 2:13:11 PM,"Regeneron, Sanofi: European Commission Approves New Indication For Dupixent ",RTTNews,/news/stocks/regeneron-sanofi-european-commission-approves-new-indication-for-dupixent-1028639652,negative,0.7073976993560791
377,11/5/2019 12:36:14 PM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1028659131,negative,0.8955163359642029
378,11/5/2019 12:40:08 PM,Regeneron Pharmaceuticals Board Approves $1 Bln Share Buyback - Quick Facts ,RTTNews,/news/stocks/regeneron-pharmaceuticals-board-approves-1-bln-share-buyback-quick-facts-1028659129,positive,0.6611244678497314
379,11/5/2019 12:40:55 PM,Why This Just Might Be the Biggest Week for CARA Stock,InvestorPlace,/news/stocks/biggest-week-cara-stock-1028659655,positive,0.5292770862579346
380,11/5/2019 8:27:04 PM,Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat,InvestorPlace,/news/stocks/regeneron-pharmaceuticals-earnings-send-regn-stock-soaring-1028661895,negative,0.8826191425323486
381,11/6/2019 1:46:19 PM,"Regeneron, Vyriad To Collaborate On New Oncolytic Virus Treatments For Cancer ",RTTNews,/news/stocks/regeneron-vyriad-to-collaborate-on-new-oncolytic-virus-treatments-for-cancer-1028664311,negative,0.7869879007339478
382,11/7/2019 12:19:09 PM,"3 Big Stock Charts for Thursday: Kraft Heinz, Wabtec, and Regeneron Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-kraft-heinz-wabtec-and-regeneron-pharmaceuticals-1028669126,positive,0.9232885241508484
383,11/7/2019 9:25:33 PM,"Stock Market Today: Record Highs for Dow, Nasdaq and S&P 500",InvestorPlace,/news/stocks/stock-market-today-record-highs-for-dow-nasdaq-and-sp-500-1028671683,negative,0.8708054423332214
384,11/8/2019 9:31:09 PM,This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma,InvestorPlace,/news/stocks/biotech-stocks-big-pharma-deal-1028674828,negative,0.637085497379303
385,11/12/2019 6:50:33 PM,7 Biotech Stocks to Buy With Plenty of Power in the Pipeline,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-plenty-of-power-in-the-pipeline-1028682538,positive,0.8071872591972351
386,12/5/2019 1:19:00 PM,Regeneron Pharma Announces Positive Phase 2 Results In Rare Blood Disorder ,RTTNews,/news/stocks/regeneron-pharma-announces-positive-phase-2-results-in-rare-blood-disorder-1028740345,negative,0.816736102104187
387,12/31/2019 5:01:53 PM,"Vascepa’s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock",InvestorPlace,/news/stocks/vascepa-future-amarin-stock-amrn-fishy-1028789803,neutral,0.8319942951202393
388,1/6/2020 5:18:24 PM,7 Investing Resolutions to Follow in 2020,InvestorPlace,/news/stocks/7-investing-resolutions-to-follow-in-2020-1028797249,positive,0.9337491393089294
389,1/28/2020 7:41:10 AM,"Regeneron, Sanofi: FDA To Review SBLA For Dupixent - Quick Facts ",RTTNews,/news/stocks/regeneron-sanofi-fda-to-review-sbla-for-dupixent-quick-facts-1028849018,positive,0.6193356513977051
390,1/28/2020 2:46:23 PM,7 Big Biotech Stocks to Avoid,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-avoid-1028851372,positive,0.929349958896637
391,2/5/2020 3:02:20 PM,Regeneron Pharmaceuticals earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/regeneron-stock-q4-earnings-preview-1028876801,positive,0.9071983098983765
392,2/5/2020 4:43:16 PM,Coronavirus cases remain modest in U.S.,Seeking Alpha,https://seekingalpha.com/news/3538634-coronavirus-cases-remain-modest-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4481508731842041
393,2/6/2020 10:14:47 AM,"This $3B biotech has been a three-bagger since November, and it still has upside",Seeking Alpha,https://seekingalpha.com/news/3538998-this-3b-biotech-three-bagger-since-november-and-still-upside?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7673792839050293
394,2/6/2020 12:33:58 PM,Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-1028880420,negative,0.9092124104499817
395,2/6/2020 12:44:29 PM,"Regeneron, Sanofi To Restructure Antibody Collaboration For Kevzara, Praluent ",RTTNews,/news/stocks/regeneron-sanofi-to-restructure-antibody-collaboration-for-kevzara-praluent-1028880453,positive,0.6035354137420654
396,2/6/2020 4:49:53 PM,Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda,InvestorPlace,/news/stocks/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-1028882432,positive,0.7825398445129395
397,2/7/2020 4:30:20 PM,Coronavirus cases inch up in U.S. but still very light,Seeking Alpha,https://seekingalpha.com/news/3539753-coronavirus-cases-inch-up-in-u-s-still-light?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7748228311538696
398,2/10/2020 3:15:53 PM,Kodiak Sciences up 9% on positive early-stage KSI-301 data,Seeking Alpha,https://seekingalpha.com/news/3540063-kodiak-sciences-up-9-on-positive-early-stage-ksiminus-301-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9522855281829834
399,2/10/2020 8:35:52 PM,"Coronavirus outbreak continues to spread, still largely restricted to Hubei province",Seeking Alpha,https://seekingalpha.com/news/3540190-coronavirus-outbreak-continues-to-spread-still-largely-restricted-to-hubei-province?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.42718085646629333
400,2/11/2020 12:54:00 PM,Argus upgrades Regeneron in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3540444-argus-upgrades-regeneron-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.719196617603302
401,2/11/2020 5:30:01 PM,China’s Coronavirus Highlights the Risks of a Changing Oil Industry,InvestorPlace,/news/stocks/chinas-coronavirus-highlights-the-risks-of-a-changing-oil-industry-1028895128,positive,0.6181427836418152
402,2/18/2020 2:16:49 PM,"Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares",InvestorPlace,/news/stocks/moderna-stock-rebound-wait-for-dip-1028914534,negative,0.3802567422389984
403,2/24/2020 5:46:23 PM,Novartis slammed by warning on macular degeneration drug,Seeking Alpha,https://seekingalpha.com/news/3544852-novartis-slammed-warning-on-macular-degeneration-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9343705773353577
404,2/24/2020 9:25:33 PM,"4 Top Stock Trades for Tuesday: SPY, QQQ, MSFT, REGN",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-spy-qqq-msft-regn-1028933312,positive,0.932197630405426
405,2/24/2020 9:35:34 PM,"Stock Market Today: Coronavirus Sparks 1,000-Point Dow Fall",InvestorPlace,/news/stocks/stock-market-today-coronavirus-sparks-1000-point-dow-fall-1028933310,neutral,0.5890527963638306
406,2/25/2020 10:00:17 AM,A Stock That Defies Conventions & Corona - Regeneron Pharma ,RTTNews,/news/stocks/a-stock-that-defies-conventions-corona-regeneron-pharma-1028934596,positive,0.8977982997894287
407,2/25/2020 1:07:28 PM,"Now That Teva Has Stabilized, Teva Stock Looks Undervalued",InvestorPlace,/news/stocks/stabilized-teva-stock-looks-undervalued-1028935585,neutral,0.48388734459877014
408,2/25/2020 5:58:24 PM,Regeneron Pharma hits two-year high amid Novartis woes,Seeking Alpha,https://seekingalpha.com/news/3545331-regeneron-pharma-hits-two-year-high-amid-novartis-woes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8723946213722229
409,2/27/2020 2:36:23 PM,Fighting The Deadly Coronavirus ,RTTNews,/news/stocks/fighting-the-deadly-coronavirus-1028945765,positive,0.888126015663147
410,2/27/2020 2:51:41 PM,Momentum Stocks Benefitting From Coronavirus ,RTTNews,/news/stocks/momentum-stocks-benefitting-from-coronavirus-1028945853,negative,0.9087464809417725
411,2/27/2020 3:13:26 PM,Stock Alert: REGN Shares Gain As Coronavirus Outbreak Intensifies ,RTTNews,/news/stocks/stock-alert-regn-shares-gain-as-coronavirus-outbreak-intensifies-1028946179,negative,0.7389528155326843
412,2/28/2020 3:49:19 PM,Traders Are Treating Inovio Like 2018’s Pot Stock Stars,InvestorPlace,/news/stocks/inovio-ino-stock-coronavirus-speculation-1028950545,positive,0.5932244062423706
413,3/3/2020 6:42:24 PM,"Coronavirus plays - vaccines, drugs & infection control products",Seeking Alpha,https://seekingalpha.com/news/3548189-coronavirus-plays-vaccines-drugs-infection-control-products?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9463247656822205
414,3/4/2020 11:40:01 AM,Buy Regeneron Stock for Coronavirus 2.0 and Beyond,InvestorPlace,/news/stocks/buy-regeneron-stock-coronavirus-1028963665,positive,0.8938838839530945
415,3/4/2020 4:00:11 PM,Regeneron expects coronavirus med to be ready by August; shares up 4%,Seeking Alpha,https://seekingalpha.com/news/3548591-regeneron-expects-coronavirus-med-to-be-ready-august-shares-up-4?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9458067417144775
416,3/5/2020 6:56:36 PM,Inovio Pharmaceuticals Rapidly Becoming The Premier Coronavirus Play,InvestorPlace,/news/stocks/ino-stock-rapidly-becoming-the-premier-coronavirus-play-1028969894,negative,0.7987537980079651
417,3/6/2020 1:02:03 PM,Regeneron Stock May Need More Than the Coronavirus,InvestorPlace,/news/stocks/regeneron-stock-needs-more-than-vaccine-1028971858,positive,0.922259509563446
418,3/9/2020 2:53:41 PM,Moderna Stock’s Winning Streak Seems Likely to End,InvestorPlace,/news/stocks/moderna-mrna-stock-winning-streak-likely-to-end-1028977188,positive,0.6383908987045288
419,3/10/2020 2:29:46 PM,Its Powerful Pipeline Shows Pfizer Stock Is Undervalued by 15%,InvestorPlace,/news/stocks/pfe-stock-is-undervalued-by-at-least-15-1028981675,negative,0.8663246035575867
420,3/10/2020 10:23:58 PM,Generic anti-malarial may treat COVID-19 - Raymond James,Seeking Alpha,https://seekingalpha.com/news/3550389-generic-anti-malarial-may-treat-covidminus-19-raymond-james?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7612016201019287
421,3/11/2020 7:39:18 AM,Which S&P 500 stocks have gained over the past month?,Seeking Alpha,https://seekingalpha.com/news/3550399-which-s-and-p-500-stocks-gained-over-past-month?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7760976552963257
422,3/11/2020 6:28:42 PM,3 Diverse and Critical Stocks to Watch For a Market Bottom,InvestorPlace,/news/stocks/3-diverse-and-critical-stocks-to-watch-for-a-market-bottom-1028986967,positive,0.8402940034866333
423,3/16/2020 12:29:25 PM,Regeneron and Sanofi launch Kevzara clinical program for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3551978-regeneron-and-sanofi-launch-kevzara-clinical-program-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5883235931396484
424,3/16/2020 1:30:09 PM,"Sanofi, Regeneron Begin Kevzara Clinical Trial For Severe COVID-19 - Quick Facts ",RTTNews,/news/stocks/sanofi-regeneron-begin-kevzara-clinical-trial-for-severe-covid-19-quick-facts-1028999261,negative,0.5067554116249084
425,3/16/2020 2:31:48 PM,7 Biotech Stocks to Buy and Hold in 2020,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-and-hold-in-2020-1028769847,positive,0.8950077891349792
426,3/16/2020 3:05:13 PM,"Focus on iBio’s Tech, Not Its Coronavirus Story",InvestorPlace,/news/stocks/focus-on-ibios-tech-not-its-coronavirus-story-1029000187,positive,0.9352659583091736
427,3/17/2020 12:55:59 PM,Stock Alerts: Regeneron Says Identified Antibodies For Treating COVID-19 ,RTTNews,/news/stocks/stock-alerts-regeneron-says-identified-antibodies-for-treating-covid-19-1029003477,positive,0.695694088935852
428,3/17/2020 1:01:29 PM,Regeneron Discovers Antibodies For COVID-19 Treatment ,RTTNews,/news/stocks/regeneron-discovers-antibodies-for-covid-19-treatment-1029003510,positive,0.5725558400154114
429,3/17/2020 3:03:32 PM,Stock Alert: Regeneron Pharma Rises 10% ,RTTNews,/news/stocks/stock-alert-regeneron-pharma-rises-10-1029004346,negative,0.927006721496582
430,3/17/2020 5:12:05 PM,8 Best Performing Stocks During the 2020’s Market Meltdown,InvestorPlace,/news/stocks/best-stocks-for-2020-market-meltdown-1029005251,negative,0.8578590154647827
431,3/18/2020 6:55:12 AM,"BNTX On Fire, QDEL's Coronavirus Test Gets FDA's EUA, CureVac Back In The News ",RTTNews,/news/stocks/bntx-on-fire-qdel-s-coronavirus-test-gets-fda-s-eua-curevac-back-in-the-news-1029006665,positive,0.7537549138069153
432,3/19/2020 4:44:51 PM,"FDA ""close"" to nod for Gilead drug for Covid-19 - President Trump",Seeking Alpha,https://seekingalpha.com/news/3553431-fda-close-to-nod-for-gilead-drug-for-covidminus-19-president-trump?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7400610446929932
433,3/19/2020 5:00:38 PM,Profit-taking pressures Moderna after Hahn comments on vaccine timeline,Seeking Alpha,https://seekingalpha.com/news/3553448-profit-taking-pressures-moderna-after-hahn-comments-on-vaccine-timeline?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9628137350082397
434,3/19/2020 5:29:02 PM,Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play,InvestorPlace,/news/stocks/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-1029014502,positive,0.8325722813606262
435,3/21/2020 7:30:19 PM,Coronavirus offers a rare opportunity in these stocks,Seeking Alpha,https://seekingalpha.com/news/3554021-coronavirus-offers-rare-opportunity-in-stocks?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7684345245361328
436,3/23/2020 5:31:58 PM,Don’t Forget About Stocks to Buy During the Coronavirus Crisis,InvestorPlace,/news/stocks/dont-forget-about-stocks-to-buy-during-the-coronavirus-crisis-1029024218,positive,0.9331583976745605
437,3/24/2020 10:50:33 AM,Why Consider These 2 Stocks When Markets Are Crashing? ,RTTNews,/news/stocks/why-consider-these-2-stocks-when-markets-are-crashing-1029025752,positive,0.5683201551437378
438,3/24/2020 5:55:21 PM,Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet,InvestorPlace,/news/stocks/ibio-stock-could-be-worth-speculation-on-a-covid-19-vaccine-1029028361,negative,0.7425907850265503
439,3/25/2020 2:26:35 PM,It’s Time for Investors to Run Far Away From iBio Stock,InvestorPlace,/news/stocks/its-time-for-investors-to-run-far-away-from-ibio-stock-1029031724,positive,0.8435794711112976
440,3/27/2020 4:59:14 PM,The Easy Gains May Be Over for American Airlines Stock,InvestorPlace,/news/stocks/easy-gains-over-american-airlines-aal-stock-1029040380,negative,0.47719842195510864
441,3/30/2020 8:05:42 AM,"Regeneron, Sanofi Begin COVID-19 Clinical Program Outside Of U.S. ",RTTNews,/news/stocks/regeneron-sanofi-begin-covid-19-clinical-program-outside-of-u-s-1029043121,positive,0.7784356474876404
442,3/30/2020 8:53:11 AM,"Sanofi, Regeneron expand testing of Kevzara",Seeking Alpha,https://seekingalpha.com/news/3556140-sanofi-regeneron-expand-testing-of-kevzara?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6565914154052734
443,3/30/2020 8:16:47 PM,Stock Market Today: Healthcare Stocks Leads the Way; Buy Zoom?,InvestorPlace,/news/stocks/stock-market-today-healthcare-stocks-leads-the-way-buy-zoom-1029046564,positive,0.8414232134819031
444,3/31/2020 11:32:18 AM,"3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-abbott-laboratories-johnson-johnson-and-regeneron-pharmaceuticals-1029048681,positive,0.9266859889030457
445,3/31/2020 12:45:45 PM,A Market Roadmap Shows the Stimulus Will Save the Economy,InvestorPlace,/news/stocks/market-roadmap-stimulus-package-coronavirus-1029049482,negative,0.8043650984764099
446,3/31/2020 3:55:00 PM,5 Hot Stocks for 2020 That Are Soaring While the Market Plunges,InvestorPlace,/news/stocks/5-hot-stocks-2020-soaring-market-plunges-1029050325,negative,0.585474967956543
447,3/31/2020 4:19:54 PM,Is iBio Stock Worth the Risk as Coronavirus Continues to Spread?,InvestorPlace,/news/stocks/is-ibio-stock-worth-the-risk-as-coronavirus-continues-to-spread-1029050739,positive,0.9000698924064636
448,4/2/2020 11:13:44 AM,"3 Big Stock Charts for Thursday: Kellogg, Regeneron Pharmaceuticals, Newmont",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-kellogg-regeneron-pharmaceuticals-newmont-1029058454,positive,0.9198582768440247
449,4/2/2020 7:06:50 PM,Don’t Pull the Trigger on AIM ImmunoTech Stock,InvestorPlace,/news/stocks/dont-pull-the-trigger-on-aim-immunotech-stock-1029060632,positive,0.8853376507759094
450,4/3/2020 7:23:24 AM,"Regeneron, Sanofi Announce Detailed Positive Results From Dupixent Trial ",RTTNews,/news/stocks/regeneron-sanofi-announce-detailed-positive-results-from-dupixent-trial-1029061424,negative,0.6038549542427063
451,4/3/2020 6:40:36 PM,Regeneron launches studies of Kevzara for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3558341-regeneron-launches-studies-of-kevzara-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7221755981445312
452,4/3/2020 8:14:49 PM,Stock Market Today: Huge Jobs Miss; Amazon Prime Day Delay,InvestorPlace,/news/stocks/stock-market-today-huge-jobs-miss-amazon-prime-day-delay-1029064645,neutral,0.954083263874054
453,4/5/2020 6:55:44 PM,Incyte details late-stage data on ruxolitinib cream for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3558456-incyte-details-late-stage-data-on-ruxolitinib-cream-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8612488508224487
454,4/6/2020 9:16:13 PM,Regeneron reworks Praluent agreements with Sanofi,Seeking Alpha,https://seekingalpha.com/news/3558806-regeneron-reworks-praluent-agreements-sanofi?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8725759387016296
455,4/8/2020 11:25:58 AM,BofA likes Molina Healthcare in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3559236-bofa-likes-molina-healthcare-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7580435276031494
456,4/8/2020 12:13:50 PM,"Zai Lab To Commercialize REGN1979 In Oncology In Mainland China, Hong Kong ",RTTNews,/news/stocks/zai-lab-to-commercialize-regn1979-in-oncology-in-mainland-china-hong-kong-1029075012,positive,0.7770886421203613
457,4/9/2020 8:39:10 PM,Goldman Sachs: These Are the 5 Best Stocks for an Economic Recovery,InvestorPlace,/news/stocks/goldman-sachs-these-are-the-5-best-stocks-for-an-economic-recovery-1029081925,positive,0.8684148788452148
458,4/14/2020 2:46:55 PM,Moderna Stock Is the Greatest Coronavirus Speculation Play,InvestorPlace,/news/stocks/moderna-mrna-stock-greatest-coronavirus-speculation-1029090629,positive,0.9106491804122925
459,4/14/2020 6:53:58 PM,Three Reasons to Consider Buying Regeneron Stock,InvestorPlace,/news/stocks/three-reasons-to-consider-buying-regeneron-stock-1029091256,positive,0.8971723318099976
460,4/16/2020 11:16:45 AM,FDA accepts Regeneron application for Ebola treatment,Seeking Alpha,https://seekingalpha.com/news/3561202-fda-accepts-regeneron-application-for-ebola-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6873732805252075
461,4/16/2020 12:03:07 PM,Stock Alert: Regeneron Touches New High ,RTTNews,/news/stocks/stock-alert-regeneron-touches-new-high-1029097470,negative,0.8375712633132935
462,4/16/2020 1:12:55 PM,Regeneron Pharma: FDA To Review BLA For REGN-EB3 - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-fda-to-review-bla-for-regn-eb3-quick-facts-1029097803,positive,0.7542600035667419
463,4/17/2020 7:55:00 AM,"BTAI On Track To Report SERENITY Data, REGN Hits All-time High, THMO On Watch ",RTTNews,/news/stocks/btai-on-track-to-report-serenity-data-regn-hits-all-time-high-thmo-on-watch-1029101040,negative,0.8700405955314636
464,4/17/2020 11:18:06 AM,Benchmark likes Regeneron in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3561611-benchmark-likes-regeneron-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.838840663433075
465,4/21/2020 12:21:00 PM,7 of the Best Large-Cap Stocks to Buy Now,InvestorPlace,/news/stocks/7-of-the-best-large-cap-stocks-to-buy-now-1029112995,positive,0.659598708152771
466,4/21/2020 4:33:49 PM,10 S&P 500 Stocks That Are Still Overvalued By Discounted Cash Flow,InvestorPlace,/news/stocks/10-sp-500-stocks-that-are-still-overvalued-by-discounted-cash-flow-1029113970,neutral,0.7640334963798523
467,4/24/2020 3:41:09 PM,7 Beautiful Biotech Stocks to Buy Here,InvestorPlace,/news/stocks/7-beautiful-biotech-stocks-to-buy-here-1029127761,positive,0.8712263107299805
468,4/27/2020 11:23:34 AM,Regeneron and Sanofi's Kevzara shows no clinical benefit in COVID-19 study,Seeking Alpha,https://seekingalpha.com/news/3564541-regeneron-and-sanofis-kevzara-shows-no-clinical-benefit-in-covidminus-19-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5675385594367981
469,4/27/2020 11:33:55 AM,Sanofi and Regeneron's Libtayo successful in lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3564552-sanofi-and-regenerons-libtayo-successful-in-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8619304299354553
470,4/27/2020 1:38:15 PM,"Regeneron, Sanofi: Libtayo Meets Primary Endpoint In Phase 3 Trial ",RTTNews,/news/stocks/regeneron-sanofi-libtayo-meets-primary-endpoint-in-phase-3-trial-1029132372,negative,0.8847687840461731
471,4/27/2020 1:57:33 PM,"Regeneron, Sanofi To Amend Trial To Enroll Only Critical COVID-19 Patients ",RTTNews,/news/stocks/regeneron-sanofi-to-amend-trial-to-enroll-only-critical-covid-19-patients-1029132423,positive,0.7133467793464661
472,4/27/2020 8:18:18 PM,Stock Market Today: Small-Cap Stocks Roar to Life; GM Cuts Dividend,InvestorPlace,/news/stocks/stock-market-today-small-cap-stocks-roar-to-life-gm-cuts-dividend-1029134906,neutral,0.8372467756271362
473,4/28/2020 4:29:38 AM,Biotech Stocks Facing FDA Decision In May 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2020-1029135147,positive,0.862282931804657
474,4/28/2020 3:00:56 PM,10 Stocks to Buy for an Aging Population,InvestorPlace,/news/stocks/10-stocks-to-buy-for-an-aging-population-1029139728,positive,0.8501477241516113
475,4/30/2020 7:27:25 PM,It’s Still Best to Avoid IBIO Stock Despite Any Hype,InvestorPlace,/news/stocks/its-still-best-to-avoid-ibio-stock-despite-any-hype-1029152394,positive,0.8995352387428284
476,5/4/2020 3:01:31 PM,Regeneron Pharmaceuticals earnings: here's what to expect,Markets Insider Automation,/news/stocks/regeneron-q1-earnings-preview-stock-1029160210,positive,0.9397029280662537
477,5/4/2020 9:35:56 PM,Regeneron Pharmaceuticals Q1 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3568418-regeneron-pharmaceuticals-q1-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8613038659095764
478,5/5/2020 7:32:27 AM,Sanofi: Libtayo Shows Clinically-Meaningful And Durable Responses In Skin Cancer ,RTTNews,/news/stocks/sanofi-libtayo-shows-clinically-meaningful-and-durable-responses-in-skin-cancer-1029163766,negative,0.9207467436790466
479,5/5/2020 11:46:06 AM,Regeneron Pharma Q1 Dupixent sales up 129%; shares up 5% premarket,Seeking Alpha,https://seekingalpha.com/news/3569017-regeneron-pharma-q1-dupixent-sales-up-129-shares-up-5-premarket?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9484201073646545
480,5/5/2020 12:35:20 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-beat-estimates-1029164727,negative,0.9073371887207031
481,5/5/2020 7:10:15 PM,The Trends are Mostly Friendly for Moderna Stock Investors,InvestorPlace,/news/stocks/the-trends-are-mostly-friendly-for-mrna-stock-investors-1029167815,positive,0.9092831611633301
482,5/5/2020 8:48:05 PM,Regeneron widens its lead as the S&P 500's top performer after saying key COVID-19 drug may be available in the fall (REGN),Business Insider,https://markets.businessinsider.com/news/stocks/regeneron-stock-price-earnings-coronavirus-drug-update-sp500-best-performer-2020-5-1029167569,negative,0.9412729740142822
483,5/15/2020 5:23:40 PM,3 Earnings Stocks to Buy While They Climb Above Everything Else,InvestorPlace,/news/stocks/3-earnings-stocks-to-buy-while-they-climb-1029207569,positive,0.871998131275177
484,5/22/2020 1:52:27 PM,Gilead Stock Is Worth Owning With or Without a Coronavirus Cure,InvestorPlace,/news/stocks/gilead-stock-is-worth-owning-with-or-without-a-coronavirus-cure-1029227089,positive,0.9261690974235535
485,5/25/2020 3:46:08 PM,Regeneron's Dupixent successful in esophagus inflammation study,Seeking Alpha,https://seekingalpha.com/news/3577368-regenerons-dupixent-successful-in-esophagus-inflammation-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6900773644447327
486,5/25/2020 6:08:02 PM,Sanofi to shed 20.6% stake in Regeneron,Seeking Alpha,https://seekingalpha.com/news/3577375-sanofi-to-shed-20_6-stake-in-regeneron?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6947305798530579
487,5/26/2020 4:13:15 PM,Stock Alert: Regeneron Pharma Down 4% ,RTTNews,/news/stocks/stock-alert-regeneron-pharma-down-4-1029233935,neutral,0.9665046334266663
488,5/27/2020 2:57:35 AM,Regeneron Announces Pricing Of Secondary Offering Of Its Stock Held By Sanofi At $515.00/shr ,RTTNews,/news/stocks/regeneron-announces-pricing-of-secondary-offering-of-its-stock-held-by-sanofi-at-515-00-shr-1029235441,positive,0.9246060848236084
489,5/27/2020 4:07:36 AM,Sanofi : FDA Approves Dupixentas To Treat Moderate-to-severe Atopic Dermatitis ,RTTNews,/news/stocks/sanofi-fda-approves-dupixentas-to-treat-moderate-to-severe-atopic-dermatitis-1029235458,negative,0.9239439368247986
490,5/27/2020 7:58:51 AM,Regeneron prices secondary equity offering at $515,Seeking Alpha,https://seekingalpha.com/news/3577758-regeneron-prices-secondary-equity-offering-515?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9402478933334351
491,5/27/2020 2:55:53 PM,Regeneron Stock Is a Solid Long-Term Buy,InvestorPlace,/news/stocks/regeneron-stock-buy-now-hold-long-run-coronavirus-1029238777,negative,0.8699305653572083
492,5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9381866455078125
493,5/29/2020 2:28:08 PM,"Regeneron : Data On Libtayo Shows Longer Durability, Higher Complete Response Rates In Skin Cancer ",RTTNews,/news/stocks/regeneron-data-on-libtayo-shows-longer-durability-higher-complete-response-rates-in-skin-cancer-1029263185,negative,0.9427574872970581
494,5/29/2020 3:12:19 PM,Regeneron and Sanofi's cemiplimab shows benefit in type of skin cancer,Seeking Alpha,https://seekingalpha.com/news/3578703-regeneron-and-sanofis-cemiplimab-shows-benefit-in-type-of-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9015604257583618
495,5/29/2020 8:09:08 PM,Regeneron completes offering of Sanofi-held stock,Seeking Alpha,https://seekingalpha.com/news/3578773-regeneron-completes-offering-of-sanofi-held-stock?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8616374731063843
496,6/1/2020 11:56:09 AM,Regeneron and Intellia expand partnership into hemophilia,Seeking Alpha,https://seekingalpha.com/news/3578922-regeneron-and-intellia-expand-partnership-hemophilia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9045961499214172
497,6/1/2020 5:31:52 PM,Is Inovio Pharmaceuticals Really Just the Next Theranos?,InvestorPlace,/news/stocks/is-ino-stock-really-just-the-next-theranos-1029269780,positive,0.9232044816017151
498,6/2/2020 6:27:39 AM,"NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps ",RTTNews,/news/stocks/ntla-gains-on-amended-regn-deal-gild-reports-simple-results-myov-on-watch-nvus-slumps-1029270685,neutral,0.7538188695907593
499,6/2/2020 9:06:00 AM,Genzyme Corporation -- Moody's affirms Sanofi's A1 ratings following the sale of its stake in Regeneron,Moodys,/news/bonds/genzyme-corporation-moody-s-affirms-sanofi-s-a1-ratings-following-the-sale-of-its-stake-in-regeneron-1029271093,negative,0.5698994994163513
500,6/3/2020 11:49:25 AM,Replimune lead drug shows benefit in non-melanoma skin cancer,Seeking Alpha,https://seekingalpha.com/news/3579961-replimune-lead-drug-shows-benefit-in-non-melanoma-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9196963906288147
501,6/11/2020 7:14:42 AM,Sanofi To Present Strategy For Dupixent In Type 2 Inflammatory Diseases ,RTTNews,/news/stocks/sanofi-to-present-strategy-for-dupixent-in-type-2-inflammatory-diseases-1029299266,positive,0.8174867033958435
502,6/11/2020 11:23:56 AM,Regeneron initiates study of antibody cocktail for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3582201-regeneron-initiates-study-of-antibody-cocktail-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7311070561408997
503,6/11/2020 1:02:44 PM,Regeneron's (REGN) Resplendent Journey From $60 To $600 In 9 Years ,RTTNews,/news/stocks/regeneron-s-regn-resplendent-journey-from-60-to-600-in-9-years-1029300043,negative,0.8095430135726929
504,6/11/2020 1:29:14 PM,Regeneron Begins Clinical Trial Of Anti-Viral Antibody Cocktail Against COVID-19 ,RTTNews,/news/stocks/regeneron-begins-clinical-trial-of-anti-viral-antibody-cocktail-against-covid-19-1029300159,negative,0.6329129934310913
505,6/11/2020 3:22:25 PM,Momentum mover candidates on a down market day,Seeking Alpha,https://seekingalpha.com/news/3582348-momentum-mover-candidates-on-down-market-day?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.571069598197937
506,6/15/2020 6:09:17 PM,Warren Buffett stock screen yields seven picks,Seeking Alpha,https://seekingalpha.com/news/3583116-warren-buffett-stock-screen-yields-seven-picks?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7674035429954529
507,6/17/2020 6:50:26 PM,"As Biogen Stock Struggles, Look Elsewhere for Biotech Exposure",InvestorPlace,/news/stocks/as-biogen-stock-struggles-look-elsewhere-for-biotech-exposure-1029319275,positive,0.8430029153823853
508,6/19/2020 11:54:37 AM,Regeneron and Sanofi's Dupixent OK'd in China for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3584472-regeneron-and-sanofis-dupixent-okd-in-china-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4972640573978424
509,6/19/2020 1:46:24 PM,Regeneron : China Okays Dupixent To Treat Moderate-to-Severe Atopic Dermatitis In Adults ,RTTNews,/news/stocks/regeneron-china-okays-dupixent-to-treat-moderate-to-severe-atopic-dermatitis-in-adults-1029325303,negative,0.838141679763794
510,6/22/2020 6:27:39 PM,3 Great Growth Stocks That Kept Climbing in This Tough Market,InvestorPlace,/news/stocks/3-great-growth-stocks-that-kept-climbing-in-this-tough-market-1029331174,negative,0.7372255325317383
511,6/24/2020 9:39:51 PM,Regeneron To Defend Allegations On Contributions To Patient Assistance Charity ,RTTNews,/news/stocks/regeneron-to-defend-allegations-on-contributions-to-patient-assistance-charity-1029339595,neutral,0.6116493344306946
512,6/25/2020 6:19:00 PM,Enough Already! Ditch Moderna Stock,InvestorPlace,/news/stocks/sell-mrna-stock-covid-19-catalyst-inflates-valuation-1029060294,positive,0.8919171094894409
513,7/3/2020 7:04:30 AM,"IMMU Continues Ascent, IDXG On Fire, REGN's Kevzara Disappoints In COVID-19 Trial, BLFS On Watch ",RTTNews,/news/stocks/immu-continues-ascent-idxg-on-fire-regn-s-kevzara-disappoints-in-covid-19-trial-blfs-on-watch-1029364611,neutral,0.9207609295845032
514,7/3/2020 7:45:46 AM,"Sanofi, Regeneron Stop Kevzara COVID-19 Trial In U.S. After Failing To Meet Key Goals ",RTTNews,/news/stocks/sanofi-regeneron-stop-kevzara-covid-19-trial-in-u-s-after-failing-to-meet-key-goals-1029364666,neutral,0.9570355415344238
515,7/6/2020 1:22:11 PM,Regeneron Begins Late-stage Clinical Trials Evaluating REGN-COV2 - Quick Facts ,RTTNews,/news/stocks/regeneron-begins-late-stage-clinical-trials-evaluating-regn-cov2-quick-facts-1029368476,negative,0.6008527874946594
516,7/6/2020 6:43:12 PM,Moderna Stock Has a Bright Future After the Coronavirus,InvestorPlace,/news/stocks/moderna-mrna-stock-coronavirus-vaccine-drug-discovery-1029370223,negative,0.7788195610046387
517,7/7/2020 9:45:41 AM,"BLU Plunges On RELIEF Data, FDA Places CLLS' Trial On Hold, IMMU Hits New High, OTIC Music To Ears ",RTTNews,/news/stocks/blu-plunges-on-relief-data-fda-places-clls-trial-on-hold-immu-hits-new-high-otic-music-to-ears-1029371231,neutral,0.6077059507369995
518,7/7/2020 1:21:01 PM,Regeneron Enters Manufacturing And Supply Deal With BARDA For REGN-COV2 ,RTTNews,/news/stocks/regeneron-enters-manufacturing-and-supply-deal-with-barda-for-regn-cov2-1029371939,positive,0.5488520860671997
519,7/8/2020 9:27:24 AM,"CRVS, HEPA Jump On COVID-19 Drug Bandwagon, LVGO In Good Health, NVAX Joins $100 Stock Price Club ",RTTNews,/news/stocks/crvs-hepa-jump-on-covid-19-drug-bandwagon-lvgo-in-good-health-nvax-joins-100-stock-price-club-1029375209,negative,0.9223686456680298
520,7/10/2020 12:23:01 PM,Potential Alzheimer’s Drug Not Enough to Excite Biogen Stock Investors,InvestorPlace,/news/stocks/potential-alzheimers-drug-not-enough-to-excite-biogen-stock-investors-1029384005,positive,0.5810572504997253
521,7/10/2020 2:43:24 PM,Delta Still a Strong Pick Despite Uptick in Covid-19 Cases,InvestorPlace,/news/stocks/delta-still-a-strong-pick-despite-uptick-in-covid-19-cases-1029384333,negative,0.9386024475097656
522,7/15/2020 11:36:51 AM,Novavax Stock Has Probably Topped Out Until Successful Clinical Trials,InvestorPlace,/news/stocks/nvax-stock-topped-out-clinical-trials-1029397795,negative,0.8751546740531921
523,8/4/2020 3:03:46 PM,Here's what to expect from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q2-1029466846,positive,0.9423273801803589
524,8/5/2020 12:59:38 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1029471861,negative,0.89817875623703
525,8/5/2020 1:59:32 PM,Novavax Stock Needs Solid Results Beyond Headlines,InvestorPlace,/news/stocks/nvax-stock-needs-solid-results-beyond-headlines-1029473742,negative,0.9414753913879395
526,8/5/2020 4:01:08 PM,Merck Stock Remains a Dull Biotech Play Despite Earnings Success,InvestorPlace,/news/stocks/merck-mrk-stock-remains-a-dull-biotech-play-despite-earnings-success-1029474241,neutral,0.9247965812683105
527,8/5/2020 5:42:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-assigns-baa3-issuer-rating-to-regeneron-1029474142,positive,0.8312644362449646
528,8/7/2020 3:56:00 AM,"Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-assigns-baa3-issuer-rating-to-regeneron-1029480692,positive,0.8312644362449646
529,8/7/2020 4:57:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's rates Regeneron's sr. notes Baa3; stable outlook",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-rates-regeneron-s-sr-notes-baa3-stable-outlook-1029482649,negative,0.7747155427932739
530,8/7/2020 8:13:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-assigns-baa3-issuer-rating-to-regeneron-1029483162,positive,0.8312644362449646
531,8/11/2020 4:38:00 PM,Sanofi -- Moody's announces completion of a periodic review of ratings of Sanofi,Moodys,/news/bonds/sanofi-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-sanofi-1029492648,positive,0.8552985191345215
532,8/18/2020 10:30:29 AM,"Regeneron Stock Is a Play For Covid-19, And More",InvestorPlace,/news/stocks/regeneron-stock-a-covid-19-play-and-more-1029512464,positive,0.9428723454475403
533,8/19/2020 7:31:19 AM,"Regeneron, Roche Collaborate To Manufacture And Distribute Investigational Drug For COVID-19 ",RTTNews,/news/stocks/regeneron-roche-collaborate-to-manufacture-and-distribute-investigational-drug-for-covid-19-1029515275,positive,0.7974416613578796
534,8/19/2020 9:16:39 AM,"Once Slow, Stable Sanofi Stock is Now Pharma’s Most-Talked About Name",InvestorPlace,/news/stocks/once-slow-stable-sny-stock-is-now-pharmas-most-talked-about-name-1029515915,positive,0.8727802634239197
535,8/21/2020 5:42:52 PM,7 Index Funds To Buy For A Firm Portfolio Foundation,InvestorPlace,/news/stocks/7-index-funds-to-buy-for-a-firm-portfolio-foundation-1029524805,positive,0.891994059085846
536,8/24/2020 7:21:10 PM,6 Hot Coronavirus Stocks Moving At “Warp Speed”,InvestorPlace,/news/stocks/6-hot-coronavirus-stocks-moving-at-warp-speed-1029529073,positive,0.7748833298683167
537,8/25/2020 11:30:20 AM,7 Hot Stocks to Buy Before It’s Too Late,InvestorPlace,/news/stocks/7-hot-stocks-to-buy-before-its-too-late-1029531264,positive,0.8980832695960999
538,8/25/2020 1:46:20 PM,The 5 Best Tech ETFs to Buy for Safer Growth,InvestorPlace,/news/stocks/the-5-best-tech-etfs-to-buy-for-safer-growth-1029532192,positive,0.7524566650390625
539,9/2/2020 2:21:45 PM,4 Pharmaceutical Stocks With Deep Pipelines,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-deep-pipelines-coronavirus-1029557234,positive,0.6847983002662659
540,9/5/2020 7:33:19 PM,Graybug Vision readies IPO,Seeking Alpha,https://seekingalpha.com/news/3611911-graybug-vision-readies-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9485812783241272
541,9/8/2020 7:54:31 AM,Sanofi/Regeneron Dupixent shows sustained benefit in asthma extension study,Seeking Alpha,https://seekingalpha.com/news/3611966-sanofi-regeneron-dupixent-shows-sustained-benefit-in-asthma-extension-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9538294076919556
542,9/8/2020 8:25:27 AM,Regeneron/Sanofi Reveal Promising Long-term Data Of Dupixent In Moderate-to-severe Asthma ,RTTNews,/news/stocks/regeneron-sanofi-reveal-promising-long-term-data-of-dupixent-in-moderate-to-severe-asthma-1029567740,negative,0.9527102708816528
543,9/10/2020 2:50:34 PM,5 of the Best Pharmaceutical Stocks to Buy Right Now,InvestorPlace,/news/stocks/5-best-pharmaceutical-stocks-buy-right-now-1029342722,positive,0.7569708824157715
544,9/14/2020 7:18:51 AM,Regeneron And Sanofi: Dupixent Granted FDA Breakthrough Therapy Designation For EoE ,RTTNews,/news/stocks/regeneron-and-sanofi-dupixent-granted-fda-breakthrough-therapy-designation-for-eoe-1029584396,negative,0.9185352921485901
545,9/14/2020 3:12:54 PM,Regeneron's Antibody Cocktail To Be Tested In RECOVERY COVID-19 Phase 3 Trial In UK ,RTTNews,/news/stocks/regeneron-s-antibody-cocktail-to-be-tested-in-recovery-covid-19-phase-3-trial-in-uk-1029586176,positive,0.7215518355369568
546,9/16/2020 5:35:56 PM,Eli Lilly Stock Looks Hot on New Antibody Drug Evidence,InvestorPlace,/news/stocks/eli-lilly-stock-looks-hot-on-new-antibody-drug-evidence-1029596051,negative,0.5884913206100464
547,9/17/2020 1:35:51 PM,SRNE Stock: Sorrento Therapeutics Pops on Plans to Launch Drug Trials,InvestorPlace,/news/stocks/srne-stock-sorrento-therapeutics-pops-on-plans-to-launch-drug-trials-1029599296,positive,0.809693455696106
548,9/18/2020 5:47:20 PM,Roche Stock Rallies on Promising Coronavirus Drug Results,InvestorPlace,/news/stocks/roche-stock-rallies-on-promising-coronavirus-drug-results-1029604090,negative,0.6788759231567383
549,9/21/2020 5:10:56 PM,"Tread Carefully, But Sorrento Stock Could Continue to Bounce Back",InvestorPlace,/news/stocks/tread-carefully-buy-srne-stock-continue-bounce-back-1029608339,neutral,0.4507673382759094
550,9/26/2020 7:59:23 PM,Biotech Stocks Facing FDA Decision In October 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2020-1029624668,positive,0.7615611553192139
551,9/30/2020 3:12:38 PM,Regeneron Says Antibody Cocktail REGN-COV2 Reduced Symptoms In COVID-19 Patients ,RTTNews,/news/stocks/regeneron-says-antibody-cocktail-regn-cov2-reduced-symptoms-in-covid-19-patients-1029635495,negative,0.8966124057769775
552,10/4/2020 5:58:53 AM,Trump Says 'real Test' Ahead In His COVID-19 Fight ,RTTNews,/news/stocks/trump-says-real-test-ahead-in-his-covid-19-fight-1029646001,negative,0.6709540486335754
553,10/5/2020 2:25:32 PM,This Is Why I’d Still Avoid IBio for Now,InvestorPlace,/news/stocks/this-is-why-id-still-avoid-vaccine-stock-ibio-for-now-cseo-1029649209,positive,0.9063957333564758
554,10/5/2020 4:14:48 PM,Stock Alert: Regeneron Pharmaceuticals Gains 6% ,RTTNews,/news/stocks/stock-alert-regeneron-pharmaceuticals-gains-6-1029648746,negative,0.9406123757362366
555,10/5/2020 5:51:28 PM,Regeneron jumps 10% as Trump gets the drugmaker's antibody treatment,Business Insider,https://www.businessinsider.com/regeneron-stock-price-trump-receives-antibody-treatment-drugmaker-covid19-2020-10,negative,0.9207889437675476
556,10/5/2020 7:38:56 PM,Regeneron Pharmaceuticals Stock Shoots Up 8% on Trump Treatment,InvestorPlace,/news/stocks/regeneron-pharmaceuticals-stock-shoots-up-on-trump-coronavirus-treatment-1029649665,negative,0.9461908340454102
557,10/5/2020 8:45:55 PM,"4 Top Stock Trades for Tuesday: SQ, REGN, APHA, TLRY",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-sq-regn-apha-tlry-1029650309,positive,0.9357481598854065
558,10/6/2020 3:37:29 AM,Allele Bio files two lawsuits for patent infringement of mNeonGreen used in COVID-19 vaccines,Seeking Alpha,https://seekingalpha.com/news/3619990-allele-bio-files-two-lawsuits-for-patent-infringement-of-mneongreen-used-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9281293153762817
559,10/6/2020 11:14:27 AM,Biogen files application in Europe for Lucentis biosimilar,Seeking Alpha,https://seekingalpha.com/news/3620040-biogen-files-application-in-europe-for-lucentis-biosimilar?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7950215339660645
560,10/6/2020 1:04:20 PM,OGEN Stock: Why Oragenics Is Soaring 25%,InvestorPlace,/news/stocks/ogen-stock-why-oragenics-is-soaring-25-today-1029653068,negative,0.7014327645301819
561,10/7/2020 9:01:32 AM,"At This Stage of the Vaccine Race, Is Now a Good Time to Buy iBio Stock?",InvestorPlace,/news/stocks/at-this-stage-of-the-vaccine-race-is-now-a-good-time-to-buy-ibio-stock-1029656066,positive,0.92270427942276
562,10/7/2020 12:28:15 PM,Inovio Pharmaceuticals Does Not Need Any More Misfortune,InvestorPlace,/news/stocks/ino-stock-needs-change-fortunes-1029657681,positive,0.9155678749084473
563,10/7/2020 1:01:10 PM,Lilly files for emergency use authorization in U.S. for COVID-19 antibody,Seeking Alpha,https://seekingalpha.com/news/3620445-lilly-files-for-emergency-use-authorization-in-u-s-for-covidminus-19-antibody?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5428430438041687
564,10/7/2020 10:06:46 PM,Regeneron +2.3% after Trump praises drug in new video,Seeking Alpha,https://seekingalpha.com/news/3620637-regeneronplus-2_3-after-trump-praises-drug-in-new-video?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8205900192260742
565,10/8/2020 2:55:05 AM,Regeneron seeks FDA emergency clearance for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3620656-regeneron-seeks-fda-emergency-clearance-for-covidminus-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6901600956916809
566,10/8/2020 2:55:05 AM,Regeneron seeks FDA emergency use nod for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3620656-regeneron-seeks-fda-emergency-use-nod-for-covidminus-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5264931321144104
567,10/8/2020 12:22:49 PM,Regeneron and Lilly to get emergency approval for antibody treatments - Trump,Seeking Alpha,https://seekingalpha.com/news/3620753-regeneron-and-lilly-to-get-emergency-approval-for-antibody-treatments-trump?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5635969638824463
568,10/8/2020 12:47:23 PM,"Pre-market Movers In Healthcare Sector: CDNA, IMTX, REGN, CRSP, TLC... ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-cdna-imtx-regn-crsp-tlc-1029660747,positive,0.9349287748336792
569,10/8/2020 1:56:34 PM,REGN Stock: Regeneron Pops on Trump’s Antibody Support,InvestorPlace,/news/stocks/regn-stock-regeneron-pops-on-trumps-antibody-support-1029662216,positive,0.7643977403640747
570,10/8/2020 3:37:58 PM,Regeneron Seeks Emergency Use Authorization For Its Antibody Treatment For Covid-19 ,RTTNews,/news/stocks/regeneron-seeks-emergency-use-authorization-for-its-antibody-treatment-for-covid-19-1029661974,negative,0.9113996624946594
571,10/8/2020 11:22:13 PM,Oppenheimer sees divided sector in 'critical' months for biotech,Seeking Alpha,https://seekingalpha.com/news/3620981-oppenheimer-sees-divided-sector-in-critical-months-for-biotech?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5209524035453796
572,10/9/2020 4:37:25 PM,Covid-19 Therapeutics May Push Novavax Out of the Spotlight,InvestorPlace,/news/stocks/covid-19-therapeutics-may-push-nvax-stock-out-of-the-spotlight-cseo-1029666747,neutral,0.9274026155471802
573,10/9/2020 6:09:50 PM,Sorrento Stock Investors Should Play Powerball Instead,InvestorPlace,/news/stocks/srne-stock-how-to-get-rich-off-shareholders-1029666739,positive,0.9250040054321289
574,10/9/2020 8:25:25 PM,COVID-19 drug developer Atea Pharmaceuticals files for IPO,Seeking Alpha,https://seekingalpha.com/news/3621228-covidminus-19-drug-developer-atea-pharmaceuticals-files-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9147786498069763
575,10/12/2020 8:58:31 PM,7 Highly Rated Pharmaceutical Stocks for Q4,InvestorPlace,/news/stocks/7-highly-rated-pharmaceutical-stocks-for-q4-1029679826,positive,0.8309608697891235
576,10/13/2020 5:48:44 AM,Sanofi/Regeneron Dupixent reduces asthma attacks and improves lung function in children,Seeking Alpha,https://seekingalpha.com/news/3621561-sanofi-regeneron-dupixent-reduces-asthma-attacks-and-improves-lung-function-in-children?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8970203995704651
577,10/13/2020 7:29:26 AM,Regeneron: Phase 3 Trial Shows Dupixent Significantly Reduces Severe Asthma Attacks In Children ,RTTNews,/news/stocks/regeneron-phase-3-trial-shows-dupixent-significantly-reduces-severe-asthma-attacks-in-children-1029672228,negative,0.9382403492927551
578,10/13/2020 6:46:50 PM,Eli Lilly's Covid-19 antibody trial paused over safety concerns,Seeking Alpha,https://seekingalpha.com/news/3621824-eli-lillys-covidminus-19-antibody-trial-paused-over-safety-concerns?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9175911545753479
579,10/14/2020 8:31:39 AM,"LLY Pauses COVID-19 Antibody Trial, JNJ Boosts Annual Outlook, Double Whammy For GOSS ",RTTNews,/news/stocks/lly-pauses-covid-19-antibody-trial-jnj-boosts-annual-outlook-double-whammy-for-goss-1029677498,negative,0.9347585439682007
580,10/14/2020 8:53:13 PM,Regeneron's Inmazeb becomes first FDA-approved Ebola treatment,Seeking Alpha,https://seekingalpha.com/news/3622274-regenerons-inmazeb-becomes-first-fda-approved-ebola-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5786269903182983
581,10/15/2020 5:13:33 AM,FDA Approves Regeneron's Inmazeb To Treat Ebola ,RTTNews,/news/stocks/fda-approves-regeneron-s-inmazeb-to-treat-ebola-1029681731,negative,0.8325784206390381
582,10/15/2020 8:06:24 AM,"FDA Approves 1st Ebola Drug, CYCN Drops Sickle Cell Disease Drug, VRTX Plunges In After-hours Trade ",RTTNews,/news/stocks/fda-approves-1st-ebola-drug-cycn-drops-sickle-cell-disease-drug-vrtx-plunges-in-after-hours-trade-1029682251,neutral,0.6357328295707703
583,10/16/2020 10:26:34 AM,Get Ready To Bull Trade Novavax Stock For A Second Wave,InvestorPlace,/news/stocks/get-ready-to-bull-trade-novavax-stock-for-a-second-wave-1029688136,positive,0.9231420755386353
584,10/16/2020 12:58:15 PM,European advisory group backs expanded use of Regeneron/Sanofi's Dupixent,Seeking Alpha,https://seekingalpha.com/news/3622868-european-advisory-group-backs-expanded-use-of-regeneron-sanofis-dupixent?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9081977009773254
585,10/16/2020 1:03:00 PM,7 Short-Term Stocks to Make a Quick Buck,InvestorPlace,/news/stocks/7-short-term-stocks-to-buy-for-quick-buck-1029688757,positive,0.8304802775382996
586,10/16/2020 5:53:26 PM,Can Cytonics Pivot Successfully to Covid-19 Therapeutics?,InvestorPlace,/news/stocks/cytonics-stock-pivot-coronavirus-therapeutics-1029689508,positive,0.7348707318305969
587,10/16/2020 5:53:36 PM,Novavax Stock Looks Volatile As Vaccine Enthusiasm Wanes,InvestorPlace,/news/stocks/nvax-stock-looks-volatile-as-vaccine-enthusiasm-wanes-1029689507,neutral,0.9606714248657227
588,10/20/2020 7:37:18 PM,7 Ways to Minimize Your Risk in Growth Stocks,InvestorPlace,/news/stocks/7-ways-to-minimize-your-risk-in-growth-stocks-1029700736,positive,0.8829183578491211
589,10/21/2020 4:35:08 PM,"While Risky, Sorrento Therapeutics Has Many Options to Win",InvestorPlace,/news/stocks/while-risky-sorrento-therapeutics-has-many-options-to-win-1029706542,positive,0.8506829142570496
590,10/22/2020 5:31:38 PM,Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?,InvestorPlace,/news/stocks/is-it-too-late-for-novavax-to-profit-from-a-covid-19-vaccine-1029712056,positive,0.827395498752594
591,10/22/2020 9:37:48 PM,GILD News: Gilead Stock Pops as FDA Approves Remdesivir Treatment,InvestorPlace,/news/stocks/gild-news-gilead-stock-pops-as-fda-approves-remdesivir-treatment-1029712808,negative,0.48570021986961365
592,10/26/2020 6:45:58 AM,Biotech Stocks Facing FDA Decision In November 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2020-1029718001,positive,0.7490039467811584
593,10/26/2020 5:19:07 PM,Don’t Get Swept Up In the Unproven Promise of Aptorum Group,InvestorPlace,/news/stocks/apm-stock-late-entry-covid-trade-1029722700,positive,0.8850303292274475
594,10/27/2020 6:48:04 AM,Lilly ends COVID-19 antibody trial after lack of improvement,Seeking Alpha,https://seekingalpha.com/news/3626170-lilly-ends-covidminus-19-antibody-trial-after-lack-of-improvement?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9469443559646606
595,10/27/2020 8:54:51 PM,Repligen scoops up bioprocessing systems provider for $200M,Seeking Alpha,https://seekingalpha.com/news/3626867-repligen-scoops-up-bioprocessing-systems-provider-for-200m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6002461314201355
596,10/28/2020 12:59:39 PM,7 Cutting-Edge Biotech Stocks for Tomorrow ,InvestorPlace,/news/stocks/7-cutting-edge-biotech-stocks-for-tomorrow-1029734117,positive,0.8713727593421936
597,10/28/2020 9:43:52 PM,Regeneron +2.5% as prospective COVID-19 trial results show reduced medical visits,Seeking Alpha,https://seekingalpha.com/news/3627869-regeneronplus-2_5-prospective-covidminus-19-trial-results-show-reduced-medical-visits?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.890565812587738
598,10/29/2020 11:42:20 AM,Regeneron Says Its Covid-19 Outpatient Therapy Could Reduce Virus Levels ,RTTNews,/news/stocks/regeneron-says-its-covid-19-outpatient-therapy-could-reduce-virus-levels-1029739764,negative,0.9339518547058105
599,10/29/2020 2:18:17 PM,Sanofi/Regeneron prevail in European patent dispute with Amgen over cholesterol drugs,Seeking Alpha,https://seekingalpha.com/news/3628348-sanofi-regeneron-prevail-in-european-patent-dispute-amgen-over-cholesterol-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8635274767875671
600,10/29/2020 3:21:32 PM,"European Patent Office Rules In Favor Of Sanofi, Regeneron On Praluent ",RTTNews,/news/stocks/european-patent-office-rules-in-favor-of-sanofi-regeneron-on-praluent-1029742079,positive,0.9250186085700989
601,10/30/2020 1:50:44 PM,Regeneron to exclude severely/critically ill COVID-19 patients from antibody cocktail study,Seeking Alpha,https://seekingalpha.com/news/3629118-regeneron-to-exclude-severely-critically-ill-covidminus-19-patients-from-antibody-cocktail?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8950051665306091
602,10/30/2020 3:21:03 PM,Regeneron : IDMC Recommends To Hold Enrollment In Hospitalized High Risk COVID-19 Patients ,RTTNews,/news/stocks/regeneron-idmc-recommends-to-hold-enrollment-in-hospitalized-high-risk-covid-19-patients-1029746946,positive,0.8544440865516663
603,11/2/2020 6:35:52 PM,"Despite Pandemic Catalysts, Tread Carefully With Sorrento Stock",InvestorPlace,/news/stocks/despite-pandemic-catalysts-tread-carefully-srne-stock-1029755014,positive,0.8151612281799316
604,11/2/2020 7:57:28 PM,Avoid Taking a Bet on the Deep Correction In Inovio Stock,InvestorPlace,/news/stocks/avoid-taking-a-bet-on-the-deep-correction-in-inovio-ino-stock-1029755366,positive,0.5376816987991333
605,11/3/2020 6:52:27 AM,"AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial ",RTTNews,/news/stocks/auph-s-dry-eye-syndrome-study-fails-kpti-s-seal-study-hits-goal-regn-halts-rare-bone-disease-trial-1029756437,negative,0.47074827551841736
606,11/3/2020 1:42:00 PM,Your First Instinct About Sorrento Therapeutics Is Probably Right,InvestorPlace,/news/stocks/srne-stock-day-late-dollar-short-1029759222,positive,0.9101305603981018
607,11/3/2020 3:01:20 PM,4 Top Biotech Stocks to Buy for Operation Warp Speed,InvestorPlace,/news/stocks/4-top-biotech-stocks-to-buy-for-operation-warp-speed-1029759219,positive,0.833585798740387
608,11/4/2020 5:09:18 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3631230-notable-earnings-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8825733065605164
609,11/4/2020 6:22:59 PM,Regeneron Pharmaceuticals Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3631354-regeneron-pharmaceuticals-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8555964231491089
610,11/5/2020 12:37:31 PM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1029769618,negative,0.8955163359642029
611,11/9/2020 4:55:35 PM,COVID-19 treatment developers under pressure on positive COVID-19 vaccine data,Seeking Alpha,https://seekingalpha.com/news/3633767-covidminus-19-treatment-developers-under-pressure-on-positive-covidminus-19-vaccine-data?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6168063282966614
612,11/10/2020 10:32:33 PM,Market Insight: What’s Behind Monday’s Huge Rally,InvestorPlace,/news/stocks/market-insight-whats-behind-mondays-huge-rally-1029789442,positive,0.8550593852996826
613,11/11/2020 2:24:45 PM,9 Outbreak-Fueled Stocks to Buy This Week,InvestorPlace,/news/stocks/stocks-to-buy-this-week-second-coronavirus-wave-1029421408,positive,0.7889739274978638
614,11/16/2020 8:18:13 AM,New Drugs Approved In October ,RTTNews,/news/stocks/new-drugs-approved-in-october-1029804585,positive,0.569122314453125
615,11/17/2020 12:28:35 PM,Health Canada OKs Sanofi/Regeneron's Dupixent for severe asthma,Seeking Alpha,https://seekingalpha.com/news/3637000-health-canada-oks-sanofi-regenerons-dupixent-for-severe-asthma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.683096170425415
616,11/17/2020 3:10:41 PM,7 Pharmaceutical Stocks to Buy for 2021 and Beyond ,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-2021-and-beyond-1029811903,positive,0.9023517370223999
617,11/17/2020 10:27:20 PM,Roche on track to produce Regeneron antibody treatment - Reuters,Seeking Alpha,https://seekingalpha.com/news/3637313-roche-on-track-to-produce-regeneron-antibody-treatment-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6740338206291199
618,11/18/2020 3:38:01 PM,These 3 Companies Currently Provide Much Better Value Than Nio,InvestorPlace,/news/stocks/these-3-companies-currently-provide-much-better-value-than-nio-stock-cseo-1029817356,negative,0.7823305130004883
619,11/20/2020 11:48:18 AM,Roche anticipates COVID-19 antibody deliveries in Q1 2021: CEO Severin Schwan,Seeking Alpha,https://seekingalpha.com/news/3638254-roche-anticipates-covidminus-19-antibody-deliveries-in-q1-2021-ceo-severin-schwan?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8817499279975891
620,11/20/2020 1:34:02 PM,"Inovio's INO-5401 + INO-9012 with Libtayo combo shows potential treatment for glioblastoma, shares +5%",Seeking Alpha,https://seekingalpha.com/news/3638311-inovios-inominus-5401-inominus-9012-libtayo-combo-shows-potential-treatment-for-glioblastoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8287156820297241
621,11/22/2020 2:53:22 AM,FDA grants emergency clearance for Regeneron's COVID-19 threapy,Seeking Alpha,https://seekingalpha.com/news/3638520-fda-grants-emergency-clearance-for-regenerons-covidminus-19-threapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8491759896278381
622,11/22/2020 4:38:50 PM,"Coronavirus update: Senator in quarantine, U.K. sets lockdown end, Japan spikes",Seeking Alpha,https://seekingalpha.com/news/3638526-coronavirus-update-senator-in-quarantine-u-k-sets-lockdown-end-japan-spikes?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7239035367965698
623,11/23/2020 7:51:59 AM,FDA Grants Emergency Use Approval To Regeneron's COVID-19 Antibody Therapy ,RTTNews,/news/stocks/fda-grants-emergency-use-approval-to-regeneron-s-covid-19-antibody-therapy-1029828026,negative,0.7997376918792725
624,11/23/2020 11:16:48 AM,"Pre-market Movers In Healthcare Sector: EIGR, SNOA, REGN, TTNP, OCGN… ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-eigr-snoa-regn-ttnp-ocgn-1029828667,positive,0.9389923214912415
625,11/23/2020 11:31:46 AM,Take Your Victory Lap and Take Your Profits in Moderna,InvestorPlace,/news/stocks/moderna-mrna-stock-take-your-victory-lap-1029829432,positive,0.921023964881897
626,11/23/2020 3:52:03 PM,REGN Stock: 11 Things for Investors to Know About Regeneron Approval,InvestorPlace,/news/stocks/regn-stock-11-things-for-investors-to-know-about-regeneron-approval-1029830793,positive,0.9467133283615112
627,11/24/2020 7:21:41 PM,"Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand",InvestorPlace,/news/stocks/7-biotech-stocks-locked-in-the-race-for-a-vaccine-1029836075,positive,0.9004662036895752
628,11/25/2020 10:56:26 AM,U.S. aims to release 6.4M COVID-19 vaccine doses in first tranche - Reuters,Seeking Alpha,https://seekingalpha.com/news/3639320-u-s-aims-to-release-6_4m-covidminus-19-vaccine-doses-in-first-tranche-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6884705424308777
629,11/25/2020 6:25:04 PM,Merck and Biotech’s Swashbuckling Era,InvestorPlace,/news/stocks/swashbuckling-era-merck-mrk-stock-1029839832,positive,0.9027481079101562
630,11/30/2020 7:08:25 AM,Regeneron Reports Approval Of Dupixent In Europe For Children With Severe Atopic Dermatitis ,RTTNews,/news/stocks/regeneron-reports-approval-of-dupixent-in-europe-for-children-with-severe-atopic-dermatitis-1029847506,negative,0.8939053416252136
631,11/30/2020 9:31:33 AM,EC OKs expanded use of Sanofi/Regeneron's Dupixent for children with atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3639833-ec-oks-expanded-use-of-sanofi-regenerons-dupixent-for-children-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8496113419532776
632,11/30/2020 4:06:20 PM,Windows of Opportunity Are Tightening for Sorrento Therapeutics,InvestorPlace,/news/stocks/opportunity-tightening-for-sorrento-therapeutics-srne-stock-1029849981,negative,0.8734881281852722
633,12/1/2020 6:01:43 PM,4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-ino-regn-abbv-nvax-that-arent-worth-their-2020-gains-1029854808,positive,0.752234935760498
634,12/2/2020 8:11:23 AM,"OVID Plunges, VNDA's Hetlioz Scores Another FDA Nod, Auris Investors Smile Ear To Ear ",RTTNews,/news/stocks/ovid-plunges-vnda-s-hetlioz-scores-another-fda-nod-auris-investors-smile-ear-to-ear-1029856042,positive,0.6996879577636719
635,12/4/2020 6:30:49 AM,Reality Hits Home for Shares of Inovio Pharmaceuticals,InvestorPlace,/news/stocks/ino-stock-reality-hits-home-inovio-pharmaceuticals-1029866169,negative,0.3952213525772095
636,12/4/2020 9:21:23 PM,Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk,InvestorPlace,/news/stocks/dont-chase-rebound-in-srne-stock-not-worth-the-risk-1029866504,positive,0.6648005843162537
637,12/7/2020 3:26:47 PM,Regeneron Pharmaceuticals stands out at ASH after positive data on lead programs,Seeking Alpha,https://seekingalpha.com/news/3642120-regeneron-pharmaceuticals-stands-out-ash-after-positive-data-on-lead-programs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9432917833328247
638,12/8/2020 9:52:33 PM,The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure,InvestorPlace,/news/stocks/the-7-best-coronavirus-vaccine-stocks-still-in-the-race-for-a-cure-1029875288,negative,0.5180488228797913
639,12/10/2020 11:01:11 AM,Government and Institutional Support Are Positives for Sorrento Stock,InvestorPlace,/news/stocks/government-institutional-support-sorrento-snre-stock-1029880666,negative,0.946810781955719
640,12/15/2020 3:35:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's announces completion of a periodic review of ratings of Regeneron Pharmaceuticals, Inc.",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-regeneron-pharmaceuticals-inc-1029894379,positive,0.7982850074768066
641,12/15/2020 8:04:08 PM,Regeneron's odronextamab hit with FDA partial hold on lymphoma trials,Seeking Alpha,https://seekingalpha.com/news/3644594-regenerons-odronextamab-hit-fda-partial-hold-on-lymphoma-trials?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8544842600822449
642,12/18/2020 7:41:39 PM,Vir Biotech’s COVID-19 agents could be ‘NPV negative’: Baird,Seeking Alpha,https://seekingalpha.com/news/3645867-vir-biotech-s-covidminus-19-agents-be-npv-negative-baird?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8025674819946289
643,12/23/2020 10:21:52 AM,7 Short-Term Stocks To Buy for a Happy New Year  ,InvestorPlace,/news/stocks/7-short-term-stocks-to-buy-for-a-happy-new-year-1029916535,positive,0.8187479376792908
644,12/24/2020 12:36:39 PM,Judge blocks ‘Most-Favored Nation’ rule for drug pricing,Seeking Alpha,https://seekingalpha.com/news/3647316-judge-blocks-favored-nation-rule-for-drug-pricing?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5158914923667908
645,12/29/2020 8:08:08 PM,COVID-19 antibody therapies left unused; developers carry on regardless,Seeking Alpha,https://seekingalpha.com/news/3647775-covidminus-19-antibody-therapies-left-unused-developers-carry-on-regardless?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.822996973991394
646,12/29/2020 10:17:06 PM,Regeneron's COVID-19 antibody therapy yields 'encouraging' trial data,Seeking Alpha,https://seekingalpha.com/news/3647800-regenerons-covidminus-19-antibody-therapy-yields-encouraging-trial-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9501919150352478
647,12/30/2020 6:13:38 AM,Regeneron Says Initial Data From COVID-19 Antibody Cocktail Trial Encouraging ,RTTNews,/news/stocks/regeneron-says-initial-data-from-covid-19-antibody-cocktail-trial-encouraging-1029924395,positive,0.7647813558578491
648,12/30/2020 2:08:28 PM,"The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data",Benzinga,/news/stocks/the-daily-biotech-pulse-osmotica-faces-second-fda-rejection-uk-conditionally-approves-astrazeneca-s-vaccine-candidate-hepion-nash-data-1029925168,positive,0.47888317704200745
649,12/30/2020 9:14:30 PM,Big Winners In 2020! Could These Stocks Outperform Again In 2021? ,RTTNews,/news/stocks/big-winners-in-2020-could-these-stocks-outperform-again-in-2021-1029926076,positive,0.6256939768791199
650,12/31/2020 6:30:40 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3648089-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
651,1/4/2021 10:11:21 AM,Latest Pivot Does Little To Bolster Case for IDEX Stock Charging Higher,InvestorPlace,/news/stocks/latest-pivot-does-little-to-bolster-case-for-idex-stock-charging-higher-1029929897,negative,0.40309277176856995
652,1/7/2021 9:30:51 PM,"Moderna Is An Example of Why You Should Buy Systems, Not Drugs",InvestorPlace,/news/stocks/mrna-stock-is-an-example-of-why-you-should-buy-systems-not-drugs-1029942264,positive,0.9299733638763428
653,1/8/2021 1:08:50 PM,Regeneron upgraded to Buy at Citi on overlooked Dupixent opportunity,Seeking Alpha,https://seekingalpha.com/news/3649901-regeneron-upgraded-to-buy-citi-on-overlooked-dupixent-opportunity?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5671349167823792
654,1/11/2021 6:04:42 PM,Regeneron Pharmaceuticals reports Q4 and FY20 net product sales,Seeking Alpha,https://seekingalpha.com/news/3650415-regeneron-pharmaceuticals-reports-q4-and-fy20-net-product-sales?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.928472101688385
655,1/12/2021 7:36:22 PM,7 Potential IPOs in 2021 That Could Build Out Your Portfolio,InvestorPlace,/news/stocks/7-potential-ipos-in-2021-that-could-build-out-portfolio-1029961808,negative,0.7261664271354675
656,1/12/2021 10:59:40 PM,"U.S. Gov to purchase additional COVID-19 antibody cocktail doses from Regeneron, stock +4.2%",Seeking Alpha,https://seekingalpha.com/news/3650922-u-s-gov-to-purchase-additional-covidminus-19-antibody-cocktail-doses-from-regeneron-stockplus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7425812482833862
657,1/13/2021 3:27:43 AM,Roche : US To Purchase Addl Doses Of Antibody Cocktail For Use In Non-hospitalised COVID-19 Patients ,RTTNews,/news/stocks/roche-us-to-purchase-addl-doses-of-antibody-cocktail-for-use-in-non-hospitalised-covid-19-patients-1029962233,negative,0.6774840950965881
658,1/13/2021 4:05:52 PM,"Benzinga's Top Upgrades, Downgrades For January 13, 2021",Benzinga,/news/stocks/benzinga-s-top-upgrades-downgrades-for-january-13-2021-1029965040,neutral,0.6085268259048462
659,1/13/2021 7:01:52 PM,"Why Regeneron, Jaguar Health And Seneca Are Moving Today",Benzinga,/news/stocks/why-regeneron-jaguar-health-and-seneca-are-moving-today-1029965717,positive,0.9426310062408447
660,1/13/2021 10:27:20 PM,Regeneron secures $2.63B U.S. Army contract,Seeking Alpha,https://seekingalpha.com/news/3651306-regeneron-secures-2_63b-u-s-army-contract?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.905075192451477
661,1/13/2021 10:36:36 PM,"4 Top Stock Trades for Thursday: AMZN, PLUG, GME, REGN",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-amzn-plug-gme-regn-1029966329,positive,0.927871823310852
662,1/18/2021 9:38:34 AM,New drugs and injections to overcome challenges in COVID-19 antibody therapies - WSJ,Seeking Alpha,https://seekingalpha.com/news/3652061-new-drugs-and-injections-to-overcome-challenges-in-covidminus-19-antibody-therapies-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8107872605323792
663,1/21/2021 4:25:23 PM,Biden Stocks: 16 Stocks to Watch for a Defense Production Act Boost,InvestorPlace,/news/stocks/biden-stocks-16-stocks-to-watch-for-a-defense-production-act-boost-1029991455,positive,0.895939290523529
664,1/22/2021 10:13:36 PM,The Best 4 Pharmaceutical Stocks to Buy in Any Climate,InvestorPlace,/news/stocks/the-best-4-pharmaceutical-stocks-to-buy-in-any-climate-1030014921,positive,0.7539841532707214
665,1/25/2021 4:03:24 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-25-2021-1029999797,neutral,0.6350283026695251
666,1/25/2021 5:23:09 PM,Regeneron upgraded at BMO; says ‘well-positioned’ for 2021,Seeking Alpha,https://seekingalpha.com/news/3653976-regeneron-upgraded-at-bmo-says-well-positioned-for-2021?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8994720578193665
667,1/25/2021 5:29:30 PM,"Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today",Benzinga,/news/stocks/why-aurinia-pharma-astrazeneca-and-more-are-trading-higher-today-1030000230,positive,0.77898770570755
668,1/25/2021 6:32:59 PM,"Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation",Benzinga,/news/stocks/pharma-stock-ideas-why-bmo-is-recommending-regeneron-constellation-1030000467,positive,0.924015462398529
669,1/25/2021 10:29:05 PM,Germany to become first in EU to use COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3654167-germany-to-become-first-in-eu-to-use-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6590954661369324
670,1/26/2021 3:16:17 PM,Regeneron's Interim Late-stage Study Shows Antibody Cocktail Effective To Prevent COVID-19 ,RTTNews,/news/stocks/regeneron-s-interim-late-stage-study-shows-antibody-cocktail-effective-to-prevent-covid-19-1030004885,negative,0.8631086349487305
671,1/26/2021 4:08:12 PM,Regeneron COVID-19 antibody drug effective in preventing COVID-19,Seeking Alpha,https://seekingalpha.com/news/3654348-regeneron-covid-19-antibody-drug-effective-in-preventing-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8632693290710449
672,1/27/2021 8:56:46 AM,"AGIO's ACTIVATE-T Hits Goals, EDSA Catches Eye, JNJ Provides Rosy Outlook, VXRT On Watch ",RTTNews,/news/stocks/agio-s-activate-t-hits-goals-edsa-catches-eye-jnj-provides-rosy-outlook-vxrt-on-watch-1030008289,negative,0.8746792674064636
673,1/27/2021 12:40:52 PM,Regeneron’s antibody cocktail neutralizes new COVID-19 variants,Seeking Alpha,https://seekingalpha.com/news/3654838-regenerons-antibody-cocktail-neutralizes-new-covid-19-variants?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.49047961831092834
674,1/27/2021 1:33:40 PM,Regeneron: Researchers Confirm Ability Of REGEN-COV To Neutralize SARS-CoV-2 Variants ,RTTNews,/news/stocks/regeneron-researchers-confirm-ability-of-regen-cov-to-neutralize-sars-cov-2-variants-1030009203,negative,0.9427556991577148
675,1/27/2021 1:35:59 PM,"The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement",Benzinga,/news/stocks/the-daily-biotech-pulse-sorrento-immutep-surge-on-covid-19-study-data-t2-biosystems-sinks-on-preannouncement-1030009241,positive,0.8347625136375427
676,1/29/2021 10:01:50 AM,More Convincing Reasons to Just Buy Palantir Technologies Stock,InvestorPlace,/news/stocks/more-convincing-reasons-to-just-buy-palantir-technologies-stock-1030019233,positive,0.9037519097328186
677,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250,positive,0.8783656358718872
678,1/31/2021 11:22:18 AM,Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-february-pdufa-dates-1030022689,positive,0.9469277858734131
679,2/3/2021 3:02:05 PM,Regeneron Pharmaceuticals earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q4-1030038599,positive,0.9300113916397095
680,2/4/2021 10:46:47 AM,7 Safe Growth Stocks to Put In Your Buy-and-Hold Portfolio,InvestorPlace,/news/stocks/7-safe-growth-stocks-to-put-your-trust-in-this-year-1030042740,positive,0.9276878237724304
681,2/4/2021 5:58:30 PM,Regeneron Pharmaceuticals Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3658545-regeneron-pharmaceuticals-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8732079863548279
682,2/4/2021 6:05:16 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3658555-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
683,2/5/2021 11:32:49 AM,"Regeneron Pharmaceuticals EPS beats by $1.24, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3658972-regeneron-pharmaceuticals-eps-beats-1_24-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.840747594833374
684,2/5/2021 12:01:49 PM,"Regeneron Pharma posts double-digit top and bottom-line growth, shares up 3%",Seeking Alpha,https://seekingalpha.com/news/3658987-regeneron-pharma-posts-double-digit-top-and-bottom-line-growth-shares-up-3?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9514346122741699
685,2/5/2021 12:33:41 PM,Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-1030048002,negative,0.9092124104499817
686,2/5/2021 1:44:38 PM,"The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-files-for-covid-19-vaccine-approval-zimmer-biomet-s-spin-off-ipo-deluge-hits-street-1030048263,positive,0.7921019792556763
687,2/5/2021 8:30:24 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3659213-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
688,2/5/2021 10:30:34 PM,"4 Top Stock Trades for Monday: F, CLX, REGN, LKNCY",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-f-clx-regn-lkncy-1030049953,positive,0.9255874156951904
689,2/6/2021 6:42:05 PM,"The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-7-13-regeneron-fda-decision-earnings-ipos-and-conference-presentations-in-the-spotlight-1030050676,positive,0.9400112628936768
690,2/8/2021 2:41:10 PM,3 Under-the-Radar Biotech Stocks to Buy After Dull Earnings Reactions,InvestorPlace,/news/stocks/3-under-the-radar-biotech-stocks-to-buy-after-earnings-1030055864,positive,0.687945544719696
691,2/9/2021 12:35:27 PM,"Jaguar Health Isn’t a Healthy Investment, but It Could Be a Profitable One",InvestorPlace,/news/stocks/jagx-stock-not-healthy-but-could-be-profitable-1030060217,negative,0.6908979415893555
692,2/10/2021 1:34:43 PM,"The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-covid-19-antibody-cocktail-approved-for-emergency-use-gamida-genfit-jump-on-data-2-ipos-1030066164,positive,0.6823869347572327
693,2/11/2021 9:53:37 AM,"BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod ",RTTNews,/news/stocks/bpth-on-steady-path-cgix-on-watch-glpg-gild-scrap-ipf-drug-regn-s-libtayo-gets-fda-nod-1030071399,negative,0.880437970161438
694,2/11/2021 11:45:23 AM,Regeneron/ Sanofi score an early win for Libtayo in basal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3661076-regeneron-sanofi-score-an-early-win-for-libtayo-in-basal-cell-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9342089891433716
695,2/11/2021 1:26:22 PM,"The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-dermtech-soars-on-contract-fluidigm-plunges-on-earnings-decision-day-for-regeneron-bioventus-debuts-1030072237,neutral,0.9134436845779419
696,2/11/2021 7:13:20 PM,FDA approves Regeneron's Evkeeza to treat ultra-rare inherited form of high cholesterol,Seeking Alpha,https://seekingalpha.com/news/3661347-fda-approves-regenerons-evkeeza-to-treat-ultra-rare-inherited-form-of-high-cholesterol?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8249462842941284
697,2/11/2021 11:28:21 PM,"US Federal Court Upholds Appeal In Favor Of Regeneron, Sanofi On Praluent ",RTTNews,/news/stocks/us-federal-court-upholds-appeal-in-favor-of-regeneron-sanofi-on-praluent-1030074901,positive,0.5418220162391663
698,2/12/2021 12:06:06 PM,"Regeneron, Sanofi's Libtayo shows extended overall survival in lung cancer study",Seeking Alpha,https://seekingalpha.com/news/3661630-regeneron-sanofis-libtayo-shows-extended-overall-survival-in-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9309925436973572
699,2/14/2021 2:10:15 PM,"The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week",Benzinga,/news/stocks/the-week-ahead-in-biotech-fda-decision-on-g1-therapeutics-earnings-in-the-mix-for-light-calendar-week-1030080314,positive,0.8677409291267395
700,2/22/2021 6:24:16 PM,Regeneron and Sanofi get FDA approval for Libtayo in non-small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3664445-regeneron-and-sanofi-get-fda-approval-for-libtayo-in-non-small-cell-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8798506855964661
701,2/23/2021 7:02:29 PM,Why You Should Keep Your Distance from Ocugen Stock,InvestorPlace,/news/stocks/ocgn-stock-stay-your-distance-from-ocugen-1030114797,positive,0.9112824201583862
702,2/24/2021 1:03:12 PM,Decibel Therapeutics posts hearing loss gene therapy preclinical data,Seeking Alpha,https://seekingalpha.com/news/3665457-decibel-therapeutics-posts-hearing-loss-gene-therapy-preclinical-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8940960764884949
703,2/24/2021 1:17:19 PM,RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today,InvestorPlace,/news/stocks/rlftf-why-little-known-relief-therapeutics-is-climbing-today-brpa-stock-1030119085,negative,0.6067991852760315
704,2/25/2021 2:31:07 PM,Regeneron Pharma Stops Placebo Group Enrollment For REGEN-COV On Advice From IDMC ,RTTNews,/news/stocks/regeneron-pharma-stops-placebo-group-enrollment-for-regen-cov-on-advice-from-idmc-1030123866,neutral,0.7717036008834839
705,2/26/2021 1:41:14 PM,Roche : CHMP Opinion Supports Use Of Casirivimab-imdevimab Antibody Cocktail For COVID Treatment ,RTTNews,/news/stocks/roche-chmp-opinion-supports-use-of-casirivimab-imdevimab-antibody-cocktail-for-covid-treatment-1030129212,negative,0.6487096548080444
706,2/26/2021 2:21:08 PM,Regeneron's antibody cocktail is set for marketing approval in EU,Seeking Alpha,https://seekingalpha.com/news/3667153-regenerons-antibody-cocktail-is-set-for-marketing-approval-in-eu?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.792083740234375
707,2/28/2021 2:04:13 AM,Regeneron’s antibody cocktail shows promise in cat-allergic patients with mild asthma,Seeking Alpha,https://seekingalpha.com/news/3667404-regenerons-antibody-cocktail-shows-promise-in-cat-allergic-patients-with-mild-asthma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9420695304870605
708,2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296,positive,0.9465387463569641
709,3/3/2021 10:07:23 PM,Regeneron and Kiniksa sign commercial supply agreement for Rilonacept,Seeking Alpha,https://seekingalpha.com/news/3669127-regeneron-and-kiniksa-sign-commercial-supply-agreement-for-rilonacept?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8616917729377747
710,3/4/2021 6:32:26 AM,"FDA accepts Regeneron, Sanofi's Dupixent application for children with asthma",Seeking Alpha,https://seekingalpha.com/news/3669188-fda-accepts-regenerons-dupixent-application-for-children-with-asthma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8302858471870422
711,3/4/2021 7:29:27 AM,Sanofi : FDA Accepts Dupixent For Review In Children With Moderate-to-severe Asthma ,RTTNews,/news/stocks/sanofi-fda-accepts-dupixent-for-review-in-children-with-moderate-to-severe-asthma-1030148564,negative,0.6990871429443359
712,3/4/2021 2:12:10 PM,"The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-pfizer-kiniksa-rises-on-commercialization-pact-with-regeneron-bio-techne-to-buy-diagnostic-company-1030150188,negative,0.9189565181732178
713,3/9/2021 5:46:49 PM,Why Is Graybug Vision Stock Plunging Today?,Benzinga,/news/stocks/why-is-graybug-vision-stock-plunging-today-1030165040,neutral,0.9123253226280212
714,3/9/2021 8:59:47 PM,Bet on Black With These 7 Risky Stocks  ,InvestorPlace,/news/stocks/bet-on-black-with-these-7-risky-stocks-1030165824,positive,0.9042626619338989
715,3/11/2021 4:58:29 PM,7 Stocks That Cathie Wood Likes and You Should Too,InvestorPlace,/news/stocks/7-stocks-that-cathie-wood-likes-and-you-should-too-1030174707,positive,0.9235195517539978
716,3/11/2021 9:44:40 PM,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,InvestorPlace,/news/stocks/what-did-the-stock-market-do-today-3-big-stories-cpng-stock-ocgn-stock-stimulus-1030175736,positive,0.9254742860794067
717,3/12/2021 6:04:49 PM,Merck and Pfizer among top picks to lead 2021 biopharma M&A activity: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3672343-merck-and-pfizer-among-top-picks-to-lead-2021-biopharma-ma-activity-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7542275786399841
718,3/15/2021 7:47:53 AM,Sanofi : Phase 3 Trial Of Libtayo In Advanced Cervical Cancer Stopped Early For Positive Result ,RTTNews,/news/stocks/sanofi-phase-3-trial-of-libtayo-in-advanced-cervical-cancer-stopped-early-for-positive-result-1030200977,positive,0.49187421798706055
719,3/15/2021 11:00:56 AM,"Regeneron, Sanofi winds up late-stage Libtayo study after positive data in cervical cancer",Seeking Alpha,https://seekingalpha.com/news/3672496-regeneron-sanofi-winds-up-llibtayo-study-after-positive-data-in-cervical-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9369626641273499
720,3/16/2021 7:44:00 AM,"EMA Safety Committee To Further Review AZD1222, RUBY Sparkles, DMD Trial Data Fails To Ignite SLDB ",RTTNews,/news/stocks/ema-safety-committee-to-further-review-azd1222-ruby-sparkles-dmd-trial-data-fails-to-ignite-sldb-1030212169,neutral,0.6348035931587219
721,3/17/2021 2:15:17 PM,3 Biotech Stocks That Could Double In 12 Months,Benzinga,/news/stocks/3-biotech-stocks-that-could-double-in-12-months-1030219865,negative,0.5742611885070801
722,3/23/2021 6:47:24 AM,"Regeneron's COVID-19 antibody reduces hospitalization, death by 70%",Seeking Alpha,https://seekingalpha.com/news/3675066-regenerons-covid-19-antibody-reduces-hospitalization-death-by-70?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.889670193195343
723,3/23/2021 7:29:24 AM,REGN : Antibody Cocktail Reduces Hospitalization/Death By 70% In Non-hospitalized COVID-19 Patients ,RTTNews,/news/stocks/regn-antibody-cocktail-reduces-hospitalization-death-by-70-in-non-hospitalized-covid-19-patients-1030234691,negative,0.9177993535995483
724,3/23/2021 1:18:20 PM,"The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approvals-for-merck-pacira-and-zealand-roche-regeneron-ace-late-stage-covid-19-study-allovir-appoints-gilead-virology-chief-as-ceo-1030236141,positive,0.853547990322113
725,3/25/2021 4:30:01 PM,Pfizer’s tanezumab in osteoarthritis turned down by FDA expert panel (updated),Seeking Alpha,https://seekingalpha.com/news/3676348-pfizers-marketing-application-on-tanezumab-fails-in-adcom-vote?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.528425931930542
726,3/26/2021 6:00:46 AM,"Alibaba, Amazon, Palantir, Google, Takeda, Unity — What Cathie Wood's Ark Bought And Sold On Thursday",Benzinga,/news/stocks/alibaba-amazon-palantir-google-takeda-unity-—-what-cathie-wood-s-ark-bought-and-sold-on-thursday-1030248437,positive,0.937481701374054
727,3/26/2021 12:37:55 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1030249587,positive,0.7916322350502014
728,3/31/2021 7:58:21 AM,Regeneron's Eylea reduces vision loss by 68% after two years in diabetic retinopathy,Seeking Alpha,https://seekingalpha.com/news/3677905-regenerons-eylea-reduces-vision-loss-by-68-after-two-years-in-diabetic-retinopathy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9512600898742676
729,3/31/2021 1:41:12 PM,"The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-vaccine-100-effective-in-adolescents-equillium-readout-amgen-goes-shopping-achilles-ipo-1030263061,positive,0.8173462748527527
730,4/2/2021 2:01:55 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1030271706,positive,0.9468021392822266
731,4/3/2021 3:11:24 PM,"The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-regeneron-supernus-fda-decisions-cancer-conference-presentations-in-the-spotlight-1030272481,positive,0.9472838640213013
732,4/6/2021 3:19:02 PM,7 Best Stocks on the Nasdaq,InvestorPlace,/news/stocks/7-best-stocks-on-the-nasdaq-1030278186,positive,0.8731510043144226
733,4/9/2021 2:30:37 PM,Regeneron: NIH Panel Recommends Use Of REGEN-COV In COVID-19 Outpatients At High Risk Of Progression ,RTTNews,/news/stocks/regeneron-nih-panel-recommends-use-of-regen-cov-in-covid-19-outpatients-at-high-risk-of-progression-1030289116,positive,0.7148765325546265
734,4/11/2021 5:43:59 PM,4 Undervalued Stocks To Watch For In April,Benzinga,/news/stocks/4-undervalued-stocks-to-watch-for-in-april-1030291469,neutral,0.5980991721153259
735,4/12/2021 6:50:56 AM,Regeneron/Roche's antibody cocktail reduces risk of COVID-19 infections,Seeking Alpha,https://seekingalpha.com/news/3680865-regeneronroches-antibody-cocktail-reduces-risk-of-covid-19-infections?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9064121842384338
736,4/12/2021 7:29:15 AM,REGN :Phase 3 Trial Shows 81% Reduced Risk Of SARS-CoV-2 Infections With Administration Of REGEN-COV ,RTTNews,/news/stocks/regn-phase-3-trial-shows-81-reduced-risk-of-sars-cov-2-infections-with-administration-of-regen-cov-1030292319,negative,0.9273947477340698
737,4/12/2021 5:02:08 PM,Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks,InvestorPlace,/news/stocks/vaccine-passport-potential-could-boost-these-7-pharmaceutical-stocks-1030295137,negative,0.9323841333389282
738,4/13/2021 9:36:54 AM,"U.K. COVID-19 variant doesn't cause more deaths, study finds",Seeking Alpha,https://seekingalpha.com/news/3681226-uk-covid-19-variant-doesnt-cause-more-deaths-study-finds?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6644791960716248
739,4/15/2021 2:55:06 PM,"Cramer Weighs In On Paysafe, Xilinx And More",Benzinga,/news/stocks/cramer-weighs-in-on-paysafe-xilinx-and-more-1030308355,positive,0.6475961208343506
740,4/15/2021 5:39:05 PM,Merck hurt by another setback in its battle against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682287-merck-hurt-by-another-setback-in-its-battle-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9712752103805542
741,4/19/2021 4:58:40 PM,Large NIH-funded study to explore repurposed drugs for mild-to-moderate COVID-19,Seeking Alpha,https://seekingalpha.com/news/3683056-large-nih-funded-study-to-explore-repurposed-drugs-for-mild-to-moderate-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4961980879306793
742,4/20/2021 7:48:23 AM,"Cathie Wood Buys Peloton, Coinbase Dips, Cuts Nvidia Stake",Benzinga,/news/stocks/cathie-wood-buys-peloton-coinbase-dips-cuts-nvidia-stake-1030321133,neutral,0.863761842250824
743,4/22/2021 6:45:08 AM,"Cathie Wood Loads Up Heavily On Debutant Uipath, Trims Tesla",Benzinga,/news/stocks/cathie-wood-loads-up-heavily-on-debutant-uipath-trims-tesla-1030331328,negative,0.8177163004875183
744,4/26/2021 3:06:57 PM,7 Healthcare Stocks for a Reopening World,InvestorPlace,/news/stocks/7-healthcare-stocks-for-a-reopening-world-1030346737,positive,0.827012300491333
745,4/29/2021 6:10:51 PM,7 Health-Focused ETFs To Buy Now For the Post-Covid Future,InvestorPlace,/news/stocks/7-health-focused-etfs-to-buy-now-for-the-post-covid-future-1030366420,positive,0.847977340221405
746,4/30/2021 5:39:43 AM,"Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla",Benzinga,/news/etf/cathie-wood-piles-up-teladoc-as-shares-slump-on-q1-miss-also-adds-more-tesla-1030367623,neutral,0.7233296036720276
747,5/1/2021 7:19:25 PM,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",Benzinga,/news/stocks/week-ahead-in-biotech-may-2-8-chemocentryx-adcom-ophthalmology-conference-presentations-earnings-deluge-1030373608,positive,0.8418352007865906
748,5/4/2021 6:17:24 AM,"Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD — Also Adds Skillz",Benzinga,/news/stocks/cathie-wood-loads-up-more-on-alibaba-rivals-pinduoduo-jd-—-also-adds-skillz-1030381350,negative,0.8276785612106323
749,5/4/2021 3:02:12 PM,Regeneron Pharmaceuticals is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-quarter-earnings-preview-q1-1030384412,positive,0.9330263137817383
750,5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6773343086242676
751,5/5/2021 8:52:20 AM,Cathie Wood Loaded Up Further On Skillz On Earnings Day,Benzinga,/news/stocks/cathie-wood-loaded-up-further-on-skillz-on-earnings-day-1030388979,negative,0.8949488401412964
752,5/5/2021 4:48:53 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3691210-notable-earnings-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8825733065605164
753,5/5/2021 4:54:48 PM,Regeneron Pharmaceuticals Q1 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3691215-regeneron-pharmaceuticals-q1-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8182869553565979
754,5/6/2021 7:18:58 AM,"Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip",Benzinga,/news/stocks/cathie-wood-loads-up-more-on-peloton-skillz-teladoc-on-the-dip-1030394379,positive,0.7985936403274536
755,5/6/2021 12:33:18 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Miss Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-miss-estimates-1030395441,neutral,0.9388075470924377
756,5/6/2021 1:49:39 PM,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-keytruda-snags-another-fda-approval-moderna-slips-on-revenue-miss-chemocentryx-adcom-1030395950,neutral,0.9611167907714844
757,5/6/2021 6:28:44 PM,"Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study",Benzinga,/news/stocks/ocugen-shares-sink-despite-ocu200-being-comparable-to-aflibercept-in-reducing-neovascularization-damage-to-retina-in-animal-study-1030397918,negative,0.9415081739425659
758,5/7/2021 8:22:04 AM,"Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know",Benzinga,/news/stocks/cathie-wood-slashes-apple-stake-to-half-—-also-trims-google-fastly-what-you-need-to-know-1030401084,positive,0.6804787516593933
759,5/10/2021 10:52:10 AM,Checkmate Pharma teams up with Regeneron to evaluate vidutolimod + Libtayo in skin cancer,Seeking Alpha,https://seekingalpha.com/news/3693677-checkmate-pharma-teams-up-with-regeneron-to-evaluate-vidutolimod-libtayo-in-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8622562289237976
760,5/10/2021 11:00:59 PM,"Tesla, Qualcomm Plummet, Lead QQQ Sharply Lower Monday",Benzinga,/news/stocks/tesla-qualcomm-plummet-lead-qqq-sharply-lower-monday-1030411174,neutral,0.969455361366272
761,5/11/2021 5:07:42 AM,"Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings",Benzinga,/news/stocks/cathie-wood-cuts-apple-stake-by-30-and-buys-coinbase-draftkings-1030411583,positive,0.593415379524231
762,5/12/2021 7:05:05 AM,Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat,Benzinga,/news/stocks/cathie-wood-loads-up-57m-in-palantir-as-stock-stages-reversal-on-q1-earnings-beat-1030418631,negative,0.9281323552131653
763,5/12/2021 6:32:02 PM,Regeneron and Sanofi updates data from late-stage trial for Libtayo in cervical cancer,Seeking Alpha,https://seekingalpha.com/news/3695433-regeneron-and-sanofi-updates-data-from-late-stage-trial-for-libtayo-in-cervical-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8451792001724243
764,5/13/2021 4:21:27 AM,"Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares",Benzinga,/news/stocks/cathie-wood-piles-up-palantir-for-third-day-in-a-row-adding-39m-worth-of-shares-1030423564,positive,0.5324515700340271
765,5/13/2021 6:59:49 AM,Cramer is calling them 'WoodStocks'; latest changes to ARK ETFs,Seeking Alpha,https://seekingalpha.com/news/3695694-cramer-is-calling-them-woodstocks-latest-changes-to-ark-etfs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9219450950622559
766,5/14/2021 7:04:33 AM,Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day,Benzinga,/news/stocks/cathie-wood-sheds-33-6m-alibaba-shares-on-earnings-day-1030429592,neutral,0.6546709537506104
767,5/17/2021 5:33:43 AM,Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know,Benzinga,/news/stocks/cathie-wood-buys-26m-disney-shares-and-sells-13m-in-netflix-what-you-need-to-know-1030433399,positive,0.9386593699455261
768,5/17/2021 2:09:53 PM,"Regeneron, Sanofi post promising data from late-stage Dupixent asthma trial",Seeking Alpha,https://seekingalpha.com/news/3697179-regeneron-sanofi-post-promising-data-from-late-stage-dupixent-asthma-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9447329640388489
769,5/17/2021 4:23:36 PM,Regeneron Presents Detailed Results From Phase 3 Pivotal Trial For REGEN-COV - Quick Facts ,RTTNews,/news/stocks/regeneron-presents-detailed-results-from-phase-3-pivotal-trial-for-regen-cov-quick-facts-1030437226,positive,0.8666764497756958
770,5/17/2021 4:25:51 PM,Regeneron : Phase 3 Data Show Dupixent Reduces Asthma Attacks And Improves Lung Function In Children ,RTTNews,/news/stocks/regeneron-phase-3-data-show-dupixent-reduces-asthma-attacks-and-improves-lung-function-in-children-1030437243,negative,0.9478890895843506
771,5/20/2021 6:16:48 PM,Moderna Holds the Key to the Future of mRNA Vaccines,InvestorPlace,/news/stocks/mrna-stock-holds-the-key-to-the-future-of-vaccines-1030452921,positive,0.8024299740791321
772,5/24/2021 5:38:17 AM,"EMA advisory group backs Regeneron, Sanofi's Libtayo in lung and skin cancer",Seeking Alpha,https://seekingalpha.com/news/3699313-ema-advisory-group-backs-regeneron-sanofis-libtayo-in-lung-and-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7283565998077393
773,5/24/2021 7:20:19 AM,Regeneron : Libtayo Gets Positive CHMP Opinion For Treatment Of Two Advanced Cancers ,RTTNews,/news/stocks/regeneron-libtayo-gets-positive-chmp-opinion-for-treatment-of-two-advanced-cancers-1030457690,negative,0.9550645351409912
774,5/26/2021 1:04:33 PM,"Agilent price target lifted after guidance raise,  Travere downgraded on regulatory update; more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3700286-agilent-price-target-lifted-after-guidance-raise-travere-downgraded-on-regulatory-update?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6008889675140381
775,5/27/2021 3:12:17 AM,GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization; Vir up 9%,Seeking Alpha,https://seekingalpha.com/news/3700603-gsk-vir-covid-19-biologic-wins-fda-emergency-use-authorization-vir-up-9?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9460386633872986
776,6/3/2021 2:02:55 PM,Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics,Benzinga,/news/stocks/diversifying-to-conquer-fortress-biotech-fbio-partnering-expansion-driving-progress-in-cancer-immunotherapy-and-rare-disease-therapeutics-1030490924,negative,0.7314745783805847
777,6/4/2021 11:51:31 AM,FDA updates REGEN-COV EUA to treat patients with COVID-19 at lower dose,Seeking Alpha,https://seekingalpha.com/news/3703251-fda-updates-regen-cov-eua-to-treat-patients-with-covid-19-at-lower-dose?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6236539483070374
778,6/4/2021 1:27:22 PM,"FDA Updates EUA For REGEN-COV With Lower Dosage Of 1,200 Mg - Quick Facts ",RTTNews,/news/stocks/fda-updates-eua-for-regen-cov-with-lower-dosage-of-1-200-mg-quick-facts-1030494782,negative,0.7002330422401428
779,6/4/2021 3:39:13 PM,"The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-astrazeneca-novartis-among-early-presenters-at-asco-sanofi-strikes-breast-cancer-study-pact-1030495387,positive,0.9197812080383301
780,6/4/2021 7:30:04 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3703423-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
781,6/9/2021 6:40:28 PM,INO Stock: 2 Big Reasons Inovio Pharmaceuticals Is Shooting Higher Today,InvestorPlace,/news/stocks/ino-stock-2-big-reasons-inovio-pharmaceuticals-is-shooting-higher-today-1030509269,negative,0.9412119388580322
782,6/15/2021 9:59:16 AM,AstraZeneca’s STORM CHASER trial in COVID-19 misses primary endpoint of preventing COVID-19,Seeking Alpha,https://seekingalpha.com/news/3706281-astrazenecas-storm-chaser-trial-in-covid-19-misses-primary-endpoint-of-preventing-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7501548528671265
783,6/16/2021 5:33:32 AM,Regeneron's REGEN-COV reduces death by 20% in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3706734-regenerons-regen-cov-reduces-death-by-20-in-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9231515526771545
784,6/16/2021 7:00:00 AM,"REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2",PR Newswire,/news/stocks/regen-cov-casirivimab-and-imdevimab-phase-3-recovery-trial-meets-primary-outcome-improving-survival-in-hospitalized-covid-19-patients-lacking-an-immune-response-to-sars-cov-2-1030526463,negative,0.9538000226020813
785,6/16/2021 7:29:05 AM,Regeneron's REGEN-COV Improves Survival In Hospitalized COVID-19 Patients ,RTTNews,/news/stocks/regeneron-s-regen-cov-improves-survival-in-hospitalized-covid-19-patients-1030526490,negative,0.9539433717727661
786,6/16/2021 2:20:39 PM,"The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-covid-19-antibody-cocktail-data-fda-nod-for-mallinckrodt-molecular-partners-ipo-1030527915,positive,0.9316365122795105
787,6/17/2021 1:44:32 PM,"CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3707230-curevac-downgraded-following-lackluster-covid-vaccine-data-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5054667592048645
788,6/18/2021 9:25:21 AM,Dosing underway in BioNTech's BNT111 Phase 2 cancer vaccine trial in advanced melanoma,Seeking Alpha,https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4989084005355835
789,6/18/2021 12:43:34 PM,BioNTech Doses First Patient In BNT111 Phase 2 Cancer Vaccine Trial ,RTTNews,/news/stocks/biontech-doses-first-patient-in-bnt111-phase-2-cancer-vaccine-trial-1030534955,positive,0.6816555261611938
790,6/22/2021 10:15:00 PM,Regeneron to Participate in Guggenheim Biopharma Strategy Series,PR Newswire,/news/stocks/regeneron-to-participate-in-guggenheim-biopharma-strategy-series-1030544733,positive,0.804244339466095
791,6/25/2021 5:38:07 AM,Regeneron/Sanofi's Libtayo OK'd in Europe for skin cancer,Seeking Alpha,https://seekingalpha.com/news/3710015-regeneronsanofis-libtayo-okd-in-europe-for-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6633966565132141
792,6/25/2021 7:00:00 AM,Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-50-pd-l1-expression-1030553680,negative,0.8763667345046997
793,6/25/2021 7:15:00 AM,Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma-1030553689,negative,0.8848425149917603
794,6/25/2021 7:19:53 AM,Regeneron : EC Approves Libtayo For First-line Treatment Of Advanced Non-small Cell Lung Cancer ,RTTNews,/news/stocks/regeneron-ec-approves-libtayo-for-first-line-treatment-of-advanced-non-small-cell-lung-cancer-1030553701,negative,0.922146201133728
795,6/25/2021 1:32:32 PM,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-gets-authorization-for-covid-19-treatment-nods-for-sanofi-regeneron-in-europe-osmotica-divestment-2-ipos-1030554577,negative,0.7482125759124756
796,6/25/2021 6:39:42 PM,Eli Lilly COVID-19 antibody shipments halted in the U.S. citing prevalence of variants,Seeking Alpha,https://seekingalpha.com/news/3710240-eli-lilly-covid-19-antibody-shipments-halted-in-the-us-citing-prevalence-of-variants?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9594301581382751
797,6/26/2021 4:05:37 PM,"In a first, Intellia, Regeneron demonstrate CRISPR therapy benefit in the body",Seeking Alpha,https://seekingalpha.com/news/3710317-in-a-first-intellia-regeneron-demonstrate-crispr-therapy-benefit-in-the-body?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6189896464347839
798,6/26/2021 5:16:00 PM,"Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (AT...",PR Newswire,/news/stocks/intellia-and-regeneron-announce-landmark-clinical-data-showing-deep-reduction-in-disease-causing-protein-after-single-infusion-of-ntla-2001-an-investigational-crispr-therapy-for-transthyretin-at-1030556573,negative,0.9431265592575073
799,6/26/2021 5:41:03 PM,Intellia Announces Positive Interim Data On Transthyretin Amyloidosis Study ,RTTNews,/news/stocks/intellia-announces-positive-interim-data-on-transthyretin-amyloidosis-study-1030556579,negative,0.7731984853744507
800,6/28/2021 6:59:00 AM,Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/dupixent-dupilumab-smpc-updated-with-long-term-data-reinforcing-well-established-safety-profile-in-adults-with-moderate-to-severe-atopic-dermatitis-1030557369,negative,0.9430011510848999
801,6/28/2021 7:17:20 AM,EMA to update Regeneron/Sanofi's Dupixent SmPC for adults with atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3710337-ema-to-update-regeneronsanofis-dupixent-smpc-for-adults-with-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.848868191242218
802,6/28/2021 7:45:25 AM,"Regeneron, Sanofi: EMA To Update Dupixent SmPC With Long-term Safety Data ",RTTNews,/news/stocks/regeneron-sanofi-ema-to-update-dupixent-smpc-with-long-term-safety-data-1030557432,positive,0.8591659069061279
803,6/28/2021 9:38:42 AM,Gene editing stocks take off as Intellia development slices through sector,Seeking Alpha,https://seekingalpha.com/news/3710343-gene-editing-stocks-take-off-after-intellia-development-slices-through-sector?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.45866718888282776
804,6/28/2021 12:25:07 PM,"Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks",InvestorPlace,/news/stocks/gene-editing-stocks-the-big-news-lifting-edit-bngo-crsp-and-ntla-stocks-1030558761,positive,0.9515775442123413
805,6/28/2021 12:25:17 PM,"Intellia in focus after landmark trial data, Unity Biotech wins double upgrade: in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3710437-intellia-in-focus-after-landmark-trial-data-unity-biotech-wins-double-upgrade-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9082427620887756
806,6/28/2021 2:49:22 PM,Why Intellia Therapeutics Stock Is Soaring Today,Benzinga,/news/stocks/why-intellia-therapeutics-stock-is-soaring-today-1030558924,negative,0.7468340396881104
807,6/28/2021 6:25:01 PM,Gene editing stocks buoyed in afternoon trading by Intellia CRISPR success,Seeking Alpha,https://seekingalpha.com/news/3710667-gene-editing-stocks-buoyed-in-afternoon-trading-by-intellia-crispr-success?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8805329203605652
808,6/29/2021 3:54:15 PM,Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3711042-lilly-and-regeneron-monoclonal-antibodies-among-preferred-therapies-in-eu-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5084574222564697
809,6/29/2021 4:03:41 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-29-2021-1030563442,neutral,0.5795726180076599
810,6/29/2021 6:29:56 PM,"Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated",Benzinga,/news/stocks/why-regeneron-pharmaceuticals-analyst-says-competitive-concerns-are-overblown-pipeline-opportunity-underappreciated-1030564059,neutral,0.9371546506881714
811,6/30/2021 12:55:23 PM,"Altimmune price targets lowered, Tilray’s next move predicted at BofA - in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3711337-altimmune-price-targets-lowered-tilrays-next-move-predicted-at-bofa-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8291890621185303
812,6/30/2021 5:37:41 PM,The 3 Biotech Firms Riding High on CRISPR News,InvestorPlace,/news/stocks/the-3-biotech-firms-riding-high-on-crispr-news-1030568633,negative,0.8648343682289124
813,6/30/2021 7:53:24 PM,Intellia co-founder and gene editing pioneer Jennifer Doudna outlines future of CRISPR,Seeking Alpha,https://seekingalpha.com/news/3711569-intellia-co-founder-and-gene-editing-pioneer-jennifer-doudna-outlines-future-of-crispr?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9349033236503601
814,7/1/2021 7:48:05 PM,Regeneron scientists discover genetic mutations associated with obesity protection,Seeking Alpha,https://seekingalpha.com/news/3712154-regeneron-scientists-discover-genetic-mutations-associated-with-obesity-protection?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8340991735458374
815,7/1/2021 8:05:00 PM,Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity,PR Newswire,/news/stocks/regeneron-genetics-center-discovers-gpr75-gene-mutations-that-protect-against-obesity-1030572996,positive,0.7795137166976929
816,7/1/2021 9:28:26 PM,"4 Top Stock Trades for Friday: SQ, REGN, WBA, CRWD",InvestorPlace,/news/stocks/4-top-stock-trades-for-friday-sq-regn-wba-crwd-1030573802,positive,0.9287893176078796
817,7/3/2021 3:26:32 AM,Intellia and gene editors lead weekly healthcare gainers; CEL-SCI and Citius trail,Seeking Alpha,https://seekingalpha.com/news/3712730-intellia-and-gene-editors-lead-weekly-healthcare-gainers-cel-sci-and-citius-trail?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8811821937561035
818,7/5/2021 6:40:00 PM,Sanofi -- Moody's announces completion of a periodic review of ratings of Sanofi,Moodys,/news/bonds/sanofi-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-sanofi-1030579233,positive,0.8552985191345215
819,7/7/2021 11:58:17 AM,Silverback surges 12% after supply agreement with Regeneron (updated),Seeking Alpha,https://seekingalpha.com/news/3713216-regeneron-to-provide-libtayo-to-silverback-for-evaluation-of-nsclc-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9190039038658142
820,7/7/2021 10:15:00 PM,"Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021",PR Newswire,/news/stocks/regeneron-to-report-second-quarter-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-5-2021-1030587450,positive,0.9501614570617676
821,7/15/2021 10:12:42 PM,AMD And Biogen Lead The QQQ Lower Thursday,Benzinga,/news/stocks/amd-and-biogen-lead-the-qqq-lower-thursday-1030613067,neutral,0.9637587070465088
822,7/16/2021 5:13:32 PM,Regeneron spending $1.8B to expand footprint in New York,Seeking Alpha,https://seekingalpha.com/news/3716057-regeneron-spending-18b-to-expand-footprint-in-new-york?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9022322297096252
823,7/20/2021 7:00:00 AM,Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19,PR Newswire,/news/stocks/japan-becomes-first-country-to-approve-regeneron-antibody-cocktail-casirivimab-and-imdevimab-for-the-treatment-of-mild-to-moderate-covid-19-1030623299,negative,0.8040019273757935
824,7/20/2021 7:13:55 AM,Japan Approves Regeneron's Antibody Cocktail To Treat Mild To Moderate COVID-19 ,RTTNews,/news/stocks/japan-approves-regeneron-s-antibody-cocktail-to-treat-mild-to-moderate-covid-19-1030623314,negative,0.8892221450805664
825,7/20/2021 10:20:02 AM,Japan approves Regeneron/Roche's antibody cocktail REGEN-COV in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3716701-japan-approves-regeneronroches-antibody-cocktail-regen-cov-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5618153810501099
826,7/27/2021 1:00:00 PM,"Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity",PR Newswire,/news/stocks/regeneron-and-astrazeneca-to-research-develop-and-commercialize-new-small-molecule-medicines-for-obesity-1030649466,positive,0.7210286259651184
827,7/27/2021 1:48:33 PM,"The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-obseva-surges-on-out-licensing-deal-eyegate-appoints-new-ceo-2-positive-catalysts-for-merck-candel-therapeutics-debuts-1030649705,negative,0.7360387444496155
828,7/27/2021 1:55:24 PM,Regeneron In R&D Deal With AstraZeneca For Treatment Of Obesity ,RTTNews,/news/stocks/regeneron-in-r-d-deal-with-astrazeneca-for-treatment-of-obesity-1030649717,negative,0.672123908996582
829,7/29/2021 6:59:00 AM,"Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients",PR Newswire,/news/stocks/dupixent-dupilumab-significantly-improved-itch-and-hives-in-patients-with-chronic-spontaneous-urticaria-a-step-forward-in-demonstrating-the-role-of-type-2-inflammation-in-these-patients-1030660351,negative,0.9450897574424744
830,7/29/2021 7:27:52 AM,"Regeneron, Sanofi: Phase 3 Trial On Dupixent Met Key Endpoints At 24 Weeks ",RTTNews,/news/stocks/regeneron-sanofi-phase-3-trial-on-dupixent-met-key-endpoints-at-24-weeks-1030660417,negative,0.914832592010498
831,7/29/2021 2:18:48 PM,"The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-disappointing-q2-atreca-falls-on-data-fda-nod-for-viatris-nuvalent-icosavax-ipos-1030662210,neutral,0.9680227041244507
832,7/30/2021 7:35:50 PM,Regeneron wins expanded authorization from FDA for COVID-19 antibody cocktail,Seeking Alpha,https://seekingalpha.com/news/3722627-regeneron-wins-expanded-authorization-from-fda-for-covid-19-antibody-cocktail?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9359912276268005
833,7/30/2021 7:45:00 PM,FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab),PR Newswire,/news/stocks/fda-expands-authorized-use-of-regen-cov-casirivimab-and-imdevimab-1030669155,negative,0.8407917022705078
834,8/2/2021 1:51:01 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1030675837,positive,0.7998325824737549
835,8/3/2021 1:00:00 PM,Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation,PR Newswire,/news/stocks/regeneron-announces-the-2021-winners-of-the-regeneron-prize-for-creative-innovation-1030682388,positive,0.9179695844650269
836,8/3/2021 3:02:13 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-quarter-earnings-preview-q2-1030683241,positive,0.9262580871582031
837,8/4/2021 2:00:37 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3724959-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8825733065605164
838,8/4/2021 11:05:00 PM,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-positive-phase-3-trial-results-for-regen-cov-casirivimab-and-imdevimab-to-prevent-sars-cov-2-infection-1030691545,negative,0.938692033290863
839,8/5/2021 10:23:59 AM,Regeneron/Sanofi stops late-stage Libtayo study early after improvement in survival in NSCLC patients,Seeking Alpha,https://seekingalpha.com/news/3725803-regeneronsanofi-stops-late-stage-libtayo-study-early-after-improvement-in-survival-in-nsclc-patients?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8720980286598206
840,8/5/2021 10:33:51 AM,"Regeneron Pharmaceuticals EPS beats by $8.09, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3725815-regeneron-pharmaceuticals-eps-beats-8_09-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8639373779296875
841,8/5/2021 10:54:06 AM,"Regeneron shares rise on Q2 earnings beat, FY forecast",Seeking Alpha,https://seekingalpha.com/news/3725849-regeneron-shares-rise-on-q2-earnings-beat-fy-forecast?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9411307573318481
842,8/5/2021 12:00:00 PM,Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer,PR Newswire,/news/stocks/phase-3-trial-of-libtayo-cemiplimab-rwlc-combined-with-chemotherapy-stopped-early-due-to-significant-improvement-in-overall-survival-in-patients-with-first-line-advanced-non-small-cell-lung-cancer-1030694742,neutral,0.5455323457717896
843,8/5/2021 12:30:00 PM,Regeneron Reports Second Quarter 2021 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-second-quarter-2021-financial-and-operating-results-1030694934,negative,0.39365354180336
844,8/5/2021 12:37:01 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1030694948,negative,0.89817875623703
845,8/5/2021 1:45:20 PM,Regeneron/Sanofi's Libtayo Combined With Chemo Reduced Death By 29% In Non-small Cell Lung Cancer ,RTTNews,/news/stocks/regeneron-sanofi-s-libtayo-combined-with-chemo-reduced-death-by-29-in-non-small-cell-lung-cancer-1030695454,negative,0.931048572063446
846,8/5/2021 2:48:43 PM,"Daimler Truck, Cummins Partner For Medium-duty Engines ",RTTNews,/news/stocks/daimler-truck-cummins-partner-for-medium-duty-engines-1030696042,positive,0.8775543570518494
847,8/5/2021 2:52:21 PM,What Will the Stock Market Do Today? 3 Big Stories to Watch.,InvestorPlace,/news/stocks/what-will-the-stock-market-do-today-3-big-stories-eth-hard-fork-mrna-stock-1030696904,positive,0.9298974871635437
848,8/6/2021 4:09:35 PM,"Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases",Benzinga,/news/stocks/ocular-therapeutix-regeneron-cull-aflibercept-agreement-for-retinal-diseases-1030701793,positive,0.593589723110199
849,8/18/2021 6:20:06 AM,Texas Governor Greg Abbott tests positive for coronavirus,Seeking Alpha,https://seekingalpha.com/news/3731691-texas-governor-greg-abbott-tests-positive-for-coronavirus?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6812540888786316
850,8/18/2021 1:37:56 PM,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",Benzinga,/news/stocks/the-daily-biotech-pulse-azurrx-jumps-on-data-agios-regulatory-application-for-mitapivat-accepted-for-priority-review-fda-nod-for-glaxosmithkline-1030741574,negative,0.5053824782371521
851,8/19/2021 11:04:02 AM,Roche COVID-19 drug is in short supply with pandemic’s resurgence,Seeking Alpha,https://seekingalpha.com/news/3732167-roche-covid-19-drug-is-in-short-supply-with-pandemics-resurgence?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5168828368186951
852,8/19/2021 1:37:27 PM,"The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck",Benzinga,/news/stocks/the-daily-biotech-pulse-coherus-soars-on-lung-cancer-data-illumina-closes-on-grail-buy-without-regulatory-clearance-adagene-strikes-collaboration-with-merck-1030745371,neutral,0.7770193219184875
853,8/20/2021 1:00:00 PM,UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection,PR Newswire,/news/stocks/uk-authorizes-regeneron-antibody-cocktail-to-prevent-and-treat-acute-covid-19-infection-1030748590,negative,0.5308906435966492
854,8/20/2021 1:21:38 PM,U.K. Authorizes Regeneron's Antibody Cocktail To Prevent & Treat Acute COVID-19 Infection ,RTTNews,/news/stocks/u-k-authorizes-regeneron-s-antibody-cocktail-to-prevent-treat-acute-covid-19-infection-1030748625,positive,0.6592333316802979
855,8/20/2021 1:45:43 PM,"The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-announces-ceo-transition-fibrogen-s-roxadustat-approved-in-europe-geovax-sorrento-announce-covid-19-vaccine-data-1030748705,positive,0.8679837584495544
856,8/23/2021 1:27:52 PM,COVID-19 vaccinations pick up as some states face with a ‘tsunami of patients’,Seeking Alpha,https://seekingalpha.com/news/3733039-covid-19-vaccinations-pick-up-as-some-states-face-with-a-tsunami-of-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.791989803314209
857,8/24/2021 1:00:00 PM,Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration,PR Newswire,/news/stocks/regeneron-announces-encouraging-topline-phase-2-data-of-high-dose-aflibercept-in-wet-age-related-macular-degeneration-1030754529,negative,0.9244195222854614
858,8/24/2021 2:09:21 PM,"The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-cara-s-korsuva-greenlighted-by-fda-clinical-trial-disappointments-for-novartis-theravance-vertex-inks-crispr-licensing-deal-1030754775,positive,0.5257502198219299
859,8/27/2021 1:19:54 PM,7 Best ETFs to Buy to Cover a Broad Spectrum of Opportunities,InvestorPlace,/news/stocks/7-best-etfs-to-buy-to-cover-a-broad-spectrum-of-opportunities-1030763716,positive,0.838179886341095
860,8/27/2021 1:35:25 PM,"The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration",Benzinga,/news/stocks/the-daily-biotech-pulse-morphosys-incyte-snag-european-nod-immutep-granted-chinese-patent-bolt-biotherapeutics-strike-oncology-collaboration-1030763431,negative,0.5113007426261902
861,8/30/2021 6:59:00 AM,Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in...,PR Newswire,/news/stocks/dupixent-dupilumab-pivotal-trial-meets-all-primary-and-secondary-endpoints-becoming-first-biologic-medicine-to-significantly-reduce-signs-and-symptoms-of-moderate-to-severe-atopic-dermatitis-in-1030765913,negative,0.9291813373565674
862,8/30/2021 7:18:20 AM,Regeneron : Phase 3 Trial Of Dupixent On Atopic Dermatitis Meets Primary And Secondary Endpoints ,RTTNews,/news/stocks/regeneron-phase-3-trial-of-dupixent-on-atopic-dermatitis-meets-primary-and-secondary-endpoints-1030765935,positive,0.6928699016571045
863,8/31/2021 2:06:37 PM,"The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical",Benzinga,/news/stocks/the-daily-biotech-pulse-vectivbio-in-m-a-mix-sonnet-biotherapeutics-advances-candidate-to-clinics-ceo-transitions-at-galapagos-talis-biomedical-1030769575,positive,0.8613703846931458
864,9/1/2021 1:32:13 PM,"The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-releases-twin-dose-of-positive-tidings-astellas-voluntarily-pauses-gene-therapy-study-ascendis-offering-1030772643,positive,0.8366305232048035
865,9/2/2021 2:19:58 PM,"The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab",Benzinga,/news/stocks/the-daily-biotech-pulse-assembly-bio-halts-hbv-study-moderna-initiates-submission-for-covid-19-booster-dose-fda-nod-for-beigene-tiziana-out-licenses-foralumab-1030776427,positive,0.808341920375824
866,9/7/2021 6:43:34 PM,Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1030784971,positive,0.9010616540908813
867,9/8/2021 1:11:10 PM,GlaxoSmithKline/ Vir COVID-19 antibody drug may get Japanese approval this month - NHK,Seeking Alpha,https://seekingalpha.com/news/3737914-gsk-stock-vir-covid-19-antibody-drug-may-get-japanese-approval-this-month-nhk?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6133323311805725
868,9/8/2021 10:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1030788331,positive,0.9291732907295227
869,9/14/2021 9:18:39 PM,Regeneron Pharmaceuticals nabs $2.94B U.S. Army modification contract for antibody therapeutic doses,Seeking Alpha,https://seekingalpha.com/news/3739719-regeneron-pharmaceuticals-nabs-294b-us-army-modification-contract-for-antibody-therapeutic-doses?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8221724033355713
870,9/14/2021 11:33:00 PM,Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail,PR Newswire,/news/stocks/regeneron-announces-new-u-s-government-agreement-to-purchase-additional-doses-of-regen-cov-casirivimab-and-imdevimab-antibody-cocktail-1030799885,negative,0.9352477192878723
871,9/15/2021 5:31:41 AM,Regeneron To Supply Additional 1.4 Mln Doses Of COVID-19 Therapy To U.S. ,RTTNews,/news/stocks/regeneron-to-supply-additional-1-4-mln-doses-of-covid-19-therapy-to-u-s-1030800084,negative,0.8659690022468567
872,9/15/2021 1:38:39 PM,"The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-calliditas-theravance-to-cut-75-jobs-4-ipos-1030801226,neutral,0.9463478326797485
873,9/15/2021 2:27:07 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1030801508,positive,0.8142690658569336
874,9/15/2021 4:35:49 PM,Breaking Down The Inflation Numbers Draws Attention To Oil Prices,Benzinga,/news/stocks/breaking-down-the-inflation-numbers-draws-attention-to-oil-prices-1030802140,neutral,0.7245739698410034
875,9/15/2021 4:45:22 PM,7 Gene Editing Stocks Promising to Change our DNA,InvestorPlace,/news/stocks/7-gene-editing-stocks-promising-to-change-our-dna-1030802558,negative,0.49636170268058777
876,9/15/2021 6:13:07 PM,Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1030802416,positive,0.9010616540908813
877,9/19/2021 5:30:00 PM,ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC,PR Newswire,/news/stocks/esmo-late-breaking-data-show-libtayo-cemiplimab-and-chemotherapy-first-line-treatment-combination-significantly-improved-overall-survival-in-patients-with-advanced-nsclc-1030808522,negative,0.9568464756011963
878,9/21/2021 6:59:00 AM,New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV,PR Newswire,/news/stocks/new-dupixent-dupilumab-data-in-patients-as-young-as-six-years-old-with-moderate-to-severe-atopic-dermatitis-to-be-presented-at-wcpd-and-eadv-1030811635,positive,0.8725515007972717
879,9/21/2021 7:23:57 PM,NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?,InvestorPlace,/news/stocks/nnvc-stock-what-is-going-on-with-red-hot-nanoviricides-today-1030814063,neutral,0.5694593191146851
880,9/28/2021 1:00:00 PM,FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer,PR Newswire,/news/stocks/fda-accepts-libtayo-cemiplimab-rwlc-for-priority-review-for-advanced-cervical-cancer-1030827586,negative,0.7206634879112244
881,9/28/2021 1:50:22 PM,Regeneron's Supplemental BLA For Libtayo To Treat Cervical Cancer Gets Priority Review ,RTTNews,/news/stocks/regeneron-s-supplemental-bla-for-libtayo-to-treat-cervical-cancer-gets-priority-review-1030827704,positive,0.654283881187439
882,9/28/2021 2:18:52 PM,"The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive",Benzinga,/news/stocks/the-daily-biotech-pulse-eisai-biogen-pursue-approval-of-second-alzheimer-s-treatment-sanofi-changes-mrna-strategy-gsk-subsidiary-to-develop-long-acting-hiv-preventive-1030827880,positive,0.5831677317619324
883,9/28/2021 7:30:23 PM,7 Biotech Stocks Entering the Golden Boom Phase,InvestorPlace,/news/stocks/7-biotech-stocks-entering-the-golden-boom-phase-1030829968,positive,0.7444129586219788
884,9/28/2021 7:36:06 PM,Editas Medicine slips ahead of key data readout for gene editing candidate,Seeking Alpha,https://seekingalpha.com/news/3745477-edit-stock-slips-ahead-of-key-data-readout-for-gene-editing-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9096224308013916
885,9/29/2021 11:00:00 PM,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-positive-phase-3-trial-results-for-regen-cov-casirivimab-and-imdevimab-to-treat-covid-19-1030832320,negative,0.9207836389541626
886,9/30/2021 7:00:00 AM,New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19,PR Newswire,/news/stocks/new-regen-cov-casirivimab-and-imdevimab-data-show-supportive-results-in-patients-hospitalized-with-covid-19-1030832783,negative,0.9498710036277771
887,9/30/2021 7:41:21 AM,Regeneron's REGEN-COV Data Show Supportive Results In Patients Hospitalized With COVID-19 ,RTTNews,/news/stocks/regeneron-s-regen-cov-data-show-supportive-results-in-patients-hospitalized-with-covid-19-1030832860,negative,0.9473446607589722
888,9/30/2021 8:58:51 AM,Biotech Stocks Facing FDA Decision In October 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2021-1030833014,positive,0.7297406196594238
889,10/1/2021 8:17:08 PM,Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-october-pdufa-dates-1030838143,positive,0.9432098269462585
890,10/1/2021 8:18:24 PM,Adverum posts promising two-year data for one-time injection in Wet AMD,Seeking Alpha,https://seekingalpha.com/news/3747317-adverum-posts-promising-two-year-data-for-one-time-injection-in-wet-amd?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9443464875221252
891,10/2/2021 2:00:00 PM,"Moderna, BioNTech top performing pharmas in Q3; Alzheimer's drug developers lag",Seeking Alpha,https://seekingalpha.com/news/3747328-moderna-biontech-top-best-performing-pharmas-in-q3-alzheimers-drug-developers-lag?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5793244242668152
892,10/7/2021 4:21:57 PM,"Cramer Likes DraftKings, Skyworks, And These Automakers",Benzinga,/news/stocks/cramer-likes-draftkings-skyworks-and-these-automakers-1030850756,positive,0.9411685466766357
893,10/8/2021 2:56:49 PM,Intellia Therapeutics slides after insider selling,Seeking Alpha,https://seekingalpha.com/news/3750967-intellia-therapeutics-slides-after-insider-selling?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9030740857124329
894,10/11/2021 10:15:00 PM,"Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021",PR Newswire,/news/stocks/regeneron-to-report-third-quarter-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-4-2021-1030856992,positive,0.9490759372711182
895,10/12/2021 6:21:59 PM,Expert Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/expert-ratings-for-regeneron-pharmaceuticals-1030859989,positive,0.8309355974197388
896,10/14/2021 1:21:00 PM,FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19,PR Newswire,/news/stocks/fda-accepts-regen-cov-casirivimab-and-imdevimab-for-priority-review-for-treatment-and-prophylaxis-of-covid-19-1030866132,negative,0.8616993427276611
897,10/14/2021 1:45:49 PM,Regeneron Pharma: FDA To Review BLA For REGEN-COV Antibody Cocktail To Treat COVID-19 ,RTTNews,/news/stocks/regeneron-pharma-fda-to-review-bla-for-regen-cov-antibody-cocktail-to-treat-covid-19-1030866211,positive,0.5228332877159119
898,10/15/2021 7:00:55 PM,"Catalyst watch for next week: Apple event, Tesla earnings, WeWork SPAC and earnings rush",Seeking Alpha,https://seekingalpha.com/news/3753345-catalyst-watch-for-next-week-apple-event-tesla-earnings-wework-spac-and-earnings-rush?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9319095611572266
899,10/18/2021 1:34:17 PM,"The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-18-23-j-j-biogen-kickstart-big-pharma-earnings-regeneron-sanofi-roche-await-fda-decisions-and-ipos-1030873336,positive,0.7243751883506775
900,10/20/2021 3:58:12 PM,Intellia granted Orphan Drug designation for transthyretin amyloidosis program,Seeking Alpha,https://seekingalpha.com/news/3755595-intellia-granted-orphan-drug-designation-for-transthyretin-amyloidosis-program?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8141198754310608
901,10/20/2021 11:29:00 PM,FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma,PR Newswire,/news/stocks/fda-expands-approval-of-dupixent-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma-1030883439,negative,0.8535524606704712
902,10/21/2021 2:05:16 PM,"The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-moderna-j-j-booster-shots-regulatory-approvals-for-bristol-myers-squibb-sanofi-regeneron-ventyx-ipo-1030885538,positive,0.8053774833679199
903,10/22/2021 6:59:00 AM,"Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease",PR Newswire,/news/stocks/dupixent-dupilumab-is-the-first-biologic-to-significantly-reduce-itch-and-skin-lesions-in-phase-3-trial-for-prurigo-nodularis-demonstrating-the-role-of-type-2-inflammation-in-this-disease-1030888015,negative,0.8088738918304443
904,10/22/2021 7:20:25 AM,Regeneron : Dupixent Reduces Itch And Skin Lesions In Phase 3 Trial For Prurigo Nodularis ,RTTNews,/news/stocks/regeneron-dupixent-reduces-itch-and-skin-lesions-in-phase-3-trial-for-prurigo-nodularis-1030888044,negative,0.749887228012085
905,10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741,positive,0.9414970874786377
906,10/25/2021 6:59:00 AM,"Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease",PR Newswire,/news/stocks/second-dupixent-dupilumab-phase-3-eosinophilic-esophagitis-trial-to-demonstrate-significant-disease-improvements-underscoring-role-of-type-2-inflammation-in-this-complex-disease-1030892721,negative,0.951191246509552
907,10/25/2021 7:29:31 AM,"Regeneron, Sanofi Report Positive Data From Second Phase 3 Trial Of Dupixent In EoE Patients ",RTTNews,/news/stocks/regeneron-sanofi-report-positive-data-from-second-phase-3-trial-of-dupixent-in-eoe-patients-1030893462,negative,0.9496718049049377
908,10/25/2021 4:28:26 PM,Sanofi's Dupixent could generate over EUR 1B in sales from new indication - BofA,Seeking Alpha,https://seekingalpha.com/news/3757550-sanfis-dupixent-could-generate-over-eur-1b-in-sales-from-new-indication-bofa?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7861002087593079
909,10/25/2021 4:51:46 PM,Sanofi's Dupixent could generate over EUR 1B in sales from new indication - BofA,Seeking Alpha,https://seekingalpha.com/news/3757550-sanofis-dupixent-could-generate-over-eur-1b-in-sales-from-new-indication-bofa?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7861002087593079
910,10/26/2021 6:31:52 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1030901040,positive,0.8993901014328003
911,10/29/2021 11:14:26 AM,Health Canada approves Regeneron/Sanofi's Libtayo for advanced basal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3760710-health-canada-approves-regeneronsanofis-libtayo-for-advanced-basal-cell-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7057573795318604
912,10/30/2021 8:00:00 PM,"BioNTech, GSK top pharma performers in October; Bristol, Amgen biggest laggards",Seeking Alpha,https://seekingalpha.com/news/3761145-biontech-gsk-top-pharma-performers-in-october-bristol-amgen-biggest-laggards?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8818862438201904
913,10/31/2021 7:23:54 PM,"The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-31-nov-6-earnings-pick-up-pace-eton-awaits-seizure-drug-approval-kidney-conference-more-ipos-in-the-pipeline-1030917750,negative,0.939061164855957
914,11/3/2021 3:01:13 PM,Here's what to expect from Regeneron Pharmaceuticals's earnings report,Markets Insider Automation,/news/stocks/regeneron-stock-quarter-earnings-preview-q3-1030932390,positive,0.9301917552947998
915,11/3/2021 3:55:55 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3764124-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8825733065605164
916,11/3/2021 4:16:27 PM,Will Regeneron Pharmaceuticals maintain EPS beat run in Q3?,Seeking Alpha,https://seekingalpha.com/news/3764149-will-regeneron-pharmaceuticals-maintain-eps-beat-run-in-q3?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.803516685962677
917,11/4/2021 10:33:30 AM,"Regeneron Pharmaceuticals EPS beats by $5.43, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3764903-regeneron-pharmaceuticals-eps-beats-5_43-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8232247233390808
918,11/4/2021 11:07:50 AM,Regeneron posts Q3 beat powered by EYLEA and Dupixent,Seeking Alpha,https://seekingalpha.com/news/3764976-regeneron-posts-q3-beat-powered-by-eylea-and-dupixent?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9162578582763672
919,11/4/2021 11:30:00 AM,Regeneron Reports Third Quarter 2021 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-third-quarter-2021-financial-and-operating-results-1030936350,negative,0.40604689717292786
920,11/4/2021 11:36:09 AM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1030936345,negative,0.8955163359642029
921,11/4/2021 1:14:49 PM,"The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-oral-covid-19-pill-authorized-in-uk-novartis-cashes-out-of-roche-chimerix-plunges-on-data-evotec-ipo-1030937079,neutral,0.8839086890220642
922,11/4/2021 3:00:00 PM,Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders,PR Newswire,/news/stocks/regeneron-presentations-at-ash-highlight-expanding-clinical-research-in-blood-cancers-and-disorders-1030937898,negative,0.6865482926368713
923,11/4/2021 6:35:27 PM,7 European Stocks to Buy to Diversify Your Portfolio,InvestorPlace,/news/stocks/7-european-stocks-to-buy-to-diversify-your-portfolio-1030938704,positive,0.811861515045166
924,11/5/2021 3:07:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-5-2021-1030942943,neutral,0.5551420450210571
925,11/5/2021 3:12:19 PM,Regeneron Pharmaceuticals files for mixed shelf offering,Seeking Alpha,https://seekingalpha.com/news/3766204-regeneron-pharmaceuticals-files-for-mixed-shelf-offering?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9381603598594666
926,11/5/2021 5:12:26 PM,What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-regeneron-pharmaceuticals-1030943211,positive,0.9464401006698608
927,11/5/2021 6:24:23 PM,"Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro",Benzinga,/news/stocks/wall-street-crime-and-punishment-martin-shkreli-the-self-destructive-pharma-bro-1030943422,positive,0.9109874367713928
928,11/6/2021 10:25:37 PM,"As Nasdaq 100 extends big winning streak, getting selective on tech can pay: Alpha Tactics",Seeking Alpha,https://seekingalpha.com/news/3766504-as-nasdaq-100-extends-big-winning-streak-getting-selective-on-tech-can-pay?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7118894457817078
929,11/8/2021 12:25:28 PM,Regeneron says single dose of antibody cocktail cut COVID-19 risk by 82% over six months,Seeking Alpha,https://seekingalpha.com/news/3766652-regeneron-says-single-dose-of-antibody-cocktail-cut-covid-19-risk-by-82-over-six-months?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9420170187950134
930,11/8/2021 1:00:00 PM,New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19,PR Newswire,/news/stocks/new-phase-3-analyses-show-that-a-single-dose-of-regen-cov-casirivimab-and-imdevimab-provides-long-term-protection-against-covid-19-1030948564,negative,0.8891832232475281
931,11/8/2021 1:46:32 PM,Regeneron: REGEN-COV Show Long-term Protection Against COVID-19 In Follow-up Period ,RTTNews,/news/stocks/regeneron-regen-cov-show-long-term-protection-against-covid-19-in-follow-up-period-1030948727,negative,0.91390460729599
932,11/8/2021 4:05:36 PM,"What are the differences between Merck, Pfizer, and Regeneron COVID treatments?",Seeking Alpha,https://seekingalpha.com/news/3766836-whats-the-difference-between-merck-pfizer-and-regeneron-covid-treatments?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.913979709148407
933,11/9/2021 3:27:12 PM,"Intellia Therapeutics, Alnylam seen as potential Regeneron targets, analyst says",Seeking Alpha,https://seekingalpha.com/news/3767761-intellia-therapeutics-alnylam-seen-as-potential-regeneron-targets-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6634109616279602
934,11/11/2021 3:35:15 PM,Regeneron-Roche COVID-19 antibody cocktail gets European backing for authorization,Seeking Alpha,https://seekingalpha.com/news/3769552-regeneron-covid-19-antibody-cocktail-gets-european-backing-for-authorization?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8905514478683472
935,11/11/2021 5:03:00 PM,CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19,PR Newswire,/news/stocks/chmp-recommends-eu-approval-of-regeneron-antibody-cocktail-to-treat-and-prevent-covid-19-1030966053,negative,0.8561393022537231
936,11/12/2021 4:20:00 PM,Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19,PR Newswire,/news/stocks/regeneron-antibody-cocktail-approved-by-european-commission-to-treat-and-prevent-covid-19-1030970460,negative,0.8315045833587646
937,11/12/2021 4:42:14 PM,Regeneron-Roche COVID-19 antibody cocktail approved in Europe,Seeking Alpha,https://seekingalpha.com/news/3770147-regeneron-roche-covid-19-antibody-cocktail-approved-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.661882758140564
938,11/12/2021 9:27:00 PM,Regeneron announces $3 billion share buyback program,Seeking Alpha,https://seekingalpha.com/news/3770298-regeneron-announces-3-billion-share-buyback-program?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8356442451477051
939,11/12/2021 10:11:00 PM,Regeneron Announces $3 Billion Share Repurchase Program,PR Newswire,/news/stocks/regeneron-announces-3-billion-share-repurchase-program-1030971169,positive,0.8526312112808228
940,11/13/2021 5:04:05 AM,EU Approves Regeneron Antibody Cocktail To Treat And Prevent COVID-19 ,RTTNews,/news/stocks/eu-approves-regeneron-antibody-cocktail-to-treat-and-prevent-covid-19-1030971351,negative,0.8385071754455566
941,11/15/2021 1:00:00 PM,Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year,PR Newswire,/news/stocks/regeneron-listed-on-dow-jones-sustainability-world-index-for-third-consecutive-year-1030975778,positive,0.6490073204040527
942,11/16/2021 5:09:44 AM,Cathie Wood Buys $13.7M In Disney And Sells $7.95M In Google On Monday — Here Are Other Key Trades,Benzinga,/news/etf/cathie-wood-buys-13-7m-in-disney-and-sells-7-95m-in-google-on-monday-—-here-are-other-key-trades-1030978530,positive,0.9442065954208374
943,11/16/2021 2:04:33 PM,Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower,Seeking Alpha,https://seekingalpha.com/news/3771400-pfizer-moves-to-allow-cheaper-covid-19-pills-sending-shares-of-rivals-lower?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9393699169158936
944,11/16/2021 10:15:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1030981959,positive,0.9291732907295227
945,11/18/2021 12:19:35 PM,Alnylam Pharma is said to be a potential target for Novartis - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3772337-alnylam-pharma-is-said-to-be-a-potential-target-for-novartis-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.696034848690033
946,11/19/2021 2:20:15 PM,"The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-connect-biopharma-sinks-on-eczema-drug-readout-enanta-pulls-plug-on-hbv-drug-clinical-setback-for-merck-in-hiv-trial-1030991438,neutral,0.4585235118865967
947,11/19/2021 5:53:31 PM,Connect Biopharma sinks 54% following phase 2 results on atopic dermatitis candidate,Seeking Alpha,https://seekingalpha.com/news/3772988-connect-biopharma-sinks-54-following-phase-2-results-on-atopic-dermatitis-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6016778945922852
948,11/22/2021 12:09:21 PM,Novartis plans new sales approach for cholesterol lowering drug - WSJ,Seeking Alpha,https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5225130319595337
949,11/22/2021 2:27:36 PM,Decibel up 4% on research extension with Regeneron for hearing loss therapies,Seeking Alpha,https://seekingalpha.com/news/3773276-decibel-up-4-on-research-extension-with-regeneron-for-hearing-loss-therapies?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9420835971832275
950,11/23/2021 7:57:53 AM,"Nykode Inks Multi-mln Dollar Deal With Regeneron To Develop Cancer, Infectious Diseases Vaccines ",RTTNews,/news/stocks/nykode-inks-multi-mln-dollar-deal-with-regeneron-to-develop-cancer-infectious-diseases-vaccines-1030996755,negative,0.7614640593528748
951,11/23/2021 1:44:27 PM,"Nykode Therapeutics in up to $925M license, development deal with Regeneron",Seeking Alpha,https://seekingalpha.com/news/3773771-nykode-therapeutics-in-up-to-925m-license-development-deal-with-regeneron?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6888453364372253
952,11/29/2021 2:21:46 PM,"Moderna, Pfizer, and Adagio likely to benefit from Omicron variant - Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3774880-moderna-pfizer-and-adagio-likely-to-benefit-from-omicron-covid-variant-morgan-stanley?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8247672319412231
953,11/29/2021 6:58:45 PM,3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries,Benzinga,/news/stocks/3-pharma-stocks-morgan-stanley-says-will-be-omicron-variant-beneficiaries-1031009763,positive,0.9128556847572327
954,11/29/2021 9:57:43 PM,ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential,InvestorPlace,/news/stocks/adgi-stock-soars-as-analysts-lock-on-to-its-omicron-fighting-potential-1031010138,neutral,0.6825145483016968
955,11/30/2021 11:54:22 AM,"Regeneron, Eli Lilly COVID-19 antibody drugs said to lose efficacy against Omicron - WSJ",Seeking Alpha,https://seekingalpha.com/news/3775238-regeneron-eli-lilly-covid-19-antibody-drugs-said-to-lose-efficacy-against-omicron-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9503864645957947
956,11/30/2021 12:17:53 PM,Moderna CEO warns “material drop” in vaccine efficacy against new COVID-19 variant,Seeking Alpha,https://seekingalpha.com/news/3775258-moderna-ceo-warns-material-drop-in-vaccine-efficacy-against-new-covid-19-variant?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9687873721122742
957,11/30/2021 2:12:23 PM,"The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-cumberland-jumps-on-fda-nod-regeneron-says-antibody-treatment-may-be-less-effective-against-omicron-immunogen-readout-1031011982,neutral,0.6165550947189331
958,11/30/2021 7:29:27 PM,7 Drug Stocks to Buy Now While They’re Still on Sale,InvestorPlace,/news/stocks/7-drug-stocks-to-buy-now-while-theyre-still-on-sale-1031013701,positive,0.8935650587081909
959,11/30/2021 9:05:31 PM,Why Are Stocks Down Today? 4 Things to Know.,InvestorPlace,/news/stocks/why-are-stocks-down-today-4-things-to-know-1031013891,positive,0.5906426310539246
960,11/30/2021 9:11:26 PM,HC Wainwright Sees 'Buying Opportunity' For This COVID-19 Antibody Stock After Sell-Off,Benzinga,/news/stocks/hc-wainwright-sees-buying-opportunity-for-this-covid-19-antibody-stock-after-sell-off-1031013771,negative,0.9084420204162598
961,12/2/2021 6:44:27 PM,"Regeneron: Surfing on Covid, With More Under the Surface",InvestorPlace,/news/stocks/regn-stock-regeneron-surfing-on-covid-1031021097,positive,0.9220339059829712
962,12/3/2021 4:00:00 PM,Regeneron to Participate in H.C. Wainwright & Co. Virtual Event,PR Newswire,/news/stocks/regeneron-to-participate-in-h-c-wainwright-co-virtual-event-1031023294,positive,0.9080154299736023
963,12/6/2021 12:07:24 PM,"The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-6-dec-11-daré-fda-decision-adcom-tryst-for-reata-multiple-conference-presentations-and-more-1031025543,positive,0.9361634850502014
964,12/6/2021 4:05:46 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-6-2021-1031026544,neutral,0.5734043121337891
965,12/6/2021 5:11:13 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1031026729,positive,0.8993901014328003
966,12/6/2021 10:00:50 PM,2 Big Stock Bets That Are Insiders Are Buying Now,InvestorPlace,/news/stocks/2-big-stock-bets-that-are-insiders-are-buying-now-1031027396,positive,0.9235526919364929
967,12/8/2021 11:29:00 PM,New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to-severe Asthma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-positive-phase-3-dupixent-dupilumab-results-in-children-with-moderate-to-severe-asthma-1031033805,negative,0.900188684463501
968,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161,neutral,0.5978407859802246
969,12/9/2021 7:19:25 PM,Regeneron initiated at overweight at Wells Fargo on high-dose Eylea potential,Seeking Alpha,https://seekingalpha.com/news/3778854-regeneron-initiated-at-overweight-at-wells-fargo-on-high-dose-eylea-potential?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6910147666931152
970,12/10/2021 8:00:40 PM,"Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings",Seeking Alpha,https://seekingalpha.com/news/3779254-catalyst-watch-for-next-week-fomc-drama-events-for-lowes-and-delta-air-lines-rivian-earnings?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9469307065010071
971,12/11/2021 6:00:00 PM,New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma,PR Newswire,/news/stocks/new-regn5458-bcmaxcd3-phase-1-data-show-75-response-rate-at-highest-dose-levels-studied-in-patients-with-heavily-pretreated-multiple-myeloma-1031040028,negative,0.9467626810073853
972,12/11/2021 6:55:31 PM,Regeneron : REGN5458 Phase 1 Data Show 75% Response Rate At Highest Dose Levels In  Multiple Myeloma ,RTTNews,/news/stocks/regeneron-regn5458-phase-1-data-show-75-response-rate-at-highest-dose-levels-in-multiple-myeloma-1031040031,negative,0.9266303181648254
973,12/13/2021 6:32:43 AM,"Regeneron, Sanofi report positive Dupixent data in children 6 months to 5 years with atopic dermatitis",Seeking Alpha,https://seekingalpha.com/news/3779368-regeneron-sanofi-report-positive-dupixent-data-in-children-6-months-to-5-years-with-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9277724027633667
974,12/13/2021 6:59:00 AM,Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session,PR Newswire,/news/stocks/positive-phase-3-dupixent-dupilumab-data-in-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-featured-in-rad-2021-late-breaking-session-1031045716,negative,0.5101473331451416
975,12/13/2021 7:20:33 AM,Regeneron : Phase 3 Results Show Dupixen Improved Skin Clearance In Children With  Atopic Dermatitis ,RTTNews,/news/stocks/regeneron-phase-3-results-show-dupixen-improved-skin-clearance-in-children-with-atopic-dermatitis-1031040746,negative,0.9518569707870483
976,12/15/2021 2:48:17 PM,Regeneron downgraded at Bernstein on risk to Eylea outlook,Seeking Alpha,https://seekingalpha.com/news/3780392-regeneron-downgraded-at-bernstein-on-risk-to-eylea-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7066978812217712
977,12/15/2021 4:05:47 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-15-2021-1031047709,neutral,0.582796573638916
978,12/16/2021 1:50:52 PM,Regeneron says it has experimental monoclonal antibodies effective against Omicron,Seeking Alpha,https://seekingalpha.com/news/3780749-regeneron-says-it-has-experimental-monoclonal-antibodies-effective-against-omicron?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8591718077659607
979,12/16/2021 8:22:33 PM,Cantor raises Pfizer price target ahead of company event highlighting COVID treatments,Seeking Alpha,https://seekingalpha.com/news/3781034-cantor-raises-pfizer-price-target-ahead-of-company-event-highlighting-covid-treatments?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9030519127845764
980,12/19/2021 2:00:00 PM,"Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022",Seeking Alpha,https://seekingalpha.com/news/3781488-alnylam-pharma-crispr-therapeutics-among-goldmans-healthcare-targets-for-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7041938304901123
981,12/22/2021 1:37:10 PM,Alnylam Pharma Files Clinical Trial Authorization Application For ALN-APP In The UK ,RTTNews,/news/stocks/alnylam-pharma-files-clinical-trial-authorization-application-for-aln-app-in-the-uk-1031061636,positive,0.820154070854187
982,12/22/2021 4:02:28 PM,Alnylam Pharma slips despite plans for Alzheimer’s disease study in 2022,Seeking Alpha,https://seekingalpha.com/news/3782728-alnylam-pharma-slips-despite-plans-for-alzheimers-disease-study-in-2022?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9695538282394409
983,12/22/2021 10:15:00 PM,Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/regeneron-announces-presentation-at-the-40th-annual-j-p-morgan-healthcare-conference-1031062810,positive,0.8532353639602661
984,12/23/2021 12:27:47 PM,Top 10 Blockbuster Drugs In 2021 ,RTTNews,/news/stocks/top-10-blockbuster-drugs-in-2021-1031063755,positive,0.7226237654685974
985,12/28/2021 6:30:25 PM,Why did Intellia soar in 2021 while other gene editing stocks faltered? CRISPR in humans,Seeking Alpha,https://seekingalpha.com/news/3783739-why-did-intellia-soar-in-2021-while-other-gene-editing-stocks-faltered-crispr-in-humans?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8541568517684937
986,12/31/2021 8:40:54 PM,Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-january-pdufa-dates-1031072671,positive,0.9451626539230347
987,1/3/2022 5:36:13 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-3-2022-1031074541,neutral,0.4979900121688843
988,1/5/2022 3:34:41 PM,Regeneron downgraded to underperform at BofA on minimal COVID contribution in 2022,Seeking Alpha,https://seekingalpha.com/news/3785458-regeneron-downgraded-to-underperform-at-bofa-on-minimal-covid-contribution-in-2022?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9020345211029053
989,1/5/2022 4:08:49 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-5-2022-1031079571,neutral,0.4978620409965515
990,1/5/2022 6:18:29 PM,"Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays",Benzinga,/news/stocks/why-this-pfizer-regeneron-analyst-has-contrasting-recommendations-for-the-covid-stock-plays-1031079936,positive,0.7009210586547852
991,1/7/2022 12:08:43 PM,"Regeneron, Ultragenyx collaborate to commercialize Evkeeza outside U.S.",Seeking Alpha,https://seekingalpha.com/news/3786134-regeneron-ultragenyx-collaborate-to-commercialize-evkeeza-outside-us?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6014885902404785
992,1/7/2022 1:00:00 PM,Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States,PR Newswire,/news/stocks/regeneron-and-ultragenyx-collaborate-to-commercialize-evkeeza-evinacumab-outside-the-united-states-1031083471,negative,0.5899370908737183
993,1/7/2022 2:25:53 PM,Regeneron Signs Up To $93 Mln Deal With Ultragenyx To Commercialize Evkeeza Outside U.S. ,RTTNews,/news/stocks/regeneron-signs-up-to-93-mln-deal-with-ultragenyx-to-commercialize-evkeeza-outside-u-s-1031083698,negative,0.8733755350112915
994,1/7/2022 6:17:06 PM,Biden administration to ask Congress for more COVID funding - WaPo,Seeking Alpha,https://seekingalpha.com/news/3786338-biden-administration-to-ask-congress-for-more-covid-funding?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7112752199172974
995,1/11/2022 3:24:36 PM,"Regeneron sees Q4 EYLEA U.S. sales of $1.54B, REGEN-COV sales of $2.29B",Seeking Alpha,https://seekingalpha.com/news/3787144-regeneron-sees-q4-eylea-us-sales-of-154b-regen-cov-sales-of-229b?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8113735914230347
996,1/12/2022 8:20:01 PM,Vir extends gains as Needham lifts sales outlook for COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3787638-vir-extends-gains-as-needham-lifts-sales-outlook-for-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9440396428108215
997,1/13/2022 10:05:00 PM,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on,PR Newswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-1031101516,positive,0.9437575936317444
998,1/14/2022 11:51:18 AM,Eli Lilly and GlaxoSmithKline/Vir COVID-19 therapies get WHO backing,Seeking Alpha,https://seekingalpha.com/news/3788201-eli-lilly-and-glaxosmithklinevir-covid-19-therapies-get-who-backing?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8087514638900757
999,1/19/2022 6:59:00 AM,Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis,PR Newswire,/news/stocks/second-positive-phase-3-dupixent-dupilumab-trial-confirms-significant-improvements-for-patients-with-prurigo-nodularis-1031111328,negative,0.9504884481430054
1000,1/19/2022 7:34:12 AM,Sanofi Says Second Phase 3 Dupixent Trial Confirms Improvements For Patients With Prurigo Nodularis ,RTTNews,/news/stocks/sanofi-says-second-phase-3-dupixent-trial-confirms-improvements-for-patients-with-prurigo-nodularis-1031111707,negative,0.9514135718345642
1001,1/19/2022 12:29:51 PM,Sanofi-Regeneron Dupixent meets main goal of reducing itch in phase 3 skin disease trial,Seeking Alpha,https://seekingalpha.com/news/3789077-sanofi-regeneron-dupixent-meets-main-goal-of-reducing-itch-in-phase-3-skin-disease-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5821255445480347
1002,1/19/2022 1:00:00 PM,FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC,PR Newswire,/news/stocks/fda-accepts-for-review-libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-for-first-line-treatment-of-advanced-nsclc-1031112159,negative,0.8418160676956177
1003,1/19/2022 1:27:53 PM,REGN : FDA Accepts For Review Libtayo-Chemotherapy Combination For Advanced Lung Cancer Treatment ,RTTNews,/news/stocks/regn-fda-accepts-for-review-libtayo-chemotherapy-combination-for-advanced-lung-cancer-treatment-1031112248,negative,0.7777230143547058
1004,1/19/2022 1:40:21 PM,"The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data",Benzinga,/news/stocks/the-daily-biotech-pulse-gamida-gains-on-positive-regulatory-development-orphazyme-adma-preannouncements-immunitybio-leap-present-positive-data-1031112313,negative,0.9416454434394836
1005,1/19/2022 4:52:22 PM,Sanofi-Regeneron's Libtayo combo accepted for review by FDA for lung cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3789265-sanofi-regenerons-libtayo-combo-accepted-for-review-by-fda-for-lung-cancer-subtype?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8143031001091003
1006,1/20/2022 6:00:00 PM,Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search,PR Newswire,/news/stocks/forty-accomplished-young-scientists-named-finalists-in-the-2022-regeneron-science-talent-search-1031117052,negative,0.6661344170570374
1007,1/20/2022 6:00:00 PM,Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search,PR Newswire,/news/stocks/forty-accomplished-young-scientists-named-finalists-in-the-2022-regeneron-science-talent-search-1031117048,negative,0.6661344170570374
1008,1/21/2022 7:09:36 PM,GlaxoSmithKline and Vir to boost U.S. output of COVID-19 antibody - Reuters,Seeking Alpha,https://seekingalpha.com/news/3790412-glaxosmithkline-and-vir-to-boost-us-output-of-covid-19-antibody-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9439486265182495
1009,1/24/2022 5:14:47 PM,FDA to restrict COVID-19 antibody therapies from Regeneron and Eli Lilly - WaPo,Seeking Alpha,https://seekingalpha.com/news/3790807-fda-to-restrict-covid-19-antibody-therapies-from-regeneron-and-eli-lilly-wapo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7098705172538757
1010,1/28/2022 12:32:46 PM,"Regeneron, Sanofi withdraw Libtayo application in cervical cancer",Seeking Alpha,https://seekingalpha.com/news/3792978-regeneron-sanofi-withdraw-libtayo-application-in-cervical-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6010913848876953
1011,1/28/2022 1:00:00 PM,Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer,PR Newswire,/news/stocks/regeneron-and-sanofi-provide-regulatory-update-on-libtayo-cemiplimab-rwlc-in-advanced-cervical-cancer-1031138960,positive,0.8774682879447937
1012,1/28/2022 1:40:55 PM,"Regeneron, Sanofi Withdraw SBLA For Libtayo To Treat Advanced Cervical Cancer ",RTTNews,/news/stocks/regeneron-sanofi-withdraw-sbla-for-libtayo-to-treat-advanced-cervical-cancer-1031139133,negative,0.8084722757339478
1013,1/28/2022 2:21:16 PM,"The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron",Benzinga,/news/stocks/the-daily-biotech-pulse-biogen-liquidates-out-of-biosimilar-jv-provention-bio-plots-diabetes-drug-resubmission-merck-finds-covid-pill-effective-against-omicron-1031139273,negative,0.8550984263420105
1014,1/29/2022 9:00:00 PM,"Vaccines to dominate pharma sales this year, but Bristol could have most best-sellers",Seeking Alpha,https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7369604706764221
1015,1/30/2022 2:06:35 AM,Goldman screens for best and worst stocks for tightening financial conditions,Seeking Alpha,https://seekingalpha.com/news/3793311-goldman-screens-for-stocks-for-tightening-financial-conditions?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.645543098449707
1016,1/31/2022 6:59:00 AM,CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation,PR Newswire,/news/stocks/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation-1031142905,positive,0.614679753780365
1017,1/31/2022 7:28:39 AM,Sanofi: CHMP Recommends Approval Of Dupixent For Children With Severe Asthma With Type2 Inflammation ,RTTNews,/news/stocks/sanofi-chmp-recommends-approval-of-dupixent-for-children-with-severe-asthma-with-type2-inflammation-1031142986,negative,0.7060438990592957
1018,1/31/2022 10:50:03 AM,EMA OKs expanded use of Regeneron/Sanofi's asthma med Dupixent in kids aged 6 to 11,Seeking Alpha,https://seekingalpha.com/news/3793371-ema-oks-expanded-use-of-regeneronsanofis-asthma-med-dupixent-in-kids-aged-6-to-11?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8562071919441223
1019,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306,positive,0.9110234379768372
1020,1/31/2022 3:16:17 PM,Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031144718,positive,0.9010616540908813
1021,1/31/2022 8:21:28 PM,Why did Regeneron Pharmaceuticals stock drop today? Roche gets FDA OK for Eylea rival,Seeking Alpha,https://seekingalpha.com/news/3793704-why-did-regeneron-pharmaceuticals-stock-drop-today-roche-gets-fda-ok-for-eylea-rival?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8744555115699768
1022,1/31/2022 9:38:38 PM,5 Things To Expect This Week,InvestorPlace,/news/stocks/5-things-to-expect-this-week-1031147156,positive,0.8923013806343079
1023,2/1/2022 11:00:28 AM,3 Biotech Stocks That Could Boom or Bust in Q1,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-boom-or-bust-in-q1-1031148371,positive,0.7662330865859985
1024,2/1/2022 3:22:51 PM,Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-key-february-pdufa-dates-1031149588,positive,0.946699321269989
1025,2/1/2022 6:57:20 PM,Will the poor performance of biotechs in January be a barometer for 2022? Look to 2016,Seeking Alpha,https://seekingalpha.com/news/3794328-will-the-poor-performance-of-biotechs-in-january-be-a-barometer-for-2022-look-to-2016?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5294581651687622
1026,2/1/2022 10:04:14 PM,Regeneron-Sanofi report positive Dupixent data in 5 diseases; results at AAAAI meeting,Seeking Alpha,https://seekingalpha.com/news/3794560-regeneron-sanofi-report-positive-dupixent-data-in-5-diseases-results-at-aaaai-meeting?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9048863649368286
1027,2/1/2022 10:29:00 PM,Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting,PR Newswire,/news/stocks/positive-dupixent-dupilumab-data-across-five-diseases-with-underlying-type-2-inflammation-to-be-presented-at-2022-aaaai-annual-meeting-1031150939,positive,0.8888974785804749
1028,2/3/2022 2:12:10 PM,Can Regeneron Pharma top Q4 earnings forecast amid COVID challenges?,Seeking Alpha,https://seekingalpha.com/news/3795545-can-regeneron-pharma-top-q4-earnings-forecast-amid-covid-challenges?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9193610548973083
1029,2/3/2022 3:01:13 PM,Here's what Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q4-1031158984,positive,0.9321866631507874
1030,2/3/2022 3:48:38 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3795618-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
1031,2/4/2022 11:31:22 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $23.72 beats by $3.67, revenue of $4.95B beats by $460M",Seeking Alpha,https://seekingalpha.com/news/3795949-regeneron-pharmaceuticals-non-gaap-eps-of-23_72-beats-3_67-revenue-of-4_95b-beats-460m?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.550186038017273
1032,2/4/2022 12:01:47 PM,Sanofi meets earnings estimates even as vaccine business underperforms,Seeking Alpha,https://seekingalpha.com/news/3795966-sanofi-meets-earnings-estimates-even-as-vaccine-business-underperforms?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9441863894462585
1033,2/4/2022 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2021-financial-and-operating-results-1031162138,positive,0.5519717335700989
1034,2/4/2022 12:33:13 PM,"Regeneron Pharmaceuticals Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-increases-beats-estimates-1031162155,negative,0.9440788626670837
1035,2/4/2022 1:03:05 PM,Regeneron more than doubles Q4 revenue powered by sales for COVID-19 antibody,Seeking Alpha,https://seekingalpha.com/news/3795998-regeneron-more-than-doubles-q4-revenue-powered-by-sales-for-covid-19-antibody?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9085493683815002
1036,2/4/2022 1:34:06 PM,"The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-bristol-myers-squibb-gain-on-earnings-valneva-pfizer-tout-positive-lyme-disease-vaccine-data-unity-biotech-restructures-1031162384,negative,0.8567988872528076
1037,2/8/2022 2:22:28 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1031171586,positive,0.8152946829795837
1038,2/10/2022 6:59:00 AM,FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/fda-accepts-dupixent-dupilumab-for-priority-review-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-1031180488,negative,0.7429103851318359
1039,2/10/2022 7:19:29 AM,"Regeneron, Sanofi: FDA Accepts Dupixent Priority Review In Children With Atopic Dermatitis ",RTTNews,/news/stocks/regeneron-sanofi-fda-accepts-dupixent-priority-review-in-children-with-atopic-dermatitis-1031180548,negative,0.6904952526092529
1040,2/10/2022 11:12:22 AM,Sanofi-Regeneron Dupixent gets FDA priority review as add-on therapy for kids with eczema,Seeking Alpha,https://seekingalpha.com/news/3798393-sanofi-regeneron-dupixent-gets-fda-priority-review-as-add-on-therapy-for-kids-with-eczema?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9095051288604736
1041,2/10/2022 2:29:52 PM,"The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-q4-gets-covid-boost-seagen-plunges-on-earnings-adcom-test-awaits-lilly-1031182008,neutral,0.7779287695884705
1042,2/11/2022 1:50:00 PM,Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting,PR Newswire,/news/stocks/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-age-related-macular-degeneration-at-angiogenesis-meeting-1031186439,negative,0.9522847533226013
1043,2/11/2022 3:06:37 PM,Regeneron: Phase 2 Data In Wet AMD Shows Potential Of Aflibercept 8 Mg Compared To EYLEA ,RTTNews,/news/stocks/regeneron-phase-2-data-in-wet-amd-shows-potential-of-aflibercept-8-mg-compared-to-eylea-1031186735,negative,0.9484415650367737
1044,2/11/2022 8:38:42 PM,Regeneron gains on new long-term Phase 2 data for Eylea in wet AMD,Seeking Alpha,https://seekingalpha.com/news/3799334-regeneron-gains-on-new-long-term-phase-2-data-for-eylea-in-wet-amd?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9205642938613892
1045,2/14/2022 5:12:39 PM,UNITY posts 24-week data from Phase 1 trial for UBX1325 in vascular eye diseases,Seeking Alpha,https://seekingalpha.com/news/3799673-unity-posts-24-week-data-from-phase-1-trial-for-ubx1325-in-vascular-eye-diseases?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7826777696609497
1046,2/17/2022 10:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031206418,positive,0.9291732907295227
1047,2/18/2022 6:59:00 AM,Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program,PR Newswire,/news/stocks/regeneron-and-sanofi-provide-update-on-ongoing-dupixent-dupilumab-chronic-spontaneous-urticaria-phase-3-program-1031207499,positive,0.8899044990539551
1048,2/18/2022 7:26:44 AM,"Regeneron, Sanofi To Stop Dupixent Phase 3 Trial In Chronic Spontaneous Urticaria Due To Futility ",RTTNews,/news/stocks/regeneron-sanofi-to-stop-dupixent-phase-3-trial-in-chronic-spontaneous-urticaria-due-to-futility-1031207538,neutral,0.8229560852050781
1049,2/18/2022 11:29:26 AM,Regeneron-Sanofi stopping phase 3 trial of Dupixent to treat hives due to futility,Seeking Alpha,https://seekingalpha.com/news/3801849-regeneron-sanofi-stopping-phase-3-trial-of-dupixent-for-hives-due-to-futility?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6337881684303284
1050,2/18/2022 1:22:40 PM,"The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-sanofi-halt-late-stage-dupixent-study-agios-gets-fda-nod-safety-scare-for-gsk-s-rsv-vaccine-shockwave-jumps-on-earnings-1031208337,positive,0.4345225393772125
1051,2/20/2022 2:06:46 PM,"The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-20-26-reata-awaits-fda-decision-bausch-health-moderna-lead-earnings-news-flow-1031210514,positive,0.9087624549865723
1052,2/22/2022 11:00:51 AM,Is Moderna the Next Gilead or the Next Regeneron?,InvestorPlace,/news/stocks/mrna-stock-is-moderna-the-next-gilead-or-the-next-regeneron-1031215173,positive,0.9160948395729065
1053,2/23/2022 8:16:22 PM,KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?,InvestorPlace,/news/stocks/kod-stock-alert-why-is-kodiak-sciences-plunging-80-percent-today-1031222899,neutral,0.9409677386283875
1054,2/23/2022 8:43:44 PM,Kodiak sheds over $2B market cap after wet AMD setback for lead asset,Seeking Alpha,https://seekingalpha.com/news/3804379-kod-stock-crashes-after-wet-amd-trial-setback?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.918286144733429
1055,2/24/2022 8:58:17 PM,7 Low Volatility Stocks to Buy Right Now for Steady Returns,InvestorPlace,/news/stocks/7-low-volatility-stocks-to-buy-right-now-for-steady-returns-1031228612,positive,0.8245874643325806
1056,2/25/2022 3:33:26 PM,3 Moonshot Stocks Insiders Are Buying. What Do They Know?,InvestorPlace,/news/stocks/3-moonshot-stocks-insiders-are-buying-what-do-they-know-1031232679,positive,0.889276385307312
1057,2/26/2022 5:59:00 PM,Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria,PR Newswire,/news/stocks/late-breaking-phase-3-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significantly-reduced-itch-and-hives-in-patients-with-chronic-spontaneous-urticaria-1031234177,negative,0.9340318441390991
1058,2/26/2022 6:04:00 PM,Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis,PR Newswire,/news/stocks/late-breaking-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significantly-improved-signs-and-symptoms-of-eosinophilic-esophagitis-1031234180,negative,0.9416549801826477
1059,2/28/2022 8:34:39 PM,Why did Vir Biotechnology stock drop today?,Seeking Alpha,https://seekingalpha.com/news/3807154-why-did-vir-stock-drop-today-falling-covid-19-cases?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9167329668998718
1060,2/28/2022 10:02:00 PM,"Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sust...",PR Newswire,/news/stocks/intellia-and-regeneron-announce-updated-phase-1-data-demonstrating-a-single-dose-of-ntla-2001-investigational-crispr-therapy-for-transthyretin-attr-amyloidosis-resulted-in-rapid-deep-and-sust-1031239820,negative,0.8906201720237732
1061,3/1/2022 1:51:14 PM,"The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution",Benzinga,/news/stocks/the-daily-biotech-pulse-legend-biotech-cti-biopharma-receive-fda-approvals-abbvie-announces-delay-in-skyrizi-review-editas-gains-on-crispr-patent-resolution-1031242590,positive,0.7575392723083496
1062,3/2/2022 1:35:33 PM,"Biden pushes for insulin price cap, Medicare drug negotiations in SOTU",Seeking Alpha,https://seekingalpha.com/news/3808400-biden-pushes-for-insulin-price-cap-medicare-drug-negotiations-in-sotu?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6005553603172302
1063,3/3/2022 10:31:55 AM,WHO backs restriction of Regeneron's REGEN-COV for Omicron patients,Seeking Alpha,https://seekingalpha.com/news/3808848-who-restricts-use-of-regenerons-antibody-cocktail-regen-cov-in-omicron-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7795350551605225
1064,3/3/2022 3:57:17 PM,U.S. to share government-backed COVID-19 tech with WHO - Washington Post,Seeking Alpha,https://seekingalpha.com/news/3809199-us-to-share-government-backed-covid-19-tech-with-who-washington-post?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.697287917137146
1065,3/3/2022 4:24:54 PM,Regeneron maintained as overweight at Piper but concern over Eylea outlook,Seeking Alpha,https://seekingalpha.com/news/3809217-regeneron-maintained-as-overweight-at-piper-but-concern-over-eylea-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7116130590438843
1066,3/4/2022 2:23:54 PM,Adicet Bio initiated Buy at Jefferies citing upcoming data readouts,Seeking Alpha,https://seekingalpha.com/news/3809606-acet-stock-higher-as-jefferies-upgrade-citing-upcoming-data?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6599317789077759
1067,3/8/2022 2:43:33 PM,"BioNTech, Regeneron To Advance Clinical Development Of FixVac And Libtayo Combination In NSCLC ",RTTNews,/news/stocks/biontech-regeneron-to-advance-clinical-development-of-fixvac-and-libtayo-combination-in-nsclc-1031262595,positive,0.6941027641296387
1068,3/10/2022 3:35:56 PM,After Amazon these 20 companies could follow a stock split wave,Seeking Alpha,https://seekingalpha.com/news/3812200-after-amazon-these-20-companies-could-follow-a-stock-split-wave?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9360999464988708
1069,3/10/2022 6:02:14 PM,Upcoming Stock Splits 2022: 20 Companies That Could Follow Amazon’s Lead,InvestorPlace,/news/stocks/upcoming-stock-splits-2022-20-companies-that-could-follow-amazons-lead-1031271410,positive,0.9322134852409363
1070,3/16/2022 2:16:00 AM,"Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation",PR Newswire,/news/stocks/students-win-1-8-million-at-regeneron-science-talent-search-2022-for-exceptional-research-on-neutron-star-black-hole-systems-narrowband-radar-and-ribosome-movement-in-protein-translation-1031283193,negative,0.7960584759712219
1071,3/26/2022 2:59:00 PM,Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis,PR Newswire,/news/stocks/late-breaking-phase-3-data-at-aad-2022-show-dupixent-dupilumab-significantly-improved-signs-and-symptoms-of-prurigo-nodularis-1031309487,negative,0.9423472285270691
1072,3/28/2022 7:31:43 AM,Biotech Stocks Facing FDA Decision In April 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2022-1031310826,positive,0.9148067831993103
1073,4/1/2022 10:37:35 AM,World's 1st COVID human challenge trial suggests spread of virus not correlated to symptoms,Seeking Alpha,https://seekingalpha.com/news/3819725-worlds-1st-covid-human-challenge-trial-suggests-spread-of-virus-not-correlated-to-symptoms?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8839459419250488
1074,4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374,positive,0.9468021392822266
1075,4/4/2022 6:59:00 AM,FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis,PR Newswire,/news/stocks/fda-accepts-dupixent-dupilumab-for-priority-review-in-patients-aged-12-years-and-older-with-eosinophilic-esophagitis-1031328700,negative,0.7315170764923096
1076,4/4/2022 7:21:34 AM,Regeneron : FDA Accepts Dupixent For Priority Review In Patients Aged 12 Yrs And Older With EoE ,RTTNews,/news/stocks/regeneron-fda-accepts-dupixent-for-priority-review-in-patients-aged-12-yrs-and-older-with-eoe-1031328728,negative,0.7375526428222656
1077,4/4/2022 9:00:38 PM,Lawmakers agree on $10 billion additional funding for U.S. COVID response (Updated),Seeking Alpha,https://seekingalpha.com/news/3820489-lawmakers-set-to-announce-10-billion-additional-funding-for-us-covid-response?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6900182366371155
1078,4/5/2022 3:00:00 PM,Annual Boosters Might Not Give Moderna the Boost It Needs,InvestorPlace,/news/stocks/mrna-stock-annual-booster-may-not-give-it-the-boost-it-needs-1031333944,negative,0.6086446046829224
1079,4/5/2022 10:05:00 PM,"Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022",PR Newswire,/news/stocks/regeneron-to-report-first-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-4-2022-1031334615,positive,0.9504155516624451
1080,4/5/2022 10:17:17 PM,7 Safe Stocks to Buy to Guard Against a Recession,InvestorPlace,/news/stocks/7-safe-stocks-to-buy-to-guard-against-a-recession-1031334812,positive,0.8407782912254333
1081,4/6/2022 1:33:41 AM,"GlaxoSmithKline, Vir COVID-19 therapy is no longer authorized in U.S. - FDA",Seeking Alpha,https://seekingalpha.com/news/3820993-glaxosmithkline-vir-covid-19-therapy-is-no-longer-authorized-in-us-fda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9018964171409607
1082,4/7/2022 6:59:00 AM,Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation,PR Newswire,/news/stocks/dupixent-dupilumab-approved-by-european-commission-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation-1031338685,positive,0.7129051685333252
1083,4/7/2022 7:28:42 AM,"Regeneron, Sanofi: EU Approves Dupixent For Children Aged 6 To 11 Years With Severe Asthma ",RTTNews,/news/stocks/regeneron-sanofi-eu-approves-dupixent-for-children-aged-6-to-11-years-with-severe-asthma-1031338728,negative,0.7115673422813416
1084,4/7/2022 1:27:58 PM,"Regeneron, Sanofi win EU approval for Dupixent in younger children with asthma",Seeking Alpha,https://seekingalpha.com/news/3821670-regeneron-sanofi-win-eu-nod-for-dupixent-in-younger-children-with-asthma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9273502230644226
1085,4/7/2022 2:24:52 PM,"The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-goes-shopping-astrazeneca-inks-bispecific-antibody-deal-aptinyx-faces-clinical-study-setback-erytech-jumps-on-data-and-more-1031339904,positive,0.6574383974075317
1086,4/7/2022 7:38:30 PM,Life sciences companies drive healthcare stocks to lead S&P 500,Seeking Alpha,https://seekingalpha.com/news/3821820-life-sciences-companies-drive-healthcare-stocks-to-lead-sp-500?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8493631482124329
1087,4/10/2022 10:42:49 PM,"The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-10-april-16-regeneron-fda-decision-cancer-conference-presentations-and-more-1031344759,positive,0.9415993690490723
1088,4/11/2022 6:05:53 PM,Michael Grimm Purchases $5.66 Million Worth Of Energy Transfer & Other Notable Insider Buys,Benzinga,/news/stocks/michael-grimm-purchases-5-66-million-worth-of-energy-transfer-other-notable-insider-buys-1031347106,positive,0.9258779287338257
1089,4/12/2022 7:25:20 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031350722,positive,0.9010616540908813
1090,4/13/2022 2:15:54 PM,"The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More",Benzinga,/news/stocks/the-daily-biotech-pulse-glaxosmithkline-and-halozyme-go-shopping-mylan-s-insulin-glargine-recall-turning-point-shares-lung-cancer-data-and-more-1031353335,positive,0.9408669471740723
1091,4/14/2022 11:59:20 AM,FDA extends review of Regeneron's REGEN-COV to treat/prevent COVID-19,Seeking Alpha,https://seekingalpha.com/news/3823380-fda-extends-review-of-regenerons-regen-cov-to-treatprevent-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.824245274066925
1092,4/14/2022 1:00:00 PM,U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19,PR Newswire,/news/stocks/u-s-fda-extends-review-of-biologics-license-application-for-regen-cov-casirivimab-and-imdevimab-for-treatment-and-prophylaxis-of-covid-19-1031356293,positive,0.48248380422592163
1093,4/14/2022 1:36:36 PM,Regeneron Says FDA Extends Review Of BLA For REGEN-COV By 3 Months ,RTTNews,/news/stocks/regeneron-says-fda-extends-review-of-bla-for-regen-cov-by-3-months-1031356464,positive,0.7869744896888733
1094,4/14/2022 3:35:45 PM,"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regeneron-s-covid-19-therapy-decision-pushed-protagonist-s-rusfertide-breakthrough-tag-update-and-more-1031357104,positive,0.9389084577560425
1095,4/17/2022 8:31:32 PM,"The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-17-april-23-j-j-abbott-earnings-adcom-test-for-tg-therapeutics-and-more-1031359853,positive,0.9330936670303345
1096,4/19/2022 11:31:08 AM,Regeneron to acquire Checkmate Pharma in $250 million all-cash deal,Seeking Alpha,https://seekingalpha.com/news/3824208-cmpi-stock-soars-on-plans-by-regeneron-to-acquire-it-in-250-million-deal?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9060550332069397
1097,4/19/2022 1:00:00 PM,Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types,PR Newswire,/news/stocks/regeneron-to-acquire-checkmate-pharmaceuticals-and-its-investigational-immune-activator-for-potential-use-in-multiple-tumor-types-1031363503,positive,0.7120006680488586
1098,4/19/2022 1:07:23 PM,"SpringWorks, Regeneron To Evaluate Nirogacestat In Combination With REGN5458 In Multiple Myeloma ",RTTNews,/news/stocks/springworks-regeneron-to-evaluate-nirogacestat-in-combination-with-regn5458-in-multiple-myeloma-1031363562,negative,0.5068651437759399
1099,4/19/2022 1:32:25 PM,Regeneron Pharma To Buy Checkmate Pharmaceuticals In $250 Mln All Cash Deal ,RTTNews,/news/stocks/regeneron-pharma-to-buy-checkmate-pharmaceuticals-in-250-mln-all-cash-deal-1031363645,positive,0.9180623888969421
1100,4/19/2022 2:48:29 PM,Regeneron - Checkmate deal propels other developers with similar drugs,Seeking Alpha,https://seekingalpha.com/news/3824326-corp-idra-stocks-gain-on-regeneron---checkmate-deal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9323209524154663
1101,4/19/2022 3:05:03 PM,"The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-acquires-checkmate-pharma-moderna-s-bivalent-booster-covid-19-vaccine-update-priority-review-for-astrazeneca-s-enhertu-1031364260,positive,0.606448233127594
1102,4/19/2022 4:57:59 PM,Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?,InvestorPlace,/news/stocks/why-is-checkmate-pharmaceuticals-cmpi-stock-up-300-today-1031364947,negative,0.8273887038230896
1103,4/19/2022 6:16:31 PM,38 Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/38-stocks-moving-in-tuesday-s-mid-day-session-1031364862,positive,0.5384174585342407
1104,4/20/2022 11:43:34 AM,54 Biggest Movers From Yesterday,Benzinga,/news/stocks/54-biggest-movers-from-yesterday-1031367316,positive,0.850827693939209
1105,4/20/2022 3:37:14 PM,Adaptimmune in two-day rally thanks to Regeneron/Checkmate deal; shares up 15%,Seeking Alpha,https://seekingalpha.com/news/3824792-adaptimmune-in-two-day-rally-thanks-to-regeneroncheckmate-deal-shares-up-15?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9452891945838928
1106,4/23/2022 8:00:00 PM,COVID therapies and vaccines propel rise in spending on medicines in 2021,Seeking Alpha,https://seekingalpha.com/news/3825965-covid-therapies-and-vaccines-propel-rise-in-spending-on-medicines-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9413689374923706
1107,4/28/2022 9:19:04 AM,"Sanofi Q1 sales climb on the back of Dupixent, consumer healthcare show; maintains outlook",Seeking Alpha,https://seekingalpha.com/news/3828323-sanofi-q1-sales-climb-on-the-back-of-dupixent-consumer-healthcare-show-maintains-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.924562394618988
1108,4/28/2022 5:24:27 PM,Intellia wins Outperform rating at Credit Suisse on ATTR potential,Seeking Alpha,https://seekingalpha.com/news/3828773-ntla-stock-gains-on-outperform-rating-at-credit-suisse?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9326803088188171
1109,5/2/2022 2:26:53 PM,"The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-1-7-phathom-fda-decision-pfizer-vertex-pharma-lead-earnings-news-ophthalmology-conference-presentations-and-more-1031408449,positive,0.9381586909294128
1110,5/2/2022 9:46:27 PM,Here's Why This Analyst Cut Price Target On Regeneron,Benzinga,/news/stocks/here-s-why-this-analyst-cut-price-target-on-regeneron-1031410197,positive,0.8664911985397339
1111,5/2/2022 10:04:25 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1031410285,positive,0.8993901014328003
1112,5/2/2022 10:15:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031410295,positive,0.9291732907295227
1113,5/3/2022 3:01:13 PM,Here's what Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-q1-earnings-preview-1031413639,positive,0.9321866631507874
1114,5/3/2022 3:43:39 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3831146-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.855887770652771
1115,5/3/2022 5:10:46 PM,"All eyes on Regeneron Q1 earnings amid REGEN-COV, Eylea challenges",Seeking Alpha,https://seekingalpha.com/news/3831239-all-eyes-on-regeneron-q1-earnings-amid-regen-cov-eylea-challenges?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9344474077224731
1116,5/4/2022 10:33:23 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $11.49 beats by $1.69, revenue of $2.97B beats by $280M",Seeking Alpha,https://seekingalpha.com/news/3831809-regeneron-pharmaceuticals-non-gaap-eps-of-11_49-beats-1_69-revenue-of-2_97b-beats-280m?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6390399932861328
1117,5/4/2022 11:35:34 AM,"Regeneron Q1 revenue rises on the back of blockbuster drugs Eylea, Dupixent",Seeking Alpha,https://seekingalpha.com/news/3831892-regeneron-q1-revenue-rises-on-the-back-of-blockbuster-drugs-eylea-dupixent?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9465112090110779
1118,5/4/2022 12:30:00 PM,Regeneron Reports First Quarter 2022 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-first-quarter-2022-financial-and-operating-results-1031418881,negative,0.49191316962242126
1119,5/4/2022 12:44:11 PM,"Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-profit-decreases-but-beats-estimates-1031418941,neutral,0.9666802883148193
1120,5/4/2022 2:44:29 PM,"The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints",Benzinga,/news/stocks/the-daily-biotech-pulse-kezar-life-s-lead-asset-fails-brickell-biotech-offloads-late-stage-asset-connect-biopharma-ulcerative-colitis-trial-disappoints-1031419730,neutral,0.9565200209617615
1121,5/12/2022 2:14:54 PM,Federal flags to fly at half-staff to mark one million COVID deaths,Seeking Alpha,https://seekingalpha.com/news/3837849-federal-flags-to-fly-at-half-staff-to-mark-one-million-covid-deaths?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9106363654136658
1122,5/13/2022 5:52:00 PM,"High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair",PR Newswire,/news/stocks/high-school-scientists-from-around-the-world-win-nearly-8m-in-awards-scholarships-at-regeneron-international-science-and-engineering-fair-1031459367,negative,0.7665807008743286
1123,5/13/2022 7:13:00 PM,"High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair",PR Newswire,/news/stocks/high-school-scientists-from-around-the-world-win-nearly-8m-in-awards-scholarships-at-regeneron-international-science-and-engineering-fair-1031459523,negative,0.7665807008743286
1124,5/17/2022 1:00:00 PM,"Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur",PR Newswire,/news/stocks/vyriad-inc-raises-29-5m-in-series-b-funding-led-by-renowned-genetics-entrepreneur-1031467802,negative,0.7496776580810547
1125,5/20/2022 7:24:28 PM,Sanofi wins FDA label expansion for Dupixent for new inflammatory condition,Seeking Alpha,https://seekingalpha.com/news/3841473-sanofi-wins-fda-label-expansion-for-dupixent-for-new-inflammatory-condition?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9349470138549805
1126,5/20/2022 9:15:00 PM,FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis,PR Newswire,/news/stocks/fda-approves-dupixent-dupilumab-as-first-treatment-for-adults-and-children-aged-12-and-older-with-eosinophilic-esophagitis-1031479461,negative,0.7952315211296082
1127,5/21/2022 1:00:00 PM,Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol,PR Newswire,/news/stocks/evkeeza-evinacumab-phase-3-trial-demonstrates-48-ldl-c-reduction-in-children-with-ultra-rare-form-of-high-cholesterol-1031479707,negative,0.94120192527771
1128,5/22/2022 9:58:01 PM,"The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-22-28-verrica-bristol-myers-squibb-fda-decisions-medtronic-earnings-conference-presentations-more-1031480317,positive,0.9357399940490723
1129,5/23/2022 9:55:20 AM,"Regeneron, Ultragenyx's Evkeeza helps reduce bad cholesterol in kids 5 to 11 with rare disorder in study",Seeking Alpha,https://seekingalpha.com/news/3841595-regeneron-ultragenyxs-evkeeza-helps-reduce-bad-cholesterol-in-kids-5-to-11-with-rare-disorder-in-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5727502107620239
1130,5/23/2022 2:11:23 PM,FDA Approves Regeneron's Dupixent To Treat Eosinophilic Esophagitis ,RTTNews,/news/stocks/fda-approves-regeneron-s-dupixent-to-treat-eosinophilic-esophagitis-1031481730,negative,0.7958720922470093
1131,5/23/2022 3:38:14 PM,"Regeneron initiated at outperform at Leerink on strength of Dupixent, Eylea, and pipeline",Seeking Alpha,https://seekingalpha.com/news/3841788-regeneron-initiated-at-outperform-at-leerink-on-strength-of-dupixent-eylea-and-pipeline?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9479963183403015
1132,5/23/2022 4:33:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-23-2022-1031482320,positive,0.527824878692627
1133,5/27/2022 4:04:02 PM,Biotech Stocks Facing FDA Decision In June 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2022-1031493578,positive,0.9180289506912231
1134,5/28/2022 4:22:39 PM,BioPharma M&A premiums could moderate amid rate hikes – Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3843664-biopharma-ma-premiums-could-moderate-amid-rate-hikes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9036207795143127
1135,5/30/2022 4:51:59 PM,"As COVID Subsidies, Here Are 8 Infectious Diseases That Could Emerge As Potent Threats",Benzinga,/news/stocks/as-covid-subsidies-here-are-8-infectious-diseases-that-could-emerge-as-potent-threats-1031496301,positive,0.8753746747970581
1136,5/31/2022 6:59:00 AM,FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis,PR Newswire,/news/stocks/fda-accepts-dupixent-dupilumab-for-priority-review-in-adults-with-prurigo-nodularis-1031496994,negative,0.6127923727035522
1137,5/31/2022 7:28:36 AM,Regeneron : FDA Accepts Dupixent For Priority Review In Adults With Prurigo Nodularis ,RTTNews,/news/stocks/regeneron-fda-accepts-dupixent-for-priority-review-in-adults-with-prurigo-nodularis-1031497041,negative,0.779049277305603
1138,5/31/2022 2:31:00 PM,Regeneron Completes Acquisition of Checkmate Pharmaceuticals,PR Newswire,/news/stocks/regeneron-completes-acquisition-of-checkmate-pharmaceuticals-1031498228,positive,0.8747426271438599
1139,5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9459705948829651
1140,5/31/2022 8:24:35 PM,7 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/7-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031499558,positive,0.9295507669448853
1141,5/31/2022 9:42:54 PM,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-dates-1031499656,positive,0.9482179284095764
1142,6/2/2022 9:25:31 AM,Xoma to get $2.5M from Kuros as Checkmate's acquisition by Regeneron triggers milestone payout,Seeking Alpha,https://seekingalpha.com/news/3844870-xoma-to-get-25m-from-kuros-as-checkmates-acquisition-by-regeneron-triggers-milestone-payout?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9306442737579346
1143,6/2/2022 1:30:00 PM,"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of ...",PR Newswire,/news/stocks/regeneron-strengthens-commitment-to-oncology-through-purchase-of-sanofi-s-stake-in-the-regeneron-and-sanofi-collaboration-on-libtayo-cemiplimab-a-pd-1-inhibitor-approved-for-multiple-forms-of-1031504901,negative,0.9044250249862671
1144,6/2/2022 1:57:43 PM,"Regeneron To Acquire Global Rights To Libtayo From Sanofi For $900 Mln, Plus Royalties ",RTTNews,/news/stocks/regeneron-to-acquire-global-rights-to-libtayo-from-sanofi-for-900-mln-plus-royalties-1031504971,positive,0.8297452926635742
1145,6/5/2022 10:09:23 PM,"The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnings-and-more-1031509946,positive,0.804358184337616
1146,6/6/2022 5:12:03 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-6-2022-1031511325,positive,0.5026875734329224
1147,6/7/2022 9:04:18 PM,"FDA approves Regeneron, Sanofi's Dupixent in babies, young children for eczema",Seeking Alpha,https://seekingalpha.com/news/3846498-fda-approves-regeneron-sanofis-dupixent-in-babies-young-children-for-eczema?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6405644416809082
1148,6/7/2022 10:44:00 PM,FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-1031514664,negative,0.7985045909881592
1149,6/8/2022 4:27:20 AM,Sanofi : FDA Approves Dupixent For Young Children With Moderate-to-severe Atopic Dermatitis ,RTTNews,/news/stocks/sanofi-fda-approves-dupixent-for-young-children-with-moderate-to-severe-atopic-dermatitis-1031514826,negative,0.9004517197608948
1150,6/8/2022 3:07:53 PM,"The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-adcomm-backing-for-novavax-s-covid-19-shot-new-data-on-moderna-s-omicron-vaccine-dbv-tech-s-encouraging-peanut-allergy-trial-data-1031516521,positive,0.781650960445404
1151,6/9/2022 11:22:09 AM,Alnylam says kidney disease therapy led to 37% drop in key indicator,Seeking Alpha,https://seekingalpha.com/news/3847095-alny-stock-in-focus-as-kidney-disease-drug-causes-37-drop-in-key-indicator?utm_source=businessinsider&utm_medium=referral,neutral,0.9534047245979309
1152,6/9/2022 1:31:18 PM,Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran ,RTTNews,/news/stocks/alnylam-pharma-reports-positive-topline-results-from-phase-2-study-of-cemdisiran-1031518926,negative,0.9524417519569397
1153,6/9/2022 2:47:31 PM,Adverum wet AMD candidate ADVM-022 shows long-term benefit after single injection,Seeking Alpha,https://seekingalpha.com/news/3847228-adverum-wet-amd-candidate-advm-022-shows-long-term-benefit-after-single-injection?utm_source=businessinsider&utm_medium=referral,negative,0.9534595608711243
1154,6/24/2022 12:56:24 PM,"Intellia, Regeneron post 12-month data for gene editing therapy in ATTR amyloidosis",Seeking Alpha,https://seekingalpha.com/news/3851508-ntla-regn-stocks-in-focus-after-long-term-data-for-gene-editing-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.5031850934028625
1155,6/24/2022 1:31:00 PM,Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions ...,PR Newswire,/news/stocks/intellia-and-regeneron-present-updated-interim-data-from-phase-1-study-of-crispr-based-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-demonstrating-that-deep-serum-ttr-reductions-1031548486,negative,0.9131185412406921
1156,6/24/2022 2:03:57 PM,NTLA : Study Of NTLA-2001 On Transthyretin Amyloidosis Shows Serum TTR Reductions Remained Durable ,RTTNews,/news/stocks/ntla-study-of-ntla-2001-on-transthyretin-amyloidosis-shows-serum-ttr-reductions-remained-durable-1031548571,negative,0.7730420827865601
1157,6/28/2022 9:17:30 AM,Biotech Stocks Facing FDA Decision In July 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2022-1031553516,positive,0.9208682775497437
1158,6/29/2022 1:30:00 PM,EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review,PR Newswire,/news/stocks/eylea-aflibercept-injection-sbla-for-every-16-week-dosing-regimen-in-patients-with-diabetic-retinopathy-accepted-for-fda-review-1031557129,positive,0.6413233280181885
1159,6/29/2022 1:55:11 PM,Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review ,RTTNews,/news/stocks/regeneron-s-eylea-sbla-for-16-week-dosing-regimen-in-diabetic-retinopathy-accepted-for-fda-review-1031557201,negative,0.8540852069854736
1160,6/29/2022 2:17:52 PM,FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindness,Seeking Alpha,https://seekingalpha.com/news/3852874-fda-accepts-regenerons-application-for-eylea-extended-regimen-to-treat-diabetic-blindness?utm_source=businessinsider&utm_medium=referral,negative,0.8751267790794373
1161,7/1/2022 11:26:23 AM,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-july-pdufa-dates-1031562548,positive,0.9478204250335693
1162,7/1/2022 1:00:00 PM,Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab),PR Newswire,/news/stocks/regeneron-completes-purchase-of-sanofi-s-stake-in-libtayo-cemiplimab-1031562785,positive,0.8334523439407349
1163,7/1/2022 1:17:14 PM,Regeneron Completes Acquiring Sanofi's Stake In Libtayo ,RTTNews,/news/stocks/regeneron-completes-acquiring-sanofi-s-stake-in-libtayo-1031562845,positive,0.8643763065338135
1164,7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral,negative,0.7087149620056152
1165,7/6/2022 10:01:00 PM,"Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022",PR Newswire,/news/stocks/regeneron-to-report-second-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-3-2022-1031571486,positive,0.9502334594726562
1166,7/7/2022 1:00:29 PM,Alvotech starts confirmatory study for its AVT06 biosimilar to Regeneron's Eylea,Seeking Alpha,https://seekingalpha.com/news/3854978-alvotech-starts-confirmatory-study-for-its-avt06-biosimilar-to-regenerons-eylea?utm_source=businessinsider&utm_medium=referral,positive,0.5372731685638428
1167,7/8/2022 6:30:36 PM,"Catalyst watch: Inflation reads, major banks report and Alphabet splits",Seeking Alpha,https://seekingalpha.com/news/3855426-catalyst-watch-inflation-reads-major-banks-report-and-alphabet-splits?utm_source=businessinsider&utm_medium=referral,positive,0.9206340909004211
1168,7/8/2022 7:53:05 PM,7 Moonshot Investments Upending a $10 Trillion Industry,InvestorPlace,/news/stocks/7-moonshot-investments-upending-a-10-trillion-industry-1031576272,negative,0.5756996273994446
1169,7/8/2022 8:12:42 PM,The 3 Leaders of the Gene Editing Revolution,InvestorPlace,/news/stocks/the-3-leaders-of-the-gene-editing-revolution-1031576321,positive,0.9342885613441467
1170,7/12/2022 3:00:00 PM,Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development,PR Newswire,/news/stocks/ultima-genomics-signs-development-agreement-with-regeneron-aimed-at-driving-the-scale-of-genomic-information-for-drug-discovery-and-development-1031581233,negative,0.8820047974586487
1171,7/13/2022 3:00:53 PM,"The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-s-covid-19-vaccine-as-effective-as-mrna-shots-humanigen-s-lenzilumab-disappoints-in-covid-19-study-positive-preclinical-data-from-hoth-s-alzheimer-s-program-1031584590,negative,0.7949234247207642
1172,7/14/2022 6:59:00 AM,Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis,PR Newswire,/news/stocks/dupixent-dupilumab-phase-3-trial-shows-positive-results-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-1031586521,negative,0.9211310744285583
1173,7/14/2022 7:30:46 AM,Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal ,RTTNews,/news/stocks/regeneron-phase-3-trial-of-dupixent-in-children-with-eosinophilic-esophagitis-meets-main-goal-1031586559,positive,0.80044025182724
1174,7/14/2022 3:01:11 PM,"The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-much-awaited-fda-nod-for-novavax-s-covid-19-shot-dsmb-suggests-contrafect-to-stop-antimicrobial-resistant-infection-study-cytomx-restructures-1031587666,positive,0.5929545164108276
1175,7/20/2022 7:06:26 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1031602001,positive,0.8993901014328003
1176,7/21/2022 3:49:50 PM,AstraZeneca COVID-19 therapy less effective against new Omicron strains: study,Seeking Alpha,https://seekingalpha.com/news/3859171-astrazeneca-covid-19-therapy-less-protection-against-new-omicron-strains?utm_source=businessinsider&utm_medium=referral,neutral,0.845219612121582
1177,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral,positive,0.8448383808135986
1178,7/25/2022 2:31:28 PM,Meta Platforms To $250? Plus This Analyst Lowers Price Target On Microsoft,Benzinga,/news/stocks/meta-platforms-to-250-plus-this-analyst-lowers-price-target-on-microsoft-1031611412,positive,0.8994806408882141
1179,7/25/2022 4:22:53 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-25-2022-1031611937,positive,0.5397140383720398
1180,7/25/2022 6:25:57 PM,Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product,Benzinga,/news/stocks/regeneron-s-price-target-cut-on-dim-prospects-for-its-flagship-eye-product-1031612275,neutral,0.9555045962333679
1181,7/26/2022 1:00:00 PM,Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation,PR Newswire,/news/stocks/regeneron-announces-the-2022-winners-of-the-regeneron-prize-for-creative-innovation-1031614794,positive,0.8910680413246155
1182,7/26/2022 10:34:29 PM,7 Cathie Wood Stocks Trading at a Discount Right Now,InvestorPlace,/news/stocks/cathie-wood-stocks-trading-a-discount-1031620033,positive,0.8793302774429321
1183,7/27/2022 11:14:00 PM,Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease,PR Newswire,/news/stocks/regeneron-genetics-center-discovers-rare-mutations-in-the-cideb-gene-that-protect-against-liver-disease-1031622512,positive,0.7933688163757324
1184,7/28/2022 9:05:28 AM,Sanofi raises FY22 outlook while Q2 sales boosted by blockbuster Dupixent,Seeking Alpha,https://seekingalpha.com/news/3862033-sanofi-raises-fy22-outlook-while-q2-sales-boosted-by-blockbuster-dupixent?utm_source=businessinsider&utm_medium=referral,negative,0.9313657283782959
1185,7/28/2022 8:20:28 PM,Senate Democrats propose $21B funding for next phase of COVID-19 response,Seeking Alpha,https://seekingalpha.com/news/3862718-senate-democrats-propose-21b-funding-for-next-phase-of-covid-19-response?utm_source=businessinsider&utm_medium=referral,negative,0.6786968111991882
1186,7/31/2022 3:21:24 PM,Biotech Investors: August's Key PDUFA Catalysts You Must Know,Benzinga,/news/stocks/biotech-investors-august-s-key-pdufa-catalysts-you-must-know-1031631857,positive,0.8776605129241943
1187,8/2/2022 2:48:35 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3864711-notable-earnings-before-wednesdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.855887770652771
1188,8/2/2022 3:01:13 PM,Regeneron Pharmaceuticals earnings preview: what to expect,Markets Insider Automation,/news/stocks/regeneron-stock-quarter-earnings-preview-q2-1031640061,positive,0.9152657389640808
1189,8/2/2022 4:20:13 PM,"Eyes on sales of blockbuster drugs Eylea, Dupixent for Regeneron's Q2 2022 earnings",Seeking Alpha,https://seekingalpha.com/news/3864805-eyes-on-sales-of-blockbuster-drugs-eylea-dupixent-for-regenerons-q2-2022-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.8051224946975708
1190,8/3/2022 10:34:09 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M",Seeking Alpha,https://seekingalpha.com/news/3865525-regeneron-pharmaceuticals-non-gaap-eps-of-9_77-beats-1_02-revenue-of-2_86b-beats-60m?utm_source=businessinsider&utm_medium=referral,negative,0.5867031812667847
1191,8/3/2022 11:44:39 AM,Regeneron posts 2Q revenue drop as sales of COVID-19 therapy plummet,Seeking Alpha,https://seekingalpha.com/news/3865621-regn-stock-gains-despite-2q-revenue-drop?utm_source=businessinsider&utm_medium=referral,neutral,0.9755275249481201
1192,8/3/2022 12:25:00 PM,Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (m...,PR Newswire,/news/stocks/novel-costimulatory-bispecific-antibody-shows-encouraging-anti-tumor-activity-when-combined-with-pd-1-inhibitor-libtayo-cemiplimab-in-advanced-metastatic-castration-resistant-prostate-cancer-m-1031644495,negative,0.943787693977356
1193,8/3/2022 12:30:00 PM,Regeneron Reports Second Quarter 2022 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-second-quarter-2022-financial-and-operating-results-1031644519,negative,0.4484143853187561
1194,8/3/2022 12:49:32 PM,"Alnylam drives Intellia, Ionis higher with amyloidosis data; BridgeBio slips",Seeking Alpha,https://seekingalpha.com/news/3865700-ntla-stock-ions-stock-climb-after-alnylam-data-on-amyloidosis?utm_source=businessinsider&utm_medium=referral,negative,0.9355520606040955
1195,8/3/2022 1:05:15 PM,Regeneron's REGN5678 Shows Encouraging Anti-tumor Activity When Combined With Libtayo ,RTTNews,/news/stocks/regeneron-s-regn5678-shows-encouraging-anti-tumor-activity-when-combined-with-libtayo-1031644679,negative,0.9491336345672607
1196,8/3/2022 1:24:20 PM,"Regeneron Q2 Profit Down On Weak Revenues; Revises FY22 Margin, R&D Outlook ",RTTNews,/news/stocks/regeneron-q2-profit-down-on-weak-revenues-revises-fy22-margin-r-d-outlook-1031644756,neutral,0.9725160002708435
1197,8/3/2022 7:38:16 PM,"Moderna, CVS Health, Regeneron lead S&P 500 after Q2 earnings",Seeking Alpha,https://seekingalpha.com/news/3866296-mrna-stock-cvs-stock-regn-stock-lead-sp-500-after-2q-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.8808310031890869
1198,8/3/2022 8:42:38 PM,7 Cheap Biotech Stocks to Buy Now,InvestorPlace,/news/stocks/cheap-biotech-stocks-1031647456,positive,0.8731281161308289
1199,8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral,positive,0.5326845645904541
1200,8/8/2022 1:45:59 PM,Kodiak gains as late-stage trial for eye disease candidate meets key goal,Seeking Alpha,https://seekingalpha.com/news/3868809-kodiak-gains-as-late-stage-trial-for-eye-disease-candidate-meets-key-goal?utm_source=businessinsider&utm_medium=referral,negative,0.9420757293701172
1201,8/8/2022 2:40:28 PM,Kodiak's Eye Disease Candidate At Par With Regeneron's Eylea In Visual Acuity Gains,Benzinga,/news/stocks/kodiak-s-eye-disease-candidate-at-par-with-regeneron-s-eylea-in-visual-acuity-gains-1031661122,negative,0.6043192148208618
1202,8/11/2022 1:40:26 PM,Regeneron IPR hearing suggests Eylea patent may be in trouble - analyst,Seeking Alpha,https://seekingalpha.com/news/3871614-regeneron-ipr-hearing-suggests-eylea-patent-may-be-in-trouble-analyst?utm_source=businessinsider&utm_medium=referral,neutral,0.9611251354217529
1203,8/11/2022 7:26:06 PM,CDC eases COVID guidance for unvaccinated people,Seeking Alpha,https://seekingalpha.com/news/3871779-cdc-eases-covid-guidance-for-unvaccinated-people?utm_source=businessinsider&utm_medium=referral,neutral,0.8480912446975708
1204,8/11/2022 8:44:15 PM,3 Best Funds for Aggressive Investors,InvestorPlace,/news/stocks/best-funds-for-aggressive-investors-1031677463,positive,0.8665502071380615
1205,8/11/2022 9:22:02 PM,"J&J, Merck, Regeneron most exposed to Medicare drug price negotiation - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3871983-johnson-johnson-merck-regeneron-most-exposed-to-medicare-drug-price-negotiation-bloomberg?utm_source=businessinsider&utm_medium=referral,positive,0.9089527726173401
1206,8/12/2022 11:39:31 AM,Unity Biotech jumps 93% after data for lead asset in diabetic macular edema,Seeking Alpha,https://seekingalpha.com/news/3872259-ubx-stock-jumps-after-data-for-lead-asset-in-diabetic-macular-edema?utm_source=businessinsider&utm_medium=referral,negative,0.805801272392273
1207,8/13/2022 8:00:00 PM,"AbbVie, Roche, Regeneron could significantly benefit as AMD market expected to soar",Seeking Alpha,https://seekingalpha.com/news/3872108-abbvie-roche-regeneron-could-significantly-benefit-as-amd-market-expected-to-soar?utm_source=businessinsider&utm_medium=referral,negative,0.9175599217414856
1208,8/14/2022 5:48:06 PM,Analysts rule out major industry impact from drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3872629-analysts-rule-out-major-industry-impact-from-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.8447362780570984
1209,8/15/2022 10:51:43 AM,Unity extends gains on data for lead asset in diabetic macular edema,Seeking Alpha,https://seekingalpha.com/news/3872733-ubx-stock-extends-gains-on-data-for-lead-asset-in-diabetic-macular-edema?utm_source=businessinsider&utm_medium=referral,negative,0.8692730069160461
1210,8/17/2022 10:54:23 AM,"U.S. govt. to stop buying COVID-19 vaccines, therapies, tests from this fall – Jha",Seeking Alpha,https://seekingalpha.com/news/3874012-us-govt-to-stop-buying-covid-19-vaccines-therapies-tests-from-this-fall-jha?utm_source=businessinsider&utm_medium=referral,positive,0.7759352922439575
1211,8/17/2022 5:10:23 PM,CDC seeks reforms to correct COVID missteps,Seeking Alpha,https://seekingalpha.com/news/3874241-cdc-to-implement-reforms-to-correct-covid-missteps?utm_source=businessinsider&utm_medium=referral,negative,0.785580039024353
1212,8/19/2022 10:45:00 AM,Regeneron monoclonal antibody gets WHO recommendation for Ebola,Seeking Alpha,https://seekingalpha.com/news/3874958-regeneron-monoclonal-antibody-gets-who-recommendation-for-ebola?utm_source=businessinsider&utm_medium=referral,negative,0.8898040652275085
1213,8/21/2022 4:00:16 PM,Biotech in recovery; but Piper Sandler cites negative fund flows,Seeking Alpha,https://seekingalpha.com/news/3875226-biotech-in-recovery-but-piper-sandler-cites-negative-fund-flows?utm_source=businessinsider&utm_medium=referral,neutral,0.9548234343528748
1214,8/22/2022 6:00:58 PM,7 Cathie Wood Stocks to Buy on the Dip,InvestorPlace,/news/stocks/cathie-wood-stocks-to-buy-on-the-dip-1031588252,positive,0.829841673374176
1215,8/25/2022 7:42:04 PM,Verve upgraded to Buy at Stifel on near term catalysts for heart disease therapy,Seeking Alpha,https://seekingalpha.com/news/3876782-verv-stock-upgraded-at-stifel-on-catalysts-for-heart-disease-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8779940605163574
1216,8/25/2022 10:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031706877,positive,0.9291732907295227
1217,8/26/2022 8:53:05 PM,5 Top Stocks Cathie Wood Is Selling This Week,InvestorPlace,/news/stocks/5-top-stocks-cathie-wood-is-selling-this-week-1031708967,positive,0.9074086546897888
1218,8/27/2022 9:08:07 AM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1031709034,positive,0.6874357461929321
1219,8/29/2022 2:21:04 PM,"Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of 
proteinuria ",RTTNews,/news/stocks/alnylam-additional-data-shows-favorable-effects-of-cemdisiran-on-different-measures-of-proteinuria-1031710700,negative,0.9215457439422607
1220,8/31/2022 8:52:36 PM,"Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know",Benzinga,/news/stocks/bluebird-bio-seeks-back-to-back-nods-go-or-no-go-for-revance-s-botox-rival-amylyx-twin-hurdles-and-more-september-s-key-pdufa-catalysts-biotech-investors-must-know-1031717312,positive,0.7547863721847534
1221,9/4/2022 1:18:40 PM,"M&A may be a tailwind for biotech sector into end of year, analyst says",Seeking Alpha,https://seekingalpha.com/news/3880197-ma-may-be-a-tailwind-for-biotech-sector-into-end-of-year-analyst-says?utm_source=businessinsider&utm_medium=referral,neutral,0.929253339767456
1222,9/5/2022 12:05:00 AM,"ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers",PR Newswire,/news/stocks/esmo-presentations-of-libtayo-cemiplimab-fianlimab-and-novel-bispecific-antibodies-showcase-expanding-potential-of-regeneron-s-oncology-pipeline-in-multiple-cancers-1031723465,negative,0.8886180520057678
1223,9/5/2022 9:28:29 AM,Sanofi: Dupixent Data Show Sustained Improvement For Up To 2 Yrs In 6-11 Years With Asthma ,RTTNews,/news/stocks/sanofi-dupixent-data-show-sustained-improvement-for-up-to-2-yrs-in-6-11-years-with-asthma-1031723820,negative,0.9562097191810608
1224,9/5/2022 10:18:09 AM,Sanofi/Regeneron Dupixent shows efficacy for up to 2 years in children with asthma,Seeking Alpha,https://seekingalpha.com/news/3880235-sanofiregeneron-dupixent-shows-efficacy-for-up-to-2-years-in-children-with-asthma?utm_source=businessinsider&utm_medium=referral,negative,0.926137387752533
1225,9/5/2022 1:29:00 PM,Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma,PR Newswire,/news/stocks/late-breaking-dupixent-dupilumab-data-at-ers-2022-show-consistent-efficacy-and-safety-profile-for-up-to-two-years-in-children-aged-6-to-11-years-with-moderate-to-severe-asthma-1031724138,negative,0.9366452693939209
1226,9/8/2022 1:17:10 PM,Regeneron says pivotal trials for less frequent Eylea injections reached main goals,Seeking Alpha,https://seekingalpha.com/news/3881228-regn-stock-on-watch-as-less-frequent-eylea-reaches-main-goals-in-trials?utm_source=businessinsider&utm_medium=referral,negative,0.9004595279693604
1227,9/8/2022 1:53:34 PM,Regeneron jumps 16% as pivotal trials for less frequent Eylea reach main goals,Seeking Alpha,https://seekingalpha.com/news/3881226-regn-stock-on-watch-as-less-frequent-eylea-reaches-main-goals-in-trials?utm_source=businessinsider&utm_medium=referral,negative,0.9445390105247498
1228,9/8/2022 3:00:00 PM,"Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals",PR Newswire,/news/stocks/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wamd-with-a-vast-majority-of-patients-maintained-on-12-and-16-week-dosing-intervals-1031732094,negative,0.6785791516304016
1229,9/8/2022 3:23:31 PM,Regeneron: Aflibercept 8 Mg Meets Primary Endpoints In Two Trials For DME And WAMD ,RTTNews,/news/stocks/regeneron-aflibercept-8-mg-meets-primary-endpoints-in-two-trials-for-dme-and-wamd-1031732226,negative,0.899559497833252
1230,9/8/2022 4:42:22 PM,"AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday",Benzinga,/news/stocks/aerovironment-snap-and-some-other-big-stocks-moving-higher-on-thursday-1031732569,negative,0.9203115701675415
1231,9/8/2022 4:54:38 PM,"PTN, ERAS  and Merc among mid-day movers",Seeking Alpha,https://seekingalpha.com/news/3881320-ptn-eras-and-merc-among-mid-day-movers?utm_source=businessinsider&utm_medium=referral,positive,0.8840926885604858
1232,9/8/2022 5:29:00 PM,Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-late-breaking-phase-3-data-at-the-eadv-2022-congress-showed-significant-improvements-in-signs-and-symptoms-of-prurigo-nodularis-1031732732,negative,0.9409199357032776
1233,9/8/2022 6:15:08 PM,"Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session",Benzinga,/news/stocks/why-bilibili-is-trading-lower-by-over-around-14-here-are-50-stocks-moving-in-thursday-s-mid-day-session-1031732864,neutral,0.6859022378921509
1234,9/9/2022 12:17:21 AM,"Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-8-2022---end-of-the-day-summary-1031733508,positive,0.943282961845398
1235,9/9/2022 8:58:43 AM,Sanofi/Regeneron presents full data of Dupixent efficacy in skin disease prurigo nodularis,Seeking Alpha,https://seekingalpha.com/news/3881547-sanofiregeneron-presents-full-results-of-dupixent-efficacy-in-skin-disease-prurigo-nodularis?utm_source=businessinsider&utm_medium=referral,positive,0.8329031467437744
1236,9/9/2022 10:14:31 AM,Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-shiftpixy-surged-around-177-here-are-71-biggest-movers-from-yesterday-1031734097,positive,0.9170605540275574
1237,9/9/2022 11:41:43 AM,US Stock Futures Surge; Fed Speakers In Focus,Benzinga,/news/stocks/us-stock-futures-surge-fed-speakers-in-focus-1031734210,neutral,0.4175565838813782
1238,9/9/2022 12:07:19 PM,Regeneron draws upgrades after data for high dose Eylea,Seeking Alpha,https://seekingalpha.com/news/3881595-regn-stock-draws-upgrades-after-data-for-high-dose-eylea?utm_source=businessinsider&utm_medium=referral,negative,0.8719577193260193
1239,9/9/2022 1:56:06 PM,Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday,Benzinga,/news/stocks/regeneron-pharmaceuticals-to-851-here-are-5-other-price-target-changes-for-friday-1031734478,positive,0.927784264087677
1240,9/9/2022 4:00:00 PM,Regeneron Announces Investor Call and Webcast at ESMO 2022,PR Newswire,/news/stocks/regeneron-announces-investor-call-and-webcast-at-esmo-2022-1031734830,positive,0.9531917572021484
1241,9/9/2022 4:40:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-9-2022-1031734920,positive,0.5274080634117126
1242,9/9/2022 5:15:29 PM,'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added,Benzinga,/news/stocks/highly-compelling-eye-drug-data-has-wall-street-stampeding-to-buy-this-large-cap-growth-story-even-after-15b-in-market-cap-was-added-1031735020,negative,0.7255878448486328
1243,9/9/2022 6:08:43 PM,Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/jefferies-upgrades-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1031735143,positive,0.9401547908782959
1244,9/9/2022 6:23:55 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031735199,positive,0.9010616540908813
1245,9/9/2022 7:16:36 PM,9 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/9-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031735273,positive,0.928493857383728
1246,9/9/2022 10:00:48 PM,The 3 Best Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/best-healthcare-stocks-1031568641,positive,0.8521314859390259
1247,9/10/2022 8:30:00 AM,Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors,PR Newswire,/news/stocks/novel-regeneron-bispecific-antibodies-show-encouraging-anti-tumor-activity-in-two-advanced-solid-tumors-1031735615,negative,0.9462693929672241
1248,9/12/2022 8:30:00 AM,Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 In...,PR Newswire,/news/stocks/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-demonstrates-greater-than-60-response-rates-in-two-independent-cohorts-of-patients-with-advanced-melanoma-naïve-to-pd-1-or-pd-l1-in-1031736428,negative,0.9444465041160583
1249,9/12/2022 8:54:06 AM,Regeneron: Fianlimab With Libtayo Shows Greater Than 60% Response Rates In Phase 1 Trial ,RTTNews,/news/stocks/regeneron-fianlimab-with-libtayo-shows-greater-than-60-response-rates-in-phase-1-trial-1031736459,negative,0.9369646310806274
1250,9/12/2022 10:30:00 AM,Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM,PR Newswire,/news/stocks/positive-neoadjuvant-libtayo-cemiplimab-monotherapy-data-in-resectable-cutaneous-squamous-cell-carcinoma-presented-at-esmo-and-published-in-nejm-1031736583,positive,0.8530778288841248
1251,9/13/2022 12:49:52 AM,"Regeneron Stock: Next Stop, $900?",TipRanks,/news/stocks/regeneron-stock-next-stop-900-1031738499,positive,0.9256178736686707
1252,9/13/2022 8:02:35 PM,"A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says",Benzinga,/news/stocks/a-major-october-catalyst-could-make-this-eye-stock-a-ten-bagger-analyst-says-1031740991,neutral,0.7876807451248169
1253,9/14/2022 2:18:38 PM,"End in sight for COVID-19 pandemic, WHO chief says",Seeking Alpha,https://seekingalpha.com/news/3882728-end-in-sight-for-covid-19-pandemic-who-chief-says?utm_source=businessinsider&utm_medium=referral,positive,0.8521955013275146
1254,9/15/2022 11:29:28 AM,Alnylam/Regeneron say early-stage data support Phase 2 trial for NASH therapy,Seeking Alpha,https://seekingalpha.com/news/3882947-alnylam-regeneron-say-early-stage-data-back-phase-2-trial-for-nash-drug?utm_source=businessinsider&utm_medium=referral,negative,0.8651153445243835
1255,9/15/2022 1:00:00 PM,Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers,PR Newswire,/news/stocks/regeneron-and-alnylam-report-promising-data-from-ongoing-phase-1-study-of-aln-hsd-in-nash-patients-and-healthy-volunteers-1031744989,negative,0.9481549263000488
1256,9/16/2022 12:38:00 AM,Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet,PR Newswire,/news/stocks/positive-dupixent-dupilumab-phase-3-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-published-in-the-lancet-1031746988,positive,0.8271026015281677
1257,9/16/2022 12:47:03 AM,"Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-15-2022---end-of-the-day-summary-1031746992,positive,0.9436883330345154
1258,9/16/2022 10:32:21 AM,"WHO advises against use of GSK/Vir, Regeneron COVID drugs, backs limited use of Gilead's remdesivir",Seeking Alpha,https://seekingalpha.com/news/3883338-who-advises-against-gskvir-regeneron-covid-drugs-backs-limited-use-of-gileads-remdesivir?utm_source=businessinsider&utm_medium=referral,positive,0.857836902141571
1259,9/16/2022 12:08:13 PM,"Intellia, Regeneron post early data to highlight gene editing in ATTR amyloidosis cardiomyopathy",Seeking Alpha,https://seekingalpha.com/news/3883370-intellia-regeneron-tout-gene-editing-in-attr-amyloidosis-cardiomyopathy?utm_source=businessinsider&utm_medium=referral,positive,0.8920265436172485
1260,9/16/2022 1:15:00 PM,"Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis",PR Newswire,/news/stocks/intellia-and-regeneron-announce-initial-data-from-the-cardiomyopathy-arm-of-ongoing-phase-1-study-of-ntla-2001-an-investigational-crispr-therapy-for-the-treatment-of-transthyretin-attr-amyloidosis-1031747874,positive,0.7679533362388611
1261,9/16/2022 1:36:00 PM,Intellia: Interim Data Show NTLA-2001 Can Profoundly Reduce Serum TTR Levels ,RTTNews,/news/stocks/intellia-interim-data-show-ntla-2001-can-profoundly-reduce-serum-ttr-levels-1031747945,negative,0.8389626741409302
1262,9/16/2022 4:16:02 PM,Intellia falls as analysts react to CRISPR readouts,Seeking Alpha,https://seekingalpha.com/news/3883494-intellia-falls-as-analysts-react-to-crispr-readouts?utm_source=businessinsider&utm_medium=referral,neutral,0.9149408936500549
1263,9/17/2022 8:00:18 PM,"BioNTech, Moderna, Pfizer led biopharma revenue growth from 2020-2021",Seeking Alpha,https://seekingalpha.com/news/3883566-biontech-moderna-pfizer-led-biopharma-revenue-growth-from-2020-2021?utm_source=businessinsider&utm_medium=referral,negative,0.9150789380073547
1264,9/19/2022 11:39:37 AM,Roche wins European approval for Vabysmo for wet AMD and diabetic macular edema,Seeking Alpha,https://seekingalpha.com/news/3883682-roche-wins-european-approval-for-vabysmo-for-wet-amd-and-diabetic-macular-edema?utm_source=businessinsider&utm_medium=referral,negative,0.9366734623908997
1265,9/20/2022 5:45:25 PM,The 7 Best Biotech Stocks to Buy,InvestorPlace,/news/stocks/best-biotech-stocks-1031575358,positive,0.6688135266304016
1266,9/21/2022 12:20:51 PM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Baudax Bio (BXRX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-baudax-bio-bxrx-1031756422,positive,0.8857547640800476
1267,9/22/2022 3:55:15 PM,"WHO chief reiterates belief that COVID-19 pandemic end near, says work still needed",Seeking Alpha,https://seekingalpha.com/news/3885339-who-chief-reiterates-belief-that-covid-19-pandemic-end-near-says-work-still-needed?utm_source=businessinsider&utm_medium=referral,positive,0.5798600316047668
1268,9/23/2022 8:43:14 PM,The Top 5 Stocks Cathie Wood Is Buying This Week,InvestorPlace,/news/stocks/the-top-5-stocks-cathie-wood-is-buying-this-week-1031762742,positive,0.9048951864242554
1269,9/27/2022 11:07:53 AM,Ocular stock rises as eye drug implant OTX-TKI shows promise in vision disorder in trial,Seeking Alpha,https://seekingalpha.com/news/3886254-ocular-stock-rises-as-eye-implant-otx-tki-shows-promise-in-vision-disorder-in-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9421277046203613
1270,9/27/2022 11:15:11 AM,The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market,InvestorPlace,/news/stocks/the-7-best-stocks-to-buy-to-tap-into-a-hidden-bull-market-1031766644,positive,0.8398815989494324
1271,9/27/2022 4:21:02 PM,"Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea",Benzinga,/news/stocks/ocular-therapeutix-s-wet-amd-candidate-shows-sustained-comparable-clinical-activity-vs-eylea-1031767475,negative,0.9568893909454346
1272,9/28/2022 11:44:00 PM,Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-approved-by-fda-as-the-first-and-only-treatment-indicated-for-prurigo-nodularis-1031771410,negative,0.7529295682907104
1273,9/29/2022 4:30:31 AM,Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment ,RTTNews,/news/stocks/regeneron-fda-approves-dupixent-for-prurigo-nodularis-treatment-1031771519,negative,0.8894177079200745
1274,9/29/2022 10:51:02 AM,"Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin condition",Seeking Alpha,https://seekingalpha.com/news/3887050-sanofi-regeneron-win-fda-label-expansion-for-dupixent-in-chronic-skin-condition?utm_source=businessinsider&utm_medium=referral,negative,0.7867976427078247
1275,9/30/2022 11:04:00 PM,Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO,PR Newswire,/news/stocks/aflibercept-8-mg-positive-pivotal-results-in-diabetic-macular-edema-and-wet-age-related-macular-degeneration-presented-at-aao-1031776867,negative,0.7038100361824036
1276,10/2/2022 4:00:31 PM,COVID stocks lag U.S. biopharma in Q3; Alzheimer’s theme regains focus,Seeking Alpha,https://seekingalpha.com/news/3887740-covid-stocks-lag-us-biopharma-in-q3-alzheimers-theme-regains-focus?utm_source=businessinsider&utm_medium=referral,neutral,0.8604695200920105
1277,10/3/2022 10:14:22 AM,"Svante Pääbo gets Nobel Prize for Medicine for discoveries on genome, human evolution",Seeking Alpha,https://seekingalpha.com/news/3887839-svante-pbo-gets-nobel-prize-for-medicine-for-discoveries-on-genome-human-evolution?utm_source=businessinsider&utm_medium=referral,positive,0.7340630292892456
1278,10/3/2022 1:00:00 PM,Regeneron Elects Dr. Craig B. Thompson to Board of Directors,PR Newswire,/news/stocks/regeneron-elects-dr-craig-b-thompson-to-board-of-directors-1031778376,positive,0.9210574626922607
1279,10/3/2022 4:18:32 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031779157,positive,0.9010616540908813
1280,10/3/2022 4:35:17 PM,Goldman Sachs Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/goldman-sachs-sticks-to-their-buy-rating-for-regeneron-regn-1031779530,positive,0.8751589059829712
1281,10/3/2022 7:23:24 PM,AstraZeneca COVID-19 antibodies unlikely to protect against new Omicron subvariant,Seeking Alpha,https://seekingalpha.com/news/3888160-astrazeneca-covid-19-antibody-unlikely-to-act-against-new-omicron-subvariant?utm_source=businessinsider&utm_medium=referral,negative,0.8156739473342896
1282,10/3/2022 9:38:35 PM,What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/what-13-analyst-ratings-have-to-say-about-regeneron-pharmaceuticals-1031779884,positive,0.9446253180503845
1283,10/3/2022 11:04:23 PM,13 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/13-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031780097,positive,0.9362481236457825
1284,10/4/2022 2:00:44 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Aeglea Biotherapeutics (AGLE) and Autolus Therapeutics (AUTL)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-aeglea-biotherapeutics-agle-and-autolus-therapeutics-autl-1031782098,neutral,0.9393271207809448
1285,10/4/2022 10:00:00 PM,"Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022",PR Newswire,/news/stocks/regeneron-to-report-third-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-3-2022-1031782897,positive,0.9490804672241211
1286,10/5/2022 7:04:15 PM,"Apple Short Sellers Made $2B In Profits In September, And Shorts In This Biotech Stock Lost $307M",Benzinga,/news/stocks/apple-short-sellers-made-2b-in-profits-in-september-and-shorts-in-this-biotech-stock-lost-307m-1031785435,neutral,0.7634546160697937
1287,10/10/2022 10:15:48 AM,These 7 Biotech Stocks Are Set to Boom in 2023,InvestorPlace,/news/stocks/7-biotech-stocks-set-to-boom-2023-1031792647,negative,0.8603333234786987
1288,10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral,positive,0.5134317874908447
1289,10/11/2022 6:59:00 AM,Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old,PR Newswire,/news/stocks/dupixent-dupilumab-late-breaking-phase-3-data-presented-at-ueg-week-2022-showed-significant-histological-remission-of-eosinophilic-esophagitis-eoe-in-children-1-to-11-years-old-1031794713,negative,0.8037183880805969
1290,10/11/2022 7:22:50 AM,Regeneron Reports Positive Results From Dupixent Phase 3 Trial In 1 To 11 Yrs With EoE ,RTTNews,/news/stocks/regeneron-reports-positive-results-from-dupixent-phase-3-trial-in-1-to-11-yrs-with-eoe-1031794756,negative,0.9531283974647522
1291,10/11/2022 9:34:36 AM,Sanofi/Regeneron Dupixent shows efficacy in kids with esophagus inflammation in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3890221-sanofiregeneron-dupixent-shows-efficacy-in-kids-with-esophagus-inflammation-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral,negative,0.933251142501831
1292,10/12/2022 12:53:54 PM,"Regeneron, Bayer Eylea gets FDA priority review for eye disorder in infants",Seeking Alpha,https://seekingalpha.com/news/3890687-regeneron-bayer-eylea-gets-fda-priority-review-for-eye-disorder-in-infants?utm_source=businessinsider&utm_medium=referral,negative,0.8532045483589172
1293,10/12/2022 1:00:00 PM,EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review,PR Newswire,/news/stocks/eylea-aflibercept-injection-sbla-for-treatment-of-retinopathy-of-prematurity-rop-accepted-for-fda-priority-review-1031799016,negative,0.7399221062660217
1294,10/12/2022 1:18:20 PM,Regeneron: EYLEA SBLA Gets FDA Priority Review - Quick Facts ,RTTNews,/news/stocks/regeneron-eylea-sbla-gets-fda-priority-review-quick-facts-1031799100,negative,0.7164537310600281
1295,10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral,negative,0.8669121861457825
1296,10/14/2022 1:04:00 PM,Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer,PR Newswire,/news/stocks/libtayo-cemiplimab-receives-positive-chmp-opinion-recommending-approval-to-treat-advanced-cervical-cancer-1031805821,negative,0.9469121098518372
1297,10/14/2022 1:07:48 PM,EMA committee recommends expanded approval of Regeneron's Libtayo for cervical cancer,Seeking Alpha,https://seekingalpha.com/news/3891410-ema-committee-recommends-expanded-approval-of-regenerons-libtayo-for-cervical-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.577216386795044
1298,10/14/2022 1:27:37 PM,Regeneron Pharma: CHMP Adopts Positive Opinion For Libtayo - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-chmp-adopts-positive-opinion-for-libtayo-quick-facts-1031805874,negative,0.9318267107009888
1299,10/17/2022 12:27:54 PM,Regeneron downgraded at Evercore citing eyecare landscape,Seeking Alpha,https://seekingalpha.com/news/3891781-regeneron-downgraded-at-evercore-citing-eyecare-landscape?utm_source=businessinsider&utm_medium=referral,neutral,0.938147246837616
1300,10/17/2022 12:50:35 PM,Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial,Seeking Alpha,https://seekingalpha.com/news/3891792-decibel-stock-surges-as-fda-clears-hearing-loss-gene-therapy-to-enter-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9253177642822266
1301,10/17/2022 2:34:50 PM,Morgan Stanley says large cap healthcare remains attractive amid macro concerns,Seeking Alpha,https://seekingalpha.com/news/3891861-morgan-stanely-says-large-cap-healthcare-remains-attractive-amid-macro-concerns?utm_source=businessinsider&utm_medium=referral,negative,0.9349676966667175
1302,10/17/2022 3:13:09 PM,13 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/13-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031810137,positive,0.9362481236457825
1303,10/17/2022 4:02:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-17-2022-1031810315,positive,0.5120808482170105
1304,10/17/2022 8:32:16 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031810971,positive,0.9010616540908813
1305,10/18/2022 3:30:49 PM,Decibel Therapeutics hears it may be a takeout target after Lilly acquisition of Akouos,Seeking Alpha,https://seekingalpha.com/news/3892281-decibel-therapeutics-hears-it-may-be-a-takeou-ttarget-after-eli-lilly-acquisition-of-akouos?utm_source=businessinsider&utm_medium=referral,positive,0.4988768398761749
1306,10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral,positive,0.7574050426483154
1307,10/21/2022 11:38:17 AM,Regeneron wins six-month pediatric exclusivity for Eylea in U.S. market,Seeking Alpha,https://seekingalpha.com/news/3893624-regeneron-wins-six-month-pediatric-exclusivity-for-eylea-in-us-market?utm_source=businessinsider&utm_medium=referral,negative,0.9456194639205933
1308,10/21/2022 1:00:00 PM,Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection,PR Newswire,/news/stocks/regeneron-receives-six-months-of-u-s-pediatric-exclusivity-for-eylea-aflibercept-injection-1031824017,negative,0.8606930375099182
1309,10/21/2022 1:19:10 PM,Regeneron: FDA Grants Pediatric Exclusivity For EYLEA ,RTTNews,/news/stocks/regeneron-fda-grants-pediatric-exclusivity-for-eylea-1031824078,negative,0.7976908683776855
1310,10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral,positive,0.6700782775878906
1311,10/26/2022 11:41:21 AM,Regeneron slips as Raymond James downgrades on Eylea concerns,Seeking Alpha,https://seekingalpha.com/news/3895394-regn-stock-slips-as-raymond-james-downgrades-on-eylea-concerns?utm_source=businessinsider&utm_medium=referral,neutral,0.9560714364051819
1312,10/26/2022 4:07:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-26-2022-1031838805,positive,0.4896213412284851
1313,10/27/2022 8:48:32 AM,GSK to abandon regulatory filings for arthritis drug as phase 3 trial fails,Seeking Alpha,https://seekingalpha.com/news/3896202-gsk-to-abandon-regulatory-filings-for-arthritis-drug-as-a-phase-3-trial-fails?utm_source=businessinsider&utm_medium=referral,positive,0.8088551163673401
1314,10/27/2022 9:19:06 AM,Roche Vabysmo matches Eylea in 2 phase 3 trials for vision disorder,Seeking Alpha,https://seekingalpha.com/news/3896209-roche-vabysmo-matches-eylea-in-2-phase-3-trials-for-vision-disorder?utm_source=businessinsider&utm_medium=referral,negative,0.7076388001441956
1315,10/27/2022 3:54:30 PM,Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’,InvestorPlace,/news/stocks/midterm-elections-2022-3-stocks-to-avoid-like-the-plague-for-a-blue-wave-1031844449,positive,0.8777721524238586
1316,10/28/2022 9:09:39 AM,"Sanofi Q3 sales boosted by Dupixent, Vaccines business; raises FY22 outlook again",Seeking Alpha,https://seekingalpha.com/news/3897079-sanofi-q3-sales-boosted-by-dupixent-vaccines-business-raises-fy22-outlook-again?utm_source=businessinsider&utm_medium=referral,negative,0.9483436346054077
1317,10/28/2022 2:00:00 PM,"Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award",PR Newswire,/news/stocks/inmazeb-atoltivimab-maftivimab-and-odesivimab-ebgn-wins-prestigious-2022-prix-galien-usa-best-biotechnology-product-award-1031848126,negative,0.9315377473831177
1318,11/1/2022 3:27:53 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-1-2022-1031859215,positive,0.5344393253326416
1319,11/2/2022 3:01:13 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-q3-earnings-preview-stock-1031864404,positive,0.9262580871582031
1320,11/2/2022 6:15:48 PM,Can Regeneron maintain EPS beat run in Q3 as eye care space heats up?,Seeking Alpha,https://seekingalpha.com/news/3900058-can-regeneron-maintain-eps-beat-run-in-q3-as-eye-care-space-heats-up?utm_source=businessinsider&utm_medium=referral,negative,0.6972948908805847
1321,11/3/2022 10:31:52 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $11.14 beats by $1.52, revenue of $2.94B beats by $80M",Seeking Alpha,https://seekingalpha.com/news/3900659-regeneron-pharmaceuticals-non-gaap-eps-of-11_14-beats-1_52-revenue-of-2_94b-beats-80m?utm_source=businessinsider&utm_medium=referral,negative,0.5039380192756653
1322,11/3/2022 11:12:19 AM,Regeneron Q3 sales sans COVID products grow on back of blockbuster Eylea,Seeking Alpha,https://seekingalpha.com/news/3900728-regeneron-q3-sales-sans-covid-products-grow-on-back-of-bloackbuster-eylea?utm_source=businessinsider&utm_medium=referral,negative,0.9572058916091919
1323,11/3/2022 11:30:00 AM,Regeneron Reports Third Quarter 2022 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-third-quarter-2022-financial-and-operating-results-1031869460,negative,0.4501703679561615
1324,11/3/2022 11:44:23 AM,"Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-profit-decreases-but-beats-estimates-1031869538,neutral,0.9668293595314026
1325,11/3/2022 12:12:16 PM,"US Stocks In For Another Tough Day After Fed Rate Hike As Nasdaq, S&P 500 Futures Fall — Roku, Qualcomm Plunge On Earnings Disappointment",Benzinga,/news/stocks/us-stocks-in-for-another-tough-day-after-fed-rate-hike-as-nasdaq-s-p-500-futures-fall-—-roku-qualcomm-plunge-on-earnings-disappointment-1031869714,neutral,0.937606930732727
1326,11/3/2022 2:00:00 PM,Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders,PR Newswire,/news/stocks/regeneron-presents-new-data-at-ash-from-advancing-hematology-pipeline-across-multiple-blood-cancers-and-disorders-1031870529,positive,0.5149886012077332
1327,11/3/2022 9:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031872325,positive,0.9291732907295227
1328,11/4/2022 12:16:39 PM,"Analysts Conflicted on These Healthcare Names: Humana (HUM), Myriad Genetics (MYGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-humana-hum-myriad-genetics-mygn-and-regeneron-regn-1031875727,positive,0.6421110033988953
1329,11/4/2022 12:46:38 PM,"Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Illumina (ILMN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-avadel-pharmaceuticals-avdl-illumina-ilmn-and-regeneron-regn-1031875849,positive,0.9005793929100037
1330,11/4/2022 1:56:05 PM,BMO Capital Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-regeneron-regn-1031876202,positive,0.6004652976989746
1331,11/4/2022 6:22:18 PM,7 Cash-Rich Stocks to Buy for Peace of Mind ,InvestorPlace,/news/stocks/7-cash-rich-stocks-to-buy-for-peace-of-mind-1031876991,positive,0.891815721988678
1332,11/4/2022 9:04:17 PM,"Supreme Court to hear Amgen appeal on Repatha spat with Sanofi, Regeneron",Seeking Alpha,https://seekingalpha.com/news/3902317-supreme-court-to-hear-amgen-appeal-on-repatha-spat-with-sanofi-regeneron?utm_source=businessinsider&utm_medium=referral,positive,0.7319070100784302
1333,11/5/2022 12:30:00 AM,Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration,PR Newswire,/news/stocks/aflibercept-8-mg-late-breaking-data-presented-at-retina-society-in-diabetic-macular-edema-and-wet-age-related-macular-degeneration-1031877286,negative,0.6401706337928772
1334,11/8/2022 10:41:00 PM,Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC),PR Newswire,/news/stocks/libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-approved-by-the-fda-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer-nsclc-1031888646,negative,0.880577564239502
1335,11/8/2022 10:52:20 PM,Regeneron's Libtayo approved as first-line advanced NSCLC treatment with chemotherapy,Seeking Alpha,https://seekingalpha.com/news/3904187-regeneron-libtayo-approved-as-first-line-advanced-nsclc-treatment-with-chemotherapy?utm_source=businessinsider&utm_medium=referral,negative,0.6883314251899719
1336,11/9/2022 7:18:25 PM,Regeneron pares gains after PTAB rules agains Eylea patent claims (update),Seeking Alpha,https://seekingalpha.com/news/3904717-ptab-rules-against-regeron-eylea-patent?utm_source=businessinsider&utm_medium=referral,positive,0.46817755699157715
1337,11/10/2022 6:36:22 PM,"Apellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA market",Seeking Alpha,https://seekingalpha.com/news/3905875-apls-stock-isee-stock-cut-to-hold-at-jefferies-on-overestimated-ga-market?utm_source=businessinsider&utm_medium=referral,positive,0.6882485747337341
1338,11/11/2022 12:00:12 PM,Sanofi wins EU nod for Dupixent to include new skin condition,Seeking Alpha,https://seekingalpha.com/news/3906338-sanofi-wins-eu-nod-for-dupixent-to-include-new-skin-condition?utm_source=businessinsider&utm_medium=referral,negative,0.9094422459602356
1339,11/11/2022 12:30:04 PM,"EMA panel backs approval of Regeneron, Bayer's Eylea for eye disorder in infants",Seeking Alpha,https://seekingalpha.com/news/3906356-ema-panel-back-approval-of-regeneron-bayers-eylea-for-eye-disorder-in-infants?utm_source=businessinsider&utm_medium=referral,negative,0.5772229433059692
1340,11/11/2022 12:59:00 PM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-prurigo-nodularis-1031904218,negative,0.6899747252464294
1341,11/11/2022 1:08:05 PM,"Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU ",RTTNews,/news/stocks/regeneron-sanofi-chmp-recommends-approval-of-dupixent-in-the-eu-1031904259,negative,0.56080561876297
1342,11/13/2022 1:59:54 AM,U.S. COVID health emergency to stay in place,Seeking Alpha,https://seekingalpha.com/news/3906753-us-covid-health-emergency-to-stay-in-place?utm_source=businessinsider&utm_medium=referral,neutral,0.6932175159454346
1343,11/14/2022 8:15:54 PM,4D Molecular says its wet AMD therapy cuts Eylea burden,Seeking Alpha,https://seekingalpha.com/news/3907376-fdmt-stock-spikes-as-wet-amd-therapy-cuts-eylea-burden?utm_source=businessinsider&utm_medium=referral,neutral,0.6227132081985474
1344,11/16/2022 5:17:42 PM,"Pfizer, Roche, Lilly COVID treatments get draft recommendation from UK NHS advisors",Seeking Alpha,https://seekingalpha.com/news/3908715-pfizer-roche-lilly-covid-treatments-get-draft-recommendation-from-uk-nhs-advisors?utm_source=businessinsider&utm_medium=referral,positive,0.8119016885757446
1345,11/17/2022 1:50:22 AM,"Analysts Are Neutral on These Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-neutral-on-these-healthcare-stocks-amgen-amgn-regeneron-regn-1031920436,positive,0.8004636764526367
1346,11/17/2022 1:00:00 PM,Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer,PR Newswire,/news/stocks/regeneron-and-cytomx-announce-strategic-research-collaboration-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer-1031921721,negative,0.8893908262252808
1347,11/17/2022 3:47:51 PM,Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?,InvestorPlace,/news/stocks/why-is-cytomx-therapeutics-ctmx-stock-up-29-today-1031922868,negative,0.8330848813056946
1348,11/18/2022 2:36:50 PM,"Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'",Benzinga,/news/stocks/cramer-on-this-stock-down-65-year-to-date-i-do-believe-it-s-bottoming-but-i-don-t-know-what-gets-it-higher-1031925193,neutral,0.9705872535705566
1349,11/22/2022 1:00:00 PM,Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-in-second-line-recurrent-or-metastatic-cervical-cancer-irrespective-of-pd-l1-expression-level-or-tumor-histology-1031930814,negative,0.8192188143730164
1350,11/22/2022 1:29:14 PM,Regeneron :EC Oks Libtayo As First Immunotherapy In Second Line Recurrent/Metastatic Cervical Cancer ,RTTNews,/news/stocks/regeneron-ec-oks-libtayo-as-first-immunotherapy-in-second-line-recurrent-metastatic-cervical-cancer-1031930946,positive,0.7018120884895325
1351,11/24/2022 1:52:02 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN) and Medios AG (OtherMEDOF),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-and-medios-ag-othermedof-1031935209,neutral,0.7917177081108093
1352,11/30/2022 2:05:00 PM,Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review,PR Newswire,/news/stocks/evkeeza-evinacumab-dgnb-sbla-for-children-with-ultra-rare-inherited-form-of-high-cholesterol-accepted-for-fda-priority-review-1031944739,negative,0.9036935567855835
1353,11/30/2022 2:14:45 PM,Regeneron Pharma: Evkeeza SBLA Granted FDA Priority Review ,RTTNews,/news/stocks/regeneron-pharma-evkeeza-sbla-granted-fda-priority-review-1031944777,negative,0.810663104057312
1354,12/1/2022 1:00:00 PM,Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types,PR Newswire,/news/stocks/regeneron-esmo-io-presentations-highlight-potential-of-fianlimab-and-libtayo-cemiplimab-in-multiple-solid-tumor-types-1031947402,negative,0.5666728019714355
1355,12/7/2022 4:30:46 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Ascendis Pharma (ASND) and Beam Therapeutics (BEAM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-ascendis-pharma-asnd-and-beam-therapeutics-beam-1031956941,positive,0.90446937084198
1356,12/9/2022 10:42:48 PM,Our 7 Top Biotech Stock Picks for 2023,InvestorPlace,/news/stocks/our-7-top-biotech-stock-picks-for-2023-1031963677,positive,0.8780429363250732
1357,12/11/2022 4:30:00 PM,Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH,PR Newswire,/news/stocks/pivotal-odronextamab-cd20xcd3-phase-2-data-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-debut-at-ash-1031964159,positive,0.8345126509666443
1358,12/12/2022 1:30:00 PM,Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year,PR Newswire,/news/stocks/regeneron-named-on-dow-jones-sustainability-world-index-for-fourth-consecutive-year-1031965077,positive,0.7452060580253601
1359,12/12/2022 4:00:00 PM,Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma,PR Newswire,/news/stocks/linvoseltamab-bcmaxcd3-initial-pivotal-phase-2-data-show-clinically-meaningful-responses-in-patients-with-heavily-pre-treated-multiple-myeloma-1031965536,negative,0.950952410697937
1360,12/12/2022 6:55:43 PM,Regeneron Pharma Announces Positive Data From Mid-stage Study Of Linvoseltamab ,RTTNews,/news/stocks/regeneron-pharma-announces-positive-data-from-mid-stage-study-of-linvoseltamab-1031967418,negative,0.8712341785430908
1361,12/12/2022 11:30:00 PM,Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial,PR Newswire,/news/stocks/odronextamab-cd20xcd3-demonstrates-high-and-durable-complete-response-rate-among-patients-with-relapsed-refractory-follicular-lymphoma-in-pivotal-phase-2-trial-1031967802,negative,0.9480785727500916
1362,12/15/2022 6:59:00 AM,Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-prurigo-nodularis-1031973593,negative,0.6003394722938538
1363,12/15/2022 7:16:19 AM,"Regeneron, Sanofi: Dupixent Approved In EU For Prurigo Nodularis ",RTTNews,/news/stocks/regeneron-sanofi-dupixent-approved-in-eu-for-prurigo-nodularis-1031973619,positive,0.633577287197113
1364,12/15/2022 10:02:08 AM,"Sanofi, Regeneron Dupixent gets approval in EU for expanded use in skin disorder",Seeking Alpha,https://seekingalpha.com/news/3917422-sanofiregeneron-dupixent-gets-approval-in-eu-for-expanded-use-in-skin-disorder?utm_source=businessinsider&utm_medium=referral,negative,0.9216676354408264
1365,12/16/2022 5:25:33 AM,SVB Securities Keeps Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/svb-securities-keeps-their-hold-rating-on-regeneron-regn-1031976238,positive,0.9278811812400818
1366,12/16/2022 1:29:00 PM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis,PR Newswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-eosinophilic-esophagitis-1031977148,negative,0.7864686250686646
1367,12/16/2022 1:58:30 PM,Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis ,RTTNews,/news/stocks/regeneron-chmp-recommends-dupixent-for-eu-approval-to-treat-eosinophilic-esophagitis-1031977213,negative,0.9099334478378296
1368,12/16/2022 2:18:34 PM,"Sanofi, Regeneron Dupixent's expanded use gets EMA panel nod for approval in EU",Seeking Alpha,https://seekingalpha.com/news/3918011-sanofi-regeneron-dupixents-expanded-use-gets-ema-panel-nod-for-approval-in-eu?utm_source=businessinsider&utm_medium=referral,negative,0.8589859008789062
1369,12/19/2022 10:01:00 PM,Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/regeneron-announces-presentation-at-the-41st-annual-j-p-morgan-healthcare-conference-1031981141,positive,0.896286129951477
1370,12/21/2022 11:29:00 PM,Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine,PR Newswire,/news/stocks/positive-dupixent-dupilumab-phase-3-results-in-adults-and-adolescents-with-eosinophilic-esophagitis-published-in-the-new-england-journal-of-medicine-1031985944,positive,0.8271656036376953
1371,12/22/2022 2:01:13 AM,Regeneron : Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published ,RTTNews,/news/stocks/regeneron-positive-dupixent-phase-3-results-in-eosinophilic-esophagitis-published-1031986006,negative,0.8436973690986633
1372,12/23/2022 2:01:57 PM,Regeneron's Libtayo approved in Japan for cervical cancer,Seeking Alpha,https://seekingalpha.com/news/3920272-regeneron-libtayo-approved-in-japan-for-cervical-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.7400092482566833
1373,12/23/2022 2:30:00 PM,Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-in-japan-for-advanced-or-recurrent-cervical-cancer-1031988846,negative,0.6192148327827454
1374,12/23/2022 2:39:20 PM,Regeneron Granted Marketing Authorization For Libtayo In Japan For Recurrent Cervical Cancer ,RTTNews,/news/stocks/regeneron-granted-marketing-authorization-for-libtayo-in-japan-for-recurrent-cervical-cancer-1031988858,negative,0.8939491510391235
1375,12/27/2022 3:11:57 PM,"Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors",Benzinga,/news/stocks/biogen-s-2nd-alzheimer-s-antibody-beigene-s-cancer-drug-label-expansion-adcom-test-for-regeneron-and-more-january-pdufa-catalysts-for-biotech-investors-1031991144,positive,0.86749267578125
1376,12/29/2022 4:30:22 PM,7 Undervalued Biotech Stocks to Buy Before They Boom,InvestorPlace,/news/stocks/undervalued-biotech-stocks-1031612013,positive,0.7585014700889587
1377,1/5/2023 2:19:19 PM,"Regeneron, Sensei in clinical supply agreement for tumor studies",Seeking Alpha,https://seekingalpha.com/news/3922345-regeneron-sensei-in-clinical-supply-agreement-for-tumor-studies?utm_source=businessinsider&utm_medium=referral,negative,0.6271312832832336
1378,1/5/2023 2:23:10 PM,Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo ,RTTNews,/news/stocks/sensei-biotherapeutics-enters-clinical-supply-agreement-with-regeneron-for-libtayo-1032002045,negative,0.8831579685211182
1379,1/6/2023 3:42:41 AM,Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq,Benzinga,/news/stocks/jim-cramer-says-he-s-still-feeling-good-about-these-5-stocks-from-mutilated-nasdaq-1032003315,negative,0.8712353706359863
1380,1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182,positive,0.8010979890823364
1381,1/7/2023 1:50:17 AM,"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Regeneron (REGN) and Illumina (ILMN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-regeneron-regn-and-illumina-ilmn-1032005207,positive,0.9141290783882141
1382,1/9/2023 4:16:27 PM,Coherus stock dips amid deal to acquire US rights to Eylea biosimilar FYB203,Seeking Alpha,https://seekingalpha.com/news/3923032-coherus-stock-dips-amid-deal-to-acquire-rights-to-eylea-biosimilar-fyb203?utm_source=businessinsider&utm_medium=referral,neutral,0.9573609232902527
1383,1/9/2023 5:49:29 PM,Regeneron slips after $0.21 per share impact to Q4 2022 earnings,Seeking Alpha,https://seekingalpha.com/news/3923069-regn-stock-slips-after-impact-to-q4-2022-earnings?utm_source=businessinsider&utm_medium=referral,neutral,0.9708720445632935
1384,1/11/2023 12:30:30 PM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Halozyme (HALO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-halozyme-halo-1032012114,positive,0.9006079435348511
1385,1/11/2023 2:40:32 PM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-abbvie-abbv-and-establishment-labs-holdings-esta-1032012560,positive,0.9047911167144775
1386,1/11/2023 5:00:32 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1032012807,positive,0.9010616540908813
1387,1/11/2023 8:35:28 PM,Medicare to publish drugs targeted for pricing negotiations in September,Seeking Alpha,https://seekingalpha.com/news/3923880-medicare-publish-drugs-targeted-pricing-negotiations-in-september?utm_source=businessinsider&utm_medium=referral,positive,0.9117305874824524
1388,1/12/2023 5:31:02 AM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Illumina (ILMN) and Dexcom (DXCM)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-illumina-ilmn-and-dexcom-dxcm-1032013960,neutral,0.7508841753005981
1389,1/13/2023 5:23:21 PM,"WHO updates COVID-19 guidelines on masks, treatments",Seeking Alpha,https://seekingalpha.com/news/3924561-who-updates-covid-19-guidelines-on-masks-treatments?utm_source=businessinsider&utm_medium=referral,positive,0.938355565071106
1390,1/17/2023 1:50:31 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Teleflex (TFX),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-teleflex-tfx-1032021083,neutral,0.9483120441436768
1391,1/20/2023 1:38:18 PM,Regeneron upgraded at JPMorgan on upcoming catalysts,Seeking Alpha,https://seekingalpha.com/news/3926311-regn-stock-upgraded-at-jpmorgan-on-upcoming-catalysts?utm_source=businessinsider&utm_medium=referral,positive,0.8264943957328796
1392,1/20/2023 4:00:43 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-20-2023-1032031061,neutral,0.5302141308784485
1393,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,negative,0.8150349855422974
1394,1/24/2023 12:48:17 PM,"Decibel, Regeneron get UK regulator nod to start trial of hearing loss gene therapy",Seeking Alpha,https://seekingalpha.com/news/3927084-decibel-regeneron-get-uk-regulator-nod-to-start-trial-of-hearing-loss-gene-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.7281174063682556
1395,1/24/2023 4:30:18 PM,Analysts Conflicted on These Healthcare Names: Regeneron (REGN) and Revance Therapeutics (RVNC),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-and-revance-therapeutics-rvnc-1032037532,neutral,0.5658583641052246
1396,1/24/2023 6:02:00 PM,"Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition",PR Newswire,/news/stocks/top-40-high-school-scientists-selected-as-finalists-in-the-regeneron-science-talent-search-the-nation-s-oldest-and-most-prestigious-science-and-math-competition-1032037590,negative,0.7215980887413025
1397,1/27/2023 9:30:24 AM,"Sanofi, Regeneron Dupixent gets EMA panel nod to treat eczema in kids under 5",Seeking Alpha,https://seekingalpha.com/news/3928835-sanofi-regeneron-dupixent-gets-ema-panel-nod-to-treat-eczema-in-kids-under-5?utm_source=businessinsider&utm_medium=referral,negative,0.903826892375946
1398,1/27/2023 2:47:08 PM,Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent ,RTTNews,/news/stocks/regeneron-pharma-chmp-adopts-positive-opinion-for-dupixent-1032046779,negative,0.9297041296958923
1399,1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.936018705368042
1400,1/29/2023 12:18:56 PM,Biotech Stocks Facing FDA Decision In February 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-2023-1032048270,positive,0.9100891351699829
1401,1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678,positive,0.745915949344635
1402,1/30/2023 9:26:14 AM,"Sanofi, Regeneron Dupixent gets approval in EU for expanded use in eosinophilic esophagitis",Seeking Alpha,https://seekingalpha.com/news/3929244-sanofi-regeneron-dupixent-gets-approval-in-eu-for-expanded-use-in-eosinophilic-esophagitis?utm_source=businessinsider&utm_medium=referral,negative,0.9274740815162659
1403,1/30/2023 2:50:33 PM,Regeneron upgraded at Cowen on potential of high dose Eylea,Seeking Alpha,https://seekingalpha.com/news/3929389-regn-stock-upgraded-cowen-potential-high-dose-eylea?utm_source=businessinsider&utm_medium=referral,negative,0.8882205486297607
1404,1/30/2023 3:00:46 PM,What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-regeneron-pharmaceuticals-1032051072,positive,0.9464401006698608
1405,1/30/2023 4:00:50 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-30-2023-1032051242,neutral,0.522699236869812
1406,1/31/2023 12:10:35 AM,7 CRISPR Stocks With the Best Long-Term Potential ,InvestorPlace,/news/stocks/7-crispr-stocks-with-the-best-long-term-potential-1032052123,negative,0.8282150030136108
1407,1/31/2023 8:33:01 PM,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",Benzinga,/news/stocks/february-pdufa-catalysts-biotech-investors-must-know-sanofi-s-bleeding-disorder-drug-regeneron-s-twin-eylea-label-expansions-3-delayed-approvals-and-more-1032055559,positive,0.8971438407897949
1408,2/1/2023 7:07:28 PM,"Editas, Beam win bullish views as Cantor launches gene editing coverage",Seeking Alpha,https://seekingalpha.com/news/3930688-edit-stock-beam-stock-bullish-views-cantor-gene-editing?utm_source=businessinsider&utm_medium=referral,negative,0.7511203289031982
1409,2/1/2023 9:10:43 PM,The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-nasdaq-stocks-to-buy-in-february-2023-1032060416,positive,0.7067696452140808
1410,2/2/2023 1:12:31 PM,Clearside gains 12% as eye disease therapy cuts need for additional treatment,Seeking Alpha,https://seekingalpha.com/news/3931204-clsd-stock-gains-eye-disease-therapy-cuts-additional-treatment?utm_source=businessinsider&utm_medium=referral,negative,0.9458613395690918
1411,2/2/2023 3:01:13 PM,Regeneron Pharmaceuticals earnings: here's what to expect,Markets Insider Automation,/news/stocks/regeneron-stock-price-q4-earnings-preview-1032062955,positive,0.9397029280662537
1412,2/2/2023 3:29:38 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3931310-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8830810189247131
1413,2/2/2023 4:31:00 PM,"All eyes on Regeneron Q4 results with focus on blockbusters Dupixent, Eylea",Seeking Alpha,https://seekingalpha.com/news/3931344-all-eyes-on-regeneron-q4-results-with-focus-on-blockbusters-dupixent-eylea?utm_source=businessinsider&utm_medium=referral,positive,0.9375036954879761
1414,2/2/2023 7:19:39 PM,The 7 Most Undervalued Biotech Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-biotech-stocks-to-buy-in-february-2023-1032063992,positive,0.7679316997528076
1415,2/2/2023 8:19:36 PM,The 7 Most Undervalued Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-stocks-to-buy-in-february-2023-1032064059,positive,0.693999171257019
1416,2/3/2023 10:13:13 AM,Sanofi stock dips as Q4 revenue grows but vaccine sales fall; Dupixent drives moderate profit outlook,Seeking Alpha,https://seekingalpha.com/news/3931721-sanofi-q4-revenue-grows-on-dupixent-but-vaccine-sales-fall-dupixent-demand-drives-modes-profit-outlook?utm_source=businessinsider&utm_medium=referral,neutral,0.973347008228302
1417,2/3/2023 11:05:12 AM,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-sell-rating-on-regeneron-regn-1032065675,positive,0.9155040383338928
1418,2/3/2023 11:34:18 AM,Regeneron Pharmaceuticals reports Q4 earnings beat; initiates FY23 guidance,Seeking Alpha,https://seekingalpha.com/news/3931749-regeneron-pharmaceuticals-reports-q4-earnings-beat-initiates-fy23-guidance?utm_source=businessinsider&utm_medium=referral,negative,0.8516261577606201
1419,2/3/2023 12:28:01 PM,Regeneron posts Q4 beat as COVID therapy offsets Eylea impact,Seeking Alpha,https://seekingalpha.com/news/3931776-regeneron-posts-q4-beat-as-covid-therapy-offsets-eylea-impact?utm_source=businessinsider&utm_medium=referral,negative,0.9403448700904846
1420,2/3/2023 12:40:40 PM,Regeneron Pharmaceuticals Q4 Profit Declines,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-declines-1032065770,neutral,0.9663311839103699
1421,2/3/2023 1:03:43 PM,Regeneron Pharma Q4 Profit Declines; Adj. Total Revenues Up 14% ,RTTNews,/news/stocks/regeneron-pharma-q4-profit-declines-adj-total-revenues-up-14-1032065817,neutral,0.7726448774337769
1422,2/3/2023 5:00:21 PM,4D Molecular cleared to start mid-stage trial for diabetic macular edema candidate,Seeking Alpha,https://seekingalpha.com/news/3931754-fdmt-stock-gains-as-fda-clears-mid-stage-diabetic-macular-edema-trial?utm_source=businessinsider&utm_medium=referral,negative,0.6479185223579407
1423,2/3/2023 7:30:12 PM,"Catalyst watch: Google talks AI, Nordstrom drama and Canada Goose event",Seeking Alpha,https://seekingalpha.com/news/3931946-catalyst-watch-google-talks-ai-nordstrom-drama-and-canada-goose-event?utm_source=businessinsider&utm_medium=referral,positive,0.948539137840271
1424,2/5/2023 5:00:57 PM,Drug price inflation continues upward momentum at 3.8% – report,Seeking Alpha,https://seekingalpha.com/news/3932101-drug-price-inflation-continues-upward-momentum-at-38-report?utm_source=businessinsider&utm_medium=referral,negative,0.9158604145050049
1425,2/6/2023 12:06:13 PM,BMO Capital Releases a Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-releases-a-buy-rating-on-regeneron-regn-1032070060,positive,0.917184591293335
1426,2/6/2023 12:10:37 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032070049,negative,0.5521676540374756
1427,2/6/2023 12:30:37 PM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Genmab (GMAB) and Immunovant (IMVT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-genmab-gmab-and-immunovant-imvt-1032070133,positive,0.8972763419151306
1428,2/6/2023 4:31:12 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-regeneron-regn-and-seagen-sgen-1032070948,positive,0.9220420122146606
1429,2/7/2023 10:03:22 AM,Bayer files for approval of high/extended dosing regimens of Eylea in EU,Seeking Alpha,https://seekingalpha.com/news/3932692-bayer-files-for-approval-of-highextended-dosing-regimens-of-eylea-in-eu?utm_source=businessinsider&utm_medium=referral,negative,0.8281629085540771
1430,2/7/2023 6:51:59 PM,The 7 Best Biotech Stocks to Buy for February 2023,InvestorPlace,/news/stocks/the-7-best-biotech-stocks-to-buy-for-february-2023-1032075170,positive,0.8734033107757568
1431,2/9/2023 12:47:18 PM,Regeneron wins FDA nod for Eylea to prevent infant blindness,Seeking Alpha,https://seekingalpha.com/news/3934169-regeneron-wins-fda-nod-eylea-prevent-infant-blindness?utm_source=businessinsider&utm_medium=referral,negative,0.8486053943634033
1432,2/10/2023 10:29:24 AM,Roche Vabysmo matches Eylea in 2 phase 3 trials for eye disorder,Seeking Alpha,https://seekingalpha.com/news/3934689-roche-vabysmo-matches-eylea-in-2-phase-3-trials-for-eye-disorder?utm_source=businessinsider&utm_medium=referral,negative,0.6326585412025452
1433,2/13/2023 10:05:21 AM,Ocular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trial,Seeking Alpha,https://seekingalpha.com/news/3935085-ocular-stock-rises-15-as-eye-drug-implant-shows-promise-in-ongoing-phase-1-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9508353471755981
1434,2/13/2023 7:49:54 PM,ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood,InvestorPlace,/news/stocks/ark-invest-the-7-words-that-explain-why-wall-street-cant-stand-cathie-wood-1032092169,positive,0.8888998031616211
1435,2/16/2023 1:52:22 PM,"3 Super Profitable S&P 500 Stocks to Buy, Other Than ExxonMobil",TipRanks,/news/stocks/3-super-profitable-s-p-500-stocks-to-buy-other-than-exxonmobil-1032102851,positive,0.8816415071487427
1436,2/17/2023 4:31:25 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Shockwave Medical (SWAV) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bio-rad-laboratories-bio-shockwave-medical-swav-and-regeneron-regn-1032106651,neutral,0.9128776788711548
1437,2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral,negative,0.9136704802513123
1438,2/21/2023 2:04:53 PM,Regeneron Pharma: FDA Accepts For Priority Review BLA For Pozelimab ,RTTNews,/news/stocks/regeneron-pharma-fda-accepts-for-priority-review-bla-for-pozelimab-1032111460,negative,0.48831209540367126
1439,2/23/2023 1:24:06 PM,Regeneron's high-dose Eylea application accepted for FDA priority review,Seeking Alpha,https://seekingalpha.com/news/3939903-regeneron-high-dose-eylea-application-accepted-for-fda-priority-review?utm_source=businessinsider&utm_medium=referral,negative,0.8611397743225098
1440,2/23/2023 1:42:01 PM,"Intellia, Novartis end gene editing partnership for sickle cell disease",Seeking Alpha,https://seekingalpha.com/news/3939919-intellia-novartis-end-gene-editing-partnership-for-sickle-cell-disease?utm_source=businessinsider&utm_medium=referral,positive,0.7858304381370544
1441,2/24/2023 12:30:18 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032123469,negative,0.5521676540374756
1442,2/24/2023 1:53:45 PM,Regeneron wins EU nod for Libtayo in PD-L1 positive lung cancer,Seeking Alpha,https://seekingalpha.com/news/3940635-regeneron-wins-eu-nod-libtayo-in-pd-l1-positive-lung-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9464885592460632
1443,2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral,positive,0.6739813089370728
1444,2/27/2023 7:42:19 PM,Replimune ends selloff after FDA response to mid-stage cancer trial,Seeking Alpha,https://seekingalpha.com/news/3941352-repl-stock-ends-selloff-fda-response-mid-stage-cancer-trial?utm_source=businessinsider&utm_medium=referral,neutral,0.9386165142059326
1445,2/28/2023 9:45:54 AM,Biotech Stocks Facing FDA Decision In March 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2023-1032130420,positive,0.9167791604995728
1446,2/28/2023 10:43:10 AM,"Bayer's Q4 sales grow on back of crop products, pharma declines; FY23 EPS to see impact",Seeking Alpha,https://seekingalpha.com/news/3941611-bayers-q4-sales-grow-on-back-of-crop-products-pharma-declines-fy23-eps-to-see-impact?utm_source=businessinsider&utm_medium=referral,neutral,0.5088449716567993
1447,3/1/2023 2:44:23 AM,FDA Approves Regeneron's Kevzara To Treat Inflammatory Rheumatic Disease ,RTTNews,/news/stocks/fda-approves-regeneron-s-kevzara-to-treat-inflammatory-rheumatic-disease-1032133644,negative,0.7885051965713501
1448,3/1/2023 9:36:47 AM,Bayer files for approval of high dose Eylea in Japan,Seeking Alpha,https://seekingalpha.com/news/3942383-bayer-files-for-approval-of-high-dose-eylea-in-japan?utm_source=businessinsider&utm_medium=referral,negative,0.6621033549308777
1449,3/6/2023 7:11:36 AM,Roche Announces FDA Approval Of Label Expansion For VENTANA PD-L1 Assay ,RTTNews,/news/stocks/roche-announces-fda-approval-of-label-expansion-for-ventana-pd-l1-assay-1032146267,negative,0.7093836665153503
1450,3/6/2023 6:45:59 PM,Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results,Seeking Alpha,https://seekingalpha.com/news/3944574-merck-to-start-phase-3-of-oral-pcsk9-inhibitor-for-cholesterol-following-mid-stage-results?utm_source=businessinsider&utm_medium=referral,negative,0.7322389483451843
1451,3/7/2023 11:39:11 AM,FDA accepts for review Regeneron/Sanofi's Dupixent application for inflammatory skin condition,Seeking Alpha,https://seekingalpha.com/news/3944785-fda-accepts-for-review-regeneronsanofis-dupixent-application-for-inflammatory-skin-condition?utm_source=businessinsider&utm_medium=referral,positive,0.7207740545272827
1452,3/9/2023 3:01:33 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032157025,positive,0.8993901014328003
1453,3/9/2023 6:55:10 PM,Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs,Seeking Alpha,https://seekingalpha.com/news/3946094-biden-budget-to-save-160b-by-allowing-medicare-to-negotiate-prices-for-more-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.8639830946922302
1454,3/13/2023 9:20:07 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Regeneron (REGN),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-acadia-pharmaceuticals-acad-and-regeneron-regn-1032162542,neutral,0.6564132571220398
1455,3/15/2023 3:56:00 AM,"Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease",PR Newswire,/news/stocks/students-win-more-than-1-8-million-at-2023-regeneron-science-talent-search-for-remarkable-scientific-research-on-rna-molecule-structure-media-bias-and-diagnostics-for-pediatric-heart-disease-1032167769,negative,0.8048726320266724
1456,3/15/2023 3:31:39 PM,The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector,InvestorPlace,/news/stocks/the-7-best-biotech-etfs-to-buy-for-exposure-to-the-healthcare-sector-1032170074,positive,0.6613713502883911
1457,3/19/2023 7:47:43 PM,Easing COVID pandemic sees many pharmas seeking alternate revenue streams,Seeking Alpha,https://seekingalpha.com/news/3948704-easing-covid-pandemic-pfizer-astrazeneca-seeking-alternate-revenue-streams?utm_source=businessinsider&utm_medium=referral,positive,0.7959105372428894
1458,3/21/2023 7:47:44 AM,Sanofi : EU Approves Dupixent To Treat Severe Atopic Dermatitis In Children ,RTTNews,/news/stocks/sanofi-eu-approves-dupixent-to-treat-severe-atopic-dermatitis-in-children-1032180870,negative,0.9126641154289246
1459,3/21/2023 8:33:15 AM,Sanofi and Regeneron's Dupixent gets approval in EU to treat eczema in kids over 6 months,Seeking Alpha,https://seekingalpha.com/news/3949321-sanofi-regeneron-dupixent-gets-approval-in-eu-to-treat-eczema-in-kids-over-6-months?utm_source=businessinsider&utm_medium=referral,negative,0.9324327707290649
1460,3/22/2023 11:54:23 AM,Regeneron gets FDA approval for expanded use of high cholesterol drug Evkeeza in kids,Seeking Alpha,https://seekingalpha.com/news/3949847-regeneron-gets-fda-approval-for-expanded-use-of-high-cholesterol-drug-evkeeza-in-kids?utm_source=businessinsider&utm_medium=referral,negative,0.916721761226654
1461,3/22/2023 1:00:52 PM,Regeneron : FDA Approves Evkeeza To Treat Ultra-rare Form Of High Cholesterol In Young Children ,RTTNews,/news/stocks/regeneron-fda-approves-evkeeza-to-treat-ultra-rare-form-of-high-cholesterol-in-young-children-1032184634,negative,0.8632028698921204
1462,3/22/2023 7:46:16 PM,7 Value Stocks Worth Buying at These 52-Week Highs,InvestorPlace,/news/stocks/7-value-stocks-worth-buying-at-these-52-week-highs-1032185977,positive,0.8749464750289917
1463,3/23/2023 9:31:06 AM,"Sanofi stock rises as Dupixent shows benefit in lung disease smokers, meets phase 3 goals",Seeking Alpha,https://seekingalpha.com/news/3950240-sanofi-stock-rises-as-dupixent-shows-benefit-in-lung-disease-smokers-meets-phase-3-goals?utm_source=businessinsider&utm_medium=referral,negative,0.9455486536026001
1464,3/23/2023 12:30:32 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-regeneron-regn-and-alcon-alc-1032187724,positive,0.9025923013687134
1465,3/23/2023 2:43:13 PM,REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data,InvestorPlace,/news/stocks/regn-stock-alert-regeneron-pharmaceuticals-gains-on-dupixent-drug-data-1032188385,negative,0.9340636730194092
1466,3/23/2023 3:07:27 PM,"Regeneron up 7% following Dupixent data, Raymond James upgrade",Seeking Alpha,https://seekingalpha.com/news/3950434-regeneron-up-7-following-dupixent-data-raymond-james-upgrade?utm_source=businessinsider&utm_medium=referral,negative,0.9464492797851562
1467,3/23/2023 3:10:20 PM,Why Are Stocks Up Today?,InvestorPlace,/news/stocks/why-are-stocks-up-today-march-23-1032188383,positive,0.5933130979537964
1468,3/24/2023 10:05:33 AM,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-sell-rating-on-regeneron-regn-1032190347,positive,0.9155040383338928
1469,3/24/2023 10:25:47 AM,Morgan Stanley Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-regeneron-regn-1032190388,positive,0.8330079913139343
1470,3/24/2023 12:12:26 PM,US Stocks Cautiously Rebound Amid Positive Economic Data Following Banking Stocks Selloff,Benzinga,/news/stocks/us-stocks-on-track-for-weak-start-friday-amid-renewed-banking-concerns-and-contagion-fears-1032190537,negative,0.8798015713691711
1471,3/24/2023 12:44:10 PM,Regeneron draws more bullish views from analysts after Dupixent COPD data,Seeking Alpha,https://seekingalpha.com/news/3950893-regeneron-stock-wins-bullish-views-on-dupixent-data?utm_source=businessinsider&utm_medium=referral,negative,0.8577449321746826
1472,3/24/2023 3:09:48 PM,Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In,Benzinga,/news/stocks/regeneron-pharmaceuticals-analysts-react-to-drug-trial-results-why-whales-are-diving-in-1032191074,positive,0.8437568545341492
1473,3/24/2023 4:00:26 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-24-2023-1032191210,neutral,0.5095129013061523
1474,3/24/2023 6:00:31 PM,Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/baird-maintains-neutral-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1032191500,positive,0.9246069192886353
1475,3/27/2023 12:32:38 PM,Unity Biotech sheds 48% after mid-stage setback for wet AMD candidate,Seeking Alpha,https://seekingalpha.com/news/3951420-unity-biotech-stock-falls-phase-2-data-wet-amd-data?utm_source=businessinsider&utm_medium=referral,neutral,0.9655247926712036
1476,3/27/2023 1:38:55 PM,Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday,Benzinga,/news/stocks/pinterest-to-rally-over-27-here-are-10-other-analyst-forecasts-for-monday-1032193749,positive,0.9011921882629395
1477,3/27/2023 3:00:55 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1032194136,positive,0.9010616540908813
1478,3/27/2023 5:00:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-27-2023-1032194547,neutral,0.5154085159301758
1479,3/27/2023 5:45:10 PM,Supreme Court hears arguments in Amgen Repatha patent case against Sanofi,Seeking Alpha,https://seekingalpha.com/news/3951571-supreme-court-arguments-repatha-patent-case-sanofi-regeneron?utm_source=businessinsider&utm_medium=referral,positive,0.6958101391792297
1480,3/28/2023 10:26:08 AM,RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-regeneron-regn-1032196477,positive,0.7852190136909485
1481,3/28/2023 12:52:07 PM,Regeneron to pay Sonoma $75M upfront in pact to develop autoimmune disease drugs,Seeking Alpha,https://seekingalpha.com/news/3951840-regeneron-pay-sonoma-75m-upfront--pact--develop-autoimmune-disease-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.540533185005188
1482,3/28/2023 2:16:08 PM,Regeneron Partners With Sonoma Biotherapeutics To Develop T Cell Therapies ,RTTNews,/news/stocks/regeneron-partners-with-sonoma-biotherapeutics-to-develop-t-cell-therapies-1032196979,negative,0.6228137612342834
1483,3/29/2023 9:26:13 AM,"Amgen, AstraZeneca's asthma therapy Tezspire gets UK's NICE backing",Seeking Alpha,https://seekingalpha.com/news/3952134-amgen-astrazenecas-asthma-therapy-tezspire-gets-uks-nice-backing?utm_source=businessinsider&utm_medium=referral,positive,0.7472715377807617
1484,3/29/2023 9:50:30 AM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Intra-Cellular Therapies (ITCI) and uniQure (QURE)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-intra-cellular-therapies-itci-and-uniqure-qure-1032199702,neutral,0.6201547980308533
1485,3/29/2023 11:31:48 AM,Regeneron Libtayo gets expanded approval in EU for lung cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3952178-regeneron-libtayo-gets-expanded-approval-eu-lung-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9308313131332397
1486,3/30/2023 11:17:56 AM,Regeneron in research agreement with Xeris Biopharma,Seeking Alpha,https://seekingalpha.com/news/3952622-xeris-biopharma--stock-in-research-pact-with-regeneron?utm_source=businessinsider&utm_medium=referral,negative,0.6180424690246582
1487,3/31/2023 2:44:21 PM,NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/nvidia-to-rally-around-18-here-are-10-other-analyst-forecasts-for-friday-1032207050,positive,0.9173057675361633
1488,3/31/2023 7:00:31 PM,JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/jp-morgan-maintains-overweight-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1032207929,positive,0.9272456765174866
1489,4/8/2023 1:50:26 AM,"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Amgen (AMGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-amgen-amgn-and-regeneron-regn-1032220940,neutral,0.662185788154602
1490,4/10/2023 11:33:47 AM,Regeneron Pharmaceuticals Q1 one-off charges to be ~$56M,Seeking Alpha,https://seekingalpha.com/news/3955244-regeneron-pharmaceuticals-q1-one-off-charges-to-be-56m?utm_source=businessinsider&utm_medium=referral,positive,0.9455488920211792
1491,4/11/2023 2:25:44 AM,U.S. launches $5B program to speed up development of next-gen COVID vaccines,Seeking Alpha,https://seekingalpha.com/news/3955481-us-launches-5b-program-develop-next-gen-covid-vaccines?utm_source=businessinsider&utm_medium=referral,negative,0.8896018862724304
1492,4/12/2023 9:10:09 PM,S&P 500 will see 11% upside from the current levels - Piper Sandler's Craig Johnson,Seeking Alpha,https://seekingalpha.com/news/3956043-sp-500-will-see-11-upside-from-the-current-levels-piper-sandlers-craig-johnson?utm_source=businessinsider&utm_medium=referral,negative,0.9206171035766602
1493,4/13/2023 3:54:32 PM,Intellia up 12% as Canaccord starts with Buy citing gene editing approach,Seeking Alpha,https://seekingalpha.com/news/3956345-intellia-stock-gain-canaccord-starts-with-buy?utm_source=businessinsider&utm_medium=referral,negative,0.9015244245529175
1494,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral,negative,0.6195566654205322
1495,4/18/2023 12:40:43 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032239603,negative,0.5521676540374756
1496,4/19/2023 6:12:13 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), UnitedHealth (UNH) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-unitedhealth-unh-and-sarepta-therapeutics-srpt-1032242384,positive,0.9103142023086548
1497,4/20/2023 12:18:28 PM,Sensei gains FDA IND clearance for solid tumors candidate,Seeking Alpha,https://seekingalpha.com/news/3958192-sensei-gains-fda-ind-clearance-solid-tumors-candidate?utm_source=businessinsider&utm_medium=referral,negative,0.9293966889381409
1498,4/20/2023 12:35:27 PM,Jefferies Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-regeneron-regn-1032246879,positive,0.8025652766227722
1499,4/20/2023 5:07:09 PM,The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio,InvestorPlace,/news/stocks/the-greatest-7-blue-chip-stocks-to-buy-for-your-portfolio-1032247873,positive,0.9277865290641785
1500,4/26/2023 10:30:22 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akebia Therapeutics (AKBA) and Panbela Therapeutics (PBLA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-akebia-therapeutics-akba-and-panbela-therapeutics-pbla-1032262756,positive,0.9106135964393616
1501,4/26/2023 5:21:35 PM,Democratic senators introduce bill to enhance CMS drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3960629-democratic-senators-introduce-bill-enhance-cms-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.8721349239349365
1502,4/26/2023 9:15:43 PM,"Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer's candidate",Seeking Alpha,https://seekingalpha.com/news/3960979-partial-clinical-hold-placed-alnylam-regeneron-rnai-alzheimers-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.9104363918304443
1503,4/27/2023 10:08:25 AM,Sanofi Q1 profit climbs on Dupixent as drug on track for €10B this year,Seeking Alpha,https://seekingalpha.com/news/3961128-sanofi-q1-profit-climbs-on-back-of-dupixent-drug-to-see-10b-this-year?utm_source=businessinsider&utm_medium=referral,negative,0.9336047768592834
1504,4/27/2023 11:20:32 AM,"Analysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-edwards-lifesciences-ew-humana-hum-1032268206,negative,0.5106951594352722
1505,5/1/2023 12:40:13 PM,"Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), PTC Therapeutics (PTCT) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tg-therapeutics-tgtx-ptc-therapeutics-ptct-and-regeneron-regn-1032277966,positive,0.9104078412055969
1506,5/1/2023 2:04:48 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032277869,positive,0.8993901014328003
1507,5/3/2023 5:37:49 PM,Regeneron Pharmaceuticals Q1 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3964750-regeneron-pharmaceuticals-q1-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral,positive,0.899236261844635
1508,5/3/2023 5:59:06 PM,"Regeneron looks to strong Dupixent, Eylea sales in Q1 report",Seeking Alpha,https://seekingalpha.com/news/3964570-regeneron-looks-strong-eylea-dupixent-sales-q1-report?utm_source=businessinsider&utm_medium=referral,negative,0.9519347548484802
1509,5/4/2023 10:32:01 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M",Seeking Alpha,https://seekingalpha.com/news/3965407-regeneron-pharmaceuticals-non-gaap-eps-of-10_09-beats-0_53-revenue-of-3_16b-beats-160m?utm_source=businessinsider&utm_medium=referral,positive,0.46859726309776306
1510,5/4/2023 11:29:02 AM,Regeneron stock dips amid decline in Eylea sales despite Q1 beat,Seeking Alpha,https://seekingalpha.com/news/3965508-regeneron-stock-dips-amid-decline-in-eylea-sales-despite-q1-beat?utm_source=businessinsider&utm_medium=referral,neutral,0.9693361520767212
1511,5/4/2023 12:43:10 PM,"Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-profit-decreases-but-beats-estimates-1032291867,neutral,0.9666802883148193
1512,5/5/2023 3:35:06 AM,Goldman Sachs Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/goldman-sachs-keeps-their-buy-rating-on-regeneron-regn-1032294779,positive,0.9267477989196777
1513,5/5/2023 10:30:20 AM,"Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Regeneron (REGN) and Puma Biotechnology (PBYI)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cytokinetics-cytk-regeneron-regn-and-puma-biotechnology-pbyi-1032296794,positive,0.8962451219558716
1514,5/5/2023 11:40:19 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Ultragenyx Pharmaceutical (RARE) and Surface Oncology (SURF)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-ultragenyx-pharmaceutical-rare-and-surface-oncology-surf-1032297076,neutral,0.9142749309539795
1515,5/5/2023 12:20:28 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032297355,negative,0.5521676540374756
1516,5/8/2023 4:31:16 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Karuna Therapeutics (KRTX) and Pennant Group (PNTG)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-karuna-therapeutics-krtx-and-pennant-group-pntg-1032303160,neutral,0.9391962885856628
1517,5/10/2023 10:21:20 AM,"Alvotech, Polifarma ink pact to sell potential Eylea biosimilar in Turkey",Seeking Alpha,https://seekingalpha.com/news/3968900-alvotech-polifarma-ink-pact-to-sell-potential-eylea-biosimilar-in-turkey?utm_source=businessinsider&utm_medium=referral,negative,0.9014138579368591
1518,5/11/2023 9:22:44 AM,"Bayer Q1 sales dips as crop, pharma segments decline; glyphosate prices weigh on outlook",Seeking Alpha,https://seekingalpha.com/news/3969835-bayer-q1-sales-dips-as-crop-pharma-fall-glyphosate-weigh-on-outlook?utm_source=businessinsider&utm_medium=referral,neutral,0.9724211692810059
1519,5/12/2023 11:58:17 AM,"Regeneron, Decibel's hearing loss gene therapy trial application gets approval in Spain",Seeking Alpha,https://seekingalpha.com/news/3970742-regeneron-decibels-hearing-loss-gene-therapy-trial-application-gets-approval-in-spain?utm_source=businessinsider&utm_medium=referral,negative,0.9330329298973083
1520,5/12/2023 5:11:43 PM,AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market,Benzinga,/news/etf/ai-run-etf-dumps-apple-in-favor-of-this-chip-stock-and-hints-at-new-opportunity-brewing-in-market-1032323317,neutral,0.5373362302780151
1521,5/16/2023 4:31:17 PM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Viking Therapeutics (VKTX) and UpHealth (UPH)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-viking-therapeutics-vktx-and-uphealth-uph-1032332182,neutral,0.6669490933418274
1522,5/17/2023 2:42:12 PM,Regeneron CEO supports FTC suit against Amgen acquisition of Horizon - FT,Seeking Alpha,https://seekingalpha.com/news/3972603-regeneron-ceo-supports-ftc-suit-against-amgen-acquistion-horizon?utm_source=businessinsider&utm_medium=referral,neutral,0.3938693702220917
1523,5/17/2023 7:15:57 PM,The 7 Growth Stocks You Need to Own Now for Maximum Returns,InvestorPlace,/news/stocks/the-7-growth-stocks-you-need-to-own-now-for-maximum-returns-1032335944,positive,0.9018212556838989
1524,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral,neutral,0.7930806875228882
1525,5/19/2023 4:37:11 AM,U.S. Supreme Court Rules Against Amgen In Cholesterol Drug Patent Dispute With Sanofi ,RTTNews,/news/stocks/u-s-supreme-court-rules-against-amgen-in-cholesterol-drug-patent-dispute-with-sanofi-1032338671,neutral,0.83731609582901
1526,5/19/2023 1:01:12 PM,"Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-moderna-mrna-regeneron-regn-1032339830,positive,0.4874371290206909
1527,5/19/2023 7:00:19 PM,"Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference",Seeking Alpha,https://seekingalpha.com/news/3973501-catalyst-watch-eyes-on-ford-event-virgin-galactic-launch-nvidia-earnings-and-microsoft-conference?utm_source=businessinsider&utm_medium=referral,positive,0.9428636431694031
1528,5/19/2023 9:32:00 PM,High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023,PR Newswire,/news/stocks/high-school-scientists-and-engineers-win-nearly-9-million-at-the-regeneron-international-science-and-engineering-fair-2023-1032340488,negative,0.8211254477500916
1529,5/22/2023 4:10:56 AM,Sanofi:Dupixent Phase 3 COPD Results Presented At ATS & Published In New England Journal Of Medicine ,RTTNews,/news/stocks/sanofi-dupixent-phase-3-copd-results-presented-at-ats-published-in-new-england-journal-of-medicine-1032341401,positive,0.9422662258148193
1530,5/22/2023 11:30:11 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032342364,negative,0.5521676540374756
1531,5/23/2023 3:25:05 AM,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-sell-rating-on-regeneron-regn-1032343913,positive,0.9155040383338928
1532,6/1/2023 12:26:11 PM,Roche to divest biologics production plant in California – Reuters,Seeking Alpha,https://seekingalpha.com/news/3976552-roche-divest-biologics-production-plant-california?utm_source=businessinsider&utm_medium=referral,positive,0.8510016798973083
1533,6/2/2023 12:31:25 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032367235,negative,0.5521676540374756
1534,6/6/2023 1:11:23 PM,3 Biotech Stocks to Sell in June Before They Crash and Burn,InvestorPlace,/news/stocks/3-biotech-stocks-to-sell-in-june-before-they-crash-and-burn-1032373119,positive,0.844161868095398
1535,6/9/2023 11:11:57 AM,AstraZeneca in pact with Quell Therapeutics for Treg cell therapies,Seeking Alpha,https://seekingalpha.com/news/3978896-astrazeneca-stock-co-develop-treg-cell-therapies?utm_source=businessinsider&utm_medium=referral,negative,0.6778479814529419
1536,6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral,positive,0.5447219014167786
1537,6/9/2023 10:01:24 PM,18 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/18-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1032381574,positive,0.9354543089866638
1538,6/12/2023 12:05:20 PM,Jefferies Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-regeneron-regn-1032383348,positive,0.8025652766227722
1539,6/12/2023 7:01:57 PM,Ocular falls after 12-month data for wet AMD candidate,Seeking Alpha,https://seekingalpha.com/news/3979306-ocular-stock-falls-12-month-data-wet-amd-drug-otx-tki?utm_source=businessinsider&utm_medium=referral,neutral,0.9496855139732361
1540,6/14/2023 4:55:37 AM,SVB Securities Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/svb-securities-remains-a-buy-on-regeneron-regn-1032387731,positive,0.9481641054153442
1541,6/14/2023 9:14:33 PM,"EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035",Benzinga,/news/stocks/eyepoint-s-eyp-1901-tipped-to-transform-wet-amd-market-analyst-predicts-potential-870m-sales-by-2035-1032389967,negative,0.8404785394668579
1542,6/15/2023 10:10:38 AM,"Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Healthequity (HQY) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-acadia-pharmaceuticals-acad-healthequity-hqy-and-regeneron-regn-1032391141,positive,0.9084112048149109
1543,6/15/2023 11:10:07 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and BioMarin Pharmaceutical (BMRN),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-biomarin-pharmaceutical-bmrn-1032391325,neutral,0.9417730569839478
1544,6/18/2023 8:56:10 PM,How to Retire Rich: Biotech Stocks Edition,InvestorPlace,/news/stocks/how-to-retire-rich-biotech-stocks-edition-1032395848,positive,0.9189780354499817
1545,6/23/2023 12:31:41 PM,"Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Kezar Life Sciences (KZR)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-sarepta-therapeutics-srpt-kezar-life-sciences-kzr-1032406863,positive,0.6508937478065491
1546,6/27/2023 12:30:38 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Edwards Lifesciences (EW) and Tonix Pharma (TNXP)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-edwards-lifesciences-ew-and-tonix-pharma-tnxp-1032412234,neutral,0.9335932731628418
1547,6/27/2023 4:30:24 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032413110,negative,0.5521676540374756
1548,6/27/2023 7:18:00 PM,Regeneron falls as FDA rejects high-dose Eylea (update),Seeking Alpha,https://seekingalpha.com/news/3983374-regeneron-high-dose-eylea-rejected-by-fda?utm_source=businessinsider&utm_medium=referral,neutral,0.8930099606513977
1549,6/27/2023 8:01:06 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032413256,positive,0.8993901014328003
1550,6/28/2023 9:01:14 AM,"Analysts’ Top Healthcare Picks: Paycor HCM (PYCR), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-paycor-hcm-pycr-regeneron-regn-1032414327,negative,0.7252368330955505
1551,6/28/2023 9:10:26 AM,"Analysts Conflicted on These Healthcare Names: Paycor HCM (PYCR), Regeneron (REGN) and Pharvaris (PHVS)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-paycor-hcm-pycr-regeneron-regn-and-pharvaris-phvs-1032414318,neutral,0.7267731428146362
1552,6/28/2023 11:05:18 AM,BMO Capital Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-sticks-to-its-buy-rating-for-regeneron-regn-1032414641,positive,0.6168503165245056
1553,6/28/2023 12:20:33 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Radnet (RDNT)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-radnet-rdnt-1032414881,negative,0.513110339641571
1554,6/28/2023 12:44:32 PM,Regeneron cut to Neutral at Cannacord on FDA snub for high-dose Eylea,Seeking Alpha,https://seekingalpha.com/news/3983613-regeneron-cut-cannacord-fda-snubs-high-dose-eylea?utm_source=businessinsider&utm_medium=referral,neutral,0.43388375639915466
1555,6/28/2023 1:45:36 PM,SVB Securities Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-regeneron-regn-1032415333,positive,0.8127404451370239
1556,6/28/2023 1:53:01 PM,Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday,Benzinga,/news/stocks/amazon-com-to-rally-over-16-here-are-10-other-analyst-forecasts-for-wednesday-1032414733,positive,0.9084892272949219
1557,6/28/2023 2:42:32 PM,Catalent confirmed as manufacturer of Regeneron’s high-dose Eylea rejected by FDA,Seeking Alpha,https://seekingalpha.com/news/3983718-catalent-linked-fda-snub-regenerons-high-dose-eylea?utm_source=businessinsider&utm_medium=referral,positive,0.7261911630630493
1558,6/28/2023 5:03:03 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-28-2023-1032415597,neutral,0.516834020614624
1559,7/4/2023 5:30:13 PM,"Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Regeneron (REGN) and Blueprint Medicines (BPMC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-regeneron-regn-and-blueprint-medicines-bpmc-1032425958,positive,0.8959929943084717
1560,7/5/2023 5:05:57 PM,The 3 Best Biotech Stocks to Buy In July,InvestorPlace,/news/stocks/biotech-stocks-to-buy-2-1032428210,positive,0.7658016681671143
1561,7/6/2023 2:43:36 PM,Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday,Benzinga,/news/stocks/meta-platforms-to-rally-around-14-here-are-10-other-analyst-forecasts-for-thursday-1032430007,positive,0.9217377305030823
1562,7/11/2023 1:50:34 AM,"Analysts Conflicted on These Healthcare Names: Pacira Pharmaceuticals (PCRX), Regeneron (REGN) and Thermo Fisher (TMO)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-pacira-pharmaceuticals-pcrx-regeneron-regn-and-thermo-fisher-tmo-1032436031,neutral,0.7732768654823303
1563,7/12/2023 12:53:33 AM,Why These 7 Stocks Are the Best Ways to Play Biotech Right Now,InvestorPlace,/news/stocks/why-these-7-stocks-are-the-best-ways-to-play-biotech-right-now-1032439054,positive,0.9327079057693481
1564,7/13/2023 11:31:49 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-regeneron-regn-1032444194,positive,0.8987464308738708
1565,7/14/2023 1:24:24 AM,3 Pharma Stocks That AI is Loving in July,InvestorPlace,/news/stocks/3-pharma-stocks-that-ai-is-loving-in-july-1032445958,positive,0.9090803265571594
1566,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral,positive,0.4974316656589508
1567,7/17/2023 9:10:25 AM,"Alnylam Presents ALN-APP's Updated Positive Interim Phase 1 Results In Alzheimer's Disease, CAA ",RTTNews,/news/stocks/alnylam-presents-aln-app-s-updated-positive-interim-phase-1-results-in-alzheimer-s-disease-caa-1032450212,positive,0.5529909133911133
1568,7/24/2023 11:32:36 AM,Kodiak drops eye disease candidate after Phase 3 setback,Seeking Alpha,https://seekingalpha.com/news/3989978-kodiak-stock-falls-discontinues-eye-disease-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.6708008050918579
1569,7/24/2023 2:25:30 PM,Why Are Kodiak Sciences Shares Trading Lower Today?,Benzinga,/news/stocks/why-are-kodiak-sciences-shares-trading-lower-today-1032469988,neutral,0.9157212376594543
1570,7/24/2023 9:55:38 PM,The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-now-july-2023-2-1032471656,positive,0.9041306376457214
1571,7/26/2023 5:23:00 PM,"If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names",InvestorPlace,/news/stocks/if-you-can-only-buy-one-biotech-stock-it-better-be-one-of-these-3-names-1032481009,positive,0.9435527920722961
1572,7/26/2023 7:04:29 PM,Weight loss drugs excluded from WHO’s 'essential' medicines list,Seeking Alpha,https://seekingalpha.com/news/3991468-weight-loss-drugs-not-in-latest-who-essential-medicines-list?utm_source=businessinsider&utm_medium=referral,positive,0.914836585521698
1573,7/28/2023 9:20:31 AM,"Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), HCA Healthcare (HCA) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-exelixis-exel-hca-healthcare-hca-and-regeneron-regn-1032489174,neutral,0.7328004240989685
1574,7/28/2023 11:45:23 AM,BMO Capital Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-regeneron-regn-1032489800,positive,0.9473738670349121
1575,7/31/2023 9:46:38 AM,Biotech Stocks Facing FDA Decision In August 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2023-1032494050,positive,0.9162535071372986
1576,8/1/2023 6:59:01 PM,Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points,InvestorPlace,/news/stocks/biotech-stocks-to-buy-3-1032502314,negative,0.931571364402771
1577,8/2/2023 3:01:13 PM,Regeneron Pharmaceuticals is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/regeneron-stock-price-q2-earnings-preview-1032506842,positive,0.9392889142036438
1578,8/2/2023 3:58:20 PM,Regeneron Pharmaceuticals Q2 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3995295-regeneron-pharmaceuticals-q2-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral,positive,0.8962084650993347
1579,8/3/2023 1:50:49 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH), Regeneron (REGN) and Addus Homecare (ADUS)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-zimmer-biomet-holdings-zbh-regeneron-regn-and-addus-homecare-adus-1032509162,neutral,0.9390420317649841
1580,8/3/2023 10:31:33 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $10.24 beats by $0.34, revenue of $3.16B beats by $140M",Seeking Alpha,https://seekingalpha.com/news/3996298-regeneron-pharmaceuticals-non-gaap-eps-of-10_24-beats-0_34-revenue-of-3_16b-beats-140m?utm_source=businessinsider&utm_medium=referral,positive,0.5700470805168152
1581,8/3/2023 10:50:14 AM,"Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Humana (HUM) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-united-therapeutics-uthr-humana-hum-and-regeneron-regn-1032511965,neutral,0.5085000991821289
1582,8/3/2023 12:00:28 PM,Regeneron gains after Q2 beat; FDA action on high-dose Eylea expected in Q3,Seeking Alpha,https://seekingalpha.com/news/3996461-regeneron-stock-gains-after-q2-beat?utm_source=businessinsider&utm_medium=referral,negative,0.9277583360671997
1583,8/3/2023 1:53:42 PM,"Regeneron Pharmaceuticals Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-profit-increases-beats-estimates-1032512287,negative,0.9441160559654236
1584,8/3/2023 4:57:55 PM,"Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday",Benzinga,/news/stocks/clorox-boot-barn-herbalife-upwork-and-other-big-stocks-moving-higher-on-thursday-1032513509,negative,0.9049133062362671
1585,8/3/2023 5:05:14 PM,Replimmune down 8% on skin cancer cancer candidate data delay,Seeking Alpha,https://seekingalpha.com/news/3996749-replimmune-down-8-skin-cancer-cancer-candidate-data-delay?utm_source=businessinsider&utm_medium=referral,neutral,0.967724084854126
1586,8/4/2023 7:31:45 AM,"Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Zimmer Biomet Holdings (ZBH) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-penumbra-pen-zimmer-biomet-holdings-zbh-and-regeneron-regn-1032516644,neutral,0.7251452207565308
1587,8/4/2023 11:45:17 AM,BMO Capital Gives a Buy Rating to Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-gives-a-buy-rating-to-regeneron-regn-1032517737,positive,0.8577147126197815
1588,8/4/2023 1:26:20 PM,Regeneron halts enrollment in prostate cancer trial following two deaths,Seeking Alpha,https://seekingalpha.com/news/3997503-regeneron-halts-enrollment-prostate-cancer-trial-two-deaths?utm_source=businessinsider&utm_medium=referral,neutral,0.939852237701416
1589,8/7/2023 9:20:25 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-becton-dickinson-bdx-and-regeneron-regn-1032523168,positive,0.8969153761863708
1590,8/8/2023 4:15:25 PM,"Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy",Seeking Alpha,https://seekingalpha.com/news/3999177-stifel-guggenheim-jefferies-wedbush-start-apogee-therapeutics-at-buy?utm_source=businessinsider&utm_medium=referral,positive,0.9403935670852661
1591,8/8/2023 7:06:02 PM,3 AI Stocks You’ll Regret Not Buying Soon,InvestorPlace,/news/stocks/3-ai-stocks-youll-regret-not-buying-soon-1032530487,positive,0.9012989401817322
1592,8/9/2023 2:30:25 AM,"Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Stryker (SYK) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-axsome-therapeutics-axsm-stryker-syk-and-regeneron-regn-1032531344,neutral,0.6101054549217224
1593,8/9/2023 12:06:59 PM,Regeneron to acquire gene therapy developer Decibel for $4 per share,Seeking Alpha,https://seekingalpha.com/news/3999964-decibel-stock-rises-regeneron-inks-buyout-deal?utm_source=businessinsider&utm_medium=referral,positive,0.9015802145004272
1594,8/9/2023 2:00:22 PM,Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal,InvestorPlace,/news/stocks/decibel-therapeutics-dbtx-stock-skyrockets-71-on-regeneron-deal-1032535672,negative,0.7850990891456604
1595,8/10/2023 5:25:23 PM,Baird downgrades Decibel to neutral to reflect Regeneron takeover,Seeking Alpha,https://seekingalpha.com/news/4001204-baird-downgrades-decibel-to-neutral-to-reflect-regeneron-takeover?utm_source=businessinsider&utm_medium=referral,positive,0.8733904957771301
1596,8/11/2023 1:15:18 AM,The 7 Best Value Stocks to Buy in August,InvestorPlace,/news/stocks/the-7-best-value-stocks-to-buy-in-august-1032542533,positive,0.9103579521179199
1597,8/11/2023 4:20:36 PM,"Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Alcon (ALC) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cogent-biosciences-cogt-alcon-alc-and-regeneron-regn-1032547457,positive,0.9064181447029114
1598,8/11/2023 4:54:57 PM,Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet,Benzinga,/news/stocks/benzinga-s-stock-whisper-index-5-stocks-investors-are-secretly-monitoring-but-not-talking-about-yet-1032547189,positive,0.9360675811767578
1599,8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.5231574177742004
1600,8/15/2023 7:44:44 PM,Regeneron could see share price bounce with potential approvals,Seeking Alpha,https://seekingalpha.com/news/4003175-regeneron-could-see-share-price-bounce-potential-approvals?utm_source=businessinsider&utm_medium=referral,negative,0.9383835792541504
1601,8/16/2023 9:00:49 PM,18 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/18-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1032561036,positive,0.9354543089866638
1602,8/17/2023 1:28:09 PM,Regeneron lymphoma therapy accepted for EU review,Seeking Alpha,https://seekingalpha.com/news/4003958-regeneron-granted-eu-review-lymphoma-drug?utm_source=businessinsider&utm_medium=referral,positive,0.6652379631996155
1603,8/17/2023 2:30:11 PM,Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,GlobeNewswire,/news/stocks/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-1032563169,negative,0.9430890083312988
1604,8/17/2023 2:49:23 PM,Regeneron Pharma: EMA To Review MAA For Odronextamab ,RTTNews,/news/stocks/regeneron-pharma-ema-to-review-maa-for-odronextamab-1032563225,positive,0.8087292313575745
1605,8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral,positive,0.8961257338523865
1606,8/18/2023 6:23:01 PM,Regeneron wins approval for rare immune disease therapy pozelimab,Seeking Alpha,https://seekingalpha.com/news/4004438-regeneron-wins-approval-rare-immune-disease-therapy-pozelimab-veopoz?utm_source=businessinsider&utm_medium=referral,negative,0.934300422668457
1607,8/18/2023 7:00:03 PM,"Catalyst watch: Nvidia earnings, Twilio event, AMC drama and Jackson Hole jitters",Seeking Alpha,https://seekingalpha.com/news/4004407-catalyst-watch-nvidia-earnings-twilio-event-and-jackson-hole-jitters?utm_source=businessinsider&utm_medium=referral,positive,0.9089993834495544
1608,8/18/2023 7:43:19 PM,Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease,GlobeNewswire,/news/stocks/veopoz-pozelimab-bbfg-receives-fda-approval-as-the-first-treatment-for-children-and-adults-with-chaple-disease-1032567343,negative,0.9250820279121399
1609,8/18/2023 9:20:55 PM,Regeneron Pharma's Veopoz Receives FDA Approval For Veopoz ,RTTNews,/news/stocks/regeneron-pharma-s-veopoz-receives-fda-approval-for-veopoz-1032567445,negative,0.9073331356048584
1610,8/19/2023 12:35:00 AM,"EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)",GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-approved-by-fda-for-treatment-of-wet-age-related-macular-degeneration-wamd-diabetic-macular-edema-dme-and-diabetic-retinopathy-dr-1032567600,negative,0.9101571440696716
1611,8/19/2023 1:10:28 AM,Regeneron high-dose Eylea gains FDA approval,Seeking Alpha,https://seekingalpha.com/news/4004493-regeneron-high-dose-eylea-gains-fda-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9468011260032654
1612,8/19/2023 6:00:56 PM,"With two approvals in one day, Regeneron could be headed higher",Seeking Alpha,https://seekingalpha.com/news/4004500-two-approvals-one-day-regeneron-could-headed-higher?utm_source=businessinsider&utm_medium=referral,negative,0.7216835021972656
1613,8/21/2023 10:30:20 AM,"Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-nuvation-bio-nuvb-finch-therapeutics-group-fnch-1032569254,positive,0.7888648509979248
1614,8/21/2023 10:50:06 AM,"Analysts Offer Insights on Healthcare Companies: Nemaura Medical (NMRD), Kineta (KA) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-nemaura-medical-nmrd-kineta-ka-and-regeneron-regn-1032569283,positive,0.91457200050354
1615,8/21/2023 11:20:19 AM,Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-calliditas-therapeutics-calt-and-regeneron-regn-1032569390,positive,0.9056397676467896
1616,8/21/2023 12:20:11 PM,"Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-supernus-pharmaceuticals-supn-viatris-vtrs-1032569601,negative,0.5470502972602844
1617,8/21/2023 7:53:10 PM,Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed,Benzinga,/news/etf/value-stocks-outshine-growth-amidst-rising-treasury-yields-key-sectors-and-stocks-analyzed-1032570802,positive,0.8104676604270935
1618,8/21/2023 7:58:31 PM,"Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk",Seeking Alpha,https://seekingalpha.com/news/4004913-lillys-market-cap-soared-in-q2-eclipsing-jnj-merck-novo-nordisk?utm_source=businessinsider&utm_medium=referral,negative,0.9460121989250183
1619,8/21/2023 9:04:31 PM,Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?,Benzinga,/news/stocks/regeneron-s-crucial-eylea-hd-approval-a-shield-against-potential-biosimilar-competition-1032570892,positive,0.6802446246147156
1620,8/22/2023 10:11:27 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-regeneron-regn-and-syndax-pharmaceuticals-sndx-1032572377,positive,0.888979434967041
1621,8/22/2023 6:52:24 PM,"Regeneron, J&J receive millions to develop new COVID therapies",Seeking Alpha,https://seekingalpha.com/news/4005267-regeneron-johnson-johnson-receive-millions-develop-covid-therapies?utm_source=businessinsider&utm_medium=referral,negative,0.7993800044059753
1622,8/22/2023 8:15:41 PM,Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention,GlobeNewswire,/news/stocks/regeneron-announces-agreement-with-barda-supporting-development-of-next-generation-antibody-therapy-for-covid-19-prevention-1032574227,negative,0.9165791273117065
1623,8/23/2023 1:58:45 PM,Top 5 Health Care Stocks That May Fall Off A Cliff,Benzinga,/news/stocks/top-5-health-care-stocks-that-may-fall-off-a-cliff-1032576078,neutral,0.9527510404586792
1624,8/23/2023 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1032577795,positive,0.9291732907295227
1625,8/25/2023 2:43:48 PM,Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol,Seeking Alpha,https://seekingalpha.com/news/4006430-merck-starts-phase-3-oral-pcsk9-inhibitor-lower-cholesterol?utm_source=businessinsider&utm_medium=referral,negative,0.7989184856414795
1626,8/26/2023 7:21:22 PM,These Are the ONLY 7 Penny Stocks to Consider in August 2023,InvestorPlace,/news/stocks/these-are-the-only-7-penny-stocks-to-consider-in-august-2023-1032583984,positive,0.9448434114456177
1627,9/2/2023 6:00:00 PM,"Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag",Seeking Alpha,https://seekingalpha.com/news/4008548-lilly-novo-nordisk-top-pharma-performers-august-astrazeneca-roche-lag?utm_source=businessinsider&utm_medium=referral,negative,0.8847639560699463
1628,9/8/2023 8:58:16 PM,Regeneron CFO Robert Landry to retire,Seeking Alpha,https://seekingalpha.com/news/4010403-regeneron-cfo-robert-landry-to-retire?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9151529669761658
1629,9/8/2023 10:45:00 PM,Regeneron Announces Updates to Board of Directors,GlobeNewswire,/news/stocks/regeneron-announces-updates-to-board-of-directors-1032617282,positive,0.9174275398254395
1630,9/8/2023 10:46:00 PM,Regeneron Provides Update on Planned Chief Financial Officer Transition,GlobeNewswire,/news/stocks/regeneron-provides-update-on-planned-chief-financial-officer-transition-1032617288,positive,0.9326390624046326
1631,9/11/2023 7:30:31 PM,AI Integration In Biotech & Pharma: Companies Positioned To Benefit,Benzinga,/news/stocks/ai-integration-in-biotech-pharma-companies-positioned-to-benefit-1032621068,negative,0.5679945945739746
1632,9/15/2023 5:00:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-15-2023-1032634298,positive,0.5240795612335205
1633,9/19/2023 7:04:06 PM,3 Stocks to Buy to Ride Europe’s Coming Market Surge,InvestorPlace,/news/stocks/3-stocks-to-buy-to-ride-europes-coming-market-surge-1032641432,positive,0.7064094543457031
1634,9/21/2023 6:00:37 PM,Analyst Expectations for Regeneron Pharmaceuticals's Future,Benzinga,/news/stocks/analyst-expectations-for-regeneron-pharmaceuticals-s-future-1032647761,negative,0.8721103668212891
1635,9/25/2023 2:34:45 PM,"Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss ",GlobeNewswire,/news/stocks/regeneron-completes-acquisition-of-decibel-therapeutics-adding-promising-gene-therapy-programs-for-hearing-loss-1032652806,negative,0.8842914700508118
1636,9/26/2023 7:29:00 AM,Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review,GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-for-treatment-of-eosinophilic-esophagitis-eoe-in-children-aged-1-to-11-accepted-for-fda-priority-review-1032654537,negative,0.6379669904708862
1637,9/28/2023 10:05:00 PM,"Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023",GlobeNewswire,/news/stocks/regeneron-to-report-third-quarter-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-2-2023-1032664475,positive,0.947965145111084
1638,9/29/2023 11:12:27 AM,"Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), Regeneron (REGN) and Mirati Therapeutics (MRTX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-ptc-therapeutics-ptct-regeneron-regn-and-mirati-therapeutics-mrtx-1032666057,neutral,0.7335996627807617
1639,9/29/2023 2:30:12 PM,Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review,GlobeNewswire,/news/stocks/odronextamab-bla-for-treatment-of-relapsed-refractory-follicular-lymphoma-fl-and-diffuse-large-b-cell-lymphoma-dlbcl-accepted-for-fda-priority-review-1032666312,negative,0.8820782899856567
1640,9/29/2023 2:50:44 PM,Regeneron Pharma Reports FDA Priority Review For Odronextamab BLA - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-reports-fda-priority-review-for-odronextamab-bla-quick-facts-1032666378,positive,0.66594398021698
1641,10/3/2023 1:00:00 PM,Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases,GlobeNewswire,/news/stocks/regeneron-and-intellia-announce-expanded-research-collaboration-to-develop-crispr-based-therapies-for-the-treatment-of-neurological-and-muscular-diseases-1032673940,negative,0.9250088930130005
1642,10/3/2023 2:33:10 PM,MAIA Biotechnology Obtains FDA Clearance To Extend Go-to-market THIO-101 Trial To The U.S. ,RTTNews,/news/stocks/maia-biotechnology-obtains-fda-clearance-to-extend-go-to-market-thio-101-trial-to-the-u-s-1032674327,negative,0.9205750823020935
1643,10/5/2023 3:43:00 PM,EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-two-year-results-from-pivotal-pulsar-trial-in-wet-age-related-macular-degeneration-presented-at-euretina-1032681999,negative,0.9179789423942566
1644,10/6/2023 1:50:24 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Regeneron (REGN) and Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-regeneron-regn-and-alnylam-pharma-alny-1032683118,positive,0.9123159050941467
1645,10/11/2023 11:00:23 PM,The Latest Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/the-latest-analyst-ratings-for-regeneron-pharmaceuticals-1032698166,positive,0.9398453235626221
1646,10/13/2023 10:10:31 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Regeneron (REGN) and HashiCorp (HCP)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-alnylam-pharma-alny-regeneron-regn-and-hashicorp-hcp-1032703277,neutral,0.6997388601303101
1647,10/14/2023 1:45:33 AM,Regeneron (REGN) Receives a Hold from RBC Capital,TipRanks,/news/stocks/regeneron-regn-receives-a-hold-from-rbc-capital-1032705206,positive,0.864707887172699
1648,10/16/2023 12:05:23 AM,Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO,GlobeNewswire,/news/stocks/regeneron-to-showcase-progress-from-innovative-oncology-portfolio-in-several-difficult-to-treat-cancers-at-esmo-1032706044,negative,0.877665102481842
1649,10/16/2023 7:00:26 PM,Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/cantor-fitzgerald-maintains-neutral-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1032709568,positive,0.9209615588188171
1650,10/17/2023 9:21:19 AM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Iovance Biotherapeutics (IOVA),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-iovance-biotherapeutics-iova-1032711630,positive,0.8925535082817078
1651,10/18/2023 1:43:52 PM,Intellia Therapeutics: FDA Allows To Begin Phase 3 Trial Of NTLA-2001 - Quick Facts ,RTTNews,/news/stocks/intellia-therapeutics-fda-allows-to-begin-phase-3-trial-of-ntla-2001-quick-facts-1032716497,negative,0.5276979804039001
1652,10/18/2023 3:00:00 PM,"Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for...",GlobeNewswire,/news/stocks/together-for-change-genomics-and-equity-initiative-launched-by-a-coalition-of-meharry-medical-college-regeneron-genetics-center-astrazeneca-novo-nordisk-and-roche-to-improve-health-outcomes-for-1032717028,negative,0.7399206161499023
1653,10/18/2023 3:30:00 PM,"Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN",GlobeNewswire,/news/stocks/regeneron-builds-on-together-for-change-initiative-with-five-year-5-million-commitment-to-fuel-the-stem-talent-pipeline-in-nashville-tn-1032717151,negative,0.8044761419296265
1654,10/20/2023 11:20:36 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032724039,negative,0.5521676540374756
1655,10/20/2023 11:00:37 PM,Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria,GlobeNewswire,/news/stocks/regeneron-and-sanofi-provide-update-on-dupixent-dupilumab-sbla-for-chronic-spontaneous-urticaria-1032725260,positive,0.9109092354774475
1656,10/21/2023 2:48:15 PM,Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC),GlobeNewswire,/news/stocks/libtayo-cemiplimab-neoadjuvant-treatment-demonstrates-encouraging-event-free-survival-in-patients-with-resectable-cutaneous-squamous-cell-carcinoma-cscc-1032725598,negative,0.9498006701469421
1657,10/22/2023 8:59:00 PM,Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE),GlobeNewswire,/news/stocks/dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-eoe-1032726106,negative,0.9459930062294006
1658,10/23/2023 4:20:12 AM,Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With EoE ,RTTNews,/news/stocks/regeneron-dupixent-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-with-eoe-1032726139,negative,0.9497730135917664
1659,10/23/2023 11:20:16 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-akero-therapeutics-akro-and-essa-pharma-epix-1032733094,positive,0.9027637243270874
1660,10/25/2023 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1032740326,positive,0.9291732907295227
1661,10/26/2023 11:48:40 AM,Regeneron’s Growth Potential and R&D Conversion: Key Drivers for Buy Rating,TipRanks,/news/stocks/regeneron-s-growth-potential-and-r-d-conversion-key-drivers-for-buy-rating-1032745959,negative,0.5589645504951477
1662,10/26/2023 10:00:07 PM,Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss,GlobeNewswire,/news/stocks/regeneron-shares-preliminary-results-showing-gene-therapy-improves-auditory-responses-in-child-with-profound-genetic-hearing-loss-1032745488,negative,0.9397655129432678
1663,10/27/2023 1:25:10 PM,SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff,InvestorPlace,/news/stocks/sny-stock-sinks-15-as-sanofi-plans-consumer-unit-spinoff-1032748736,neutral,0.9670206308364868
1664,11/1/2023 3:01:13 PM,Regeneron Pharmaceuticals is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-price-q3-earnings-preview-1032765589,positive,0.9319632053375244
1665,11/1/2023 9:00:00 PM,EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-data-presentations-at-aao-reinforce-efficacy-and-safety-profile-in-wet-age-related-macular-degeneration-and-diabetic-macular-edema-1032767135,negative,0.9367231726646423
1666,11/2/2023 11:30:00 AM,Regeneron Reports Third Quarter 2023 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-third-quarter-2023-financial-and-operating-results-1032769545,negative,0.5084956884384155
1667,11/2/2023 1:12:49 PM,"Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-profit-decreases-but-beats-estimates-1032770107,neutral,0.9668293595314026
1668,11/2/2023 6:20:32 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Glaukos (GKOS) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-humana-hum-glaukos-gkos-and-regeneron-regn-1032774906,neutral,0.9277728199958801
1669,11/2/2023 6:58:06 PM,"Green Wave Boosts Stocks, Bonds As Traders Embrace Fed's Stance, Await Apple Earnings: What's Driving Markets Thursday?",Benzinga,/news/etf/green-wave-boosts-stocks-bonds-as-traders-embrace-fed-s-stance-await-apple-earnings-what-s-driving-markets-thursday-1032771843,positive,0.7291427254676819
1670,11/2/2023 9:40:17 PM,"Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-generation-bio-gbio-regeneron-regn-1032775572,positive,0.5523693561553955
1671,11/2/2023 10:10:17 PM,"Analysts Are Bullish on Top Healthcare Stocks: United Therapeutics (UTHR), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-united-therapeutics-uthr-regeneron-regn-1032775672,negative,0.6493420004844666
1672,11/3/2023 9:01:02 AM,"Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Moderna (MRNA) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-zoetis-zts-moderna-mrna-and-regeneron-regn-1032777638,positive,0.9070954918861389
1673,11/3/2023 11:40:33 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), Trupanion (TRUP) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-trupanion-trup-and-regeneron-regn-1032777825,neutral,0.9228054881095886
1674,11/3/2023 12:00:14 PM,Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH,GlobeNewswire,/news/stocks/regeneron-to-highlight-scientific-advancements-across-diversified-pipeline-in-difficult-to-treat-blood-cancers-and-disorders-at-ash-1032775794,positive,0.5335714221000671
1675,11/3/2023 8:32:58 PM,"Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review",Benzinga,/news/stocks/regeneron-pharmaceuticals-stock-upgraded-after-q3-but-there-is-a-headwind---analyst-review-1032777467,negative,0.71695876121521
1676,11/6/2023 5:58:29 AM,"Positive Outlook for Regeneron: Eylea HD Success, Dupixent COPD Phase 3 Advancement & Future Obesity Research Developments Prompts Buy Rating",TipRanks,/news/stocks/positive-outlook-for-regeneron-eylea-hd-success-dupixent-copd-phase-3-advancement-future-obesity-research-developments-prompts-buy-rating-1032783280,negative,0.9292761087417603
1677,11/7/2023 2:40:18 AM,"Analysts’ Top Healthcare Picks: Lantheus (LNTH), Cytokinetics (CYTK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-lantheus-lnth-cytokinetics-cytk-1032788295,positive,0.5009598731994629
1678,11/8/2023 9:50:07 PM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1032799748,neutral,0.700346827507019
1679,11/9/2023 8:37:06 PM,3 Biotech Stocks That Are Betting on the Future of Gene Editing ,InvestorPlace,/news/stocks/3-gene-editing-stocks-that-may-define-the-future-of-biotech-1032802453,positive,0.8985041379928589
1680,11/9/2023 10:00:39 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032802499,positive,0.8993901014328003
1681,11/10/2023 3:01:38 AM,7 Underappreciated Biotech Stocks to Pick Up on the Cheap,InvestorPlace,/news/stocks/7-underappreciated-biotech-stocks-to-pick-up-on-the-cheap-1032803108,negative,0.8734825849533081
1682,11/13/2023 3:00:00 PM,Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF),GlobeNewswire,/news/stocks/regeneron-commits-34-million-over-five-years-to-continue-to-sponsor-the-regeneron-international-science-and-engineering-fair-isef-1032813300,negative,0.6935306787490845
1683,11/15/2023 10:05:00 PM,Regeneron Announces Investor Conference Presentation,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentation-1032824569,positive,0.9252042770385742
1684,11/21/2023 1:10:30 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032841067,negative,0.5521676540374756
1685,11/27/2023 7:30:00 AM,"Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This...",GlobeNewswire,/news/stocks/dupixent-dupilumab-significantly-reduced-copd-exacerbations-in-second-positive-phase-3-trial-accelerating-fda-submission-and-confirming-potential-to-become-first-approved-biologic-for-this-1032849954,negative,0.9500338435173035
1686,11/27/2023 8:57:19 AM,Sanofi Posts Positive NOTUS Trial Result Of Dupixent In COPD ,RTTNews,/news/stocks/sanofi-posts-positive-notus-trial-result-of-dupixent-in-copd-1032850120,negative,0.8291658759117126
1687,11/27/2023 10:10:04 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032853971,negative,0.5521676540374756
1688,11/28/2023 10:20:30 AM,"Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), Masimo (MASI) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-johnson-johnson-jnj-masimo-masi-and-regeneron-regn-1032856472,neutral,0.7661224007606506
1689,11/28/2023 12:51:22 PM,"Analysts’ Top Healthcare Picks: Merus (MRUS), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-merus-mrus-regeneron-regn-1032856657,negative,0.720369279384613
1690,11/28/2023 1:20:14 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-exact-sciences-exas-and-regeneron-regn-1032856675,positive,0.8951032757759094
1691,11/28/2023 8:00:16 PM,11 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/11-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1032856120,positive,0.9353305101394653
1692,11/29/2023 6:30:24 AM,"Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Regeneron (REGN) and Outlook Therapeutics (OTLK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-regeneron-regn-and-outlook-therapeutics-otlk-1032859833,positive,0.9135262370109558
1693,11/30/2023 2:30:21 AM,"Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-point-biopharma-global-pnt-regeneron-regn-and-incyte-incy-1032862831,positive,0.9139043092727661
1694,11/30/2023 10:05:00 PM,"Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio",GlobeNewswire,/news/stocks/regeneron-to-host-investor-call-and-webcast-on-december-14-2023-to-provide-updates-across-its-hematology-portfolio-1032864259,positive,0.9122748374938965
1695,12/2/2023 6:14:39 PM,GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places,InvestorPlace,/news/stocks/goog-stock-alert-alphabet-is-spending-money-in-all-the-wrong-places-1032868110,neutral,0.528497576713562
1696,12/5/2023 9:51:55 AM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), AbbVie (ABBV) and Taysha Gene Therapies (TSHA)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-abbvie-abbv-and-taysha-gene-therapies-tsha-1032876061,neutral,0.5786846280097961
1697,12/6/2023 10:50:15 AM,"Analysts’ Top Healthcare Picks: Sanofi (SNYNF), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-sanofi-snynf-regeneron-regn-1032879943,negative,0.73652583360672
1698,12/7/2023 8:02:26 AM,"Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Regeneron (REGN) and Arvinas Holding Company (ARVN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-argenx-se-argx-regeneron-regn-and-arvinas-holding-company-arvn-1032883436,positive,0.9275488257408142
1699,12/7/2023 8:30:59 AM,Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO,GlobeNewswire,/news/stocks/regeneron-to-share-progress-of-novel-combination-therapies-in-oncology-at-esmo-io-1032880636,negative,0.663053572177887
1700,12/7/2023 1:00:45 PM,Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma,GlobeNewswire,/news/stocks/updated-linvoseltamab-pivotal-data-demonstrated-strong-rates-and-depth-of-response-in-patients-with-heavily-pre-treated-multiple-myeloma-1032881517,negative,0.9509285688400269
1701,12/8/2023 10:41:01 AM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Cooper Co (COO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-cooper-co-coo-1032886919,positive,0.923312783241272
1702,12/8/2023 12:50:25 PM,"Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Regeneron (REGN) and PAVmed (PAVM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-rhythm-pharmaceuticals-rytm-regeneron-regn-and-pavmed-pavm-1032887057,positive,0.9064944386482239
1703,12/10/2023 6:30:00 PM,Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes,GlobeNewswire,/news/stocks/updated-odronextamab-data-from-relapsed-refractory-diffuse-large-b-cell-lymphoma-pivotal-trial-showed-deep-and-durable-responses-and-the-potential-of-ctdna-to-predict-long-term-outcomes-1032887779,negative,0.9251495003700256
1704,12/11/2023 1:30:00 AM,Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes,GlobeNewswire,/news/stocks/latest-odronextamab-data-in-relapsed-refractory-follicular-lymphoma-showed-compelling-responses-and-overall-maintenance-of-patient-reported-outcomes-1032887877,negative,0.9522942900657654
1705,12/11/2023 1:30:00 PM,Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year,GlobeNewswire,/news/stocks/regeneron-named-on-dow-jones-sustainability-world-index-for-fifth-consecutive-year-1032889265,positive,0.7589263319969177
1706,12/13/2023 10:20:00 AM,3 Gene-Editing Stocks With the Potential to Mint Millionaires,InvestorPlace,/news/stocks/3-gene-editing-stocks-with-the-potential-to-mint-millionaires-1032896336,positive,0.8445789217948914
1707,12/15/2023 10:26:05 AM,Regeneron Stock Assigned Sell Rating Amid Competitive Landscape and Commercial Execution Concerns,TipRanks,/news/stocks/regeneron-stock-assigned-sell-rating-amid-competitive-landscape-and-commercial-execution-concerns-1032906149,negative,0.8833010792732239
1708,12/15/2023 10:32:22 AM,"Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Bluebird Bio (BLUE) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-rxsight-rxst-bluebird-bio-blue-and-regeneron-regn-1032906173,positive,0.9076006412506104
1709,12/15/2023 1:51:19 PM,"Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Regeneron (REGN) and Teva Pharmaceutical (TEVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-moderna-mrna-regeneron-regn-and-teva-pharmaceutical-teva-1032906327,positive,0.9052451252937317
1710,12/16/2023 1:46:17 AM,RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-regeneron-regn-1032906522,positive,0.7852190136909485
1711,12/16/2023 6:00:00 PM,AI Meets Biotech: 3 Top Stocks Transforming Medical Science,InvestorPlace,/news/stocks/ai-meets-biotech-3-top-stocks-transforming-medical-science-1032906556,positive,0.8034080266952515
1712,12/18/2023 10:00:19 PM,14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know,Benzinga,/news/stocks/14-analysts-assess-regeneron-pharmaceuticals-what-you-need-to-know-1032910308,positive,0.9381551146507263
1713,12/18/2023 10:05:00 PM,Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference ,GlobeNewswire,/news/stocks/regeneron-announces-presentation-at-the-42nd-annual-j-p-morgan-healthcare-conference-1032910326,positive,0.8923803567886353
1714,12/22/2023 1:15:47 AM,7 Undervalued Nasdaq-100 Stocks for Bargain Hunters,InvestorPlace,/news/stocks/7-undervalued-nasdaq-100-stocks-for-bargain-hunters-1032920844,negative,0.8517463803291321
1715,12/22/2023 1:00:18 PM,Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ionis-pharmaceuticals-ions-and-regeneron-regn-1032923499,positive,0.8924517035484314
1716,12/28/2023 8:18:25 AM,Biotech Stocks Facing FDA Decision In January 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2024-1032929267,positive,0.9060015678405762
1717,12/28/2023 10:31:27 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Canopy Growth (CGC),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-canopy-growth-cgc-1032931051,neutral,0.9212521314620972
1718,12/28/2023 10:40:44 AM,Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-coherus-biosciences-chrs-and-regeneron-regn-1032931047,positive,0.8894457221031189
1719,1/5/2024 5:00:51 AM,"Analysts Offer Insights on Healthcare Companies: Cigna (CI), Agios Pharma (AGIO) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cigna-ci-agios-pharma-agio-and-regeneron-regn-1032946766,positive,0.9192553758621216
1720,1/5/2024 10:55:41 AM,Eylea HD Launch Poised to Outperform and Drive Regeneron’s Stock Growth,TipRanks,/news/stocks/eylea-hd-launch-poised-to-outperform-and-drive-regeneron-s-stock-growth-1032947187,negative,0.9511504769325256
1721,1/5/2024 10:05:00 PM,"Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024",GlobeNewswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-2-2024-1032947034,positive,0.9484987258911133
1722,1/6/2024 1:50:27 AM,"Analysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-innate-pharma-sa-otheriphyf-amgen-amgn-and-regeneron-regn-1032947412,neutral,0.6982296705245972
1723,1/9/2024 10:18:37 AM,Regeneron Sell Rating Justified by Underperforming Sales and Competitive Pressures,TipRanks,/news/stocks/regeneron-sell-rating-justified-by-underperforming-sales-and-competitive-pressures-1032955184,neutral,0.9653578400611877
1724,1/9/2024 10:30:16 AM,Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ptc-therapeutics-ptct-and-regeneron-regn-1032955211,positive,0.9045701026916504
1725,1/9/2024 1:30:34 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Dexcom (DXCM)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-dexcom-dxcm-1032955405,negative,0.6304595470428467
1726,1/9/2024 2:30:20 PM,Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-and-regeneron-regn-1032955456,positive,0.8938033580780029
1727,1/9/2024 7:00:57 PM,Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock,Benzinga,/news/stocks/beyond-the-numbers-13-analysts-discuss-regeneron-pharmaceuticals-stock-1032954730,positive,0.9488558769226074
1728,1/11/2024 6:34:48 AM,Positive Outlook for Regeneron: Buy Rating Affirmed Amidst Eylea’s Resilience and Promising Pipeline Developments,TipRanks,/news/stocks/positive-outlook-for-regeneron-buy-rating-affirmed-amidst-eylea-s-resilience-and-promising-pipeline-developments-1032959790,negative,0.955269455909729
1729,1/12/2024 4:18:11 PM,Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish,Benzinga,/news/stocks/regeneron-pharma-s-pipeline-makes-this-analyst-turn-bullish-1032964340,negative,0.5331723093986511
1730,1/15/2024 5:30:44 AM,"Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Regeneron (REGN) and Pediatrix Medical Group (MD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ptc-therapeutics-ptct-regeneron-regn-and-pediatrix-medical-group-md-1032966647,positive,0.9134497046470642
1731,1/16/2024 1:00:00 PM,Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement,GlobeNewswire,/news/stocks/dupixent-dupilumab-u-s-label-updated-with-data-further-supporting-use-in-atopic-dermatitis-with-moderate-to-severe-hand-and-foot-involvement-1032970179,negative,0.9363212585449219
1732,1/16/2024 6:51:12 PM,Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market,InvestorPlace,/news/stocks/healthcare-heroes-3-biotech-stocks-poised-to-cure-what-ails-the-market-1032971697,negative,0.5010337829589844
1733,1/18/2024 9:54:53 PM,EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker,Benzinga,/news/etf/exclusive-the-buy-everything-market-is-over-synopsys-ansys-merger-provides-fertile-ground-for-this-stock-picker-1032978230,positive,0.5151099562644958
1734,1/22/2024 8:37:34 PM,"Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades",Benzinga,/news/stocks/aclaris-therapeutics-ati-1777-faces-uphill-battle-in-atopic-dermatitis-treatment-landscape-analyst-downgrades-1032984777,neutral,0.8216086626052856
1735,1/22/2024 9:00:31 PM,"Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Regeneron (REGN) and Warby Parker (WRBY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-agenus-agen-regeneron-regn-and-warby-parker-wrby-1032987227,positive,0.9168835282325745
1736,1/23/2024 10:55:47 PM,3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024,InvestorPlace,/news/stocks/3-blue-chip-healthcare-stocks-to-buy-and-hold-forever-january-2024-1032989675,positive,0.9358213543891907
1737,1/24/2024 6:00:00 PM,Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards,GlobeNewswire,/news/stocks/top-40-high-school-scientists-in-prestigious-regeneron-science-talent-search-to-compete-for-1-8-million-in-awards-1032993529,negative,0.718612790107727
1738,1/24/2024 8:55:14 PM,"Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts",Benzinga,/news/stocks/slow-market-penetration-for-biogen-s-another-alzheimer-s-drug-ubs-highlights-risks-forecasts-1032993934,neutral,0.8969920873641968
1739,1/25/2024 7:56:31 PM,Regeneron/ Sanofi win label expansion for Dupixent in esophageal disorder,Seeking Alpha,https://seekingalpha.com/news/4058699-regeneron-sanofi-win-label-expansion-dupixent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8877559900283813
1740,1/25/2024 8:29:00 PM,Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE),GlobeNewswire,/news/stocks/dupixent-dupilumab-fda-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year-and-older-with-eosinophilic-esophagitis-eoe-1032998309,negative,0.8532045483589172
1741,1/25/2024 11:04:47 PM,Regeneron Receives FDA Approval For Dupixent For Patients Aged 1 To 11 Years ,RTTNews,/news/stocks/regeneron-receives-fda-approval-for-dupixent-for-patients-aged-1-to-11-years-1032998682,negative,0.9000272154808044
1742,1/26/2024 8:00:55 PM,"Catalyst watch: Apple earnings, Boeing on the hot seat, FOMC meeting and Amer Sports IPO",Seeking Alpha,https://seekingalpha.com/news/4059230-catalyst-watch-apple-earnings-boeing-on-the-hot-seat-fomc-meeting-and-amer-sports-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9197294116020203
1743,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8954368233680725
1744,1/29/2024 12:20:49 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-regeneron-regn-1033006315,positive,0.9210485219955444
1745,1/29/2024 3:04:30 PM,"AI, Biotech, Energy Sectors Expect M&A Revival For 2024",Benzinga,/news/stocks/ai-biotech-energy-sectors-expect-m-a-revival-for-2024-1033005691,negative,0.905494213104248
1746,1/29/2024 9:00:27 PM,Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views,Benzinga,/news/stocks/breaking-down-regeneron-pharmaceuticals-14-analysts-share-their-views-1033006998,positive,0.8651591539382935
1747,1/30/2024 12:24:33 PM,2seventy stock rises as Regeneron acquires R&D assets,Seeking Alpha,https://seekingalpha.com/news/4059942-2seventy-stock-rises-as-regeneron-acquires-rd-assets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9116825461387634
1748,1/30/2024 12:25:34 PM,Piper Sandler Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-regeneron-regn-1033010906,positive,0.7703537344932556
1749,1/30/2024 1:00:41 PM,Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs,GlobeNewswire,/news/stocks/regeneron-announces-formation-of-regeneron-cell-medicines-with-the-acquisition-of-2seventy-bio-platforms-and-preclinical-and-clinical-programs-1033009547,positive,0.7629015445709229
1750,1/30/2024 1:20:20 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033011102,negative,0.5521676540374756
1751,1/30/2024 1:32:55 PM,Regeneron Announces Formation Of Regeneron Cell Medicines With Acquisition Of 2seventy Bio ,RTTNews,/news/stocks/regeneron-announces-formation-of-regeneron-cell-medicines-with-acquisition-of-2seventy-bio-1033009635,positive,0.8204025626182556
1752,1/31/2024 8:47:11 PM,"Leerink ups 2seventy to outperform, cites attractiveness as takeover target",Seeking Alpha,https://seekingalpha.com/news/4060882-leerink-ups-2seventy-to-outperform-cites-attractiveness-as-takeover-target?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9118279218673706
1753,2/1/2024 3:00:02 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4061340-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8830810189247131
1754,2/1/2024 3:01:13 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q4-1033020713,positive,0.9262580871582031
1755,2/1/2024 4:33:16 PM,Regeneron Pharmaceuticals Q4 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4061447-regeneron-pharmaceuticals-q4-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9071698784828186
1756,2/1/2024 10:00:00 PM,3 Top Pharma Stocks to Buy Now: February 2024,InvestorPlace,/news/stocks/3-top-pharma-stocks-to-buy-now-february-2024-1033022674,positive,0.9278583526611328
1757,2/2/2024 1:20:17 AM,"Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Sarepta Therapeutics (SRPT) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-quest-diagnostics-dgx-sarepta-therapeutics-srpt-and-regeneron-regn-1033022899,positive,0.90428227186203
1758,2/2/2024 8:41:39 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033024513,negative,0.5521676540374756
1759,2/2/2024 11:32:56 AM,Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4061930-regeneron-pharmaceuticals-beats-top-line-and-bottom-line-estimates-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7683674097061157
1760,2/2/2024 12:00:04 PM,Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma,GlobeNewswire,/news/stocks/linvoseltamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-multiple-myeloma-1033024336,negative,0.9447929859161377
1761,2/2/2024 12:13:00 PM,"Regeneron posts Q4 beat even as Eylea, COVID-19 sales dip",Seeking Alpha,https://seekingalpha.com/news/4061949-regeneron-posts-q4-beat-even-eylea-covid-19-sales-dip?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9430530667304993
1762,2/2/2024 12:17:52 PM,Regeneron multiple myeloma therapy accepted for EU review,Seeking Alpha,https://seekingalpha.com/news/4061953-regeneron-multiple-myeloma-therapy-undergoes-eu-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5869776606559753
1763,2/2/2024 12:20:11 PM,Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-nurix-therapeutics-nrix-and-regeneron-regn-1033025736,positive,0.9058679342269897
1764,2/2/2024 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-1033024473,positive,0.6264238953590393
1765,2/2/2024 12:38:11 PM,Regeneron Pharmaceuticals: EMA To Review Marketing Authorization Application For Linvoseltamab ,RTTNews,/news/stocks/regeneron-pharmaceuticals-ema-to-review-marketing-authorization-application-for-linvoseltamab-1033024508,positive,0.8412551879882812
1766,2/2/2024 12:40:40 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), MoonLake Immunotherapeutics (MLTX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-moonlake-immunotherapeutics-mltx-1033025789,positive,0.6056076884269714
1767,2/2/2024 12:44:48 PM,"Regeneron Pharmaceuticals Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-decreases-but-beats-estimates-1033024554,neutral,0.9664634466171265
1768,2/2/2024 12:59:52 PM,Regeneron Pharma Q4 Results Top Estimates - Update ,RTTNews,/news/stocks/regeneron-pharma-q4-results-top-estimates-update-1033024580,positive,0.9215725064277649
1769,2/2/2024 8:15:19 PM,Strong Buy for Regeneron: Outperforming Earnings and Eylea HD’s Market Dominance,TipRanks,/news/stocks/strong-buy-for-regeneron-outperforming-earnings-and-eylea-hd-s-market-dominance-1033026653,negative,0.9519480466842651
1770,2/5/2024 1:10:32 PM,"Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-4d-molecular-therapeutics-fdmt-boston-scientific-bsx-1033031034,positive,0.5134048461914062
1771,2/5/2024 1:20:36 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Arcellx Inc (ACLX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-arcellx-inc-aclx-1033031080,positive,0.5714526772499084
1772,2/6/2024 12:25:48 PM,Strong Buy: Regeneron’s Growth Potential and Strategic R&D Investments,TipRanks,/news/stocks/strong-buy-regeneron-s-growth-potential-and-strategic-r-d-investments-1033035958,negative,0.8487105369567871
1773,2/6/2024 12:50:37 PM,"Analysts’ Top Healthcare Picks: Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX)",TipRanks,/news/stocks/analysts-top-healthcare-picks-intuitive-surgical-isrg-vertex-pharmaceuticals-vrtx-1033036025,negative,0.8120447397232056
1774,2/6/2024 6:00:25 PM,Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/cantor-fitzgerald-maintains-neutral-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1033036264,positive,0.9209615588188171
1775,2/6/2024 8:05:37 PM,"4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast",Benzinga,/news/stocks/4d-molecular-therapeutics-4d-150-phase-2-data-met-investor-expectations-analyst-boosts-forecast-1033036575,negative,0.9379086494445801
1776,2/6/2024 8:27:22 PM,Veru eyes better weight loss drugs as FDA clears Phase 2 trial,Seeking Alpha,https://seekingalpha.com/news/4063394-veru-eyes-better-weight-loss-drugs-fda-clears-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8812427520751953
1777,2/6/2024 9:31:15 PM,The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition,InvestorPlace,/news/stocks/the-top-25-stocks-to-buy-immediately-according-to-ai-february-2024-edition-1033036939,positive,0.9487829208374023
1778,2/6/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1033036732,positive,0.9291732907295227
1779,2/7/2024 1:25:41 PM,Buy Rating Affirmed for Regeneron on Strong Drug Pipeline and Market Growth Potential,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-drug-pipeline-and-market-growth-potential-1033042014,negative,0.9546648859977722
1780,2/9/2024 3:02:33 PM,Ocular Therapeutix spikes as BofA starts at Buy on wet AMD prospects,Seeking Alpha,https://seekingalpha.com/news/4065169-ocular-therapeutix-stock-spikes-bofa-starts-at-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5037370920181274
1781,2/11/2024 5:17:08 PM,"After Meta debuts a dividend, Goldman does the math if big names follow suit",Seeking Alpha,https://seekingalpha.com/news/4065357-after-meta-debuts-a-dividend-goldman-does-the-math-if-big-names-follow-suit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.933788537979126
1782,2/15/2024 8:20:40 AM,"Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Regeneron (REGN) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-health-catalyst-hcat-regeneron-regn-and-merck-company-mrk-1033071011,positive,0.9122521281242371
1783,2/16/2024 6:59:00 AM,Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU) ,GlobeNewswire,/news/stocks/japan-first-in-the-world-to-approve-dupixent-dupilumab-for-chronic-spontaneous-urticaria-csu-1033074497,negative,0.769873857498169
1784,2/16/2024 7:35:52 AM,Sanofi's Dupixent Approved In Japan For Chronic Spontaneous Urticaria Treatment ,RTTNews,/news/stocks/sanofi-s-dupixent-approved-in-japan-for-chronic-spontaneous-urticaria-treatment-1033074564,negative,0.7124053835868835
1785,2/16/2024 11:17:43 AM,"Sanofi, Regeneron win Japan approval for Dupixent in CSU indication",Seeking Alpha,https://seekingalpha.com/news/4068079-sanofi-regeneron-win-japan-approval-for-dupixent-in-csu-indication?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8846317529678345
1786,2/21/2024 12:13:01 PM,"Regeneron, Vertex Pharma join $100B club in biotech",Seeking Alpha,https://seekingalpha.com/news/4069456-regeneron-vertex-pharma-join-100b-club-biotech?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6630005836486816
1787,2/21/2024 1:00:13 PM,Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review,GlobeNewswire,/news/stocks/linvoseltamab-bla-for-treatment-of-relapsed-refractory-multiple-myeloma-accepted-for-fda-priority-review-1033087202,negative,0.8369846343994141
1788,2/21/2024 1:14:13 PM,Regeneron multiple myeloma therapy granted FDA priority review,Seeking Alpha,https://seekingalpha.com/news/4069510-regeneron-wins-fda-priority-review-multiple-myeloma-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8737877607345581
1789,2/21/2024 1:50:22 PM,Regeneron: Linvoseltamab BLA To Treat RR/MM Accepted For FDA Priority Review ,RTTNews,/news/stocks/regeneron-linvoseltamab-bla-to-treat-rr-mm-accepted-for-fda-priority-review-1033087414,negative,0.8128006458282471
1790,2/23/2024 7:00:00 AM,Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation,GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-copd-with-type-2-inflammation-1033095932,negative,0.8392983078956604
1791,2/23/2024 7:36:15 AM,Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation ,RTTNews,/news/stocks/sanofi-dupixent-sbla-accepted-for-fda-priority-review-for-copd-with-type-2-inflammation-1033096002,negative,0.7077124118804932
1792,2/23/2024 10:40:38 AM,"Sanofi, Regeneron win FDA priority review for Dupixent label expansion",Seeking Alpha,https://seekingalpha.com/news/4070961-sanofi-regeneron-win-fda-priority-review-for-dupixent-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8607845306396484
1793,2/23/2024 12:25:57 PM,Buy Rating Affirmed: Regeneron’s Strategic Growth in Obesity Metabolic Space,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-strategic-growth-in-obesity-metabolic-space-1033098082,negative,0.8839504718780518
1794,2/27/2024 5:30:17 AM,"Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-korro-bio-krro-relay-therapeutics-rlay-and-regeneron-regn-1033106016,positive,0.8982660174369812
1795,2/27/2024 12:47:34 PM,Truist Financial Gives a Buy Rating to Regeneron (REGN),TipRanks,/news/stocks/truist-financial-gives-a-buy-rating-to-regeneron-regn-1033108491,positive,0.8449375629425049
1796,2/27/2024 12:51:09 PM,"Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Boston Scientific (BSX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-ani-pharmaceuticals-anip-boston-scientific-bsx-1033108458,negative,0.4891894459724426
1797,2/27/2024 4:00:23 PM,The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts,Benzinga,/news/stocks/the-analyst-verdict-regeneron-pharmaceuticals-in-the-eyes-of-10-experts-1033108205,positive,0.9020076394081116
1798,2/28/2024 9:52:49 AM,Biotech Stocks Facing FDA Decision In March 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2024-1033111344,positive,0.9174318909645081
1799,3/4/2024 9:09:21 PM,Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits,InvestorPlace,/news/stocks/biotechs-on-the-rise-3-stocks-to-buy-for-a-shot-of-profits-1033130269,positive,0.7510855793952942
1800,3/8/2024 12:30:38 PM,"Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-amgen-amgn-regeneron-regn-1033146997,negative,0.5736474990844727
1801,3/8/2024 1:00:26 PM,EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-pivotal-data-in-wet-age-related-macular-degeneration-wamd-and-diabetic-macular-edema-dme-published-in-the-lancet-1033145992,negative,0.7114400267601013
1802,3/11/2024 11:52:45 AM,Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol,Seeking Alpha,https://seekingalpha.com/news/4077906-regenerons-praluent-injection-gets-fda-approval-to-treat-kids-with-genetic-form-of-high-cholesterol?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9129544496536255
1803,3/11/2024 12:00:23 PM,Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol,GlobeNewswire,/news/stocks/praluent-alirocumab-injection-receives-fda-approval-to-treat-children-with-genetic-form-of-high-cholesterol-1033150190,negative,0.9433882236480713
1804,3/11/2024 12:33:30 PM,Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8 ,RTTNews,/news/stocks/regeneron-announces-fda-approval-extending-treatment-of-praluent-to-children-aged-8-1033150359,negative,0.8558627963066101
1805,3/13/2024 2:30:22 AM,"High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization",GlobeNewswire,/news/stocks/high-school-seniors-win-1-8-million-at-regeneron-science-talent-search-2024-for-innovative-scientific-research-on-artificial-intelligence-cancer-metabolism-and-mathematical-optimization-1033157063,negative,0.8060268759727478
1806,3/13/2024 9:01:16 AM,"Analysts’ Top Healthcare Picks: Cooper Co (COO), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-cooper-co-coo-regeneron-regn-1033159157,positive,0.5641502141952515
1807,3/13/2024 1:51:49 PM,NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday,Benzinga,/news/stocks/nvidia-to-rally-around-20-here-are-10-top-analyst-forecasts-for-wednesday-1033159347,positive,0.9203643202781677
1808,3/13/2024 2:55:32 PM,The 3 Most Undervalued Biotech Stocks to Buy in March 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-march-2024-1033160441,positive,0.7386067509651184
1809,3/15/2024 9:20:45 AM,"Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-89bio-etnb-intuitive-surgical-isrg-1033167884,positive,0.7916487455368042
1810,3/19/2024 5:36:55 AM,Buy Rating Affirmed for Regeneron on Eylea HD Success and Innovative Obesity Program,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-eylea-hd-success-and-innovative-obesity-program-1033175060,negative,0.8505319952964783
1811,3/22/2024 4:40:30 PM,Intellia opts out of hemophilia pact with Regeneron,Seeking Alpha,https://seekingalpha.com/news/4082899-intellia-opts-out-of-hemophilia-pact-with-regeneron?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8135582208633423
1812,3/22/2024 9:07:27 PM,Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs,InvestorPlace,/news/stocks/hot-stocks-the-3-best-opportunities-for-investing-in-weight-loss-drugs-1033190216,positive,0.8771572113037109
1813,3/25/2024 12:00:02 PM,Regeneron Provides Update on Biologics License Application for Odronextamab,GlobeNewswire,/news/stocks/regeneron-provides-update-on-biologics-license-application-for-odronextamab-1033192564,positive,0.9330943822860718
1814,3/25/2024 12:45:53 PM,Regeneron Says FDA Rejects BLA Approval For Odronextamab In Follicular Lyphoma ,RTTNews,/news/stocks/regeneron-says-fda-rejects-bla-approval-for-odronextamab-in-follicular-lyphoma-1033192791,neutral,0.7991584539413452
1815,3/25/2024 2:29:37 PM,FDA declines to approve Regeneron lymphoma drug odronextamab,Seeking Alpha,https://seekingalpha.com/news/4083333-fda-declines-to-approve-regeneron-lymphoma-drug-odronextamab?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.828635036945343
1816,3/25/2024 4:31:04 PM,Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alphatec-holdings-atec-and-regeneron-regn-1033194555,positive,0.912375271320343
1817,3/25/2024 4:40:14 PM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Alphatec Holdings (ATEC),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-alphatec-holdings-atec-1033194548,positive,0.9070879817008972
1818,3/26/2024 8:51:41 AM,"Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Regeneron (REGN) and Intuitive Surgical (ISRG)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-regeneron-regn-and-intuitive-surgical-isrg-1033196448,positive,0.917143702507019
1819,3/26/2024 10:44:00 AM,3 Biotech Stocks to Buy for the Next Bull Run: March 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-for-the-next-bull-run-march-2024-1033196128,positive,0.9301541447639465
1820,3/26/2024 12:45:34 PM,Truist Financial Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-regeneron-regn-1033197883,positive,0.9126016497612
1821,3/26/2024 3:01:15 PM,Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals,Benzinga,/news/stocks/decoding-12-analyst-evaluations-for-regeneron-pharmaceuticals-1033197081,positive,0.895366370677948
1822,3/28/2024 5:11:15 PM,Xeris gains as Oppenheimer highlights drug technology,Seeking Alpha,https://seekingalpha.com/news/4085090-xeris-stock-gains-oppenheimer-bullish-view?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7335243821144104
1823,4/1/2024 1:35:02 AM,Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval,Seeking Alpha,https://seekingalpha.com/news/4085383-sanofi-regeneron-dupixent-set-large-gains-likely-copd-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9456407427787781
1824,4/1/2024 10:05:00 PM,"Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 ",GlobeNewswire,/news/stocks/regeneron-to-report-first-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-2-2024-1033212450,positive,0.9494706988334656
1825,4/2/2024 3:36:00 PM,Biotech Roundtable: Who will bring the next CRISPR drug to market?,Seeking Alpha,https://seekingalpha.com/news/4083199-biotech-roundtable-who-will-bring-the-next-crispr-drug-to-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8740511536598206
1826,4/2/2024 8:30:04 PM,5 Healthcare Stocks to Buy for 2024,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-2024-1033216722,positive,0.9175675511360168
1827,4/3/2024 11:03:07 PM,"LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?",TipRanks,/news/stocks/lly-regn-bhvn-which-biotech-stock-offers-the-most-upside-1033220670,positive,0.889915406703949
1828,4/7/2024 12:00:00 PM,"Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",Seeking Alpha,https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9427610635757446
1829,4/7/2024 10:00:12 PM,Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma,GlobeNewswire,/news/stocks/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma-1033227781,negative,0.9274027347564697
1830,4/9/2024 9:50:10 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Veeva Systems (VEEV) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-veeva-systems-veev-and-ultragenyx-pharmaceutical-rare-1033233297,positive,0.8993425965309143
1831,4/9/2024 10:45:55 AM,Regeneron (REGN) Receives a Buy from RBC Capital,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-rbc-capital-1033233582,positive,0.6781207919120789
1832,4/10/2024 9:09:55 PM,DOJ files complaint against Regeneron over Eylea Medicare pricing,Seeking Alpha,https://seekingalpha.com/news/4088761-doj-sues-regeneron-over-eylea-medicare-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9212681651115417
1833,4/11/2024 12:55:34 PM,DOJ files complaint against Regeneron over Eylea Medicare pricing,Seeking Alpha,https://seekingalpha.com/news/4088761-doj-files-complaint-regeneron-over-eylea-medicare-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9212681651115417
1834,4/11/2024 5:15:17 PM,Regeneron hits three-month low after DOJ complaint; RBC defends,Seeking Alpha,https://seekingalpha.com/news/4089001-regeneron-stock-defended-rbc-doj-suit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8879175186157227
1835,4/12/2024 9:20:20 AM,"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Instil Bio (TIL) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-teladoc-tdoc-instil-bio-til-and-regeneron-regn-1033244090,positive,0.9089381098747253
1836,4/12/2024 12:33:13 PM,"Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-biomarin-pharmaceutical-bmrn-regeneron-regn-1033245004,positive,0.4964694380760193
1837,4/12/2024 4:01:51 PM,Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views,Benzinga,/news/stocks/breaking-down-regeneron-pharmaceuticals-13-analysts-share-their-views-1033244707,positive,0.8593931794166565
1838,4/16/2024 12:37:08 PM,Regeneron to 'vigorously defend' against DOJ on Eylea pricing complaint,Seeking Alpha,https://seekingalpha.com/news/4090005-regeneron-defend-in-eylea-pricing-lawsuit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8428987860679626
1839,4/17/2024 10:55:10 AM,Cantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/cantor-fitzgerald-reaffirms-their-hold-rating-on-regeneron-regn-1033258113,positive,0.8484218120574951
1840,4/17/2024 1:00:30 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033258919,negative,0.5521676540374756
1841,4/17/2024 8:39:46 PM,Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick,Benzinga,/news/stocks/amgen-astrazeneca-s-asthma-drug-tezspire-vs-sanofi-regeneron-s-blockbuster-dupixent---analyst-gives-his-pick-1033259296,positive,0.8432722091674805
1842,4/22/2024 12:29:48 PM,Regeneron (REGN) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-piper-sandler-1033271987,negative,0.7262669205665588
1843,4/22/2024 11:54:01 PM,Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT),GlobeNewswire,/news/stocks/regeneron-to-highlight-advances-in-genetic-medicine-research-at-american-society-of-gene-and-cell-therapy-asgct-1033272918,positive,0.7174474000930786
1844,4/24/2024 4:05:18 PM,Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO,GlobeNewswire,/news/stocks/regeneron-to-showcase-progress-in-advancing-novel-investigational-treatment-approaches-for-a-broad-range-of-solid-tumors-and-blood-cancers-at-asco-1033282725,negative,0.846372127532959
1845,4/25/2024 9:44:05 AM,Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-regeneron-regn-1033287880,positive,0.8186876177787781
1846,4/25/2024 12:19:01 PM,"Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies",Seeking Alpha,https://seekingalpha.com/news/4094054-regeneron-mammoth-pact-develop-crispr-based-gene-editing-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5427090525627136
1847,4/25/2024 1:00:00 PM,Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases,GlobeNewswire,/news/stocks/regeneron-and-mammoth-biosciences-collaborate-to-pursue-next-generation-crispr-based-gene-editing-for-multiple-diseases-1033287218,negative,0.619365394115448
1848,4/25/2024 3:24:05 PM,AbbVie reports positive results from Rinvoq versus Dupixent study,Seeking Alpha,https://seekingalpha.com/news/4094231-abbvie-reports-positive-results-from-rinoq-versus-dupixent-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9530646204948425
1849,4/26/2024 8:48:18 AM,Barclays Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/barclays-sticks-to-their-buy-rating-for-regeneron-regn-1033293611,positive,0.8560619354248047
1850,4/26/2024 12:21:27 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-gilead-sciences-gild-1033295043,negative,0.511370062828064
1851,4/29/2024 1:00:18 PM,EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-presentations-at-arvo-reinforce-sustained-and-clinically-meaningful-outcomes-in-serious-retinal-diseases-1033299551,negative,0.9473004341125488
1852,4/30/2024 11:20:27 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-docgo-dcgo-and-revvity-rvty-1033307295,positive,0.90546715259552
1853,5/1/2024 3:01:13 PM,Regeneron Pharmaceuticals earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-q1-quarterly-earnings-preview-1033313159,positive,0.9300113916397095
1854,5/1/2024 3:30:13 PM,Regeneron Pharmaceuticals Q1 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4097429-regeneron-pharmaceuticals-q1-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8994348645210266
1855,5/1/2024 5:18:37 PM,Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy,Seeking Alpha,https://seekingalpha.com/news/4097663-adverum-biotechnologies-new-buy-hc-wainwright-wet-amd-gene-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5101459622383118
1856,5/2/2024 10:32:10 AM,Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4098262-regeneron-pharmaceuticals-misses-top-line-and-bottom-line-estimates-updates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8047283291816711
1857,5/2/2024 11:55:40 AM,Regeneron falls after Q1 miss; announces $3B share buybacks,Seeking Alpha,https://seekingalpha.com/news/4098419-regeneron-stock-falls-despite-3b-buybacks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9192521572113037
1858,5/2/2024 12:30:00 PM,Regeneron Reports First Quarter 2024 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-first-quarter-2024-financial-and-operating-results-1033318764,negative,0.490291029214859
1859,5/2/2024 1:11:00 PM,"4 stocks to watch on Thursday: NVO, AAPL and more",Seeking Alpha,https://seekingalpha.com/news/4098511-4-stocks-to-watch-on-thursday-nvo-aapl-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9250748157501221
1860,5/2/2024 1:31:02 PM,"Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-profit-decreases-misses-estimates-1033319178,neutral,0.97112637758255
1861,5/2/2024 2:53:50 PM,"REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024",InvestorPlace,/news/stocks/regn-stock-earnings-regeneron-pharmaceuticals-for-q1-of-2024-1033320985,neutral,0.9565255045890808
1862,5/2/2024 7:42:06 PM,"Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?",Benzinga,/news/etf/wall-street-inches-up-after-powell-s-inflation-remarks-chipmakers-rebound-gold-crude-falter-what-s-driving-markets-thursday-1033321858,neutral,0.7604994177818298
1863,5/3/2024 10:15:00 AM,Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar,InvestorPlace,/news/stocks/shhh-3-secret-pharma-stocks-flying-below-wall-streets-radar-1033325813,positive,0.7317017316818237
1864,5/3/2024 10:36:35 AM,Buy Rating Affirmed: Regeneron’s Promising Pipeline and Potential for Surpassing Earnings Expectations,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-promising-pipeline-and-potential-for-surpassing-earnings-expectations-1033326637,negative,0.9544216990470886
1865,5/3/2024 10:47:50 AM,Buy Rating Affirmed for Regeneron on Strong Product Performance and Promising Pipeline Developments,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-product-performance-and-promising-pipeline-developments-1033326775,negative,0.9550155401229858
1866,5/3/2024 11:30:30 AM,Truist Financial Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-regeneron-regn-1033327379,positive,0.8969982862472534
1867,5/3/2024 12:08:35 PM,Regeneron (REGN) Receives a Buy from Oppenheimer,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-oppenheimer-1033327530,positive,0.5793201327323914
1868,5/3/2024 12:23:24 PM,"Analysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-elevation-oncology-elev-moderna-mrna-1033327573,positive,0.687083899974823
1869,5/3/2024 6:00:22 PM,Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts,Benzinga,/news/stocks/assessing-regeneron-pharmaceuticals-insights-from-16-financial-analysts-1033327843,positive,0.8024248480796814
1870,5/3/2024 7:00:00 PM,"Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit",Seeking Alpha,https://seekingalpha.com/news/4098577-catalyst-watch-disney-earnings-apple-ipad-event-and-fed-speakers-back-on-the-circuit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9189660549163818
1871,5/4/2024 4:00:00 PM,3 Biotech Stocks With the Potential to Make You an Overnight Millionaire,InvestorPlace,/news/stocks/3-biotech-stocks-with-the-potential-to-make-you-an-overnight-millionaire-1033328809,positive,0.8275285363197327
1872,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9528807997703552
1873,5/6/2024 5:15:24 AM,Buy Rating Affirmed for Regeneron on Strong Product Sales and Promising Pipeline,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-product-sales-and-promising-pipeline-1033331854,negative,0.9550231099128723
1874,5/6/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1033335104,positive,0.9291732907295227
1875,5/8/2024 6:31:56 AM,"Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Tilray (TLRY) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-siemens-healthineers-ag-othersemhf-tilray-tlry-and-regeneron-regn-1033346049,positive,0.9038944840431213
1876,5/8/2024 12:00:57 PM,Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks,GlobeNewswire,/news/stocks/latest-db-oto-results-show-dramatically-improved-hearing-to-normal-levels-in-a-child-with-profound-genetic-deafness-within-24-weeks-and-initial-hearing-improvements-in-a-second-child-at-6-weeks-1033346146,negative,0.9514350891113281
1877,5/8/2024 12:15:41 PM,Regeneron gene therapy improves hearing in child deafness,Seeking Alpha,https://seekingalpha.com/news/4102362-regeneron-therapy-improves-hearing-deaf-child?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7321155071258545
1878,5/13/2024 7:00:00 AM,Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP),GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-adolescents-with-chronic-rhinosinusitis-with-nasal-polyposis-crswnp-1033366922,negative,0.8081113696098328
1879,5/13/2024 7:56:16 AM,Regeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic Rhinosinusitis ,RTTNews,/news/stocks/regeneron-dupixent-sbla-accepted-for-fda-priority-review-for-adolescent-chronic-rhinosinusitis-1033367087,negative,0.5487655997276306
1880,5/14/2024 3:24:32 PM,Evercore says biotech ‘winter is finally thawing’,Seeking Alpha,https://seekingalpha.com/news/4105937-evercore-says-biotech-winter-is-finally-thawing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6407400965690613
1881,5/15/2024 12:21:04 PM,"Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-taysha-gene-therapies-tsha-biogen-biib-1033385532,positive,0.5026509761810303
1882,5/17/2024 6:08:34 PM,Regeneron wins temporary restraining order preventing Eylea generic launch (update),Seeking Alpha,https://seekingalpha.com/news/4107951-regeneron-wins-temporary-restraining-order-preventing-eylea-generics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6379203796386719
1883,5/17/2024 7:45:49 PM,More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024,GlobeNewswire,/news/stocks/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024-1033400511,negative,0.9084649085998535
1884,5/18/2024 6:52:07 PM,"Novo Nordisk, J&J lead R&D rankings in big pharma: report",Seeking Alpha,https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8400077223777771
1885,5/20/2024 10:32:04 AM,"Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Corbus Pharmaceuticals (CRBP)",TipRanks,/news/stocks/analysts-top-healthcare-picks-praxis-precision-medicines-prax-corbus-pharmaceuticals-crbp-1033403502,negative,0.7943565845489502
1886,5/20/2024 4:16:50 PM,Regeneron Eylea generics approved by FDA,Seeking Alpha,https://seekingalpha.com/news/4108410-regeneron-eylea-generics-approved-by-fda?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8201985955238342
1887,5/20/2024 5:34:36 PM,7 Biotech Stocks That Could Breathe New Life Into Your Portfolio,InvestorPlace,/news/stocks/7-biotech-stocks-that-could-breathe-new-life-into-your-portfolio-1033404432,positive,0.8768113255500793
1888,5/20/2024 8:15:00 PM,Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine,GlobeNewswire,/news/stocks/dupixent-dupilumab-late-breaking-data-from-notus-confirmatory-phase-3-copd-trial-presented-at-ats-and-published-in-the-new-england-journal-of-medicine-1033404505,positive,0.8167158961296082
1889,5/21/2024 12:11:09 PM,"Analysts Are Bullish on Top Healthcare Stocks: Progyny (PGNY), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-progyny-pgny-regeneron-regn-1033408140,positive,0.6691092252731323
1890,5/22/2024 9:16:57 AM,Wells Fargo Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/wells-fargo-remains-a-buy-on-regeneron-regn-1033411351,positive,0.9380198121070862
1891,5/23/2024 11:03:17 PM,Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO,GlobeNewswire,/news/stocks/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco-1033417552,negative,0.8618432879447937
1892,5/24/2024 5:42:55 PM,Sensei stock plunges 46% in wake of Phase 1 data,Seeking Alpha,https://seekingalpha.com/news/4110316-sensei-stock-plunges-in-wake-of-phase-1-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9662333726882935
1893,5/29/2024 1:27:44 PM,Biohaven stock falls 30% premarket amid drug updates,Seeking Alpha,https://seekingalpha.com/news/4111145-biohaven-stock-falls-amid-drug-updates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9589282274246216
1894,5/29/2024 3:50:26 PM,AstraZeneca touts PCSK9 inhibitor in lowering LDL cholesterol when added to statin,Seeking Alpha,https://seekingalpha.com/news/4111181-astrazeneca-touts-pcsk9-inhibitor-lowering-ldl-cholesterol-added-statin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8726117014884949
1895,5/31/2024 7:00:00 AM,Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation,GlobeNewswire,/news/stocks/update-on-fda-priority-review-of-dupixent-dupilumab-for-the-treatment-of-copd-patients-with-type-2-inflammation-1033439668,positive,0.9010756611824036
1896,5/31/2024 7:05:00 AM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD,GlobeNewswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-patients-with-copd-1033439672,negative,0.7828885912895203
1897,5/31/2024 7:18:51 AM,Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month ,RTTNews,/news/stocks/regeneron-fda-extends-review-period-for-dupixent-as-copd-treatment-by-three-month-1033439691,positive,0.7750663757324219
1898,5/31/2024 7:28:52 AM,"Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD  Patients ",RTTNews,/news/stocks/sanofi-regeneron-dupixent-recommended-for-eu-approval-by-chmp-to-treat-copd-patients-1033439706,negative,0.8284919857978821
1899,5/31/2024 10:49:06 AM,Regeneron/ Sanofi say FDA has delayed Dupixent COPD label,Seeking Alpha,https://seekingalpha.com/news/4111870-regeneron-stock-slips-dupixent-label-expansion-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5951682329177856
1900,5/31/2024 1:40:09 PM,Analysts Conflicted on These Healthcare Names: Merit Medical Systems (MMSI) and Regeneron (REGN),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-merit-medical-systems-mmsi-and-regeneron-regn-1033442296,neutral,0.502183735370636
1901,5/31/2024 6:47:47 PM,Buy Rating Affirmed for Regeneron Despite FDA Delay on Dupixent for COPD,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-despite-fda-delay-on-dupixent-for-copd-1033442740,negative,0.8967174291610718
1902,6/2/2024 6:00:00 PM,Emerging and Chinese pharmas playing greater role in oncology drug development,Seeking Alpha,https://seekingalpha.com/news/4112099-emerging-chinese-pharmas-playing-greater-role-oncology-drug-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5788828134536743
1903,6/3/2024 11:26:40 AM,Buy Rating Affirmed for REGN on Dupixent’s Strong Prospects Despite PDUFA Delay,TipRanks,/news/stocks/buy-rating-affirmed-for-regn-on-dupixent-s-strong-prospects-despite-pdufa-delay-1033446348,negative,0.9541290402412415
1904,6/3/2024 9:38:01 PM,"FibroGen stock rallies 30% after hours on FG-3165, FG-3175 updates",Seeking Alpha,https://seekingalpha.com/news/4112508-fibrogen-stock-rallies-after-hours-on-fg-3165-fg-3175-updates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8967485427856445
1905,6/4/2024 12:06:28 PM,RBC Capital Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-regeneron-regn-1033450355,positive,0.7355796098709106
1906,6/4/2024 4:01:20 PM,Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/navigating-14-analyst-ratings-for-regeneron-pharmaceuticals-1033450002,positive,0.7273972034454346
1907,6/6/2024 2:47:18 PM,"Goldman cuts 2seventy bio to neutral, cites competition concerns",Seeking Alpha,https://seekingalpha.com/news/4113699-goldman-cuts-2seventy-bio-to-neutral-cites-competition-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6006223559379578
1908,6/7/2024 8:30:54 PM,"Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside",Benzinga,/news/stocks/goldman-sachs-optimistic-about-regenxbio-s-gene-therapy-pipeline-sees-over-160-upside-1033462338,negative,0.8103159666061401
1909,6/11/2024 11:49:42 AM,"Regeneron, Sanofi win FDA label expansion for arthritis therapy Kevzara",Seeking Alpha,https://seekingalpha.com/news/4114761-regeneron-sanofi-win-new-fda-approval-kevzara?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8939806222915649
1910,6/11/2024 1:00:03 PM,Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA),GlobeNewswire,/news/stocks/kevzara-sarilumab-approved-by-fda-for-the-treatment-of-active-polyarticular-juvenile-idiopathic-arthritis-pjia-1033468406,negative,0.8539198637008667
1911,6/11/2024 1:51:11 PM,"Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA ",RTTNews,/news/stocks/regeneron-sanofi-report-fda-approval-of-kevzara-to-treat-active-pjia-1033468530,negative,0.8954861760139465
1912,6/11/2024 7:08:20 PM,Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea (update),Seeking Alpha,https://seekingalpha.com/news/4114936-regeneron-wins-permanent-injunction-blocking-generic-version-of-its-eye-drug-eylea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5751960873603821
1913,6/11/2024 11:11:16 PM,"Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Becton Dickinson (BDX) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-intuitive-surgical-isrg-becton-dickinson-bdx-and-regeneron-regn-1033470821,positive,0.912727952003479
1914,6/12/2024 11:36:51 AM,Regeneron’s Strategic Litigation and Market Exclusivity Uphold Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-litigation-and-market-exclusivity-uphold-buy-rating-1033473351,positive,0.5442877411842346
1915,6/12/2024 11:35:31 PM,"REGN, CI, BSX: Which “Strong Buy” Healthcare Stock Is the Best Bet?",TipRanks,/news/stocks/regn-ci-bsx-which-strong-buy-healthcare-stock-is-the-best-bet-1033474443,positive,0.902040421962738
1916,6/13/2024 3:39:03 PM,"Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market",Benzinga,/news/stocks/regeneron-s-dupixent-copd-sales-to-reach-20b-by-2026-analyst-sees-larger-addressable-market-1033476295,negative,0.8510369062423706
1917,6/14/2024 11:50:28 AM,"Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Regeneron (REGN) and Ocular Therapeutix (OCUL)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-r1-rcm-rcm-regeneron-regn-and-ocular-therapeutix-ocul-1033480394,positive,0.8974414467811584
1918,6/14/2024 4:44:17 PM,Regeneron wins injunction blocking Samsung Bioepis from launching generic Eylea,Seeking Alpha,https://seekingalpha.com/news/4116326-regeneron-wins-injunction-blocking-samsung-bioepis-from-launching-generic-eylea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9033765196800232
1919,6/14/2024 4:58:31 PM,Ocular Therapeutix jumps after investor day updates,Seeking Alpha,https://seekingalpha.com/news/4116345-ocular-therapeutix-stock-spikes-trial-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.36898693442344666
1920,6/16/2024 12:10:09 PM,Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma,GlobeNewswire,/news/stocks/updated-linvoseltamab-data-showcase-continued-deepening-of-responses-in-patients-with-heavily-pre-treated-multiple-myeloma-1033481447,negative,0.9204366207122803
1921,6/18/2024 12:20:24 PM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), GeoVax Labs (GOVX) and Editas Medicine (EDIT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-geovax-labs-govx-and-editas-medicine-edit-1033487871,positive,0.9052979946136475
1922,6/20/2024 6:04:17 PM,Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?,TipRanks,/news/stocks/regeneron-nasdaq-regn-is-this-stock-split-contender-a-strong-buy-1033494431,positive,0.761204183101654
1923,6/21/2024 10:30:00 AM,Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-cathie-wood-stocks-with-strong-buy-ratings-for-june-2024-1033495536,positive,0.560495138168335
1924,6/24/2024 10:35:36 AM,RBC Capital Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-sticks-to-their-buy-rating-for-regeneron-regn-1033500064,positive,0.6472666263580322
1925,6/24/2024 6:01:12 PM,The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts,Benzinga,/news/stocks/the-analyst-verdict-regeneron-pharmaceuticals-in-the-eyes-of-13-experts-1033500964,positive,0.8978100419044495
1926,6/24/2024 8:36:19 PM,Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs,Benzinga,/news/stocks/regeneron-pharmaceuticals-approach-to-improve-quality-of-weight-loss-has-merit-goldman-sachs-1033501399,positive,0.557217001914978
1927,6/26/2024 7:37:00 AM,Buy Rating on Regeneron: Promising Obesity Treatment Prospects Amid Phase 2 Trials,TipRanks,/news/stocks/buy-rating-on-regeneron-promising-obesity-treatment-prospects-amid-phase-2-trials-1033506951,negative,0.9509590864181519
1928,6/26/2024 11:30:00 PM,Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine,GlobeNewswire,/news/stocks/dupixent-dupilumab-positive-phase-3-data-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-published-in-the-new-england-journal-of-medicine-1033509296,positive,0.7098612189292908
1929,6/27/2024 7:55:39 AM,Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-sticks-to-its-buy-rating-for-regeneron-regn-1033510820,positive,0.7291895747184753
1930,6/27/2024 10:40:00 AM,3 Biotech Stocks That Could Make Your Grandchildren Rich,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-make-your-grandchildren-rich-1033510910,positive,0.9181333780288696
1931,6/27/2024 10:40:08 AM,Regeneron’s Linvoseltamab Outshines Competitor in Clinical Efficacy and Market Potential,TipRanks,/news/stocks/regeneron-s-linvoseltamab-outshines-competitor-in-clinical-efficacy-and-market-potential-1033511515,negative,0.9044803977012634
1932,6/27/2024 10:45:24 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Nurix Therapeutics (NRIX) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-nurix-therapeutics-nrix-and-merck-company-mrk-1033511599,positive,0.9080982208251953
1933,6/27/2024 10:05:00 PM,"Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024",GlobeNewswire,/news/stocks/regeneron-to-report-second-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-1-2024-1033512982,positive,0.9491375684738159
1934,6/28/2024 12:39:53 PM,Regeneron lymphoma antibody drug endorsed for conditional approval in EU,Seeking Alpha,https://seekingalpha.com/news/4120552-chmp-recommends-regeneron-lymphoma-antibody-drug-for-conditional-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7276402711868286
1935,6/28/2024 1:00:00 PM,Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,GlobeNewswire,/news/stocks/odronextamab-recommended-for-eu-approval-by-the-chmp-to-treat-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-1033514556,negative,0.9114389419555664
1936,6/28/2024 1:20:06 PM,Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU ,RTTNews,/news/stocks/regeneron-says-chmp-recommends-conditional-marketing-authorization-for-odronextamab-in-eu-1033514600,positive,0.6357854604721069
1937,7/3/2024 7:00:00 AM,Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD,GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-european-union-as-the-first-ever-targeted-therapy-for-patients-with-copd-1033525197,negative,0.8468074202537537
1938,7/3/2024 7:31:19 AM,"Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients ",RTTNews,/news/stocks/regeneron-sanofi-eu-approves-dupixent-as-first-ever-targeted-therapy-for-copd-patients-1033525224,negative,0.8828693628311157
1939,7/3/2024 10:52:20 AM,"Sanofi, Regeneron win EU label expansion for Dupixent in COPD",Seeking Alpha,https://seekingalpha.com/news/4121994-sanofi-regeneron-win-eu-nod-dupixent-copd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8136913776397705
1940,7/3/2024 1:25:56 PM,Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook,TipRanks,/news/stocks/buy-rating-for-regeneron-pharmaceuticals-amidst-eu-approval-of-dupixent-and-positive-market-outlook-1033527578,negative,0.933961033821106
1941,7/4/2024 7:45:11 PM,7 High Priced Stocks That Would Benefit From a Stock Split,InvestorPlace,/news/stocks/7-high-priced-stocks-that-would-benefit-from-a-stock-split-1033530303,positive,0.8075976371765137
1942,7/5/2024 6:14:56 PM,The 3 Best Biotech Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-july-2024-1033532887,positive,0.8355516791343689
1943,7/8/2024 10:00:00 AM,3 Pharma Stocks Already Ushering in the Next Biotech Boom,InvestorPlace,/news/stocks/3-pharma-stocks-already-ushering-in-the-next-biotech-boom-1033535178,negative,0.6573389172554016
1944,7/8/2024 2:05:14 PM,Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge ,RTTNews,/news/stocks/regeneron-pharma-expects-q4-results-to-include-24-mln-in-acquired-in-process-r-d-charge-1033535531,negative,0.6753018498420715
1945,7/8/2024 10:11:27 PM,Intellia sued for patent infringement by gene editing company BlueAllele,Seeking Alpha,https://seekingalpha.com/news/4122745-intellia-sued-for-patent-infringement-by-gene-editing-company-blueallele?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9183956980705261
1946,7/9/2024 11:00:00 AM,The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024,InvestorPlace,/news/stocks/3-undervalued-gene-editing-stocks-for-patient-investors-1033538875,positive,0.7962018847465515
1947,7/10/2024 8:57:35 AM,Barclays Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-regeneron-regn-1033542829,positive,0.8184676766395569
1948,7/11/2024 9:45:36 AM,Buy Rating for Regeneron: Anticipated Growth and Underappreciated Pipeline Offer Investment Opportunity,TipRanks,/news/stocks/buy-rating-for-regeneron-anticipated-growth-and-underappreciated-pipeline-offer-investment-opportunity-1033546987,neutral,0.8640367388725281
1949,7/11/2024 10:01:18 PM,The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals,Benzinga,/news/stocks/the-analyst-landscape-14-takes-on-regeneron-pharmaceuticals-1033548491,positive,0.9364736676216125
1950,7/12/2024 8:12:28 AM,"This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment",Seeking Alpha,https://seekingalpha.com/news/4123754-weight-loss-amgen-stock-obesity-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7048126459121704
1951,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8902468085289001
1952,7/15/2024 10:55:52 AM,Buy Rating for Regeneron: Diverse Pipeline and Market Expectations Fuel Analyst Confidence,TipRanks,/news/stocks/buy-rating-for-regeneron-diverse-pipeline-and-market-expectations-fuel-analyst-confidence-1033555496,negative,0.5258593559265137
1953,7/17/2024 11:55:00 AM,Stocks to Buy: 7 Founder-Led Companies Set to Outperform,InvestorPlace,/news/stocks/stocks-to-buy-7-founder-led-companies-set-to-outperform-1033563731,negative,0.5567771792411804
1954,7/18/2024 11:55:00 AM,3 Standout Stocks to Buy for the Next Bull Market,InvestorPlace,/news/stocks/3-standout-stocks-to-buy-for-the-next-bull-market-1033568151,positive,0.8763417601585388
1955,7/18/2024 8:51:35 PM,"Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst",Benzinga,/news/stocks/johnson-johnson-prioritizes-sustainable-growth-in-m-a-amid-sector-diversification-says-analyst-1033569993,negative,0.9231750965118408
1956,7/19/2024 10:45:25 AM,Piper Sandler Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-remains-a-buy-on-regeneron-regn-1033572493,positive,0.9470075368881226
1957,7/23/2024 10:40:23 AM,Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-reaffirms-their-buy-rating-on-regeneron-regn-1033582768,positive,0.7938250303268433
1958,7/23/2024 11:36:09 AM,TD Cowen Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/td-cowen-keeps-their-buy-rating-on-regeneron-regn-1033583302,positive,0.9167156219482422
1959,7/26/2024 6:54:05 AM,Barclays Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-regeneron-regn-1033599265,positive,0.9159238934516907
1960,7/26/2024 6:56:42 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN) and Roche Holding AG (OtherRHHVF),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-and-roche-holding-ag-otherrhhvf-1033599249,neutral,0.789087176322937
1961,7/26/2024 8:47:42 AM,Buy Rating on Regeneron: Strong Dupixent Sales and Favorable Market Dynamics Support Positive Outlook,TipRanks,/news/stocks/buy-rating-on-regeneron-strong-dupixent-sales-and-favorable-market-dynamics-support-positive-outlook-1033599914,negative,0.9500637650489807
1962,7/28/2024 12:00:00 PM,"Earnings week ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4129069-earnings-week-ahead-msft-amzn-aapl-meta-qcom-pfe-mcd-sbux-ma-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9346819519996643
1963,7/29/2024 10:15:07 AM,Biotech Stocks Facing FDA Decision In August 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2024-1033605090,positive,0.9172899127006531
1964,7/30/2024 6:12:56 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-aptargroup-atr-and-abbvie-abbv-1033610735,neutral,0.8324587941169739
1965,7/30/2024 12:35:45 PM,BioNTech posts mid-stage win for mRNA cancer drug with Regeneron’s Libtayo,Seeking Alpha,https://seekingalpha.com/news/4130080-biontech-stock-gains-win-mrna-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9179615378379822
1966,7/30/2024 2:40:01 PM,Roche's Vabysmo gains indication in Europe for retinal vein occlusion,Seeking Alpha,https://seekingalpha.com/news/4130186-roche-vabysmo-gains-indication-europe-retinal-vein-occlusion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7495940327644348
1967,7/31/2024 1:30:00 PM,Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation,GlobeNewswire,/news/stocks/regeneron-announces-the-2024-winners-of-the-regeneron-prize-for-creative-innovation-1033617499,positive,0.9007154703140259
1968,7/31/2024 3:01:13 PM,Regeneron Pharmaceuticals earnings: here's what to expect,Markets Insider Automation,/news/stocks/regeneron-q2-earnings-preview-stock-1033618179,positive,0.9397029280662537
1969,7/31/2024 3:29:09 PM,Regeneron Pharmaceuticals Q2 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4131166-regeneron-pharmaceuticals-q2-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8955532908439636
1970,8/1/2024 6:42:16 AM,Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-qiagen-qgen-and-regeneron-regn-1033625195,positive,0.8912546038627625
1971,8/1/2024 10:32:04 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $11.56 beats by $0.94, revenue of $3.55B beats by $160M",Seeking Alpha,https://seekingalpha.com/news/4132020-regeneron-pharmaceuticals-non-gaap-eps-of-11_56-beats-0_94-revenue-of-3_55b-beats-160m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5839449763298035
1972,8/1/2024 12:09:22 PM,Regeneron beats in Q2 as Eylea tops expectations,Seeking Alpha,https://seekingalpha.com/news/4132202-regeneron-stock-watch-q2-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9333457350730896
1973,8/1/2024 12:30:00 PM,Regeneron Reports Second Quarter 2024 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-second-quarter-2024-financial-and-operating-results-1033625372,negative,0.45383429527282715
1974,8/1/2024 12:38:36 PM,Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-reaffirms-their-buy-rating-on-regeneron-regn-1033627919,positive,0.8070192337036133
1975,8/1/2024 12:59:30 PM,Regeneron Pharma Q2 Results Top Estimates - Update ,RTTNews,/news/stocks/regeneron-pharma-q2-results-top-estimates-update-1033625573,positive,0.9266602993011475
1976,8/1/2024 1:07:13 PM,Buy Rating Affirmed for Regeneron on Strong Financials and Positive Sales Outlook,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-financials-and-positive-sales-outlook-1033628206,negative,0.9520621299743652
1977,8/1/2024 1:12:04 PM,Buy Rating on Regeneron: Robust Financials and Growth Prospects,TipRanks,/news/stocks/buy-rating-on-regeneron-robust-financials-and-growth-prospects-1033628190,negative,0.9499354362487793
1978,8/1/2024 2:45:00 PM,Regeneron Pharmaceuticals hosts conference call for investors,Markets Insider Automation,/news/stocks/regeneron_conference-1030020015,positive,0.940012514591217
1979,8/1/2024 6:26:08 PM,Regeneron’s Strong Market Performance and Financial Growth Bolster Buy Rating,TipRanks,/news/stocks/regeneron-s-strong-market-performance-and-financial-growth-bolster-buy-rating-1033629193,negative,0.9577975273132324
1980,8/2/2024 8:48:09 AM,Barclays Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-regeneron-regn-1033631611,positive,0.8184676766395569
1981,8/2/2024 10:43:30 AM,Regeneron (REGN) Receives a Buy from RBC Capital,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-rbc-capital-1033632290,positive,0.6781207919120789
1982,8/2/2024 11:11:29 AM,"Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-passage-bio-pasg-regeneron-regn-and-vir-biotechnology-vir-1033632652,positive,0.9052289128303528
1983,8/2/2024 12:32:10 PM,Oppenheimer Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/oppenheimer-sticks-to-its-buy-rating-for-regeneron-regn-1033633250,positive,0.8168624639511108
1984,8/5/2024 6:17:16 AM,Regeneron’s Promising Pipeline and Strong Financial Outlook Merit a Buy Rating with Increased Price Target,TipRanks,/news/stocks/regeneron-s-promising-pipeline-and-strong-financial-outlook-merit-a-buy-rating-with-increased-price-target-1033637869,negative,0.9533857703208923
1985,8/5/2024 6:30:08 AM,Balanced Outlook: Hold Rating on Regeneron Amid Robust Eylea Sales and Competitive Market Dynamics,TipRanks,/news/stocks/balanced-outlook-hold-rating-on-regeneron-amid-robust-eylea-sales-and-competitive-market-dynamics-1033637937,negative,0.9562327265739441
1986,8/5/2024 8:23:45 AM,"Analysts’ Top Healthcare Picks: Laboratory (LH), Humana (HUM)",TipRanks,/news/stocks/analysts-top-healthcare-picks-laboratory-lh-humana-hum-1033638405,negative,0.5350013375282288
1987,8/5/2024 10:22:21 AM,Strong Q2 Earnings and Robust Pipeline Reinforce Buy Rating for Regeneron,TipRanks,/news/stocks/strong-q2-earnings-and-robust-pipeline-reinforce-buy-rating-for-regeneron-1033639272,negative,0.9545127153396606
1988,8/7/2024 3:40:04 PM,3 Healthcare Stocks Positioned for Possible Market Outperformance,InvestorPlace,/news/stocks/3-healthcare-stocks-positioned-for-possible-market-outperformance-1033654380,neutral,0.48986998200416565
1989,8/7/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-and-oncology-investor-webcast-1033655182,positive,0.9510202407836914
1990,8/8/2024 10:40:00 AM,3 Biotech Stocks With Promising Drug Pipelines: August 2024,InvestorPlace,/news/stocks/3-biotech-stocks-with-promising-drug-pipelines-august-2024-1033659855,negative,0.5672460198402405
1991,8/12/2024 9:13:25 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR), Waters (WAT) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-united-therapeutics-uthr-waters-wat-and-regeneron-regn-1033676813,neutral,0.9181710481643677
1992,8/13/2024 11:30:00 AM,3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown,InvestorPlace,/news/stocks/3-biotech-stocks-poised-for-a-comeback-after-last-weeks-market-meltdown-1033681383,negative,0.7400673627853394
1993,8/13/2024 8:30:00 PM,7 Stocks That Usually Benefit From a Recession,InvestorPlace,/news/stocks/7-stocks-that-usually-benefit-from-a-recession-1033683968,positive,0.8904951810836792
1994,8/15/2024 6:02:28 PM,Alvotech’s biosimilar to Regeneron’s Eylea under EU review,Seeking Alpha,https://seekingalpha.com/news/4140717-alvotech-stock-gains-eu-review-for-eylea-rival?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7703632712364197
1995,8/16/2024 7:00:27 PM,"Catalyst Watch: Eyes on Jackson Hole, Target earnings, and Canadian rails disruption",Seeking Alpha,https://seekingalpha.com/news/4141061-catalyst-watch-eyes-on-jackson-hole-target-earnings-and-canadian-rails-disruption?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9338733553886414
1996,8/17/2024 6:00:44 PM,"J&J, Roche come out on top in S&P ratings of strongest pharma companies",Seeking Alpha,https://seekingalpha.com/news/4141255-johnson-johnson-roche-come-out-top-in-ratings-strongest-pharma-companies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8499211668968201
1997,8/19/2024 11:30:16 AM,"Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), United Therapeutics (UTHR) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-united-therapeutics-uthr-and-regeneron-regn-1033704592,positive,0.9187561273574829
1998,8/19/2024 7:07:33 PM,Small-cap and mid-cap Health Care has room to rally - Roth MKM,Seeking Alpha,https://seekingalpha.com/news/4141609-small-cap-and-mid-cap-health-care-has-room-to-rally-roth-mkm?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7902520298957825
1999,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5784038305282593
2000,8/21/2024 12:45:05 AM,Regeneron Provides Update on Biologics License Application for Linvoseltamab,GlobeNewswire,/news/stocks/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab-1033708785,positive,0.9353427886962891
2001,8/21/2024 3:23:41 AM,FDA Issues Complete Response Letter For Regeneron's Linvoseltamab In R/R Multiple Myeloma ,RTTNews,/news/stocks/fda-issues-complete-response-letter-for-regeneron-s-linvoseltamab-in-r-r-multiple-myeloma-1033708812,positive,0.8353255987167358
2002,8/21/2024 9:53:49 AM,Regeneron receives anticipated FDA rejection for blood cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4142191-regeneron-receives-anticipated-fda-rejection-for-blood-cancer-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7405625581741333
2003,8/21/2024 10:02:12 AM,"Analysts Offer Insights on Healthcare Companies: Ansell (OtherANSLF), Alcon (ALC) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ansell-otheranslf-alcon-alc-and-regeneron-regn-1033710994,positive,0.9130076169967651
2004,8/23/2024 11:07:44 AM,Piper Sandler Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-regeneron-regn-1033718550,positive,0.8465181589126587
2005,8/26/2024 7:00:00 AM,Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases,GlobeNewswire,/news/stocks/latest-dupixent-dupilumab-and-itepekimab-data-at-ers-highlight-scientific-innovation-and-leadership-in-respiratory-diseases-1033720628,negative,0.7580008506774902
2006,8/26/2024 11:26:02 AM,Regeneron’s cancer therapy gets EU approval,Seeking Alpha,https://seekingalpha.com/news/4143626-regenerons-cancer-therapy-gets-eu-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8831166625022888
2007,8/26/2024 1:00:00 PM,Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,GlobeNewswire,/news/stocks/ordspono-odronextamab-approved-in-the-european-union-for-the-treatment-of-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-1033721533,negative,0.7850419878959656
2008,8/26/2024 1:45:00 PM,Regeneron Pharma: European Commission Approves Ordspono - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-european-commission-approves-ordspono-quick-facts-1033721622,positive,0.6052764058113098
2009,8/29/2024 3:49:40 PM,J&J submits FDA application for myasthenia gravis drug nipocalimab,Seeking Alpha,https://seekingalpha.com/news/4145151-jj-submits-fda-application-for-myasthenia-gravis-drug-nipocalimab?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7476670145988464
2010,9/2/2024 4:35:44 AM,Biotech Stocks Facing FDA Decision In September 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2024-1033738787,positive,0.9196612238883972
2011,9/5/2024 10:36:44 AM,RBC Capital Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-keeps-their-buy-rating-on-regeneron-regn-1033750807,positive,0.9199317097663879
2012,9/6/2024 7:00:22 PM,"Catalyst Watch: Apple's iPhone event, Oracle earnings, Google antitrust trial, and the August CPI print",Seeking Alpha,https://seekingalpha.com/news/4147709-catalyst-watch-apples-iphone-event-oracle-earnings-google-antitrust-trial-and-the-august-cpi-print?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7490698099136353
2013,9/9/2024 5:47:29 AM,Regeneron (REGN) Receives a Buy from Wells Fargo,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-wells-fargo-1033756479,negative,0.6635436415672302
2014,9/9/2024 10:39:47 AM,RBC Capital Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-remains-a-buy-on-regeneron-regn-1033757480,positive,0.9444535374641418
2015,9/9/2024 1:00:17 PM,Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO,GlobeNewswire,/news/stocks/regeneron-to-highlight-progress-across-its-differentiated-oncology-portfolio-and-pipeline-at-wclc-and-esmo-1033756819,negative,0.8377756476402283
2016,9/9/2024 11:00:00 PM,Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer,GlobeNewswire,/news/stocks/libtayo-cemiplimab-demonstrates-durable-survival-benefit-at-five-years-in-advanced-non-small-cell-lung-cancer-1033758649,negative,0.9524480104446411
2017,9/10/2024 5:25:55 AM,Regeneron's Five-Year Phase 3 Trial Shows Durable Survival Benefit Of Libtayo In PD-L1 High NSCLC ,RTTNews,/news/stocks/regeneron-s-five-year-phase-3-trial-shows-durable-survival-benefit-of-libtayo-in-pd-l1-high-nsclc-1033758778,negative,0.9511330127716064
2018,9/11/2024 6:59:00 AM,Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial,GlobeNewswire,/news/stocks/dupixent-dupilumab-is-the-first-and-only-biologic-to-achieve-significant-improvements-in-disease-remission-and-symptoms-in-bullous-pemphigoid-bp-positive-pivotal-trial-1033762412,negative,0.9175282716751099
2019,9/11/2024 7:04:00 AM,Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU),GlobeNewswire,/news/stocks/dupixent-dupilumab-phase-3-trial-confirms-significant-improvements-in-itch-and-hives-for-patients-with-chronic-spontaneous-urticaria-csu-1033762416,negative,0.9476844668388367
2020,9/11/2024 7:27:56 AM,"Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints ",RTTNews,/news/stocks/sanofi-regeneron-adept-study-of-dupixent-in-bullous-pemphigoid-meets-endpoints-1033762443,positive,0.9202345609664917
2021,9/11/2024 11:35:11 AM,"Regeneron, Sanofi report mixed outcomes in late-stage trials for Dupixent",Seeking Alpha,https://seekingalpha.com/news/4148609-regeneron-sanofi-post-mixed-data-dupixent-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8270931839942932
2022,9/11/2024 12:25:33 PM,Buy Rating Affirmed: Regeneron’s Dupixent Poised for Market Expansion Following Positive Clinical Trials,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-dupixent-poised-for-market-expansion-following-positive-clinical-trials-1033764645,negative,0.9499355554580688
2023,9/11/2024 1:00:46 PM,"EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile",GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-data-at-euretina-reinforce-long-term-durability-sustained-fluid-control-and-safety-profile-1033763482,negative,0.9487239718437195
2024,9/11/2024 9:05:14 PM,Sanofi reports positive Phase 3 results for Dupixent for CSU,Seeking Alpha,https://seekingalpha.com/news/4148829-sanofi-reports-positive-phase-3-results-for-dupixent-for-csu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9467331767082214
2025,9/12/2024 11:10:07 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Sanofi (OtherSNYNF),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-sanofi-othersnynf-1033767534,neutral,0.9390931129455566
2026,9/13/2024 3:20:26 PM,Kiniksa draws buy at Jefferies on potential blockbuster status for lead drug,Seeking Alpha,https://seekingalpha.com/news/4149593-kiniksa-stock-draws-buy-jefferies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8942663073539734
2027,9/13/2024 6:15:28 PM,Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp-1033771127,negative,0.6388294100761414
2028,9/17/2024 9:30:44 AM,Analyst Issues Sell Rating for Regeneron Amid Competitive Challenges and Limited Market Potential,TipRanks,/news/stocks/analyst-issues-sell-rating-for-regeneron-amid-competitive-challenges-and-limited-market-potential-1033777087,neutral,0.7448415160179138
2029,9/17/2024 10:39:14 AM,RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-regeneron-regn-1033777349,positive,0.7838191390037537
2030,9/17/2024 11:16:08 AM,Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by Strong Pipeline and Market Performance,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-growth-potential-anchored-by-strong-pipeline-and-market-performance-1033777834,negative,0.945565938949585
2031,9/20/2024 1:45:00 PM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old,GlobeNewswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-esophagitis-eoe-in-children-as-young-as-1-year-old-1033786209,negative,0.7908063530921936
2032,9/20/2024 9:10:51 PM,Regeneron/Sanofi Dupixent endorsed in EU for eosinophilic esophagitis for children,Seeking Alpha,https://seekingalpha.com/news/4151728-regeneron-sanofi-dupixent-endorsed-eu-eosinophilic-esophagitis-children?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8648589849472046
2033,9/23/2024 5:41:45 PM,4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data,Seeking Alpha,https://seekingalpha.com/news/4152160-4d-molecular-therapeutics-downgraded-cantor-following-wet-amd-asset-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7293546199798584
2034,9/23/2024 7:13:36 PM,Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar,Seeking Alpha,https://seekingalpha.com/news/4152159-regeneron-falls-after-judge-denies-motion-for-injunction-in-a-patent-case-with-amgen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9543410539627075
2035,9/23/2024 8:15:22 PM,Buy Rating Affirmed for Regeneron Despite Eylea Legal Challenges: Growth and Diversification Fuels Optimism,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-despite-eylea-legal-challenges-growth-and-diversification-fuels-optimism-1033791934,negative,0.8173661231994629
2036,9/24/2024 9:05:58 AM,Regeneron’s Strategic Resilience Justifies a Buy Rating Amidst Competitive Pressures,TipRanks,/news/stocks/regeneron-s-strategic-resilience-justifies-a-buy-rating-amidst-competitive-pressures-1033793378,negative,0.6080039739608765
2037,9/24/2024 10:05:24 AM,Regeneron’s Strategic Pipeline and Management Spark Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-pipeline-and-management-spark-buy-rating-1033793670,negative,0.6539955735206604
2038,9/24/2024 10:06:01 AM,Evaluating Regeneron’s Hold Rating Amid Biosimilar Litigation Uncertainty,TipRanks,/news/stocks/evaluating-regeneron-s-hold-rating-amid-biosimilar-litigation-uncertainty-1033793668,positive,0.7036385536193848
2039,9/24/2024 10:48:17 AM,Regeneron’s Strategic R&D and Financial Health Underpin Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-r-d-and-financial-health-underpin-buy-rating-1033793887,negative,0.7490348219871521
2040,9/24/2024 11:55:44 AM,Evercore ISI Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-keeps-their-buy-rating-on-regeneron-regn-1033794402,positive,0.9159610867500305
2041,9/24/2024 1:03:50 PM,Regeneron downgraded at Leerink after Amgen’s court win; Truist defends,Seeking Alpha,https://seekingalpha.com/news/4152576-regeneron-stock-cut-leerink-amgen-court-win?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7695782780647278
2042,9/25/2024 11:27:15 AM,Piper Sandler Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-regeneron-regn-1033797491,positive,0.8465181589126587
2043,9/25/2024 12:29:08 PM,Regeneron’s Patent Resilience and Market Positioning Justify a Buy Rating,TipRanks,/news/stocks/regeneron-s-patent-resilience-and-market-positioning-justify-a-buy-rating-1033797718,negative,0.8733057975769043
2044,9/25/2024 6:29:49 PM,Amgen stock slides 5% as analysts weigh in on drug study results,Seeking Alpha,https://seekingalpha.com/news/4153393-amgen-stock-slides-as-analysts-weigh-in-on-drug-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.941432535648346
2045,9/26/2024 10:05:00 PM,"Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024",GlobeNewswire,/news/stocks/regeneron-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-october-31-2024-1033801999,positive,0.9485058188438416
2046,9/27/2024 1:00:04 PM,Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD),GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-chronic-obstructive-pulmonary-disease-copd-1033803356,negative,0.8722454905509949
2047,9/27/2024 1:36:13 PM,"Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease ",RTTNews,/news/stocks/regeneron-sanofi-say-dupixent-approved-in-china-to-treat-chronic-obstructive-pulmonary-disease-1033803470,negative,0.8187435865402222
2048,9/27/2024 2:14:25 PM,"Sanofi, Regeneron get additional Chinese approval for Dupixent",Seeking Alpha,https://seekingalpha.com/news/4154122-sanofi-regeneron-get-additional-chinese-approval-for-dupixent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8589498996734619
2049,9/27/2024 3:35:08 PM,Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD,GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-u-s-as-the-first-ever-biologic-medicine-for-patients-with-copd-1033803785,negative,0.8544257283210754
2050,9/27/2024 4:51:25 PM,"Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment ",RTTNews,/news/stocks/regeneron-sanofi-s-dupixent-get-fda-approval-for-chronic-obstructive-pulmonary-disease-treatment-1033804290,negative,0.8750181198120117
2051,9/27/2024 5:16:27 PM,Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD,Seeking Alpha,https://seekingalpha.com/news/4154190-regeneron-sanofi-win-fda-nod-dupixent-copd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8658820390701294
2052,9/28/2024 1:37:00 PM,"Notable analyst calls this week: Microsoft, Starbucks and GM among top picks",Seeking Alpha,https://seekingalpha.com/news/4154123-notable-analyst-calls-this-week-microsoft-starbucks-and-gm-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6115570068359375
2053,9/29/2024 4:12:57 PM,"Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales",Seeking Alpha,https://seekingalpha.com/news/4154326-novo-nordisk-ozempic-regeneron-sanofi-dupixent-advance-top-drug-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9307808876037598
2054,9/30/2024 7:15:34 AM,Regeneron (REGN) Receives a Buy from Barclays,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-barclays-1033806915,negative,0.5650038719177246
2055,9/30/2024 11:35:59 AM,Regeneron’s Growth Prospects Bolstered by Dupixent Approval and Promising Oncology Pipeline,TipRanks,/news/stocks/regeneron-s-growth-prospects-bolstered-by-dupixent-approval-and-promising-oncology-pipeline-1033808129,negative,0.9513896703720093
2056,10/7/2024 11:21:33 AM,Regeneron sees IPR&D impact of about $0.43/share on Q3 income,Seeking Alpha,https://seekingalpha.com/news/4156671-regeneron-sees-iprd-impact-of-about-043share-on-q3-income?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5744407176971436
2057,10/7/2024 2:30:18 PM,Regeneron Pharmaceuticals: IPR&D Charge To Negatively Impact Q3 EPS By Approx. $0.43 ,RTTNews,/news/stocks/regeneron-pharmaceuticals-ipr-d-charge-to-negatively-impact-q3-eps-by-approx-0-43-1033824503,neutral,0.9249122142791748
2058,10/9/2024 7:25:20 PM,Weight-loss drugs: How much should investors worry about side effects?,Seeking Alpha,https://seekingalpha.com/news/4157105-weight-loss-drugs-how-much-should-investors-worry-about-side-effects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8704334497451782
2059,10/11/2024 12:37:15 PM,Morgan Stanley Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/morgan-stanley-keeps-their-buy-rating-on-regeneron-regn-1033839265,positive,0.9242963790893555
2060,10/12/2024 5:58:03 PM,Weight loss drugs have one big issue; these companies want to fix it,Seeking Alpha,https://seekingalpha.com/news/4158061-these-companies-address-muscle-loss-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8579020500183105
2061,10/14/2024 9:31:07 PM,Jasper gains 11% on data for briquilimab in urticaria,Seeking Alpha,https://seekingalpha.com/news/4158360-jasper-gains-on-data-for-briquilimab-in-urticaria?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8962011933326721
2062,10/18/2024 11:05:00 PM,Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular...,GlobeNewswire,/news/stocks/three-year-results-for-eylea-hd-aflibercept-injection-8-mg-demonstrate-continued-durable-vision-gains-and-anatomic-improvements-with-extended-dosing-intervals-in-patients-with-diabetic-macular-1033860237,negative,0.9587186574935913
2063,10/19/2024 12:27:42 AM,Regeneron : EYLEA HD Three-Year Results Show Lasting Vision Gains In Diabetic Macular Edema Patients ,RTTNews,/news/stocks/regeneron-eylea-hd-three-year-results-show-lasting-vision-gains-in-diabetic-macular-edema-patients-1033860268,negative,0.9410303235054016
2064,10/21/2024 10:54:15 AM,Positive Outlook and Buy Rating for Regeneron Despite Expense Adjustment,TipRanks,/news/stocks/positive-outlook-and-buy-rating-for-regeneron-despite-expense-adjustment-1033864817,negative,0.9239387512207031
2065,10/22/2024 4:39:47 PM,Regeneron drops after court rejects request for temporary injunction for Eylea generic,Seeking Alpha,https://seekingalpha.com/news/4191238-regeneron-drops-after-court-rejects-request-for-temporary-injunction-for-eylea-generic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8920377492904663
2066,10/22/2024 5:25:18 PM,RBC would buy Regeneron on weakness with biosimilar Eylea priced in,TipRanks,/news/stocks/rbc-would-buy-regeneron-on-weakness-with-biosimilar-eylea-priced-in-1033873241,positive,0.7837697863578796
2067,10/22/2024 7:05:17 PM,"Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-050-from-1-200-at-wells-fargo-1033873548,neutral,0.7079969644546509
2068,10/22/2024 7:30:16 PM,"Amgen to launch U.S. Eylea biosimilar, Reuters reports",TipRanks,/news/stocks/amgen-to-launch-u-s-eylea-biosimilar-reuters-reports-1033873540,positive,0.9013373851776123
2069,10/23/2024 7:18:06 AM,Barclays Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-regeneron-regn-1033877406,positive,0.9159238934516907
2070,10/23/2024 9:16:14 AM,Strategic Buy Rating for Regeneron Amid Competitive Challenges with Long-Term Growth Potential,TipRanks,/news/stocks/strategic-buy-rating-for-regeneron-amid-competitive-challenges-with-long-term-growth-potential-1033878018,negative,0.9477857351303101
2071,10/23/2024 9:40:16 AM,"Regeneron price target lowered to $1,080 from $1,220 at Barclays",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-080-from-1-220-at-barclays-1033878103,neutral,0.7812787294387817
2072,10/23/2024 10:48:11 AM,Regeneron’s Legal Battles and Market Position Strengthen Buy Rating,TipRanks,/news/stocks/regeneron-s-legal-battles-and-market-position-strengthen-buy-rating-1033878720,negative,0.9489771723747253
2073,10/23/2024 11:39:35 AM,Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-reaffirms-their-buy-rating-on-regeneron-regn-1033879429,positive,0.7938250303268433
2074,10/23/2024 11:45:52 AM,Regeneron’s Growth Potential Solidified Amid Legal Challenges and Promising Pipeline,TipRanks,/news/stocks/regeneron-s-growth-potential-solidified-amid-legal-challenges-and-promising-pipeline-1033879605,negative,0.9541727900505066
2075,10/24/2024 10:16:01 AM,Regeneron: Buy Rating Reaffirmed Amid Eylea Biosimilar Challenge and Pipeline Strength,TipRanks,/news/stocks/regeneron-buy-rating-reaffirmed-amid-eylea-biosimilar-challenge-and-pipeline-strength-1033886245,negative,0.8224869966506958
2076,10/24/2024 10:21:01 AM,"JPMorgan cuts Regeneron target, says buy the recent selloff",TipRanks,/news/stocks/jpmorgan-cuts-regeneron-target-says-buy-the-recent-selloff-1033886211,neutral,0.552394449710846
2077,10/24/2024 12:26:23 PM,Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-reaffirms-their-buy-rating-on-regeneron-regn-1033887504,positive,0.8070192337036133
2078,10/24/2024 12:47:26 PM,"Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU",TipRanks,/news/stocks/regeneron-sanofi-announce-presentation-of-dupixent-phase-3-data-in-csu-1033887833,positive,0.912447988986969
2079,10/24/2024 2:00:04 PM,Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI,GlobeNewswire,/news/stocks/dupixent-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous-urticaria-to-be-presented-at-acaai-1033885634,positive,0.7875711917877197
2080,10/24/2024 2:45:32 PM,Cautious Hold Rating for Regeneron Amidst Competitive Threat from Amgen’s Eylea Biosimilar,TipRanks,/news/stocks/cautious-hold-rating-for-regeneron-amidst-competitive-threat-from-amgen-s-eylea-biosimilar-1033888437,neutral,0.6971513032913208
2081,10/25/2024 11:45:05 AM,Sanofi posts Q3 revenue beat as Dupixent sales jump,Seeking Alpha,https://seekingalpha.com/news/4203950-sanofi-stock-gains-q-3-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8926488757133484
2082,10/25/2024 11:50:26 AM,"Analysts’ Top Healthcare Picks: Inozyme Pharma (INZY), Tyra Bioscience (TYRA)",TipRanks,/news/stocks/analysts-top-healthcare-picks-inozyme-pharma-inzy-tyra-bioscience-tyra-1033893732,negative,0.6678850054740906
2083,10/25/2024 2:19:09 PM,Lilly's Ebglyss shown to be effective in former Dupixent users,Seeking Alpha,https://seekingalpha.com/news/4204992-lillys-ebglyss-shown-to-be-effective-in-former-dupixent-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9465171098709106
2084,10/28/2024 9:01:15 AM,Regeneron (REGN) Gets a Buy from Barclays,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-barclays-1033901235,negative,0.5686701536178589
2085,10/30/2024 3:14:14 PM,Regeneron Pharmaceuticals Q3 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4223936-regeneron-pharmaceuticals-q3-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8929469585418701
2086,10/30/2024 6:00:59 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033921038,positive,0.9220908284187317
2087,10/31/2024 10:31:36 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $12.46 beats by $0.75, revenue of $3.72B beats by $50M",Seeking Alpha,https://seekingalpha.com/news/4227627-regeneron-pharmaceuticals-non-gaap-eps-of-12_46-beats-0_75-revenue-of-3_72b-beats-50m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5304132699966431
2088,10/31/2024 10:36:20 AM,Regeneron lowers 2024 CapEx view to $700M-$740M from $750M-$820M,TipRanks,/news/stocks/regeneron-lowers-2024-capex-view-to-700m--740m-from-750m--820m-1033928418,neutral,0.8506942987442017
2089,10/31/2024 10:37:36 AM,"Regeneron reports Q3 non-GAAP EPS $12.46, consensus $11.69",TipRanks,/news/stocks/regeneron-reports-q3-non-gaap-eps-12-46-consensus-11-69-1033928405,positive,0.7405493855476379
2090,10/31/2024 11:30:00 AM,Regeneron Reports Third Quarter 2024 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-third-quarter-2024-financial-and-operating-results-1033926680,negative,0.45447811484336853
2091,10/31/2024 11:50:35 AM,"Regeneron Pharmaceuticals Q3 Profit Increases, Beats Estimates ",RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-profit-increases-beats-estimates-1033926762,negative,0.9431205987930298
2092,10/31/2024 1:01:20 PM,Morning Movers: Roblox surges and Estee Lauder sinks following earnings,TipRanks,/news/stocks/morning-movers-roblox-surges-and-estee-lauder-sinks-following-earnings-1033930078,positive,0.5358022451400757
2093,10/31/2024 2:40:37 PM,Regeneron down 10% despite top and bottom line beats,Seeking Alpha,https://seekingalpha.com/news/4228770-regeneron-down-10-despite-top-and-bottom-line-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9695956707000732
2094,10/31/2024 5:05:17 PM,Regeneron Buy Rating: Strong Earnings and Strategic Positioning Amid Market Challenges,TipRanks,/news/stocks/regeneron-buy-rating-strong-earnings-and-strategic-positioning-amid-market-challenges-1033931196,negative,0.9512085318565369
2095,10/31/2024 5:40:24 PM,"Regeneron price target lowered to $1,150 from $1,200 at Oppenheimer",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-150-from-1-200-at-oppenheimer-1033931388,negative,0.39614012837409973
2096,10/31/2024 5:51:09 PM,"Regeneron price target lowered to $1,215 from $1,260 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-215-from-1-260-at-rbc-capital-1033931458,neutral,0.8063495755195618
2097,10/31/2024 7:10:48 PM,Eylea headwinds said to be behind Regeneron’s post-Q3 plunge,Seeking Alpha,https://seekingalpha.com/news/4231187-regeneron-stock-falls-eylea-headwinds?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9240584373474121
2098,10/31/2024 8:42:14 PM,Regeneron files automatic mixed securities shelf,TipRanks,/news/stocks/regeneron-files-automatic-mixed-securities-shelf-1033931860,positive,0.9507118463516235
2099,10/31/2024 8:46:54 PM,Regeneron Pharmaceuticals files automatic mixed securities shelf,Seeking Alpha,https://seekingalpha.com/news/4231669-regeneron-pharmaceuticals-files-automatic-mixed-securities-shelf?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9523817300796509
2100,11/1/2024 4:48:44 AM,Regeneron Pharmaceuticals Reports Strong Q3 2024 Results,TipRanks,/news/stocks/regeneron-pharmaceuticals-reports-strong-q3-2024-results-1033934659,negative,0.9480558633804321
2101,11/1/2024 7:25:40 AM,Barclays Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-regeneron-regn-1033935510,positive,0.7767885327339172
2102,11/1/2024 9:06:11 AM,Regeneron: Strategic Strengths and Future Prospects Justify Buy Rating Despite Challenges,TipRanks,/news/stocks/regeneron-strategic-strengths-and-future-prospects-justify-buy-rating-despite-challenges-1033936052,negative,0.9085051417350769
2103,11/1/2024 9:50:26 AM,"Regeneron price target lowered to $1,065 from $1,080 at Barclays",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-065-from-1-080-at-barclays-1033936358,neutral,0.8426625728607178
2104,11/1/2024 10:25:27 AM,"Regeneron earnings selloff ‘serious overreaction,’ says Piper Sandler",TipRanks,/news/stocks/regeneron-earnings-selloff-serious-overreaction-says-piper-sandler-1033936589,neutral,0.9585583806037903
2105,11/1/2024 10:36:59 AM,Regeneron Buy Rating: Strategic Growth Prospects Amid EYLEA Challenges and Opportunities,TipRanks,/news/stocks/regeneron-buy-rating-strategic-growth-prospects-amid-eylea-challenges-and-opportunities-1033936715,negative,0.9233330488204956
2106,11/1/2024 11:01:15 AM,Regeneron price target lowered to $800 from $820 at BofA,TipRanks,/news/stocks/regeneron-price-target-lowered-to-800-from-820-at-bofa-1033936938,neutral,0.42142173647880554
2107,11/1/2024 11:39:43 AM,Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-regeneron-regn-1033937084,positive,0.6758719682693481
2108,11/1/2024 11:40:09 AM,Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-and-regeneron-regn-1033937079,positive,0.9021531343460083
2109,11/1/2024 12:06:36 PM,Regeneron: A Buy Opportunity Amid Short-Term Setbacks and Promising Pipeline Potential,TipRanks,/news/stocks/regeneron-a-buy-opportunity-amid-short-term-setbacks-and-promising-pipeline-potential-1033937650,negative,0.9336198568344116
2110,11/1/2024 12:16:53 PM,Promising Outlook for Regeneron Amidst Challenges: Buy Rating Affirmed,TipRanks,/news/stocks/promising-outlook-for-regeneron-amidst-challenges-buy-rating-affirmed-1033937740,negative,0.9078166484832764
2111,11/1/2024 12:36:34 PM,Jefferies Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/jefferies-sticks-to-its-buy-rating-for-regeneron-regn-1033937862,positive,0.8124302625656128
2112,11/1/2024 12:51:37 PM,"Regeneron selloff ‘overdone’ with pipeline catalysts coming, says Morgan Stanley",TipRanks,/news/stocks/regeneron-selloff-overdone-with-pipeline-catalysts-coming-says-morgan-stanley-1033937934,neutral,0.8759300112724304
2113,11/1/2024 1:01:28 PM,"Regeneron price target lowered to $1,215 from $1,260 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-215-from-1-260-at-rbc-capital-1033938110,neutral,0.8063495755195618
2114,11/1/2024 2:35:21 PM,"Regeneron price target lowered to $1,126 from $1,137 at Truist",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-126-from-1-137-at-truist-1033938445,neutral,0.5703516602516174
2115,11/4/2024 12:25:45 PM,TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/td-cowen-reaffirms-their-buy-rating-on-regeneron-regn-1033945028,positive,0.788241446018219
2116,11/5/2024 6:11:17 AM,"Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-travere-therapeutics-tvtx-and-regeneron-regn-1033950256,positive,0.9038772583007812
2117,11/5/2024 12:11:44 PM,"Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS), Regeneron (REGN) and IQVIA Holdings (IQV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-glaukos-gkos-regeneron-regn-and-iqvia-holdings-iqv-1033952722,positive,0.916696310043335
2118,11/6/2024 2:32:55 AM,"Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-argenx-se-argx-regeneron-regn-1033957099,positive,0.7131102085113525
2119,11/6/2024 7:00:00 AM,Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis,GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for-young-children-with-eosinophilic-esophagitis-1033958445,negative,0.7323179244995117
2120,11/6/2024 7:53:22 AM,Regeneron: EC Approves Dupixent For Young Children With EoE ,RTTNews,/news/stocks/regeneron-ec-approves-dupixent-for-young-children-with-eoe-1033958624,negative,0.5632430911064148
2121,11/6/2024 10:35:14 AM,"Regeneron, Sanofi announce EC approval for Dupixent",TipRanks,/news/stocks/regeneron-sanofi-announce-ec-approval-for-dupixent-1033961176,positive,0.6674031615257263
2122,11/6/2024 11:35:34 AM,"Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-000-from-1-150-at-oppenheimer-1033961530,negative,0.5161150097846985
2123,11/8/2024 8:00:23 PM,"Catalyst Watch: Alibaba earnings, Disney drama, CPI print, 13F filings and more election scrambling",Seeking Alpha,https://seekingalpha.com/news/4266568-catalyst-watch-alibaba-earnings-disney-drama-cpi-print-13f-filings-and-more-election-scrambling?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8763313889503479
2124,11/11/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1033994323,positive,0.9291732907295227
2125,11/13/2024 12:45:30 PM,"Regeneron announces new, updated data from hematology pipeline at ASH",TipRanks,/news/stocks/regeneron-announces-new-updated-data-from-hematology-pipeline-at-ash-1034009611,positive,0.8766464591026306
2126,11/13/2024 1:00:25 PM,Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH,GlobeNewswire,/news/stocks/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash-1034007456,negative,0.8056910037994385
2127,11/13/2024 9:22:20 PM,Regeneron initiated with a Neutral at Citi,TipRanks,/news/stocks/regeneron-initiated-with-a-neutral-at-citi-1034011770,positive,0.8353450894355774
2128,11/14/2024 2:45:32 PM,"American upgraded, Regeneron initiated: Wall Street’s top analyst calls",TipRanks,/news/stocks/american-upgraded-regeneron-initiated-wall-street-s-top-analyst-calls-1034019984,positive,0.8680362105369568
2129,11/14/2024 7:26:46 PM,"Gilead, Vertex initiated as new big biotech buys at Citi",Seeking Alpha,https://seekingalpha.com/news/4291773-gilead-vertex-initiated-new-big-biotech-buys-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.738814651966095
2130,11/14/2024 9:21:44 PM,Regeneron initiated with an Outperform at Wolfe Research,TipRanks,/news/stocks/regeneron-initiated-with-an-outperform-at-wolfe-research-1034021156,negative,0.7206435203552246
2131,11/14/2024 11:40:12 PM,"Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’",TipRanks,/news/stocks/wolfe-research-starts-regeneron-at-outperform-sees-attractive-entry-point-1034021568,negative,0.7591723799705505
2132,11/15/2024 6:59:51 AM,Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU),GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-urticaria-csu-1034021994,negative,0.7654421925544739
2133,11/15/2024 7:36:25 AM,"Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria ",RTTNews,/news/stocks/sanofi-regeneron-s-dupixent-sbla-accepted-for-fda-review-to-treat-chronic-spontaneous-urticaria-1034022058,negative,0.8930240273475647
2134,11/15/2024 10:25:30 AM,"Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review",TipRanks,/news/stocks/regeneron-sanofi-announce-fda-accepts-dupixent-sbla-for-review-1034023973,negative,0.493264377117157
2135,11/15/2024 12:50:21 PM,"Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.",Seeking Alpha,https://seekingalpha.com/news/4294221-regeneron-sanofi-bid-expand-dupixent-label-accepted?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9075340628623962
2136,11/15/2024 2:40:28 PM,"Morgan Stanley, Comerica upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/morgan-stanley-comerica-upgraded-wall-street-s-top-analyst-calls-1034025965,positive,0.8884839415550232
2137,11/22/2024 5:00:11 PM,FDA posts observations from previous Regeneron facility inspection,TipRanks,/news/stocks/fda-posts-observations-from-previous-regeneron-facility-inspection-1034056602,positive,0.938494861125946
2138,11/22/2024 8:00:04 PM,"Catalyst Watch: Robotaxi IPO, OPEC+, holiday shopping data, and movie blockbusters",Seeking Alpha,https://seekingalpha.com/news/4322051-catalyst-watch-robotaxi-ipo-opec-holiday-shopping-data-and-movie-blockbusters?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9208636283874512
2139,11/23/2024 1:26:02 PM,Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby,Seeking Alpha,https://seekingalpha.com/news/4324609-pfizer-amyloidosis-rival-bridge-bio-wins-fda-nod?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8890742659568787
2140,11/25/2024 11:25:19 AM,Buy Rating on Regeneron Driven by Promising Factor XI Program and Market Potential,TipRanks,/news/stocks/buy-rating-on-regeneron-driven-by-promising-factor-xi-program-and-market-potential-1034060584,negative,0.9388167858123779
2141,11/25/2024 11:46:29 AM,Regeneron’s Pipeline Progress and Market Potential: Hold Rating Amidst Competitive Landscape,TipRanks,/news/stocks/regeneron-s-pipeline-progress-and-market-potential-hold-rating-amidst-competitive-landscape-1034060823,positive,0.5210522413253784
2142,11/25/2024 12:40:47 PM,Intellia announces FDA granted RMAT designation to nexiguran ziclumeran,TipRanks,/news/stocks/intellia-announces-fda-granted-rmat-designation-to-nexiguran-ziclumeran-1034061398,negative,0.9091379046440125
2143,11/28/2024 1:47:01 AM,RBC Capital Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-remains-a-buy-on-regeneron-regn-1034074005,positive,0.9444535374641418
2144,12/3/2024 10:15:45 AM,Regeneron pays $1M milestone payment to Medigene,TipRanks,/news/stocks/regeneron-pays-1m-milestone-payment-to-medigene-1034091230,positive,0.8677914142608643
2145,12/3/2024 1:20:19 PM,"MAIA Biotechnology, Regeneron expand clinical supply agreement",TipRanks,/news/stocks/maia-biotechnology-regeneron-expand-clinical-supply-agreement-1034092896,negative,0.8216174840927124
2146,12/6/2024 9:21:18 PM,Lilly tops Morgan Stanley's biopharma pick list for 2025,Seeking Alpha,https://seekingalpha.com/news/4372587-lilly-tops-morgan-stanleys-biopharma-pick-list-for-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6062930822372437
2147,12/8/2024 1:00:31 AM,Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab,GlobeNewswire,/news/stocks/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved-greater-control-of-intravascular-hemolysis-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-compared-to-ravulizumab-1034110553,negative,0.9489747881889343
2148,12/8/2024 2:27:19 AM,REGN : Poze-Cemdi Combo In Phase 3 Result Shows Superior Hemolysis Control In PNH Vs. Ravulizumab ,RTTNews,/news/stocks/regn-poze-cemdi-combo-in-phase-3-result-shows-superior-hemolysis-control-in-pnh-vs-ravulizumab-1034110559,negative,0.9581863284111023
2149,12/8/2024 12:10:16 PM,Regeneron announces Phase 3 data of exploratory cohort from ACCESS-1 trial,TipRanks,/news/stocks/regeneron-announces-phase-3-data-of-exploratory-cohort-from-access-1-trial-1034110945,positive,0.8961464166641235
2150,12/9/2024 4:22:43 PM,Kodiak stock rallies 32% after Jefferies upgrades to buy,Seeking Alpha,https://seekingalpha.com/news/4378725-kodiak-stock-rallies-after-jefferies-upgrades-to-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8740083575248718
2151,12/9/2024 10:55:07 PM,Regeneron announces new data from odronextamab trial at ASH,TipRanks,/news/stocks/regeneron-announces-new-data-from-odronextamab-trial-at-ash-1034116513,positive,0.871806800365448
2152,12/9/2024 11:45:23 PM,Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma,GlobeNewswire,/news/stocks/odronextamab-ash-presentations-underscore-impressive-potential-in-earlier-lines-of-treatment-and-additional-types-of-lymphoma-1034116183,negative,0.9407422542572021
2153,12/10/2024 12:05:45 PM,Regeneron reinstated with an Underperform at BofA,TipRanks,/news/stocks/regeneron-reinstated-with-an-underperform-at-bofa-1034119705,neutral,0.9339377284049988
2154,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783,positive,0.8453127145767212
2155,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8290336728096008
2156,12/16/2024 10:30:25 PM,Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year,GlobeNewswire,/news/stocks/regeneron-named-to-dow-jones-sustainability-world-index-for-sixth-consecutive-year-1034142872,positive,0.5747909545898438
2157,12/17/2024 12:10:56 PM,Regeneron announces primary endpoint met in Phase 3 QUASAR trial,TipRanks,/news/stocks/regeneron-announces-primary-endpoint-met-in-phase-3-quasar-trial-1034146452,positive,0.6861205101013184
2158,12/17/2024 12:49:43 PM,Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion,Seeking Alpha,https://seekingalpha.com/news/4387240-regeneron-posts-phase-3-win-eylea-hd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9497491121292114
2159,12/17/2024 1:00:00 PM,EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-phase-3-trial-meets-primary-endpoint-showing-improved-vision-with-extended-dosing-intervals-in-patients-with-macular-edema-following-retinal-vein-occlusion-1034145108,negative,0.9497126936912537
2160,12/17/2024 1:29:42 PM,Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-phase-3-trial-with-eylea-hd-8-mg-meets-primary-endpoint-quick-facts-1034145232,positive,0.7315435409545898
2161,12/17/2024 10:05:00 PM,Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference,GlobeNewswire,/news/stocks/regeneron-announces-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference-1034147948,positive,0.8901702761650085
2162,12/18/2024 5:37:08 AM,Leerink Partners Keeps Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/leerink-partners-keeps-their-hold-rating-on-regeneron-regn-1034149445,positive,0.9156408309936523
2163,12/19/2024 12:12:10 PM,Regeneron to advance two Factor XI antibodies into broad Phase 3 program,TipRanks,/news/stocks/regeneron-to-advance-two-factor-xi-antibodies-into-broad-phase-3-program-1034156784,positive,0.5234987735748291
2164,12/19/2024 1:00:00 PM,Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results,GlobeNewswire,/news/stocks/regeneron-to-advance-two-factor-xi-antibodies-into-a-broad-phase-3-program-following-positive-phase-2-proof-of-concept-results-1034155335,negative,0.8045583963394165
2165,12/19/2024 6:16:03 PM,Regeneron reports positive results for two anti-coagulant drugs,Seeking Alpha,https://seekingalpha.com/news/4388091-regeneron-reports-positive-results-for-two-anti-coagulant-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9454735517501831
2166,12/20/2024 6:27:22 PM,Regeneron’s Promising Drug Pipeline and Strong Safety Profile Justify Buy Rating,TipRanks,/news/stocks/regeneron-s-promising-drug-pipeline-and-strong-safety-profile-justify-buy-rating-1034163945,negative,0.8706443905830383
2167,12/20/2024 6:36:42 PM,Regeneron (REGN) Receives a Buy from Jefferies,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-jefferies-1034164160,negative,0.5713006258010864
2168,12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9418226480484009
2169,12/23/2024 5:35:08 PM,FDA revokes EUAs for some antibody treatments for COVID-19,TipRanks,/news/stocks/fda-revokes-euas-for-some-antibody-treatments-for-covid-19-1034169449,neutral,0.8177931904792786
2170,12/28/2024 3:31:10 PM,Here are Morgan Stanley’s key oncology catalysts for 2025,Seeking Alpha,https://seekingalpha.com/news/4391298-morgan-stanley-lists-2025-oncology-catalysts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9273046255111694
2171,1/7/2025 8:27:42 AM,Bernstein Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/bernstein-remains-a-buy-on-regeneron-regn-1034199029,positive,0.9488333463668823
2172,1/7/2025 11:46:16 AM,"Regeneron price target lowered to $1,070 from $1,110 at Bernstein",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-070-from-1-110-at-bernstein-1034200272,neutral,0.5585746169090271
2173,1/7/2025 1:41:00 PM,"Regeneron price target lowered to $1,184 from $1,215 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-184-from-1-215-at-rbc-capital-1034201268,neutral,0.7977384924888611
2174,1/7/2025 10:05:00 PM,"Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025",GlobeNewswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-4-2025-1034202174,positive,0.9480682015419006
2175,1/8/2025 1:15:23 AM,"Regeneron price target lowered to $1,004 from $1,126 at Truist",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-004-from-1-126-at-truist-1034202853,neutral,0.5318255424499512
2176,1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6913239359855652
2177,1/10/2025 11:37:48 AM,Oppenheimer Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-regeneron-regn-1034214500,positive,0.9489079117774963
2178,1/10/2025 11:40:26 AM,Wells Fargo Releases a Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/wells-fargo-releases-a-buy-rating-on-regeneron-regn-1034214460,positive,0.926948606967926
2179,1/10/2025 2:45:40 PM,"Regeneron price target lowered to $950 from $1,000 at Oppenheimer",TipRanks,/news/stocks/regeneron-price-target-lowered-to-950-from-1-000-at-oppenheimer-1034216027,negative,0.5145087242126465
2180,1/10/2025 4:18:38 PM,"4D Molecular, FDA agree on phase 3 design for DME candidate",Seeking Alpha,https://seekingalpha.com/news/4394159-4d-molecular-fda-agree-phase-3-design-dme-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7509260773658752
2181,1/11/2025 8:06:44 PM,Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?,Seeking Alpha,https://seekingalpha.com/news/4394318-can-2025-jp-morgan-healthcare-conference-spark-biotech-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8774529099464417
2182,1/13/2025 11:11:05 AM,Regeneron announces strategic collaboration with Truveta,TipRanks,/news/stocks/regeneron-announces-strategic-collaboration-with-truveta-1034220482,positive,0.5147938132286072
2183,1/13/2025 11:20:27 AM,Regeneron reports ‘positive’ results from Phase 3 C-POST trial,TipRanks,/news/stocks/regeneron-reports-positive-results-from-phase-3-c-post-trial-1034220620,negative,0.9454704523086548
2184,1/13/2025 12:05:00 PM,Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery,GlobeNewswire,/news/stocks/regeneron-collaborates-with-truveta-and-leading-american-health-systems-to-massively-extend-its-dna-sequence-linked-healthcare-database-to-further-advance-scientific-innovation-and-healthcare-delivery-1034219587,negative,0.8241766691207886
2185,1/13/2025 12:15:45 PM,Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial,GlobeNewswire,/news/stocks/adjuvant-libtayo-cemiplimab-significantly-improves-disease-free-survival-dfs-after-surgery-in-high-risk-cutaneous-squamous-cell-carcinoma-cscc-in-phase-3-trial-1034219684,negative,0.9537912011146545
2186,1/13/2025 12:28:12 PM,Regeneron Pharma Reports Positive Results From C-POST Trial With Libtayo - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-reports-positive-results-from-c-post-trial-with-libtayo-quick-facts-1034219670,negative,0.9388530850410461
2187,1/13/2025 12:30:00 PM,Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference,GlobeNewswire,/news/stocks/regeneron-provides-business-updates-and-highlights-from-broad-clinical-pipeline-at-the-43rd-annual-j-p-morgan-healthcare-conference-1034219683,positive,0.906082034111023
2188,1/13/2025 1:15:39 PM,"Regeneron To Invest $119.5 Mln In Truveta's Financing Round, Launch Truveta Genome Project ",RTTNews,/news/stocks/regeneron-to-invest-119-5-mln-in-truveta-s-financing-round-launch-truveta-genome-project-1034219849,positive,0.7960944175720215
2189,1/13/2025 1:40:34 PM,Regeneron reports preliminary Q4 Eylea HD U.S. net product sales of $305M,TipRanks,/news/stocks/regeneron-reports-preliminary-q4-eylea-hd-u-s-net-product-sales-of-305m-1034221854,positive,0.7864615321159363
2190,1/13/2025 1:46:53 PM,"Regeneron down 5% after providing business updates, reporting Eylea sales",TipRanks,/news/stocks/regeneron-down-5-after-providing-business-updates-reporting-eylea-sales-1034222003,neutral,0.9676234126091003
2191,1/13/2025 1:54:38 PM,Regeneron Pharmaceuticals met primary endpoint in cell carcinoma treatment trial,Seeking Alpha,https://seekingalpha.com/news/4394523-regeneron-pharmaceuticals-met-primary-endpoint-in-cell-carcinoma-treatment-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8069273233413696
2192,1/13/2025 2:26:25 PM,4D Molecular downgraded at BMO on limited population for wet AMD candidate,Seeking Alpha,https://seekingalpha.com/news/4394529-4d-molecular-downgraded-bmo-limited-population-wet-amd-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.593521237373352
2193,1/13/2025 2:31:01 PM,Regeneron announces IPR&D charges,Seeking Alpha,https://seekingalpha.com/news/4394553-regeneron-announces-iprd-charges?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9415454864501953
2194,1/13/2025 8:38:14 PM,Regeneron Faces Sell Rating Amid Eylea’s Underperformance and Competitive Threats from Amgen’s Pavblu,TipRanks,/news/stocks/regeneron-faces-sell-rating-amid-eylea-s-underperformance-and-competitive-threats-from-amgen-s-pavblu-1034222992,neutral,0.9684273600578308
2195,1/14/2025 1:02:22 AM,Regeneron price target lowered to $795 from $895 at Citi,TipRanks,/news/stocks/regeneron-price-target-lowered-to-795-from-895-at-citi-1034223287,neutral,0.8362233638763428
2196,1/14/2025 1:05:16 AM,Regeneron’s Mixed Eylea Sales and Competitive Challenges Prompt Neutral Rating,TipRanks,/news/stocks/regeneron-s-mixed-eylea-sales-and-competitive-challenges-prompt-neutral-rating-1034223286,neutral,0.7685132026672363
2197,1/14/2025 11:31:20 AM,Regeneron (REGN) Gets a Buy from Bernstein,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-bernstein-1034225608,positive,0.6550916433334351
2198,1/14/2025 12:09:20 PM,Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/canaccord-genuity-reaffirms-their-buy-rating-on-regeneron-regn-1034226107,positive,0.7572686076164246
2199,1/14/2025 12:46:42 PM,Regeneron’s Strategic R&D Focus and Robust Pipeline Drive Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-r-d-focus-and-robust-pipeline-drive-buy-rating-1034226387,negative,0.8970064520835876
2200,1/14/2025 11:45:13 PM,Regeneron CEO: We have 40 drugs in development,TipRanks,/news/stocks/regeneron-ceo-we-have-40-drugs-in-development-1034227811,positive,0.6191121339797974
2201,1/15/2025 7:14:27 AM,"Regeneron Faces Strategic Challenges and Sales Shortfall, Leading to Hold Rating",TipRanks,/news/stocks/regeneron-faces-strategic-challenges-and-sales-shortfall-leading-to-hold-rating-1034229620,neutral,0.9721736907958984
2202,1/15/2025 11:17:22 AM,"Regeneron Buy Rating Supported by Eylea HD Launch, Dupixent Expansion, and Libtayo Success",TipRanks,/news/stocks/regeneron-buy-rating-supported-by-eylea-hd-launch-dupixent-expansion-and-libtayo-success-1034230575,positive,0.6724036335945129
2203,1/16/2025 11:20:31 AM,Regeneron downgraded to Neutral from Buy at UBS,TipRanks,/news/stocks/regeneron-downgraded-to-neutral-from-buy-at-ubs-1034235557,positive,0.812643826007843
2204,1/16/2025 2:35:30 PM,"Netflix upgraded, AMD downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/netflix-upgraded-amd-downgraded-wall-street-s-top-analyst-calls-1034237034,positive,0.6035071611404419
2205,1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772,positive,0.4902459383010864
2206,1/21/2025 1:19:17 PM,Morgan Stanley Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/morgan-stanley-remains-a-buy-on-regeneron-regn-1034250543,positive,0.9403529167175293
2207,1/23/2025 1:58:02 AM,RBC Capital Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-sticks-to-their-buy-rating-for-regeneron-regn-1034257428,positive,0.6472666263580322
2208,1/23/2025 6:00:14 PM,America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search,GlobeNewswire,/news/stocks/america-s-top-40-high-school-scientists-to-compete-for-1-8-million-in-awards-at-prestigious-regeneron-science-talent-search-1034261255,negative,0.7482805252075195
2209,1/27/2025 12:01:03 PM,Piper Sandler Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-remains-a-buy-on-regeneron-regn-1034272491,positive,0.9470075368881226
2210,1/27/2025 1:50:31 PM,"Regeneron price target lowered to $1,013 from $1,195 at Piper Sandler",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-013-from-1-195-at-piper-sandler-1034273094,neutral,0.7401151657104492
2211,1/28/2025 11:35:58 AM,Regeneron price target lowered to $750 from $795 at Citi,TipRanks,/news/stocks/regeneron-price-target-lowered-to-750-from-795-at-citi-1034277164,neutral,0.732927680015564
2212,1/29/2025 11:58:13 AM,Regeneron (REGN) Gets a Buy from TD Cowen,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-td-cowen-1034282871,negative,0.5022986531257629
2213,1/30/2025 11:27:58 AM,Regeneron: Strong Buy Rating Driven by Dupixent’s Growth and Promising Pipeline Developments,TipRanks,/news/stocks/regeneron-strong-buy-rating-driven-by-dupixent-s-growth-and-promising-pipeline-developments-1034288305,negative,0.9486675262451172
2214,2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9316384792327881
2215,2/3/2025 7:10:20 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034305420,positive,0.9220908284187317
2216,2/3/2025 7:28:29 PM,Regeneron Pharmaceuticals Q4 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4402211-regeneron-pharmaceuticals-q4-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9077449440956116
2217,2/3/2025 11:00:37 PM,Here's the major earnings before the open tomorrow,Seeking Alpha,https://seekingalpha.com/news/4402088-heres-the-major-earnings-before-the-open-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9330109357833862
2218,2/4/2025 11:33:51 AM,Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY25 outlook,Seeking Alpha,https://seekingalpha.com/news/4402560-regeneron-pharmaceuticals-beats-top-line-and-bottom-line-estimates-initiates-fy25-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8443858623504639
2219,2/4/2025 11:36:02 AM,Regeneron sees 2025 CapEx $850M-$975M,TipRanks,/news/stocks/regeneron-sees-2025-capex-850m--975m-1034308376,positive,0.757917046546936
2220,2/4/2025 11:36:40 AM,"Regeneron reports Q4 non-GAAP EPS $12.07, consensus $11.19",TipRanks,/news/stocks/regeneron-reports-q4-non-gaap-eps-12-07-consensus-11-19-1034308360,positive,0.8103594183921814
2221,2/4/2025 11:50:35 AM,"Regeneron Pharmaceuticals declares its first-ever dividend of $0.88, announces $3.0B buyback",Seeking Alpha,https://seekingalpha.com/news/4402577-regeneron-pharmaceuticals-declares-its-first-ever-dividend-of-088-announces-30b-buyback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.809650719165802
2222,2/4/2025 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion,GlobeNewswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-initiates-quarterly-dividend-and-increases-total-share-repurchase-capacity-to-4-5-billion-1034308299,negative,0.9469545483589172
2223,2/4/2025 12:39:38 PM,"Regeneron Pharmaceuticals Q4 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-decreases-but-beats-estimates-1034308322,neutral,0.9664634466171265
2224,2/4/2025 2:00:33 PM,Morning Movers: Spotify and Pfizer climb after fourth quarter results,TipRanks,/news/stocks/morning-movers-spotify-and-pfizer-climb-after-fourth-quarter-results-1034309577,negative,0.8022207021713257
2225,2/4/2025 2:01:16 PM,MAIA Biotechnology announces updated data from THIO-101 trial,TipRanks,/news/stocks/maia-biotechnology-announces-updated-data-from-thio-101-trial-1034309572,positive,0.9131611585617065
2226,2/4/2025 3:27:57 PM,"Regeneron's new dividend, Dupixent growth support strong Q4",Seeking Alpha,https://seekingalpha.com/news/4402668-regeneron-new-dividend-dupixent-growth-support-strong-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9520940184593201
2227,2/4/2025 5:05:31 PM,"China retaliates with tariffs on U.S., Merck falls after earnings: Morning Buzz",TipRanks,/news/stocks/china-retaliates-with-tariffs-on-u-s-merck-falls-after-earnings-morning-buzz-1034310568,neutral,0.9223615527153015
2228,2/5/2025 10:35:41 AM,Oppenheimer Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/oppenheimer-sticks-to-their-buy-rating-for-regeneron-regn-1034314353,positive,0.8712984323501587
2229,2/5/2025 11:16:10 AM,Regeneron upgraded to Outperform from Market Perform at Leerink,TipRanks,/news/stocks/regeneron-upgraded-to-outperform-from-market-perform-at-leerink-1034314595,negative,0.9350833296775818
2230,2/5/2025 11:40:02 AM,RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-regeneron-regn-1034314684,positive,0.7838191390037537
2231,2/5/2025 12:17:11 PM,Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-regeneron-regn-1034315105,positive,0.6758719682693481
2232,2/5/2025 12:31:05 PM,Regeneron price target lowered to $759 from $940 at Baird,TipRanks,/news/stocks/regeneron-price-target-lowered-to-759-from-940-at-baird-1034315231,neutral,0.6125584244728088
2233,2/5/2025 1:25:29 PM,Regeneron price target raised to $575 from $565 at BofA,TipRanks,/news/stocks/regeneron-price-target-raised-to-575-from-565-at-bofa-1034315530,negative,0.947442889213562
2234,2/5/2025 1:35:38 PM,Jefferies Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/jefferies-sticks-to-their-buy-rating-for-regeneron-regn-1034315682,positive,0.8543886542320251
2235,2/5/2025 1:41:28 PM,"Regeneron price target lowered to $1,045 from $1,059 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-045-from-1-059-at-rbc-capital-1034315662,neutral,0.8091102838516235
2236,2/5/2025 2:35:44 PM,"AMD, Spotify downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/amd-spotify-downgraded-wall-street-s-top-analyst-calls-1034316027,positive,0.6115320920944214
2237,2/5/2025 4:17:03 PM,EyePoint stock jumps 10% on Duravyu study results,Seeking Alpha,https://seekingalpha.com/news/4403524-eyepoint-stock-jumps-on-duravyu-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8995054364204407
2238,2/5/2025 4:25:45 PM,Regeneron upgraded at Leerink following recent share weakness,Seeking Alpha,https://seekingalpha.com/news/4403603-regeneron-upgraded-leerink-following-recent-share-weakness?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8567065000534058
2239,2/5/2025 5:11:12 PM,"Alphabet, Disney report quarterly beats: Morning Buzz",TipRanks,/news/stocks/alphabet-disney-report-quarterly-beats-morning-buzz-1034317040,positive,0.9163327813148499
2240,2/6/2025 12:10:50 PM,Immuneering announces clinical supply agreement with Regeneron,TipRanks,/news/stocks/immuneering-announces-clinical-supply-agreement-with-regeneron-1034321964,negative,0.6932625770568848
2241,2/7/2025 7:15:15 PM,Buy/Sell: Wall Street’s top 10 stock calls this week,TipRanks,/news/stocks/buy-sell-wall-street-s-top-10-stock-calls-this-week-1034329182,positive,0.8970736265182495
2242,2/8/2025 2:35:21 PM,"Notable analyst calls this week: AMD, Skyworks and Nike stocks among top picks",Seeking Alpha,https://seekingalpha.com/news/4405154-notable-analyst-calls-this-week-amd-skyworks-and-nike-stocks-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7246410250663757
2243,2/8/2025 9:55:00 PM,Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with...,GlobeNewswire,/news/stocks/three-year-results-for-eylea-hd-aflibercept-injection-8-mg-in-patients-with-wet-age-related-macular-degeneration-demonstrate-continued-durable-vision-gains-and-anatomic-improvements-with-1034329786,negative,0.9593297839164734
2244,2/8/2025 11:40:16 PM,EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-positive-phase-3-results-in-patients-with-macular-edema-following-retinal-vein-occlusion-presented-at-angiogenesis-meeting-1034329795,negative,0.8879453539848328
2245,2/9/2025 5:17:46 AM,Regeneron : EYLEA HD Shows Sustained Vision Gains In Wet AMD Patients At 3 Years ,RTTNews,/news/stocks/regeneron-eylea-hd-shows-sustained-vision-gains-in-wet-amd-patients-at-3-years-1034329885,negative,0.9517760872840881
2246,2/9/2025 5:36:47 AM,Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment ,RTTNews,/news/stocks/regeneron-announces-positive-phase-3-results-for-eylea-hd-in-retinal-vein-occlusion-treatment-1034329895,negative,0.9493774771690369
